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Abstract
Clostridium difficile is a spore-forming, anaerobic Gram-positive bacteria that
results in infection in the gastrointestinal (GI) tact. C. difficile has been known as the
costliest bacteria in terms of human mortality and financial burden. Furthermore, the
current treatments that exist for C. difficile infection (CDI) are inefficient and expensive
and often result in disease reoccurrence due to the release of spores. Therefore, it is an
important medical requirement to develop novel antibacterial compounds to effectively
treat CDI. As such this PhD project has investigated the modification of the binaphthyl
hydrophobic region of the lead compound-1 (AVX-13616) with alkyl and benzyl
substituted phenyltriazole and naphthalenetriazole peptidomimetics towards the
discovery of new CDI inhibitors.
An effective and modular synthetic route was developed to prepare twenty-nine
novel mono- and di-cationic peptide derivatives which incorporated a phenyltriazole or
naphthalenetriazole group with the aim to achieve better water solubility over previously
prepared analogues by our group which were difficult to deliver in mouse model
experiments because of their poor water solubilities. Chapter 2 describes the successful
synthesis of these analogues. In some cases, the attempted synthesis of the 1,5-triazole
moiety using the Ru-catalysed click reaction were unsuccessful when sterically hindered
azide and alkyne substrates were employed. We found, however, that the magnesium
promoted click reaction conditions reported by Sharpless et al. were useful for the
synthesis of these sterically hindered 1,5-triazoles.
x

The difficulties encountered in preparing sterically hindered 1,5-triazoles initiated a
general study into this synthetic problem. The results of this study are reported in Chapter
4.
The new analogues prepared here were tested against a wide range of bacterial
strains and two fungal strains by collaborators at three independent laboratories. These
results are reported in Chapter 3. The twenty-nine peptide derivatives had variable
minimum inhibitory concentration (MIC) values from the antimicrobial screening. All of
the compounds displayed MIC values in the range of 2 – 128 μg/mL against both Grampositive and Gram-negative bacterial pathogens. The naphthyl-triazole dicationic
compounds 42 and 43 showed the best broad-spectrum antibacterial activities, displaying
MIC values of 8 μg/mL against S. aureus, 8 μg/mL against MRSA, 8 μg/mL against E.
faecalis and 8 – 16 μg/mL against S. pneumoniae. The compounds, 29 – 30, 33 and 43 –
45, exhibited weak antifungal activity (MIC = 8 – 32 μg/mL) against C. albicans and C.
neoformans. The compounds 41 and 42, however showed MIC values of 4 μg/mL against
C. neoformans.
Compounds 41 and 43 (naphthalenetriazole derivatives) exhibited similar
antibacterial activity against C. difficile (MIC = 8 μg/mL); these molecules were also
structurally similar except for the nature of their hydrophobic termini (cyclohexyl and
benzyl, respectively). A cytotoxicity analysis revealed that these compounds had
relatively low cytotoxicity (CC50 = 32 μg/mL). Overall compound 41 showed similar
antibacterial activity against C. difficile (MIC = 8 μg/mL) to the lead compound-1 (MIC
xi

= 8 μg/mL), better water solubility (5 times better than lead compound-1) and low
cytotoxicity (CC50 = 32 μg/mL); these properties favored compound 41 for further in vivo
testing in a CDI mouse model.
Compound 41 was synthesized on a larger scale (≈ 300 mg) for further studies in
an in vivo CDI mouse model to identify its potential as an in vivo CDI inhibitor. At 24
hours post-infection, compound 41 appeared to be protecting the mice from disease as the
mice lost the least amount of weight and had mild diarrhoea. Furthermore, compound 41
displayed some promising activity, despite not completely protecting the mice over the
second day period of this trial and the mice had to be culled after 42 h due to weight loss
from the disease.
In summary, a total of 29 novel phenyltriazole and naphthyltriazole peptide
derivatives were synthesized via a modular synthetic route and tested against various
Gram-positive and Gram-negative bacteria. Compound 41 showed better antibacterial
activity against C. difficile, good water solubility and low cytotoxicity; these properties
favored the compound for further in vivo testing in a CDI mouse model. Compound 41
displayed some promising activity at 24 h, despite not completely protecting the mice in
the murine model of CDI study and the mice had to be culled after 42 h.
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1.0 – Introduction
1.1 – Resistance to Antibacterial agents
Antibacterial resistance to known antibiotics is, and will continue to be, a severe
threat to the current human healthcare services and overall security.1-6 Inflammation
disease is the second biggest medical threat globally (17 million deaths/year) and bacterial
infections from antibiotic resistant is presently viewed as a "rising universal disease" by
the World Health Organization (WHO) and the US Centers for Disease Control and
Prevention (CDC).6-7 The CDC evaluates that antibiotic resistance is responsible for
23,000 deaths and more than two million inflammation diseases every year in the USA.2
The WHO has begun an "Universal Action Plan on Antimicrobial Resistance" around the
world to control the severity of drug resistance. Both the WHO and CDC have released a
list of drug resistance microbes that are presently thought to be a critical threat to current
human healthcare services and overall security.8 Bacterial strains have developed
resistance to the most common antibacterial agents and the regularity of hypervirulent
strains just potentiates the problem.9-10 Therefore, the requirement for novel antibacterial
agents with new mechanisms of action is urgently needed.
Bacterial resistance arises in three ways: 1. natural resistance in certain types of
bacteria, 2. genetic mutation and, 3. by one bacterium acquiring resistance from another
via horizontal gene transfer.9 All classes of microbes can develop resistance, including
fungi and viruses. Bacterial resistance to antibiotics has developed quickly since the
introduction of penicillin during the 1930s, and 85% of clinically isolated Staphylococci
became penicillin resistant by the end of the 1950s.9
1

Vancomycin was quickly permitted for use as an antibacterial agent because its
effective treatment against penicillin resistant bacteria was needed urgently.11 Methicillin,
the first semi-synthetic penicillin, was developed by Beecham in 1959 and was rapidly
introduced as an antimicrobial agent because of its efficacy against penicillin resistant
bacteria.11 The consequent rise of methicillin-resistant Staphylococcus aureus (MRSA)
and its developed resistance to most other common antibacterial agents led to vancomycin
becoming “the best medicine" for the treatment of MRSA. This led to an increase in
vancomycin usage to treat MRSA and also to treat the rising cases of Clostridium difficile
infection (CDI) during the 1970’s. The massive consumption of oral vancomycin for the
treatment of CDI caused the rise of vancomycin resistant enterococci (VRE) in 1986.
Vancomycin resistant S. aureus (VRSA) additionally developed via parallel gene
transmission from VRE in a patient in 2002, who had been occasionally treated with
vancomycin.11 Some microbes have developed resistance against many antibacterial
agents and these multi-drug resistant (MDR) pathogens are a major concern for the current
healthcare system. Informally the resistant bacterial isolates are called "superbugs" and
are currently a serious concern and therefore a strong motivation for the invention of new
antibacterial agents.12-13
Recently, vancomycin has been supplanted to treat VRSA, MRSA and all Grampositive

microbial

diseases

by

tigecycline,

linezolid,

daptomycin

and

quinupristin/dalfopristin.10-11 Both linezolid and daptomycin have been used generally to
treat Gram-positive diseases; in this way, resistance of these two antibacterial agents has
been documented recently.14 Gram-negative microorganisms are normally less
2

impervious to antibacterial agents because of their impermeable external membrane and
their efflux pumps (for eliminating undesired chemicals out of the cell).13 Multi-drug
resistance in Gram-negative microorganisms is rapidly increasing, so there is an urgent
need for the development of novel antibacterial agents with better efficacy compared to
present antibiotics to treat such related inflammations.13 Thus, antibacterial drug
discovery has shifted its focus on the development of novel antibacterial agents against
MDR Gram-negative microbial inflammations.13 The ESKAPE microorganisms (i.e.
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa and Enterobacter spp.) are six anti-microbial
resistant bacterial strains that have been perceived by the Infectious Diseases Society of
America (IDSA) as the key organisms behind most nosocomial inflammations.5 These
microorganisms have been classified based on their harmfulness, steadiness, tendency for
obstacle and pathogenicity.5 Remarkably, P. aeruginosa and A. baumannii showed an inbuilt ability to oppose antibacterial agents, probably due to their capability of surviving in
hazardous environments. The lack of sustainable choices of medication for Gram-negative
microbial infections has even led to the reintroduction of polymyxin B and polymyxin E
(colistin), despite known toxicity issues – polymyxins are relatively large cyclic cationic
peptides with potent antimicrobial activity. 13
Regrettably, microbial resistance is unavoidable, and each bacterium will
eventually develop resistance to any antibacterial agent. There is an increased chance for
the development of a resistant bacterial strain by increased exposure to antibiotics. In this
way, the increased use of antibiotics by the agriculture industry for animal growth – ( >
3

50% of antibiotics consumption) and the abuse and overuse by modern medicine has
worsen the problem of resistance by accelerating the process. 15 In 2015, a five year plan
was announced by the US White House on abuse of antibacterial agents in the agriculture
industry where this is a major issue.7 Furthermore a program called “National Action Plan
for Combating Antibiotic-Resistant Bacteria” was announced by the US White House –
the objective of this program was financial support to novel anti-microbial drug discovery
research for the treatment of MDR bacterial infections.7 The resistance of pathogenic
bacteria toward antibacterial agents has become a serious issue, so the WHO recently
cautioned of a 'post-antibiotic time'; where regular diseases and minor injuries will
demonstrate as deadly because of the absence of reasonable anti-microbial therapies.16
Thus, novel antibacterial agents with distinctive mechanism of actions are desperately
required to tackle the rising problem of bacterial resistance.

1.2 – Clostridium difficile infection
C. difficile is a spore-forming, anaerobic Gram-positive microbe that results
in moderate to severe illness in the gastrointestinal (GI) tact. This bacterium produces
toxins and resilient spores (Figure 1.1).

4

Figure 1.1 – C. difficile forming an endospore (red).19
(Electron micrograph pic)

C. difficile infection (CDI) happens when the common GI microbiota is
compromised; this licenses C. difficile to grow well in the GI tract. Most standard oral
antibiotics, as well as penicillins, can target the healthy GI microflora – this undesirable
effect gives C. difficile up to a 20% chance to survive in the gut.17 C. difficile produces
vigorous endospores that are spread by the fecal-oral course; these spores are impenetrable
to most anti-infectives, hand sanitizers and heat. The hospital environment allows ideal
conditions for C. difficile spores, which can live for a significantly long time and helps
the spread of C. difficile spores via nosocomial contamination; also known as hospital
acquired contamination which usually occurs via healthcare workers, patients and hospital
equipment. The other major threat of CDI is earlier antibiotic treatment. 18 Broad range
anti-microbial treatment commonly destroys the GI microflora while treating C. difficile
infection. Most of the broad-spectrum antibacterial agents such as fluoroquinolones,
ampicillin/amoxicillin, clindamycin and cephalosporins eradicate the commensal GI
microbiota while treating CDI.17, 20

5

Patients having a C. difficile contaminated GI system endure indications such as
diarrhoea, abdominal cramping, abdominal pain and pseudomembranous colitis (PMC –
a serious gastric illness). CDI-related PMC can be so serious as to warrant colectomy (i.e.
resection of the colon) for which there is a ~55% death rate for patients that proceed to
medical surgery.21 Furthermore, poisonous megacolon can arise because of CDI, wherein
the patient encounters serious colonic irritation and stomach distension. 20 CDI shows an
overall demise rate up to 8%18 and re-occurrence of disease occurs in up to 20% of cases
treated with first-line drugs (vancomycin or metronidazole).22 Once the spores have
reached to the GI, the accessible bile salts initiate germination of the spores to convey the
vegetative C. difficile cells. The illness obtained by CDI basically creates two destructive
elements (Toxin A and Toxin B) that are released by the vegetative C. difficile cells; these
toxins develop colonic disease and damage epithelial tissue which causes loss of liquid
(diarrhoea). A third toxin (known as CDT or matched toxin) is found in significant levels
in hypervirulent C. difficile strains; the role of this poison in disease has not yet been
elucidated.20
As of late, both the earnestness and recurrence of CDI cases have increased due to
epidemics of hypervirulent C. difficile strains, for example ribotype 027 – also known as
strain B1/NAP1/027.17 The hypervirulent ribotype 027 produces larger quantities of
toxins than common C. difficile strains – these poisons are responsible for the infirmity
side effects of diarrhoea and PMC.18 Thus, ribotype 027 shows higher death rates than
normal C. difficile isolates.17

6

The inescapability of C. difficile contamination invokes an enormous monetary
burden on the current therapeutic services administrations (>$1 billion every year in the
USA);17, 23 another assessment put CDI-related human medicinal services administration
costs at $4.8 billion in 2008.18 The CDC gave a report in 2013 entitled 'Resistance Threats
to Antibiotics' in which C. difficile was noted as the prime microbial threat to humans and
the toughest test for the social insurance system. 3 A continuous update by the CDC
revealed that CDI is responsible for approximately 500,000 diseases and 15,000 deaths
consistently in the USA – the largest increase in any of the bacterial threats recorded by
the CDC.23 Due to the elevated levels of illness, expenditure, recurrence, deaths and the
absence of satisfactory therapies for CDI, there is considerable motivation to pursue
innovative antibacterial agent that successfully prevent CDI.
Antibacterial selectivity for C. difficile is an important factor for a relatively
efficient CDI antibacterial agent. The elimination of all GI microbiome by broad-spectrum
antimicrobial agents results in an ideal environment for C. difficile spores to develop; thus,
the maintenance or restoration of commensal GI microflora is necessary for stopping CDI
recurrence.17-18,

20

This explains why CDI is so difficult to treat with conventional

antimicrobial agents and why CDI reoccurs in 15-30% of patients who have been treated
with vancomycin.17 Fecal transplantation has become a feasible strategy for treating cases
of severe CDI, as it replaces the commensal GI microflora physically.17-18, 20 The typical
antibacterial agents (i.e. metronidazole and vancomycin) suffer from efficacy concerns,
especially CDI recurrence due to their lack of selectivity for C. difficile and their lack of
ability to prevent sporulation.17-18 It has been found that CDI recurrence is associated with
7

the lack of ability to develop a specific antibody response to the toxins released by C.
difficile; healthy adults naturally develop antibodies against toxins A and B.17 Nonchemotherapeutic treatments (i.e. medical surgery) are available, but they are only utilized
when traditional drugs have been unsuccessful. Surgical treatments are permanent – most
involve subtotal colectomy in an effort to substantially reduce the infection and diseased
bowel.18 Existing C. difficile medications fail to treat CDI with no recurrence. Thus, there
is a demand for more efficacious antibacterial agents for CDI treatment. A well-tolerated
and reliable drug that can selectively target C. difficile (and its spores), without effecting
the GI microbiome intact, would be vital in the treatment of severe and recurrent CDI.

1.3 – Available medicines for C. difficile infection (CDI)
There are currently only three medicines used to treat CDI. They are vancomycin,
metronidazole and fidaxomicin.20,

22, 24

Only vancomycin and fidaxomicin are FDA

approved for treatment of CDI. Vancomycin was the only FDA approved treatment for
CDI until 2011 when fidaxomicin was also approved. Metronidazole is widely used to treat
CDI in mild to moderate and recurrent cases despite not having FDA approval.

1.3.1 – Metronidazole
Metronidazole (Figure 1.2) is an imidazole derivative that has been utilized
initially as an antiprotozoal medicine to treat Trichomonas vaginalis and giardiasis,
eventually found to be effective against both Gram-positive and Gram-negative pathogens
for over 45 years. It can be utilized either alone or with different antibacterial agents to
8

treat inflammatory diseases. It is a possible medicine for mild CDI if vancomycin or
fidaxomicin is inaccessible.27-28

Figure 1.2 – Metronidazole

Metronidazole is marketed under the brand name Flagyl, Filmet and Metro.
During the 30 years of utilization, metronidazole was eminent because a low resistance
profile was observed.28 Metronidazole can be administered orally, intravenously and
topically and shows ideal pharmacokinetics for a systemic anti-infective. Metronidazole
is an inexpensive medicine that has a straightforward structure that permits efficient and
cost-effective bulk production (~$0.86 USD/dose).25
Metronidazole shows potency through a free radical mechanism where the nitro
group is reduced in vivo to a reactive 'nitro radical anion' which is unstable and readily
decomposes to give an imidazole radical and a nitrite ion. 20, 28 The imidazole radical and
nitrite ion cause oxidative damage to DNA strands, resulting in apoptosis. Metronidazole
has supplanted vancomycin to treat milder illness of CDI as it is less expensive and has a
comparative efficacy profile.25 Most orally taken metronidazole is absorbed systemically
which is not suitable for C. difficile treatment.27-28 Low oral bioavailability is fundamental
for treatment of CDI as the drug must stay and remain in the gut and not be absorbed
systemically.

9

1.3.2 – Vancomycin
Vancomycin (Figure 1.3) is a glycopeptide antibacterial agent that is utilized for
the treatment of various bacterial inflammations. This compound was developed by the
Eli Lilly pharmaceutical organization in 1959. Vancomycin was isolated from a soil
sample from the rainforests of Borneo from the microorganism Amycolatopsis orientalis.9
Fermentation of A. orientalis efficiently yields vancomycin on an industrial scale. This
production technique is financially more viable than total synthesis due to its complex
chemical structure.11 Vancomycin costs ~$31 USD per dose; which is relatively expensive
compared to the synthetically feasible small-molecule medications (e.g. metronidazole).9,
25

Figure 1.3 – Vancomycin (glycopeptide antibiotic)

The glycopeptides represent a complex class of molecular structures; the main
tricyclic structure comprises peptide, ether and biphenyl moieties with a disaccharide
attached to one of the phenol rings. Vancomycin is known to work by obstructing the
development of the bacterial cell wall. The binding of vancomycin to the terminal Dalanine amino acid of Gram-positive microorganisms forestalls the transglycosylase
10

enzyme from cross-connecting the peptide as a component of the bacterial cell wall.9
Vancomycin displays antibacterial activity (MIC) ≤ 0.50 µg/mL against C. difficile and
207 C. difficile strains.26 Vancomycin displays numerous traits that make it perfect for
extreme CDI treatment such as a low oral bioavailability and a potent MIC against C.
difficile. But unfortunately, it has a few disadvantages i.e. lack of selectivity for C.
difficile, recurrence of CDI following treatment, cost and production.11, 25 In particular,
vancomycin plays a significant role in treating MRSA and other MDR microbes and thus
it will never be given full permit for the treatment of mild or moderate CDI.

1.3.3 – Rifaximin
Rifaximin (Figure 1.4) is from the rifamycin group of semi-synthetic antibiotic.
This drug is amazingly highly potent against C. difficile and furthermore displays broadspectrum activity.
Rifaximin showed an antibacterial activity (MIC) of ≤ 0.015 µg/mL against 110
pathogenic C. difficile strains while maintaining low solubility in water.25, 31 After oral
dosing, the intestinal concentration of this drug remains high with 97% of the dose
recovered as unaltered rifaximin in the faeces. The drug maintains systemic bioavailability
under 0.4% – which is ideal for CDI treatment.32
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Figure 1.4 – Rifaximin

Ongoing investigations have shown that rifaximin can be used for resistant CDI
treatment – as a "salvage therapy" where several classic drugs have failed to do.25, 33 These
examinations indicated that the drug is well-tolerated by most patients and that it has had
some success in cases such as resilient CDI treatment, including a few strains containing
the NAP1/BI/027 ribotype.33 C. difficile resistance against rifamycin is growing as an
issue with around 2% of present strains displaying rifaximin resistance. There is
developing worry that the percentage of resistance strains will increase in the future.33
Rifaximin may also be used as an extension to vancomycin for treating patients with
relapsing C. difficile infection. However, the quality of evidence of these studies was
judged to be low. Although exposure to rifamycin may increase the risk of resistance in
the future, it should be used for severe cases only.33
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1.3.4 – Fidaxomicin
Fidaxomicin (Figure 1.5) is a macrocyclic anti-microbial agent which is explicitly
utilized to treat CDI and was endorsed by the FDA in 2011. Fidaxomicin has an intricate
structure containing an unsaturated macrolide with two sugar units connected; the
molecule was isolated from the fermentation of Dactylosporangium aurantiacum.22
Fidaxomicin is profoundly costly (~$156 USD/portion) and the chemical structure is
patent protected.25

Figure 1.5 – Macrolide structure of fidaxomicin

Fidaxomicin showed antibacterial activities (MIC) in the range of 0.008 – 0.25
μg/mL for 90% of C. difficile isolates screened and also delivered promising results in
CDI treatment.22 Significantly, fidaxomicin displays narrow-spectrum antimicrobial
potency; the medication specifically inhibits C. difficile and does not kill the useful GI
microbiota.20, 29 The rate of CDI recurrence was 22.6% for vancomycin and 11.7% for
fidaxomicin.30 Therefore, fidaxomicin better reduces the recurrence rate of CDI, when
compared to vancomycin. The reason behind the lower rate of fidaxomicin recurrence is
thought to be due to it allowing the commensal GI microbiome to remain unblemished
while also inhibiting C. difficile.30 These two properties are believed to be responsible for
fidaxomicin's decreased rates of CDI recurrence.29 Fidaxomicin inhibits RNA polymerase
in bacteria where it binds to a site different from the rifamycin-type antibiotics.29 The
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significant cytotoxicity of fidaxomicin is not a major problem as its systemic absorption
is negligible.20 The medication shows the same level of tolerability as reference
medications (i.e. vancomycin and rifaximin).29 Fidaxomicin prevents harmful strains and
diminishes the spore loads of C. difficile better than vancomycin. Studies are in progress
to determine whether fidaxomicin can act as a prophylactic for CDI or as a post-antibiotic
‘chaser’ to inhibit antibiotic treatment-produced CDI.25

1.3.5 – Resistance of C. difficile to available medicines/drugs
C. difficile has shown lower vulnerability to the basic chemotherapeutics
(vancomycin, metronidazole and fidaxomicin), however resistance has not been spread
widely. For instance, C. difficile strains with lower susceptibility to metronidazole (MIC
> 32 μg/mL) have been archived recently.34 Furthermore, the Anaerobe Research Unit,
UK - found four isolates of C. difficile with lower susceptibility to metronidazole while
screening nearly 30 isolates.34 This lower susceptibility has clinical noteworthiness due to
oral administration of metronidazole (because of the high systemic absorption).20 The
lower susceptibility to metronidazole shown by C. difficile is not enduring as it is
frequently lost after freeze-thawing or passaging of the bacteria.20 The lower susceptibility
to vancomycin (MIC - 4 μg/mL) and fidaxomicin (MIC - 6 μg/mL) has additionally been
seen in C. difficile isolates.20 The spread of C. difficile resistance is a developing issue and
various new antibacterial agents are now being developed to battle against the C. difficile
microorganisms.
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1.4 – Development of CDI inhibitors
There are a few potential novel C. difficile inhibitors presently in different phases
of advancement. Some of these CDI inhibitors will be described briefly with respect their
potency, efficacy and clinical trials.

Nitazoxanide and derivatives
Nitazoxanide (Figure 1.6) is a nitrothiazolamide group compound that is utilized
to treat intestinal parasites i.e. Cryptosporidium and Giardia. The drug was authorized by
the FDA in 2004 and then eventually used for CDI treatment.25, 39

Figure 1.6 – Amixicile (left) and Nitazoxanide (right)

Nitazoxanide displayed antibacterial activities (MIC) in the range 0.3-1.0 µg/mL
against C. difficile.22 When the medication was first trialed against CDI, it was found to
be less active than metronidazole and was shown to be effective in cases where
metronidazole was not.39,

41

Further tolerability investigations of nitazoxanide

incorporated a correlation with vancomycin for a double-blind study and the outcomes
indicated that vancomycin and nitazoxanide were similarly dynamic against CDI. 41
Nitazoxanide disrupts cell wall biosynthesis by repressing the pyruvate:ferredoxin
oxidoreductase system.22, 25 Nitazoxanide restrains the thiamine pyrophosphate nutrient
co-factor of the pyruvate:ferredoxin oxidoreductase complex by competing with pyruvate
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yet does not influence the complete chemical system. The pyruvate:ferredoxin
oxidoreductase is a nonselective enzyme system for many beneficial microflorae in the
gut but is a semi-selective enzyme system for the C. difficile target. The beneficial
microflora makes use of pyruvate dehydrogenase enzyme system instead of utilizing the
pyruvate:ferredoxin oxidoreductase enzyme system. 40 Nitazoxanide accumulates in the
intestine before excretion due to its poor water solubility.40
Amixicile (Figure 1.6) is a hydrochloride salt structurally related to nitazoxanide.
It was discovered from a library of 250+ nitazoxanide derivatives and its hydrochloride
salt

nature

increased

water

solubility.

The

increased

solubility

helps

in

pyruvate:ferredoxin oxidoreductase inhibitory activity. Amixicile showed a superior
survival rate (56%) compared to nitazoxanide (22%) and vancomycin (15%) in an
optimized murine model of CDI studies. Amixicile and nitazoxanide have low CDI
recurrence rates whereas vancomycin and fidaxomicin exhibited CDI recurrence in mice
infected with CDI.40 These promising results have confirmed that these nitrothiazolide
derivatives are upcoming new CDI inhibitors and a few more investigations are required
to consider if these two compounds are safe and more effective in the treatment of CDI.

Ridinilazole
Ridinilazole (formerly called - SMT19969) (Figure 1.7) is a dimer of
benzimidazole with a pyridine linker that shows selectively antimicrobial potency against
C. difficile but is not effective on any other Gram-positive and Gram-negative pathogens
(including intestinal microflora). Ridinilazole exhibited antibacterial activities (MIC) in
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the range of 0.125 – 0.25 µg/mL against several strains of C. difficile.42, 43 The mechanism
of action "needs to be fully ascertained" but the studies have declared that ridinilazole is
involved in the inhibition of bacterial cell division – the medication is additionally known
to diminish toxins and loads of C. difficile spores.43

Figure 1.7 – Ridinilazole

Summit Pharmaceutical International has finished phase I clinical studies on
ridinilazole and the results show excellent tolerability, low systemic absorption and
specific focus on C. difficile without making collateral damage to the natural gut flora,
and accordingly a decrease in the CDI recurrence rate. Additionally, ridinilazole passed
supremacy criteria over vancomycin in multicentre phase II trials on CDI patients.43 In
preclinical studies, ridinilazole had established a strong bactericidal viability against all
strains of C. difficile tested and Summit Pharmaceutical International is presently trialing
this compound in phase III clinical trials.43

Surotomycin
Surotomycin (formerly known as CB-183,315; Figure 1.8) was discovered by
Cubist Pharmaceuticals and developed by Merck & Co (who acquired Cubist
Pharmaceuticals). This antibacterial agent is an orally administered, cyclic lipopeptide
and is derived via semi-synthesis of the natural product daptomycin.20 Surotomycin
showed antibacterial activity (MIC) of 0.5 µg/mL against C. difficile. The efficacy and
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safety studies of phase II clinical trials confirmed that surotomycin at two doses i.e. 125
mg/day or 250 mg/day was tolerable and at that dose the medication had a higher cure
rate than vancomycin.35

Figure 1.8 – Surotomycin

The CDI survival rate for surotomycin was (83.6%) better than that of vancomycin
(79%).36 Phase III clinical trials of this antibiotic were discontinued in 2017 due to its
non-superiority to current therapies.36

Cadazolid
Cadazolid (Figure 1.9) is a crossover anti-microbial agent of the oxazolidinone
class created by Actelion Pharmaceuticals. The structure of cadazolid is a hybrid of the
known oxazolidinone and fluoroquinolone antibiotics. Cadazolid displayed antibacterial
activities (MIC) in the range of 0.125 – 0.50 µg/mL against C. difficile isolates and
obstructs biosynthesis of the bacterial cell wall. Cadazolid also restrains sporulation and
toxin formation; moreover, cadazolid has low oral bioavailability and selectively shows
potency against C. difficile, however it is benevolent to intestinal microflora.44-45
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Figure 1.9 – Cadazolid

Cadazolid effectively finished phase I and II clinical trials with better efficacy and
similar tolerability to vancomycin. The results of Phase III clinical trials concluded with
mixed results but precise details were not disclosed.46

CRS3123
A novel diaryldiamine CRS3123 (previously REP3123; Figure 1.10) showed
antibacterial activity (MIC) of 1.0 µg/mL against 108 clinical isolates of C. difficile and
is presently under development with NIAID (National Institute for Allergy and Infectious
Diseases).22, 37 CRS3123 is a novel potent small molecule that inhibits methionyl-tRNA
synthetase in C. difficile and also inhibits the production of toxins and spores.37

Figure 1.10 – CRS3123

C. difficile infection treatment with CRS3123 in a hamster model, resulted a
significant improvement in survival rate when compared to vancomycin. Hamsters (62%75%) treated with CRS3123 were alive at day 35 but all vancomycin-treated hamsters
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were dead by day 17 (rate of dose 0.5 mg/kg and 5 mg/kg, respectively).22 The phase I
clinical trials of CRS3123 have been disclosed as overall well tolerated over a wide range
of doses. This safety profile supports further investigation of CRS3123 as a treatment for
CDI.38

1.5 – Development of binaphthylpeptide derivatives as an antibacterial agent
In our research laboratory, there has been a progressing research project focused
on the discovery of novel antibacterial compounds initially around a binaphthylpeptide
scaffold.47,

48-54

The key moieties that grant antimicrobial potency to this group of

compounds are displayed on the unique lead compound-1; AVX-13616 (Figure 1.11). The
basic characteristics of compound 1 includes a hydrophobic 1,1'-binaphthyl moiety, an
isopentyl group connected to one of the naphthyl rings and a peptide back-bone connected
to the other naphthyl ring. The peptide back-bone includes one to three amino acids
(compound 1 has three), importantly one of the amino acids should contain a cationic (i.e.
positively charged/basic) side chain for activity.

Figure 1.11 – Binaphthylpeptide compound (Lead compound 1).
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The amino acids arginine and lysine have been seen as an essential in providing
an antimicrobial potency to this class of derivatives. The hydrophobic terminus is
important for guaranteeing antimicrobial potency, despite the fact that bifurcation at this
end does not appear to be vital.47, 54 These binaphthylpeptide analogues for the most part
show a wide range of Gram-positive antibacterial potency, for example AVX-13616
displayed antibacterial activities (MIC) of 2.0 µg/mL against VRSA and 4.0 µg/mL
against VRE. Notably, AVX-13616 additionally showed antibacterial potency against S.
aureus and MRSA strains that were resistant to linezolid. This compound showed
decreased potency against Gram-negative microbes i.e. K. pneumoniae and E. coli with
minimum inhibitory concentration (MIC) of

>32.0 µg/mL and 16.0 µg/mL,

respectively.49 In 2010, compound-1 (AVX-13616) was licensed to Valevia
Pharmaceuticals and the organization planned to develop AVX-13616 as a medication in
the form of creams, foams, gels, lotions and ointments for wound related infections of
body surfaces such as skin and mucous membranes.55 In vitro studies showed that
resistance to the binaphthyl peptides grows gradually in contrast to vancomycin; for S.
aureus 18 passages were required to induce vancomycin resistance, while AVX-13616
required in excess of 50 passages for in vitro resistance to develop.49 Bacteria that
inevitably evolved decreased vulnerability to AVX-13616 did not show cross-resistance
to vancomycin.49 These results demonstrated that vancomycin and AVX-13616 do not
share the same mode of action. Generally, these peptide analogues are non-drug like as
they have greater number of heteroatoms and their mono and dicationic nature gives them
poor membrane permeability. Furthermore, recently synthesized analogues were not
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appropriate for in vivo investigations on C. difficile infected mice because of their poor
water solubilities; therefore, highlighting the need for more water-soluble derivatives.
Ongoing investigations showed that different 1,2,3-triazole analogues of
compound 1 showed antimicrobial potency (MIC) in the range of 2.0 – 8.0 µg/mL against
C. difficile.47, 53 Lead derivatives 2 and 3 were synthesized as peptidomimetic analogues
of compound 1 and these were found to show exceptional in vitro antimicrobial potency
against both hypervirulent C. difficile and S. aureus (Figure 1.12 and 1.13).54 In the in
vivo murine model studies on CDI mice, compounds 2 and 3 showed some encouraging
preliminary outcomes.47 The current project aims to develop a library of novel derivatives
around the lead compounds 2 and 3 for further SAR studies with endeavors being made
to improve antimicrobial potency and selectivity for C. difficile.56 Furthermore, it was
planned to make compounds with improved water solubilities to aid oral dosing of
compounds.

Figure 1.12 – Lead compound 2 with a table of antibacterial activities against S. aureus (ATCC
29213), MRSA (NCTC 10442), E. faecalis (ATCC 29212), S. pneumoniae (ATCC 49619), C. difficile
(ATCC 700057, C. difficile (RT027 – NSW132) and E. coli (ATCC25922).
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Figure 1.13 – Lead compound 3 with a table of antibacterial activities against S. aureus (ATCC 29213),
MRSA (NCTC 10442), E. faecalis (ATCC 29212), S. pneumoniae (ATCC 49619), C. difficile (ATCC
700057, C. difficile (RT027 – NSW132) and E. coli (ATCC25922).

1.6 – Concepts and synthetic strategies for designing target compounds
1.6.1 – Incorporation of a peptidomimetic bioisostere
A previous researcher47 in our group made analogues around compound 1 by
substitution of the amide moiety (Figure 1.14a – blue circle) with a peptidomimetic
bioisostere (i.e. 1,2,3-triazole ring; Figure 1.14c – blue segment). Previous investigations
have affirmed that a 1,2,3-triazole ring is a suitable bioisostere for a typical peptide moiety
as it shows a comparable planarity, dipole (Figure 1.14b and 1.14c) and spatial
arrangement of polar atoms.57-58 1,4-Disubstituted-1,2,3-triazoles also have the possibility
to donate and accept hydrogen bonds like normal amides.58 Furthermore, they are viewed
as more impervious to hydrolysis, oxidation and enzymatic cleavage than amides.
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Figure 1.14 – a) Portion of lead compound 1 with targeted amide group (blue dotted rectangle)
b) Amide moiety (blue) and corresponding dipole moment (red)
c) 1,2,3-Triazole moiety (blue) and corresponding dipole moment (red).

In our laboratory, previous research has involved the replacement of a terminal
amide (Figure 1.14a – blue circle) with a substituted 1,2,3-triazole moiety in the peptide
chain of AVX-13616. The triazole moieties were installed via ‘copper(I)-catalyzed
alkyne-azide cycloaddition’ (CuAAC) from the azide and alkyne precursors showed in
Scheme 1.1.57-59
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Scheme 1.1 – Previously synthesized triazole analogues showing their “click” chemistry precursors.

1.6.2 – Modification of the aromatic core
In this current project, it was planned to build upon these previous studies. A
hydrophobic binaphthyl core (F) (red circle in Scheme 1.2) or its biphenyl analogue (A)
(blue circle in Scheme 1.2) is mandatory for the antibacterial potency of AVX-13616 and
its analogues. The biphenyl core (A) structure will be replaced by the N-phenyl-1,2,325

triazoles (B-E) and the binaphthyl hydrophobic core (F) structure will be replaced by the
N-naphthyl-1,2,3-triazoles (G and H).

Scheme 1.2 – Aromatic core replacement showing the changes from biphenyl core
to phenyl-1,2,3-triazole cores and binaphthalene core to naphthalene-1,2,3-triazole
cores.

These modifications were expected to provide peptide derivatives with better water
solubilities than those previously synthesized due to the enhanced polarity of these 1,2,3triazole derivatives.
1.6.3 – Design and synthesis of derivatives
The different N-phenyltriazole and N-naphthyltriazole peptide structures will be
derivatized to provide the analogues 21 – 49 (Figure 1.15 – 1.16). These will be different
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from each other based on two key structural parameters i.e., the aromatic core (Section
1.6.2), and the number and type of amino acids present in the peptide back-bone. In
compounds 47 – 49, the peptide moiety will be attached to the triazole group rather than
the phenyl or naphthyl ring as in the other derivatives 21 – 46. All these analogues 21 –
49 will be synthesized to allow structure-activity relationship (SAR) comparisons
between specific analogues.
Past examination has demonstrated that monocationic derivatives can show
valuable antibacterial potency;47, 54 therefore, simple monocationic derivatives 21 – 34
will be targeted as well, because smaller and more synthetically accessible molecules are
always preferable. Each synthesized scaffold will be derivatized by variation of the
hydrophobic terminus (R) and Cu-catalysed ‘click reactions’ will be utilized for
installation of the terminal 1,2,3-triazole moieties.

Figure 1.15 – Proposed mono-cationic derivatives 21 - 34 with variable hydrophobic structural elements (R)
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Figure 1.16 – Proposed di-cationic derivatives 35 - 49 with variable hydrophobic structural elements (R)

1.6.4 – Synthesis of analogues via a modular approach
To synthesize multiple analogue variations from a relatively simple synthetic
route, a modular approach will be adopted. The different structural analogues 21 – 49 are
initially linked by peptide bonds via peptide coupling reactions, then terminal triazole ring
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formation via Cu-catalysed click reactions will allow formation of analogues from various
building blocks (Figure 1.17) that hold these key reactive functional groups: amine (NH2),
acid (COOH), azide (N3) and alkyne (C≡CH). The acid building block can be coupled to
primary amines through formation of the required amide bonds. Furthermore, alkyne
building blocks can be coupled with the requisite azide building blocks to construct the
necessary 1,2,3-triazole moieties.

Figure 1.17 – Precursor building blocks for the modular approach to synthesis of analogues:
the acid and amine moieties (blue) can be readily linked together via peptide coupling
methods while the azide and alkyne functionalities (red) can also join together via CuAAC
reactions.

Dual functionalization of the β-azidoamine 56 residue with both a group capable
of peptide coupling (i.e. an acid) and a group capable of CuAAC reaction (i.e. an alkyne)
allows ready access to monocationic analogues (Scheme 1.3).
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Scheme 1.3 – Modular approach to synthesis of analogues: acid and amine
functionalities (blue) are combined into an amide bond while the azide and alkyne
functionalities (red) are coupled together via 1,2,3-triazole moiety

Dual functionalization of the β-azidoamine 57 residue with both a group capable of peptide
coupling (i.e. an acid) and a group capable of CuAAC reaction (i.e. an alkyne) allows rapid
access to dicationic analogues (Scheme 1.4).

Scheme 1.4 – Modular approach to synthesis of analogues: acid and amine
functionalities (blue) are combined into an amide bond while the azide and alkyne
functionalities (red) are coupled together via 1,2,3-triazole moiety.
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1.6.5 – Proposed synthetic routes and challenges
The previously mentioned forerunner building blocks (Figure 1.17) will be
synthesized from known and new synthetic precursors. The previously mentioned
analogues (section 1.6.3) will be accomplished from peptide coupling and CuAAC
reactions followed by side-chain N-deprotection and HCl salting. This iterative
derivatization of the different scaffold types will facilitate the formation of a library of
novel antibacterial derivatives. Most importantly, the proposed synthesis will require
three protecting groups i.e. Boc (I), Pbf (J) and Fmoc (K) (Figure 1.18). These protecting
groups are utilized for the protection of nucleophilic nitrogen atoms.

Figure 1.18 – Nitrogen protecting group structures and abbreviations

Boc and Fmoc protecting groups can be utilized to protect primary amines as
carbamates and the Pbf protecting group can be utilized to protect guanidino residues via
formation of an arylsulfonimide. Boc protected lysine and Pbf protected arginine amino
acid sidechains can be utilized, and these two protecting groups can be deprotected
together in the last step of a reaction sequence which permits the side chains to be
unreactive throughout the entire synthetic process except for the last step. The Fmoc group
will be used in known synthetic strategies for building the unprotected β-azidoamine
precursors 56 and 57.60
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The designed synthetic routes (Schemes 1.5 – 1.10) will permit the divergent
synthesis of numerous scaffolds from straightforward precursors. This synthetic strategy
will allow various scaffold varieties to be prepared from the key precursor building blocks,
which can be derivatized to generate a number of potential antibacterial products.
Schemes 1.5 – 1.10 employ the same pairs of β-azidoamines (56 and 57) coupling
partners with the different acids 50 – 54. Scheme 1.11 illustrates the β-azidoamine 57
coupled to the acid 55 resulting in products 47 – 49 in which the peptide side chain is
attached to the triazole moiety.
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Scheme 1.5 – Potential synthetic pathway for analogues 21, 35 and 36
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Scheme 1.6 – Potential synthetic pathway for analogues 22 - 25 and 37
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Scheme 1.7 – Potential synthetic pathway for analogues 26 – 28 and 38 - 40
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Scheme 1.8 – Potential synthetic pathway for analogues 29 - 31 and 41 – 43
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Scheme 1.9 – Potential synthetic pathway for analogues 32 - 34 and 44 - 46
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Scheme 1.10 – Potential synthetic pathway for analogues 47 - 49
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1.7 – Project Aims
It is an important medical requirement to develop novel antibacterial compounds
to effectively treat CDI. Therefore, a joint research project (NHRMC Project; Grant No.
APP1124032) was established between the University of Wollongong (drug design and
synthesis), the University of Western Australia (microbiology) and Monash University
(pharmacology) to synthesize and develop potent CDI chemotherapeutics. The aims of
this project are:
•

To incorporate a more polar hydrophilic moiety (i.e. a 1,2,3-triazole moiety) into
the hydrophobic region of the lead binaphthylpeptides 2 and 3 to increase
gastrointestinal stability and solubility.

•

To modify the hydrophobic binaphthyl core of 2 and 3 by making N-phenyl1,2,3-triazole and N-naphthyl-1,2,3-triazole derivatives in an attempt to
increase compound solubility.

•

To synthesize both dicationic and monocationic peptidomimetics.

•

To design and establish a viable and scalable synthesis of several novel
triazole-containing scaffolds.

•

To ascertain the antimicrobial activity of the synthesized derivatives against
Gram-positive bacteria, Gram-negative bacteria and fungi via MIC assays.

•

To develop and utilize a comparative solubility assay for determining the
relative water solubilities of the synthesized compounds.

•

To ascertain the general toxicity of the synthesized compounds via cytotoxicity
assays.
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•

To ascertain an efficacy of one or more compounds as a CDI chemotherapeutic
via testing in an in vivo CDI mouse model.

•

To design and identify a novel hit compound that could be utilized in the
effective treatment of CDI.
and

•

To explore the structure-activity relationships of the synthesized compounds by
utilizing the obtained MIC data.

The knowledge gained from this project would contribute to our understanding of the
cationic phenyl and naphthyl peptide antibacterial class of compounds.
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2.0 – Synthesis: results and discussion
2.1 – Synthesis of precursor building blocks
This chapter describes the synthesis of the proposed targeted antibacterial
derivatives from commercially available precursors. The known compounds are noted
with literature references.
2.1.1 – Synthesis of the aromatic core structures
2.1.1.1 – Synthesis of the carboxylic acid 50
The synthesis and incorporation of a 1,4-disubstituted-1,2,3-triazole ring in drug
like molecules has become a widespread practice and the common ‘click reaction’ [i.e., a
Cu-catalysed azide-alkyne cycloaddition (CuAAC)] is the most reliable methodology for
the formation of these moieties.57–59 Therefore, the strategy for the formation of the key
intermediate 50 (Scheme 2.1) followed a two-step process of a ‘click reaction’ followed
by O-alkylation.

Scheme 2.1 – Synthesis of acid 50 from the alkyne 69 via Cu-catalysed [3 + 2]
cycloaddition reaction between alkyne 69 and benzyl azide, followed by O-alkylation of 70
with bromoacetic acid to obtain target acid 50.

The reaction of benzylazide with the alkyne 69 in the presence of Cu(II)/sodium
ascorbate in t-BuOH/H2O for 12 h at rt gave the triazole 70 in 80% yield after purification
by flash column chromatography. Analysis of the 1H NMR spectrum of the triazole 70
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revealed a characteristic singlet resonance for the triazole proton at δH 7.72. The molecular
structure of compound 70 was further verified by the presence of an ion peak at m/z
252.1136 in the HRMS (ESI) that was assigned to the protonated molecular ion ([M +
H]+) (calculated for C15H14N3O 252.1137).
The base-promoted O-alkylation of 70 with bromoacetic acid was achieved using
K2CO3 in dry THF at reflux (Scheme 2.1) and after acidification produced acid 50 in 80%
yield. This reaction sequence was also effective on a larger scale with an 88% yield of 50
obtained starting with 2.00 g of the precursor alkyne 69.
Analysis of the 1H NMR spectrum of acid 50 revealed a characteristic singlet
resonance at δH 8.46 for the triazole proton. The C-5 carbon of the triazole ring resonated
at δC 123.8 and was assigned from the gHSQC correlation of the triazole proton (δ H 8.46)
to this 13C NMR resonance (Figure 2.1).

Figure 2.1: gHSQC spectrum of compound 50 (400 MHz, CDCl3). The one bond correlation
between the triazole proton and C-5 is highlighted.
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Analysis of the gHMBC spectrum of 50 showed the resonance at δC 143.8
correlated to δH 8.46 and was assigned to the quaternary carbon of the triazole. Further
the resonance at δC 170.8 was assigned to the carbonyl carbon of the carboxylic acid group
as it correlated to the methylene protons (δH 4.70) of the carboxylic acid side chain (Figure
2.2).

Figure 2.2: gHMBC spectrum of compound 50 (400 MHz, CDCl3). The two-bond correlations
between the triazole proton and C-4, H-1'' and carbonyl carbon of COOH are highlighted.

The molecular structure of compound 50 was further verified by the presence of
the ion peak at m/z 332.1003 in the HRMS (ESI) that was assigned to the sodiated
molecular ion ([M + Na]+) (calculated for C17H15N3O3Na 332.1011).
Mechanism of the CuAAC reaction:
The CuAAC reaction mechanism (Scheme 2.2) starts with the addition of a Cu(I)
catalyst that can be added directly or prepared in situ from a Cu(II) salt by reduction using
excess equivalents of sodium ascorbate (a single electron transfer reagent).59 The sodium
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ascorbate avoids oxidation of the active Cu(I) catalytic species to the inactive Cu(II)
species.62-63 This allows the reaction to be performed in an open-air environment without
the requirement for an inert atmosphere.
The active catalytic species Cu(I) reacts with the Cu-π bonded alkyne to form the
copper acetylide A. The π-bound copper of the copper acetylide A coordinates with the
azide to form the azido copper acetylide B. Then first nitrogen of the azido copper
acetylide B coordinates with the π-bound copper to form a six-membered copper
metallacycle C. The 2nd copper atom acts as a stabilizing donor ligand and ring contraction
results in the triazolyl-copper derivative D that further undergoes protonolysis to deliver
the triazole product and closes the catalytic cycle.

Scheme 2.2 – Proposed catalytic cycle for the CuACC reaction: [Cu] represents a Cu(I) complex
that is coordinated to the requisite number of ancillary ligands. The mechanism allows for control
over the regioselectivity of the cycloaddition by restricting the relative orientation of the 1,4substituents.
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The regioselectivity for the 1,4-disubstituted-1,2,3-triazole product is controlled
by the binding orientation of the azide and alkyne components to the active Cu(I)
complex, which controls the orientation of the resultant [3 + 2]-cycloaddition.59, 62-63 This
orientation mechanism was confirmed by multiple CuAAC studies that included kinetic
analysis and DFT calculations.59, 62-65 Kinetic analysis confirmed that the reaction is 2 nd
order with respect to the concentration of Cu(I); this involves the prospective role of a dinuclear acetylide-bridged Cu(I) complex as an active species62-63 (Scheme 2.2). Notably,
the mild catalytic reaction conditions produced consistent, clean and high-yielding
reactions for the preparation of 1,4-disubstituted-1,2,3-triazoles.

2.1.1.2 – Synthesis of the carboxylic acids 51 and 53
The synthesis of acids 51 and 53 from their respective precursors 71 and 74 was
accomplished in three steps: (i) an O-alkylation, (ii) a one pot process of azidation and a
CuAAC reaction, and (iii) an ester hydrolysis of 73 and 76 using base which produced,
after acidification, the acids 51 and 53, respectively (Scheme 2.3).
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Scheme 2.3 – Synthesis of acid 51 and 53 from respective alcohol precursor 71 and 74 via
O-alkylation of alcohol 71 and 74 to give iodo ester 72 and 75, followed by a one pot
(azidation/click reaction) synthesis of 73 and 76, then ester hydrolysis of 73 and 76 to
furnish target acids 51 and 53.

The base-promoted O-alkylation reaction of 71 and 74 with ethyl bromoacetate
produced the ethers 72 and 75 in yields of 52% and 93%, respectively (Scheme 2.3). The
known ether 72 exhibited spectroscopic data that were in agreement with those values
reported previously.78 The intermediates 72 and 75 were then treated with 5-methyl-1hexyne in the presence of CuI/NaN3/Na.ascorbate and racemic trans-N,N'dimethylcyclohexane-1,2-diamine in DMSO and water (5:1) at 75 °C and gave esters 73
and 76 in yields of 87% and 25%, respectively. In this one-pot azidation and copper
catalyzed click reaction process, the diamine ligand assists in the azidation reaction by
acting as a ligand for copper(I) or (II). The copper(I) then catalyzes the subsequent
CuAAC reaction. Analysis of the 1H NMR spectra of esters 73 and 76 revealed
characteristic singlet resonances at δH 8.16 and 7.67, respectively, assigned to the
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corresponding 1,2,3-triazole protons. The molecular structures of compounds 73 and 76
were further confirmed by the presence of the ion peaks at m/z 318.1831 and m/z
368.1985, respectively, in the HRMS (ESI) assigned to the protonated molecular ions ([M
+ H]+) (calculated for C17H24N3O3 318.1818 and C21H26N3O3 368.1974, respectively).
The target acid 51 was realized in a yield of 62% from hydrolysis of the ester 73
with 7% KOH solution in ethanol. The 1H NMR spectrum of 51 showed the characteristic
resonance for the triazole proton at δH 8.20 (s, 1H). The C-5 carbon of the triazole ring
resonated at δC 123.5 and was assigned by analysis of the gHSQC spectrum which showed
a correlation of this resonance to the triazole proton (δH 8.20) (Figure 2.3).

Figure 2.3: gHSQC spectrum of compound 51 (400 MHz, CDCl3). The one bond correlation
between the triazole proton and C-5 is highlighted.

The gHMBC spectrum analysis revealed that the resonance at δC 147.6 correlated
to δH 8.20 and was assigned to the quaternary carbon (C-4) of the triazole.
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Figure 2.4: gHMBC spectrum of compound 51 (400 MHz, CDCl3). The two-bond correlations
between the triazole proton and C-4, H-1''' and carbonyl carbon of COOH are highlighted.

Further the resonance at δC 170.8 was assigned to the carbonyl carbon of
carboxylic acid group as it correlated to the methylene protons (δH 4.77) of the acid side
chain (Figure 2.4). The molecular structure of compound 51 was further established by
the presence of an ion peak at m/z 290.1513 in the HRMS (ESI) that was assigned to the
protonated molecular ion ([M + H]+) (calculated for C15H20N3O3 290.1505).
The desired carboxylic acid 53 was realized in a yield of 85% from the hydrolysis
of the ester 76 using 7% KOH solution in ethanol. The 1H NMR spectrum of 53 showed
the characteristic singlet resonance of triazole proton at δH 7.67 which was correlated in
the gHSQC spectrum to the resonance at δC 124.6 which was assigned to C-5 (Figure 2.5).
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Figure 2.5: gHSQC spectrum of compound 53 (400 MHz, CDCl3). The one bond correlation
between the triazole proton and C-5 is highlighted.

In the gHMBC spectrum, the resonance at δH 7.67 correlated to the resonance at
δC 148.0 for C-4 (Figure 2.6), while the resonance at δC 170.4 was assigned to the carbonyl
carbon of the carboxylic acid side chain as it correlated to the methylene protons that
resonated at δH 4.74 (Figure 2.6).
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Figure 2.6: gHMBC spectrum of compound 53 (400 MHz, CDCl3). The two-bond correlations
between the triazole proton and C-4, H-1''' and carbonyl carbon of COOH are highlighted.

The molecular structure of compound 53 was further verified by the presence of
an ion peak at m/z 340.1667 in the HRMS (ESI) that was assigned to the protonated
molecular ion ([M + H]+) (calculated for C19H22N3O3 340.1661).

2.1.1.3 – Synthesis of the carboxylic acid 52
The acid 52 which possesses a 1,5-triazole ring, was synthesized from the
aryliodide 72 in three steps (i) azidation, (ii) a ruthenium-catalysed click reaction by using
Cp*RuCl(PPh3)2 (this catalyst is known to result in the formation of a 1,5-triazole; the
opposite regioisomer to that form in the CuAAC reaction) 57–59 and (iii) an ester hydrolysis
(Scheme 2.4).
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Scheme 2.4 – Synthesis of acid 52 from the iodo ester 72 via an azidation of iodo ester 72,
then Ru-catalysed [3 + 2] cycloaddition of azide 77, followed by ester hydrolysis of 78 to
achieve the target acid 52.

The azide 77 was synthesized in 70% yield by azidation of 72 (1.00 g, 3.26 mmol)
in the presence of CuI/NaN3/ Na.ascorbate and racemic trans-N,N'-dimethylcyclohexane1,2-diamine in DMSO and water (5:1) at 80 °C (Scheme 2.4). Analysis of the 13C NMR
spectrum revealed the resonance at δC 129.1 was assigned to the azide substituted carbon
(C-N3) in 77, in contrast in the starting material 72 the analogous carbon (C-I) was
assigned to a more shielded resonance at δC 86.5. This change in chemical shift supported
the formation of the required azide 77 with additional evidence from the analysis of the
FTIR spectrum and the assignment of an azide stretch to the band at νmax 2116 cm-1. The
molecular structure of compound 77 was further confirmed by the presence of an ion peak
at m/z 244.0715 in the HRMS (ESI) that was assigned to the sodiated molecular ion ([M
+ Na]+) (calculated for C10H11N3O3Na 244.0698).
The azide 77 was treated with 5-methyl-1-hexyne in the presence of
Cp*RuCl(PPh3)247 catalyst in 1,4-dioxane at 70 °C to achieve the triazole ester 78 in 37%
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yield. Analysis of the 1H NMR spectrum of 78 showed the characteristic triazole
resonance as a singlet at δH 7.56. This chemical shift was significantly upfield of that in
its regioisomer 73 which resonated at δH 8.16, which is consistent with the deshielding
effect of the N-aryl substituent in 73. The molecular structure of ester 78 was further
verified by the presence of an ion peak at m/z 340.1638 in the HRMS (ESI) that was
assigned to the sodiated molecular ion ([M + Na]+) (calculated for C17H23N3O3Na
340.1637). The target acid 52 was synthesized in 78% yield from the base catalyzed
hydrolysis of the ester 78 (Scheme 2.3). The 1H NMR spectrum of 52 showed the
characteristic singlet resonance of the triazole proton at δH 7.56. The C-4 carbon of the
triazole ring resonated at δC 131.1 and was assigned by analysis of the gHSQC spectrum
which showed a correlation between this resonance and the triazole proton at δH 7.56
(Figure 2.7).

Figure 2.7: gHSQC spectrum of compound 52 (400 MHz, CDCl3). The one bond correlation
between the triazole proton and C-4 is highlighted.
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Analysis of the gHMBC spectrum of 52 displayed a resonance at δC 140.8 which
correlated to δH 7.56, this was assigned to the C-5 carbon of the triazole. Further, the
resonance at δC 170.0 was assigned to the carbonyl carbon of the carboxylic acid as it
correlated to the methylene protons (δH 4.57) of the carboxylic acid side chain (Figure
2.8).

Figure 2.8: gHMBC spectrum of compound 52 (400 MHz, CDCl3). The two-bond correlations
between the triazole proton and C-5, H-1''' and carbonyl carbon of COOH are highlighted.

The molecular structure of acid 52 was further verified by the presence of an ion
peak at m/z 312.1329 in the HRMS (ESI) that was assigned to the sodiated molecular ion
([M + Na]+) (calculated for C15H19N3O3Na 312.1324).
Mechanism for the Ru-catalysed cycloaddition reaction:
The Ru-catalysed click reaction requires the presence of a catalytic quantity of
Ru(I); this catalyst can be added directly to the reaction. Most importantly, this allows the
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reaction to be successfully conducted in non-dried solvents under an inert atmosphere.
The Ru-catalyzed azide−alkyne cycloaddition (RuAAC) is proposed to occur via
formation of the Ru-complex A, which undergoes an oxidative coupling process to give
the ruthenacycle B. In this step, first the new carbon−nitrogen bond is formed between
the more electron rich carbon of the alkyne and the terminal, electrophilic nitrogen of the
azide (Scheme 2.5).

Scheme 2.5: Mechanism of Ru-catalysed cycloaddition reaction

A reductive elimination process then forms a ruthenated-triazole intermediate
which upon hydrolysis gives the 1,5-disubstituted triazole product (Scheme 2.5). DFT
calculations support this mechanistic proposal and indicate that the reductive elimination
step is rate-determining.
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2.1.1.4 – Synthesis of the carboxylic acid 54
The synthesis of acid 54 from the precursor 79 was accomplished in multiple steps
involving (i) nitration, (ii) reduction, (iii) an azidation, (iv) Mg-promoted click reaction,
(v) demethylation, (vi) O-alkylation and (vii) an ester hydrolysis (Scheme 2.6).

Scheme 2.6 – Synthesis of acid 54 from 2-methoxynaphthalene 79 via nitration/reduction and azidation of
starting material 79, then Mg promoted [3 + 2] cycloaddition and demethylation of azide 82, followed by
O-alkylation and ester hydrolysis of 84 to achieve the target acid 54.

The nitro intermediate 80 was synthesized in 22% yield from 2methoxynaphthalene 79 by nitration using HNO3 in acetic anhydride at -20 °C (Scheme
2.6). Analysis of the 1H NMR spectrum of the nitro compound 80 displayed six proton
resonances in the aromatic region, whereas precursor 79 displayed seven aromatic proton
resonances. Importantly the singlet resonance of precursor 79 at δH 7.12 assigned to H-1
55

was absent in the 1H NMR spectrum of the nitro compound 80. The spectroscopic data
were found to be in agreement with those previously reported.80
Reduction of the nitro compound 80 was achieved by treatment with Fe in
EtOH/AcOH/H2O81 under sonication conditions at rt to achieve the amine 81 in 82% yield
(Scheme 2.6). Analysis of the 1H NMR spectrum of amine 81 revealed a broad singlet
resonance at δH 4.22 (2H) assigned to the -NH2 group. The spectroscopic data were found
to be in agreement with those previously reported.81
The azide 82 was isolated in 31% yield under Sandmeyer conditions from the
amine 81 in the presence of NaNO2/NaN3 in 3 N HCl at rt (Scheme 2.6). Analysis of the
1

H NMR spectrum of azide 82 showed the disappearance of the broad singlet resonance

at δH 4.22, which was assigned to the NH2 group of 81. Analysis of the 13C NMR spectrum
revealed a resonance at δC 122.4 assigned to the azide substituted carbon (C-N3) of 82,
whereas the analogous carbon (C-NH2) of 81 was assigned to a more shielded resonance
at δC 120.2. The molecular structure of azide 82 was further confirmed by the presence of
an ion peak at m/z 172.0789 in the HRMS (ESI) that was assigned to the protonated
molecular ion ([M + H – N2]+) (calculated for C11H10NO 172.0762).
Initially the azide 82 was treated with 5-methyl-1-hexyne in the presence of
Cp*RuCl(PPh3)2 in 1,4-dioxane at 70 °C for 12 h. This resulted in the formation of 1amino-2-methoxynaphthalene 81 in 16% yield, with none of the desired triazole product
83 formed. It was speculated that 0.2 equivalents of PPh3 from the ruthenium catalyst
resulted in the formation of the amine 81 via a Staudinger reaction on the azide group of
82 (Scheme 2.7).
56

Scheme 2.7– Attempted synthesis of the click product 83

Proposed mechanism for the formation of 81:
The proposed

reaction

mechanism proceeds

through

the

formation

of

an iminophos- phorane 82a via nucleophilic addition of the triphenylphosphine to the
terminal nitrogen atom of the azide and then exclusion of diatomic nitrogen to form 82b.
The intermediate 82b undergoes hydrolysis to produce the amine 81 and
triphenylphosphine oxide (Scheme 2.8).

Scheme 2.8 – Mechanism for formation of amine 81 from azide 82
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Following the failure of the Ru-catalyzed conditions to produce the 1,5-triazoles,
attention turned to the Mg-promoted click reaction conditions.92 Therefore, following
conditions reported by Sharpless92 the azide 82 was treated with chloromagnesium-5methyl-1-hexynilide (prepared in situ by treating 5-methyl-1-hexyne with EtMgCl) in dry
THF at 50 °C to produce the triazole 83 in 81% yield (Scheme 2.6). Analysis of the 1H
NMR spectrum of 83 showed the characteristic triazole singlet resonance at δH 7.71. The
molecular structure of triazole 83 was further established by the presence of the ion peak
at m/z 296.1750 in the HRMS (ESI) that was assigned to the protonated molecular ion
([M + H]+) (calculated for C18H22N3O 296.1763). For further spectroscopic evidence for
the formation of the 1,5-triazole regioisomer 83, please see discussion on page 123.
The O-demethylation of 83 was achieved by treatment with BBr3 in DCM
at -78 °C to realize the naphthol 84 in 82% yield (Scheme 2.6). The 1H NMR spectrum of
naphthol 84 displayed a broad singlet resonance at δH 10.31, which was assigned to the
OH group. The molecular structure of compound 84 was further verified by the presence
of an ion peak at m/z 282.1602 in the HRMS (ESI) that was assigned to the protonated
molecular ion ([M + H]+) (calculated for C17H20N3O 282.1606).
The base-promoted O-alkylation of 84 with ethyl bromoacetate produced ester 85
in 58% yield (Scheme 2.6). Subsequent hydrolysis of 85 using 7% KOH solution in
ethanol produced the target acid 54 in 85% yield (Scheme 2.6). Analysis of the 1H NMR
spectrum of 54 revealed the characteristic triazole proton resonance at δH 7.74 (s, 1H).
The C-4 carbon of the triazole ring resonated at δC 131.4 and was assigned from the
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gHSQC correlation of the triazole proton (δH 7.74) to the resonance at δC 131.4 (Figure
2.9).

Figure 2.9: gHSQC spectrum of compound 54 (400 MHz, CDCl3). The one bond correlation
between the triazole proton and C-4 is highlighted.

The gHMBC spectrum allowed the assignment of the resonance δC 141.4 to the
quaternary C-5 carbon of the triazole (Figure 2.10), while the resonance of the carbonyl
carbon of the carboxylic acid at δC 170.0 correlated to the methylene protons (δH 4.72) of
the acid side chain (Figure 2.10).
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Figure 2.10: gHMBC spectrum of compound 54 (400 MHz, CDCl3). The two-bond correlations
between the triazole proton and C-5, H-1''' and carbonyl carbon of COOH are highlighted.

The molecular structure of compound 54 was further confirmed by the presence
of an ion peak at m/z 340.1666 in the HRMS (ESI) that was assigned to the protonated
molecular ion ([M + H]+) (calculated for C19H22N3O3 340.1661).
Mechanism for the Mg-promoted cycloaddition reaction:
The accepted mechanism (Scheme 2.9) starts with the formation of
chloromagnesium acetylide by treatment of the alkyne with EtMgCl. Then nucleophilic
addition of the acetylide to the terminal nitrogen atom of the azide occurs, followed by
spontaneous five membered ring closure to the chloromagnesium-4-metallotriazole
species. Hydrolysis of this species then gives the 1,5-disubstituted triazole product, which
is regioisomeric with the product formed using the Cu-catalysed azide-alkyne
cycloaddition (CuAAC) reaction procedure.
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Scheme 2.9: Proposed mechanism of Mg-promoted cycloaddition reaction

2.1.1.5 – Synthesis of the carboxylic acid 55
The synthesis of acid 55 from precursor 86 was accomplished in multiple steps
involving (i) azidation, (ii) an O-alkylation, (iii) Mg-promoted click reaction, (iv) THP
deprotection, (v) an O-alkylation and (vi) an ester hydrolysis (Scheme 2.10).

Scheme 2.10 – Synthesis of acid 55 from 2-aminophenol 86 via an azidation, O-alkylation
and Mg promoted [3 + 2] cycloaddition of 86, then THP deprotection and O-alkylation of
89, followed by ester hydrolysis of 91 to furnish target acid 55.
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The azide 87 was isolated in 60% yield following a Sandmeyer reaction on 2aminophenol 86 in the presence of NaNO2/NaN3 in 3 N HCl at rt (Scheme 2.10). The
spectroscopic data of 87 were found to be in agreement with those previously reported.79
The base-promoted O-alkylation of azide 87 with 1-bromo-3-methylbutane was
achieved with K2CO3 in dry DMF at rt (Scheme 2.10) and produced the ether 88 in 84%
yield. The ether 88 was treated with the chloromagnesium acetylide formed from the
reaction of tetrahydro-2-(2-propynyloxy)-2H-pyran (1.1 eq) with EtMgCl in dry THF at
50 °C to achieve the triazole 89 in 55% yield (Scheme 2.10). The 1H NMR spectrum of
89 displayed the characteristic resonance of the triazole ring proton at δH 7.76 (s, 1H). The
molecular structure of compound 89 was further established by the presence of an ion
peak at m/z 368.1964 in the HRMS (ESI) that was assigned to the sodiated molecular ion
([M + Na]+) (calculated for C19H27N3O3Na 368.1950).
The THP deprotection of 89 was achieved using p-toluenesulfonic acid.
monohydrate in MeOH at rt to obtain the alcohol 90 in 80% yield (Scheme 2.10). Analysis
of the 1H NMR spectrum of 90 showed a characteristic broad singlet resonance at δH 3.95,
which was assigned to the hydroxy group of the newly formed alcohol 90. The molecular
structure of compound 90 was further verified by the presence of an ion peak at m/z
284.1393 in the HRMS that was assigned to the sodiated molecular ion ([M + Na] +)
(calculated for C14H19N3O2Na 284.1375).
The base-promoted an O-alkylation of 90 with ethyl bromoacetate produced ester
91 in 69% yield (Scheme 2.10). The desired carboxylic acid 55 was realized in 81% yield
by the base hydrolysis of 91 (Scheme 2.10). The 1H NMR spectrum of 55 showed the
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characteristic singlet resonance for the triazole proton at δH 7.88 which was correlated in
the gHSQC spectrum to the resonance at δC 132.7 which was assigned to C-4 (Figure
2.11).

Figure 2.11: gHSQC spectrum of compound 55 (400 MHz, CDCl3). The one bond correlation
between the triazole proton and C-4 is highlighted.

In the gHMBC spectrum, the resonance at δH 7.88 correlated to the resonance at
δC 135.7 which was assigned to the quaternary C-5 carbon (Figure 2.12), while the
resonance at δC 173.1 was assigned to the carbonyl carbon of the carboxylic acid as it
correlated to the methylene protons that resonated at δH 4.01 (Figure 2.12).
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Figure 2.12: gHMBC spectrum of compound 55 (400 MHz, CDCl3). The two-bond correlations
between the triazole proton and C-5, H-1''' and carbonyl carbon of COOH are highlighted.

The molecular structure of acid 55 was further confirmed by the presence of an
ion peak at m/z 320.1603 in the HRMS (ESI) that was assigned to the protonated
molecular ion ([M + H]+) (calculated for C16H22N3O4 320.1610).

2.1.2 – Synthesis of the N-protected β-azidoamines
2.1.2.1 – Synthesis of the N-protected β-azidoamine 56
The synthesis of β-azidoamine 56 from commercially available Fmoc-(D)Arg(Pbf)-OH 92 was achieved by carboxylic acid reduction, iodination and subsequent
azidation/N-deprotection (Scheme 2.11) as previously described.47
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Scheme 2.11 – Synthesis of the azide 56 from the arginine precursor 92 via reduction of the
carboxylic acid 92 to give alcohol 93, followed by iodination and then azidation/Ndeprotection to furnish target azide 56.

Reduction of the precursor acid 92 was achieved via the mixed anhydride formed
by the treatment of the acid 92 with isobutyl chloroformate and N-methylmorpholine
which upon NaBH4 reduction gave the alcohol 93 in 73% yield. The alcohol was iodinated
with I2/PPh3/imidazole in CH2Cl2; this step was followed by an azidation reaction at rt
and a N-Fmoc deprotection at 50 °C with NaN3 in DMF to give the target β-azidoamine
56 in 80% yield over the two steps (Scheme 2.11). Compound 56 exhibited spectroscopic
data that were in agreement with those reported previously. 47

Mechanism for the formation of 56:
The reaction mechanism starts with the formation of the iodo phosphonium salt
which reacts with the alcohol 93 to give the triphenyloxyphosphonium salt 93a.
The nucleophilic displacement of this intermediate 93a by an iodide anion produces the
iodide 93b (Scheme 2.12) and triphenylphosphine oxide. Further nucleophilic
displacement of the intermediate 93b by azide anion produces the corresponding azide
which at the higher temperature of 50 °C, undergoes deprotonation highly acidic methine
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proton (on the β-carbon) of the Fmoc group by azide to give the resonance stabilized 14π
– aromatic anion 93c. This stabilized anion 93c then triggers the departure
of CO2 and dibenzofulvene to produce the β-azidoamine 56 (Scheme 2.12).

Scheme 2.12 – Mechanism for the β-azido-amine 56 formation

2.1.2.2 – Synthesis of N-protected β-azidoamine 57
The synthesis of doubly N-protected β-azidoamine 57 was achieved via a peptide
coupling reaction of β-azidoamine 56 with commercially available Fmoc-L-Lys(Boc)-OH
94, followed by Fmoc-deprotection (Scheme 2.13) using piperidine.
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Scheme 2.13 – Synthesis of azide 57 from amine 56 via peptide coupling of amine 56 with
Fmoc-L-Lys(Boc)-OH 94 to give compound 95, followed by Fmoc deprotection of 95 to
furnish target azide 57

The peptide coupling of β-azidoamine 56 with Fmoc-L-Lys(Boc)-OH 94 in the
presence of HOBt/EDC.HCl and triethylamine in DCM at rt gave product 95 in 54% yield.
The intermediate 95 was then subjected to deprotection with piperidine in MeOH at rt to
give the target azide 57 in 71% yield. Furthermore, a traditional acid/base work-up
procedure was utilized to purify the β-azidoamine 57 product instead of flash
chromatography, which led to a substantially increased overall yield from the literature
value of 64 % to 71% and a significantly easier isolation procedure (Scheme 2.13).
Compound 57 exhibited spectroscopic data that were in agreement with those reported
previously.47

Mechanism of peptide coupling:
Amide bonds are typically constructed from the union of carboxylic acids and
amines. However, the unification of these two functional groups does not occur
spontaneously at ambient temperature with the necessary elimination of water only taking
place at high temperatures (e.g. >200 °C). The higher temperature conditions are typically
detrimental to the integrity of the highly functionalized acids and amines. For this reason,
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peptide coupling reagents such as HOBt (1-hydroxy-1H-benzotriazole) and EDCI [1ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride)] are necessary for amide
bond formation under mild reaction conditions. 70-71 Initially the EDCI activates the
carboxylic acid as an O-acylisourea intermediate by the reaction of the carboxylate anion
with EDCI. Then the O-acylisourea reacts with the precursor amine to produce the
required amide product (Scheme 2.14). A side reaction is also possible by the activated
O-acylisourea undertaking an intramolecular acyl transfer to provide an inactive Nacylurea by-product (Scheme 2.14 – red route),70-72 that consumes the acid without
producing the desired product amide.

Scheme 2.14 – Mechanism of EDCI/HOBt promoted amide coupling: both the
product pathway (blue) and the undesired side reaction (red) are displayed
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The nucleophilic additive HOBt is added to prevent this side reaction.70-72 The
active O-acylisourea reacts with HOBt to produce an HOBt ester (Scheme 2.14 – blue
route) that quickly undergoes aminolysis by reacting with the precursor amine to give the
desired product amide.70-71

2.2 – Synthesis of the N-protected azides 1 – 11
2.2.1 – Synthesis of the azides 58, 60 and 62
The target azides 58, 60 and 62 were achieved in 58 – 69% yield from the coupling
reaction of the acids 50 – 52 and the β-azidoamine 56 in the presence of HOBt/EDC.HCl
and triethylamine in DCM at rt for 16 h (Scheme – 2.15).

Scheme 2.15 – Synthesis of the azides 58, 60 and 62 from the acids 50 – 52 via peptide coupling
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The 1H NMR spectrum of the azide 58 displayed a broad singlet resonance at δH
7.51 for the CONH group and the resonance at δC 169.6 was assigned to the carbonyl
carbon of the new amide group based on the gHMBC correlation of this resonance with
that of the NH proton. The molecular structure of compound 58 was verified by the
presence of an ion peak at m/z 751.3108 in the HRMS (ESI) that was assigned to the
sodiated molecular ion ([M + Na]+) (calculated for C36H44N10O5SNa 751.3109). The other
azides 60 and 62 in Scheme 2.15, was also fully characterized by NMR and HRMS
analysis.

2.2.2 – Synthesis of the azides 59, 61 and 63
The azides 59, 61 and 63 were isolated in 49-78% yield from the coupling reaction
of the acids 50 – 52 with the β-azidoamine 57 (Scheme – 2.16).

Scheme 2.16 – Synthesis of the azides 59, 61 and 63 from the acids 50 – 52 via peptide coupling
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The structure of 59 was evident from the broad singlet resonance at δH 8.98 for the
α-CONH group and the resonance at δC 165.5 was assigned to the carbonyl carbon of the
new amide group based on the gHMBC correlation of this resonance with that of the NH
proton. The molecular structure of compound 59 was further confirmed by the presence
of an ion peak at m/z 979.4587 in the HRMS (ESI) that was assigned to the sodiated
molecular ion ([M + Na]+) (calculated for C47H64N12O8SNa 979.4583). The other azides
61 and 63 in Scheme 2.16, were also fully characterized by NMR and HRMS analysis.

2.2.3 – Synthesis of the azides 64 and 66
The required azides 64 and 66 were obtained in yields 66 and 67%, respectively
from the coupling reaction of the acid 53 and 54 with the β-azidoamine 56 (Scheme –
2.17).

Scheme 2.17 – Synthesis of the azides 64 and 66 from the acids 53 and 54 via peptide coupling
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In the 1H NMR spectrum of the azide 64 showed a broad singlet resonance at δH
6.66 which was assigned to the CONH group and the resonance at δC 167.5 was assigned
to the carbonyl carbon of the new amide group based on their gHMBC correlations. The
molecular structure of compound 64 was further established by the presence of an ion
peak at m/z 781.3620 in the HRMS (ESI) that was assigned to the sodiated molecular ion
([M + Na]+) (calculated for C38H50N10O5SNa 781.3584). The other azide 66 in Scheme
2.17, was also fully characterized by NMR and HRMS analysis.

2.2.4 – Synthesis of the azides 65 and 67
The coupling reaction of the acids 53 and 54 with the β-azidoamine 57 resulted in
yields 64 and 67%, respectively of the azides 65 and 67 (Scheme – 2.18).

Scheme 2.18 – Synthesis of the azides 65 and 67 from the acids 53 and 54 via peptide coupling
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The structure of 65 was evident from the broad singlet resonance at δH 6.85 for the
α-CONH group. The

C NMR spectrum showed a resonance at δC 168.1 which was

13

assigned to the carbonyl carbon of the new amide group. The molecular structure of
compound 65 was verified by the presence of an ion peak at m/z 987.5272 in the HRMS
(ESI) that was assigned to the protonated molecular ion ([M + H]+) (calculated for
C49H71N12O8S 987.5239). The other azide 67 in Scheme 2.18, was also fully characterized
by NMR and HRMS analysis

2.2.5 – Synthesis of the azide 68
The azide 68 was isolated in 70% yield from the coupling reaction of the acid 55
with the β-azidoamine 57 (Scheme – 2.19).

Scheme 2.19 – Synthesis of the azide 68 from the acid 55 via peptide coupling

The 1H NMR spectrum of 68 displayed a broad singlet resonance at δH 6.97 for the
α-CONH group. The 13C NMR spectrum showed a resonance of the new amide carbonyl
group at δC 169.1 was assigned based on their gHMBC correlations. The molecular
structure of compound 68 was verified by the presence of an ion peak at m/z 989.5029 in
the HRMS (ESI) that was assigned to the sodiated molecular ion ([M + Na] +) (calculated
for C46H70N12O9SNa 989.5007).
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2.3 – Synthesis of derivatives
2.3.1 – Synthesis of the monocationic derivatives
The derivatization of the monocationic amino acid derivatives 21 – 34 required a
two-step transformation – installation of the terminal triazole moieties by using the azides
58, 60, 62, 64, 66 and alkynes via a CuAAC reaction, followed by N-Pbf group cleavage
with CH2Cl2/H2O/TFA.

Synthesis of the derivative 21 from the azide 58:
The hydrochloride salt derivative of 21 was synthesized in 43% yield over the two
steps from the reaction of azide 58 with 3-cyclohexyl-1-propyne, CuSO4∙5H2O and
sodium ascorbate in t-BuOH/H2O at rt for 16 h (Scheme 2.20). The N-protected triazole
derivative so obtained was then subjected to N-Pbf deprotection with TFA and 20
equivalents of H2O in CH2Cl2 at rt for 16 h followed by the treatment of the resulting TFA
salt with ethereal HCl and purification by precipitation.

Scheme 2.20 – Derivatization of the azide 58 via installation of the terminal triazole moiety followed
by deprotection of the N-Pbf side chain protecting group to give derivative 21 as hydrochloride salt

The 1H NMR spectrum of derivative 21 displayed characteristic resonances that
were assigned to the terminal cyclohexylmethyl group (i.e., a multiplet resonance at δH
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2.36 – 2.24 (2H; CH2Cy) and cyclohexyl multiplet resonances at δH 1.84 – 1.40, δH 1.16
– 1.02 and δH 0.88 – 0.78). Importantly, the 1H NMR spectrum of 21 showed two singlet
resonances that were assigned to the two triazole ring protons at δH 8.59 (H5) and δH 7.98
(Hα). These proton resonances correlated to the carbon resonances at δ C 131.2 (C-5) and
δC 125.4 (C-α), respectively. The carbon resonances at δC 145.8 (C-4) and δC 131.3 (C-β)
were assigned to the quaternary carbons of the triazole rings based on the gHMBC
correlations of these carbon resonances to those of their triazole ring protons [δH 8.59 (H5)
and δH 7.98 (Hα)], respectively. The arginine peptide chain was confirmed from the
gHMBC correlations of H-1' proton (δH 4.74) with carbon resonances C-2' (δC 50.7), C-3'
(δC 29.9) and C-α (δC 125.4), respectively. The H-2' proton (δH 4.48-4.42) correlated with
carbon resonances C-1' (δC 56.2), C-3' (δC 29.9) and C-4' (δC 26.4). Furthermore, H-5'
proton (δH 3.22-3.12) correlated with carbon resonances C-3' (δC 29.9), C-4' (δC 26.4) and
guanidine C=N (δC 158.7). The successful N-Pbf deprotection was clearly seen by the lack
of five characteristic Pbf singlet methyl resonances in the 1H NMR spectrum of derivative
21. The molecular structure of the derivative 21 was further confirmed by the appearance
of the ion peak at m/z 599.3562 in the HRMS (ESI) that was assigned to the protonated
molecular ion [M – HCl + H]+ (calculated for C32H43N10O2 599.3565).

Synthesis of the derivatives 22 – 28 from the azides 60 and 62:
The derivatives 22 – 28 (Scheme 2.21) were realized in yields ranging from 53 –
57% over the two steps from the azides 60 and 62 by reaction with their respective alkynes,
CuSO4∙5H2O and sodium ascorbate in t-BuOH/H2O at rt for 16 h. The N-protected triazole
75

derivatives so obtained were then subjected to N-Pbf deprotection with TFA and 20
equivalents of H2O in CH2Cl2 at rt for 16 h followed by the treatment with ethereal HCl
and purification of the HCl salts by precipitation.

Scheme 2.21 – Derivatization of the azides 60 and 62 via installation of the terminal triazole moiety
followed by deprotection of the N-Pbf side chain protecting group to give derivatives 22 – 28 as
hydrochloride salts

The 1H NMR spectrum of the derivative 22 showed characteristic resonances
(11H) that were assigned to the cyclohexyl group at δH 1.86 – 1.50 (m, 6H) and δH 1.48 –
1.20 (m, 5H). Importantly, the gHSQC spectrum of 22 showed that the two singlet
resonances assigned to the two triazole ring protons at δH 8.46 (H5) and δH 8.36 (Hα) were
correlated to the carbon resonances at δC 125.9 (C-5) and δC 125.3 (C-α), respectively.
The 13C NMR spectrum showed the resonances at δC 147.9 (C-β) and δC 132.8 (C-4) were
assigned to the quaternary carbons of the triazoles based on the gHMBC correlations of
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these resonances to those of their triazole ring protons [δH 8.46 (H5) and δH 8.36 (Hα)],
respectively. The deprotection of N-Pbf was clearly seen by the lack of five characteristic
Pbf singlet methyl resonances in the 1H NMR spectrum of 22. The molecular structure of
the derivative 22 was established by the appearance of the ion peak at m/z 565.3731 in
HRMS (ESI) that was assigned to the protonated molecular ion [M – HCl + H]+
(calculated for C29H45N10O2 565.3727). The other derivatives 23 – 28 in Scheme 2.21,
were also fully characterized by NMR and HRMS analysis.

Synthesis of the derivatives 29 – 34 from the azides 64 and 66:
The derivatives 29 – 34 (Scheme 2.22) were prepared in yields ranging from 51 –
72% over the two steps from the azides 64 and 66 by reaction with their respective
alkynes, CuSO4∙5H2O and sodium ascorbate in t-BuOH/H2O at rt for 16 h. The Nprotected triazole derivatives so obtained were then subjected to N-Pbf deprotection with
TFA and 20 equivalents of H2O in CH2Cl2 at rt for 16 h followed by the treatment with
ethereal HCl and purification by precipitation.
The 1H NMR spectrum of the derivative 29 displayed characteristic resonances
(11H) for the cyclohexyl group, a singlet resonance at δH 2.72 (1H), and multiplet
resonances at δH 1.79 – 1.57 (5H) and δH 1.20 – 1.16 (5H). The gHSQC spectrum of 29
showed that the two singlet resonances assigned to the two triazole ring protons at δH 8.36
(H5) and δH 8.18 (Hα) were correlated to the carbon resonances at δC 125.7 (C-5) and δC
125.2 (C-α), respectively. The gHMBC spectrum allowed the assignment of the
quaternary carbons of the triazole rings at δC 149.3 (C-4) and δC 147.6 (C-β).
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Scheme 2.22 – Derivatization of the azides 64 and 66 via installation of the terminal triazole moiety
followed by deprotection of the N-Pbf side chain protecting group to give derivatives 29 – 34 as
hydrochloride salts

The molecular structure of the derivative 29 was further verified by the appearance
of the ion peak at m/z 615.3877 in HRMS (ESI) that was assigned to the protonated
molecular ion, [M – HCl + H]+ (calcd for C33H47N10O2 615.3886). The other derivatives
30 – 34 in Scheme 2.22, were also fully characterized by NMR and HRMS analysis.
The derivatives 32 – 34 displayed amide rotamers (i.e. anti and syn) which were
evident by the presence of smaller, additional resonances in their 1H and 13C NMR spectra.

Rotamers:
Single C–N bonds that are connected to an adjacent carbon–heteroatom double
bond (e.g. C=O or C=N) are well-known to display partial double bond characteristic due
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to the delocalization of the nitrogen’s lone pair of electrons; this leads to restricted rotation
of the C–N bond. If the energy barrier to rotation is high, two distinct rotameric
conformations will be generated (i.e. anti- and syn-rotamers – Figure 2.13), with the antirotamer generally being preferred in secondary amides due to steric considerations.61

Figure 2.13 – Generic anti- and syn-rotamers

2.3.2 – Synthesis of the dicationic derivatives
The derivatization of the dual-amino acid derivatives 35 – 49 required a two-step
transformation – installation of the terminal triazole moieties by using the azides 59, 61,
63, 65, 67, 68 and respective alkyne intermediates via a CuAAC reaction, followed by
side chain N-deprotection of the N-Pbf and N-Boc groups with CH2Cl2/H2O/TFA.

Synthesis of the derivatives 35 – 36 from the azide 59:
The derivatives 35 and 36 (Scheme 2.23) were realized in yields of 55% and 57%,
respectively over the two steps from the azide 59 by reaction with respective alkynes,
CuSO4∙5H2O and sodium ascorbate in t-BuOH/H2O at rt for 16 h. The N-protected triazole
derivatives so obtained were then subjected to N-Boc/N-Pbf deprotection with TFA and
20 equivalents of the H2O in CH2Cl2 at rt for 16 h followed by the treatment with ethereal
HCl and purification by precipitation (Scheme 2.23).
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Scheme 2.23 – Derivatization of the azide 59 via installation of the terminal triazole moiety followed by
deprotection of the N-Pbf and N-Boc side chains protecting groups to give derivatives 35 and 36 as
hydrochloride salts

The 1H NMR spectrum of the derivative 35 showed a resonance for the methylene
of the benzyl unit as a singlet resonance at δH 4.03 (2H) and a multiplet resonance for the
phenyl group at δH 7.50 – 7.14 (5H). The gHSQC spectrum of 35 showed that the two
triazole ring protons at δH 8.74 (H5) and δH 8.23 (Hγ) correlated to the carbon resonances
at δC 130.0 (C-5) and δC 128.1 (C-γ), respectively. The carbon resonances at δC 143.1 (C4) and δC 130.3 (C-δ) were assigned to the quaternary carbons of the triazoles based on
the gHMBC correlations of these resonances to those of their respective triazole ring
protons [δH 8.74 (H5) and δH 8.23 (Hγ)]. The arginine peptide chain was confirmed from
the gHMBC correlations of H-1' proton (δH 4.78) with carbon resonances C-2' (δC 50.9),
C-3' (δC 29.7) and C-γ (δC 126.4), respectively. The H-2' proton (δH 4.28-4.19) correlated
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with carbon resonances C-1' (δC 57.2), C-3' (δC 29.7) and C-4' (δC 26.4). Furthermore, the
H-5' proton (δH 2.92-2.84) correlated with carbon resonances C-3' (δC 29.7), C-4' (δC 26.4)
and guanidine C=N (δC 158.7).
The protons and carbons of the lysine peptide chain were assigned based on
analysis of the gHMBC spectrum which showed correlations of the Lys5 proton (δH 4.464.32) to carbon resonances Lys4 (δC 32.4), Lys3 (δC 24.3) and βC=O (δC 174.5).
Furthermore, the Lys3 proton (δH 0.94-0.86) correlated to carbon resonances Lys1 (δC
40.7), Lys2 (δC 28.1) and Lys4 (δC 32.4). The molecular structure of the derivative 35 was
further confirmed by the appearance of the ion peak at m/z 721.4046 in HRMS (ESI) that
was assigned to the protonated molecular ion, [M – 2HCl + H]+ (calculated for
C38H49N12O3 721.4045). The other derivative 36 in Scheme 2.23, was also fully
characterized by NMR and HRMS analysis.

Synthesis of the derivatives 37 – 40 from the azides 61 and 63:
The derivatives 37 – 40 (Scheme 2.24) were realized in yields ranging from 56 –
98% over the two steps from the azides 61 and 63 by reaction with respective alkynes,
CuSO4∙5H2O and sodium ascorbate in t-BuOH/H2O at rt for 16 h. The N-protected triazole
derivatives so obtained were then subjected to N-Boc/N-Pbf deprotection with TFA and
20 equivalents of the H2O in CH2Cl2 at rt for 16 h followed by the treatment with ethereal
HCl and purification of the HCl salts by precipitation.
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Scheme 2.24 – Derivatization of the azides 61 and 63 via installation of the terminal triazole moiety
followed by deprotection of the N-Pbf and N-Boc side chains protecting groups to give derivatives 37 – 40
as hydrochloride salts

The 1H NMR spectrum of the derivative 37 displayed characteristic resonances that
were assigned to the methylene protons of the benzyl unit i.e., a singlet resonance at δH
4.12 (2H) and the multiplet resonances of the phenyl at δH 7.32 – 7.20 (5H). The gHSQC
spectrum of 37 showed that the two singlet resonances assigned to the two triazole ring
protons at δH 8.54 (H5) and δH 8.12 (Hγ) were correlated to the carbon resonances at δC
126.2 (C-5) and δC 125.9 (C-γ), respectively. The gHMBC spectrum allowed the carbon
resonances at δC 137.5 (C-δ) and δC 133.5 (C-4) to be assigned to the quaternary carbons
of the triazoles. The molecular structure of the derivative 37 was verified by the
appearance of the ion peak at m/z 773.1240 in HRMS (ESI) that was assigned to the
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protonated molecular ion, [M + H]+ (calcd for C36H55N12O3Cl2 773.1236). The other
derivatives 38 – 40 in Scheme 2.24, were also fully characterized by NMR and HRMS
analysis.

Synthesis of the derivatives 41 – 46 from the azides 65 and 67:
The derivatives 41 – 46 (Scheme 2.25) were realized in yields ranging from 46 –
55% over the two steps from the azides 65 and 67 by reaction with respective alkynes,
CuSO4∙5H2O and sodium ascorbate in t-BuOH/H2O at rt for 16 h. The N-protected triazole
derivatives so obtained were then subjected to N-Boc/N-Pbf deprotection with TFA and
20 equivalents of the H2O in CH2Cl2 at rt for 16 h followed by the treatment with ethereal
HCl and purification by precipitation.
The 1H NMR spectrum of the derivative 41 showed characteristic resonances (11H)
that were assigned to the cyclohexyl group at δH 2.84 – 2.78 (m, 1H), δH 1.74 – 1.60 (m,
5H) and δH 1.48 – 1.21 (m, 5H). The gHSQC spectrum showed that the two singlet
resonances which were assigned to the two triazole ring protons at δH 8.30 (H5) and δH
8.29 (Hγ) correlated to the carbon resonances at δ C 125.5 (C-5) and δC 125.1 (C-γ),
respectively. The carbon resonances at δC 148.7 (C-4) and δC 147.6 (C-δ) were assigned
to the quaternary carbons of the triazoles based on their gHMBC correlations.
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Scheme 2.25 – Derivatization of the azides 65 and 67 via installation of the terminal triazole moiety
followed by deprotection of the N-Pbf and N-Boc side chains protecting groups to give derivatives 41 – 46
as hydrochloride salts

The molecular structure of the derivative 41 was further established by the
appearance of the ion peak at m/z 743.4866 in HRMS (ESI) that was assigned to the
protonated molecular ion, [M – 2HCl + H]+ (calcd for C39H59N12O3 743.4833). The other
derivatives 42 – 46 in Scheme 2.25, were also fully characterized by NMR and HRMS
analysis. The derivatives 44 – 46 also displayed amide rotamers (i.e. anti and syn) which
was evident by the presence of smaller, additional resonances in their 1H and 13C NMR
spectra.
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Synthesis of the derivatives 47 – 49 from the azide 68:
The derivatives 47 – 49 (Scheme 2.26) were realized in yields ranging from 51 –
83% over the two steps from the azide 68 by reaction with respective alkynes,
CuSO4∙5H2O and sodium ascorbate in t-BuOH/H2O at rt for 16 h. The N-protected triazole
derivatives so obtained were then subjected to N-Boc/N-Pbf deprotection with TFA and
20 equivalents of the H2O in CH2Cl2 at rt for 16 h followed by the treatment with ethereal
HCl and purification of HCl salts by precipitation.

Scheme 2.26 – Derivatization of the azide 68 via installation of the terminal triazole moiety followed by
deprotection of the N-Pbf and N-Boc side chains protecting groups to give derivatives 47 – 49 as
hydrochloride salts

The 1H NMR spectrum of 47 showed characteristic resonances (11H) for the
cyclohexyl group at δH 2.74 (s, 1H), δH 1.78 – 1.55 (m, 5H) and δH 1.54 – 1.37 (m, 5H).
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The 1H NMR spectrum of 47 showed two overlapping singlet resonances at δH 8.05 (H4
and Hγ) which were assigned to the two triazole ring protons from their correlations to
the carbon resonances at δC 128.4 and δC 120.61. The carbon resonances at δC 132.06 (C5) and 132.02 (C-δ) were assigned to the two quaternary carbons of the triazoles, however
they could not be individually assigned as they could not be distinguished in the HMBC
spectrum as both triazole protons had the same chemical shift (δH 8.05). The molecular
structure of the derivative 47 was confirmed by the appearance of the ion peak at m/z
723.4810 in HRMS (ESI) that was assigned to the protonated molecular ion, [M – 2HCl
+ H]+ (calcd for C36H59N12O4 723.4782). The other derivatives 48 and 49 in Scheme 2.26,
were also fully characterized by NMR and HRMS analysis.

Mechanism of N-Boc deprotection:
The N-Boc group is particularly sensitive to acids and often uses TFA as the
deprotection agent producing the required free amine and by-products i.e. 2-methyl-1propene and CO2 (Scheme 2.27).61 The acidic deprotection mechanism starts with
protonation of the carbonyl oxygen of carbamate followed by heterolytic cleavage of the
bond between O–C(CH3)3 to produce the carbamic acid and the stable t-butyl carbocation
(Scheme 2.27) that is converted into 2-methyl-1-propene after proton abstraction by
trifluoroacetate anion. Decomposition of the carbamic acid proceeds spontaneously via
protonation of carbamic acid nitrogen to give the free amine product which rapidly
rotonates with excess TFA and CO2 as volatile by product.61 The overall reaction time is
10 – 15 minutes.
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Scheme 2.27 – N-Boc deprotection with TFA to produce the required product amine (red)
and by-products (blue)

Mechanism of N-Pbf deprotection:
The deprotection of N-Pbf group in the presence of acid requires a longer reaction
time compared to N-Boc deprotection and an electrophile SO3 scavenger, in this case H2O
is needed to control the formation of unwanted products via reaction with SO3.68
The deprotection of N-Pbf (Scheme 2.28) starts with protonation of the guanidino
nitrogen followed by heterolytic cleavage of the N – S bond to produce the required
guanidine as the TFA salt and byproduct arylsulfonyl cation.66, 68-69 The arylsulfonyl
cation reacts with the trifluoroacetate anion to form an intermediate, followed by
protonation,

with

hydrolysis

initiating

decomposition

to

produce

2,2,4,6,7-

pentamethyldihydrobenzo[b]furan and SO3.68-69 The electrophile SO3 can reacts with the
deprotected guanidine residue and form a sulfamic acid compound, 67 therefore water as a
scavenger is required to stop the formation of sulfamic acid. The overall reaction times
were 12 – 16 h for complete deprotection of the N-Pbf protecting group.
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Acidic conditions were needed for the deprotection of both the N-Boc and N-Pbf
protecting groups to produce the crude TFA-amine salt after evaporation of the reaction
mixture solvent, followed by anion exchange with anhydrous HCl in diethyl ether to
obtain final derivatives as HCl salt for antibacterial screening. The final HCl salts needed
to be triturated in diethyl ether solvent repeatedly until the benzofuran by-product was
removed.

Scheme 2.28 – Deprotection of the N-Pbf group to produce product guanidine (red) and by-products
(pink).

In conclusion, a total of 29 novel antibacterial compounds were synthesized and
fully characterized. The synthesis of these derivatives involved the synthesis of 96
intermediate compounds (i.e. 87 novel intermediate compounds and 9 known compounds)
using key reactions such as the one pot process of azidation and Cu-catalyzed
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cycloaddition reaction, Ru-catalyzed cycloaddition reaction, Mg-promoted cycloaddition
reaction, Appel reaction, peptide coupling and deprotection with TFA.
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3.0 – Biological and pharmacological assays: results and discussion
3.1 – Background information
This chapter reports the results of the in vitro, in vivo and pharmacological assays
performed on the deprotected phenyltriazole and naphthalenetriazole peptide derivatives,
as their HCl-salts, which were described in Chapter 2. These compounds were screened
in three stages (Figure 3.1).

Figure 3.1 – Summary of the biological screening process used to ascertain antimicrobial activity

Primary antibacterial testing:
Primary antibacterial testing (in vitro MIC assays) against Gram-positive bacteria
including C. difficile (Figure 3.1) was performed with project collaborators at the
University of Western Australia.†
Secondary antibacterial testing:
Secondary antibacterial testing (in vitro MIC assays) against Gram-negative
bacteria including fungi (Figure 3.1) and a cytotoxicity assay was performed by COADD.#
_____________________________

†

Prof. Thomas V. Riley, Dr. Katherine A. Hammer and Dr. Dan Knight.
# Community for Open Antimicrobial Drug Discovery (www.co-add.org) – funded by the Wellcome Trust
(UK) and The University of Queensland.
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C. difficile screening:
Compounds that displayed significant MIC values in the primary and secondary
testing stages were moved to third round in vitro MIC testing against the hypervirulent C.
difficile strain (RT027 – M7404) with project collaborators at Monash University.§ The
compounds that performed best in vitro were then selected for testing in an in vivo murine
model of CDI to determine the efficacy and viability of the compound as a potential CDI
inhibitor (Figure 3.1).

3.2 – Bacterial species used for In vitro assays (MIC)
The MIC assays were performed against four Gram-positive, or four Gramnegative bacterial species and two fungal species.
Gram +ve Bacterial Species
Staphylococcus aureus
Clostridium difficile
Enterococcus faecalis
Streptococcus pneumoniae
Gram -ve Bacterial Species
Escherichia coli
Klebsiella pneumoniae
Acinetobacter baumannii
Pseudomonas aeruginosa

Primary
Secondary
C. difficile
Screening (UWA) Screening (CO-ADD) screening (Monash)
ATCC 29213
NCTC 10442 (MRSA) ATCC 43300 (MRSA)
ATCC 700057
M7404 (RT027)
NSW132 (RT027)
ATCC 29219
ATCC 49619
-

ATCC 25922
-

Fungal Species
Candida albicans
Cryptococcus neoformans

-

ATCC 25922
ATCC 700603 (MDR)
ATCC 19606
ATCC 27853

ATCC 90028
ATCC 208821

-

-

Table 3.1 – Bacterial and fungal species that were tested against in the various in vitro MIC assays

____________________________

§ Prof. Dena Lyras, Dr. Melanie Hutton, Dr. Amy King and Dr. Yogi Srikhanta
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The compounds were screened against these bacterial pathogens and fungi to
measure their broad-spectrum antimicrobial activity i.e. activity against five of the six
ESKAPE pathogens5 (i.e. Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.)
and their activity against C. difficile strains to find potential CDI inhibitors.

3.2.1 – General methodology for in vitro assays and cytotoxicity assays
In vitro assays: For primary antibacterial screening, multi-well micro-titer plates were
loaded with immunized and developed medium and different concentrations of the
compounds to be tested. Testing concentrations of the compounds ranged from 0.125
μg/mL to 128 μg/mL in DMSO were typically utilized. The plates were cultured, and the
resultant bacterial growth inhibition was determined.
For testing at CO-ADD, initially only one concentration i.e. 32 μg/mL of every
compound was analyzed to verify antimicrobial potency. Compounds that exhibited
potency at this concentration then progressed to a comprehensive MIC test. Colistin and
vancomycin were utilized as positive controls for both Gram-positive and Gram-negative
bacteria. Fluconazole was used as the positive control for fungi.

Cytotoxicity assays: The cytotoxicity of every compound was evaluated at CO-ADD
against human embryonic kidney cells (HEK-293 – ATCC CRL – 1573) by using
tamoxifen as a control. The cytotoxicity data is described as the concentration needed to
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inhibit kidney cell growth by 50% (CC50). The experimental procedures for the various
MIC tests and cytotoxicity test are discussed in Section 6.4.1.

3.2.2 – SAR trends (MIC assay results from UWA and Monash)
Twenty-nine compounds were prepared from 11 distinctive scaffolds. In the SAR
analysis, the antibacterial activity of the twenty-nine derivatives were compared against
the antibacterial activity of AVX 13616 (lead compound 1) and the previously synthesized
compounds 18 – 20 using vancomycin as the control.

93

_______________________________________________________________
E.
S.
E.
pentyl
S. aureus faecalis pneumoniae coli
C. difficile
Compound
R position ATCC NCTC ATCC
ATCC ATCC ATCC
132
29213 10442 29212
49619 25922 700057 (RT027)
__________________________________________________________________________
i

1

-

-

2

2

2

2

16

8

16

18

Cy

-

2

4

2

4

8

16

16

19

CH2Cy

-

4

4

4

8

8

32

16

20

Bn

-

2

4

4

2

8

16

16

41

Cy

C-4

16

16

32

16

64

8

8

42

CH2Cy

C-4

8

8

8

16

128

16

16

43

Bn

C-4

8

8

8

8

32

8

8

44

Cy

C-5

16

16

64

4

64

128

128

45

CH2Cy

C-5

8

4

16

4

64

32

32

46

Bn

C-5

16

16

64

4

128

128

128

-

1

1

4

1

>16

0.5

0.5

Vancomycin -

__________________________________________________________________________
Table 3.2 – Primary screening data for compounds 41 – 46 in μg/mL (MIC values). RT 700057 tested at
UWA and RT027 tested at Monash (The data for compounds 18 – 20 from references 47 and 53)

Compounds 41 – 46 were designed from compounds 18 – 20 by modifying the
binaphthyl moiety to a naphthyltriazole base structure with variations of the isopentyl
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substituent at the C-4 and C-5 positions of the triazole ring of the naphthyl-triazole moiety
(Table 3.2). Compound 18 (R = Cy) displayed antibacterial activities (MIC values) of 2
μg/mL and 4 μg/mL against the S. aureus strains, whereas the modified compounds 41 (R
= Cy) and 44 (R = Cy) displayed MIC values of 16 μg/mL against these strains.
Compounds 18 – 20 and 45 (R = CH2Cy) showed similar antibacterial activities (MIC) of
4 μg/mL against S. aureus (NCTC 10442). Compound 19 (R = CH2Cy) exhibited a MIC
value of 4 μg/mL against the S. aureus strains, whereas the modified compound 42 (R =
CH2Cy) displayed a MIC of 8 μg/mL against these strains. Apart from compound 45, all
other compounds (41 – 44 and 46) with an isopentyl substituent at the C-4 or C-5 position
showed little difference in activity against the S. aureus strains. In general, the modified
compounds were less active than compounds 18 – 20 (Table 3.2) against the S. aureus
strains.
Compounds 42 (R = CH2Cy) and 43 (R = Bn) exhibited MIC values of 8 μg/mL
against E. faecalis, whereas the other modified compounds 41 (R = Cy) and 44 – 46 (Table
3.2) had MIC values of 32 μg/mL and 64 μg/mL, respectively against E. faecalis.
Compound 20 (R = Bn) displayed the best antibacterial activity (MIC = 2 μg/mL)
against S. pneumoniae among the compounds 18 – 20 (Table 3.2), while the modified
compounds 44 – 46, having a C-5 substituent all showed similar and significant
antibacterial activity against this bacterium (MIC = 4 μg/mL).
Compounds 18 (R = Cy) and 20 (R = Bn) displayed MIC values of 16 μg/mL
against the two C. difficile strains, however the modified compounds 41 (R = Cy) and 43
(R = Bn) showed slightly better MIC values of 8 μg/mL against these strains (Table 3.2).
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_______________________________________________________________
E.
S.
E.
S. aureus faecalis pneumoniae coli
C. difficile
Compound
R position ATCC NCTC ATCC
ATCC ATCC ATCC
132
29213 10442 29212
49619 25922 700057 (RT027)
__________________________________________________________________________
ipentyl

1

-

-

2

2

2

2

16

8

16

10

Cy

-

2

2

4

8

>128

16

32

11

CH2Cy

-

4

4

4

8

>128

32

32

12

Bn

-

2

2

4

16

128

32

32

29

Cy

C-4

8

8

16

16

128

128

>128

30

CH2Cy

C-4

4

4

8

8

32

32

32

31

Bn

C-4

4

4

4

4

64

32

32

32

Cy

C-5

8

8

8

8

32

32

32

33

CH2Cy

C-5

4

4

8

8

16

32

64

34

Bn

C-5

8

8

16

4

64

64

>128

-

1

1

4

1

>16

0.5

0.5

Vancomycin -

__________________________________________________________________________
Table 3.3 – Primary screening data for compounds 29 – 34 in μg/mL (MIC values). RT 700057 tested at
UWA and RT027 tested at Monash (The data for compounds 10 – 12 from references 47 and 53)

Compounds 29 – 34 were designed from the monocationic compounds 10 – 12 by
modifying the binaphthyl moiety to a naphthyltriazole base structure with variations of
the isopentyl substituent at the C-4 and C-5 position of the triazole ring of the
naphthyltriazole moiety (Table 3.3). Compound 10 (R = Cy) displayed antibacterial
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activity (MIC) of 2 μg/mL against S. aureus strains, whereas the modified compounds 29
(R = Cy) and 32 (R = Cy) had MIC values of 8 μg/mL against the S. aureus strains.
Compounds 11 (R = CH2Cy), 30 (R = CH2Cy) and 33 (R = CH2Cy) showed similar
antibacterial activities against the S. aureus strains (MIC = 4 μg/mL). Compound 12 (R =
Bn) exhibited antibacterial activity (MIC) of 2 μg/mL against both S. aureus strains,
whereas the modified compounds 31 (R = Bn) and 34 (R = Bn) had MIC values of 4
μg/mL and 8 μg/mL, respectively against these strains.
Compounds 10 – 12 exhibited MIC values of 4 μg/mL against E. faecalis, whereas
the modified compound 31 (R = Bn) displayed similar antibacterial activity with the others
being less active.
Compounds 10 – 11 and 30, 32 – 33 showed similar antibacterial activities against
S. pneumoniae (MIC = 8 μg/mL). While compounds 31 (R = Bn) and 34 (R = Bn)
displayed better antibacterial activities (MIC = 4 μg/mL) against S. pneumoniae and
compounds 12 (R = Bn) and 29 (R = Cy) showed the poorest activities (MIC = 16 μg/mL).
None of the compounds in Table 3.3 were particularly active against E. coli (MIC
= 16 – >128 μg/mL), while compound 33 (R = CH2Cy) showing the best activity (MIC =
16 μg/mL). None of the compounds in Table 3.3 showed significant activities against the
two C. difficile strains (MIC = 32 – >128 μg/mL).
A comparison of Tables 3.2 and 3.3 indicated that, in general the monocationic
compounds in Table 3.3 had better activities against S. aureus than the dicationic
compounds in Table 3.2. The C-4 substituted dicationic compounds 41 and 43 were the
most active against the C. difficile strains of the compounds from these two Tables.
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_______________________________________________________________
E.
S.
E.
S. aureus faecalis pneumoniae coli
C. difficile
Compound
R position ATCC NCTC ATCC
ATCC ATCC ATCC
132
29213 10442 29212
49619 25922 700057 (RT027)
__________________________________________________________________________
ipentyl

1

-

-

2

2

2

2

16

8

16

6

Cy

-

4

4

4

4

32

8

8

7

CH2Cy

-

4

4

4

4

32

8

8

8

Bn

-

4

8

8

4

32

32

16

21

CH2Cy

-

64

64

64

32

>128

64

64

22

Cy

C-4

32

32

32

16

128

32

64

23

Cp

C-4

32

32

32

16

128

32

64

24

4-F-Ph

C-4

32

32

32

16

128

32

64

25

Bn

C-4

32

32

32

16

128

32

64

26

Cy

C-5

32

32

32

32

>128

128

128

27

CH2Cy

C-5

16

16

16

16

128

64

64

28

Bn

C-5

32

32

32

32

>128

32

32

-

1

1

4

1

>16

0.5

0.5

Vancomycin -

__________________________________________________________________________
Table 3.4 – Primary screening data for compounds 21 – 28 in μg/mL (MIC values). RT 700057 tested at
UWA and RT027 tested at Monash (The data for compounds 6 – 8 from reference 89)
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The monocationic compounds 21 – 28 were designed from compounds 6 – 8 by
modifying the biphenyl to a phenyl-triazole base structure with one derivative having a
N-benzyl substituent rather than an isopentyl substituent on the triazole ring (Table 3.4).
This modification led to a decrease in the antibacterial activities from 4 – 32 μg/mL to 16
– >128 μg/mL against both Gram-positive and Gram-negative bacteria.

Primary screening data for 35-40 and 47-49
The dicationic compounds 35 – 40 were designed from compounds 14 – 16 by
modifying the biphenyl group to a phenyl-triazole base structure with 35 and 36 having a
N-benzyl substituent on the triazole ring, while compounds 37 – 40 had an isopentyl
substituent at the C-4 and C-5 positions of the triazole ring of the phenyl-triazole moiety.
These modifications led to a decrease in the antibacterial activity from 2 – 32 μg/mL to 8
– >128 μg/mL against both Gram-positive and Gram-negative bacteria (Table 3.5).
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_______________________________________________________________
E.
S.
E.
pentyl
S. aureus faecalis pneumoniae coli
C. difficile
Compound
R position ATCC NCTC ATCC
ATCC ATCC ATCC
132
29213 10442 29212
49619 25922 700057 (RT027)
__________________________________________________________________________
i

1

-

-

2

2

2

2

16

8

16

14

Cy

-

8

8

8

2

16

8

16

15

CH2Cy

-

4

4

4

2

16

8

16

16

Bn

-

8

8

8

4

32

32

16

35

Bn

-

32

32

64

16

128

128

128

36

CH2Cy

-

32

32

64

16

128

128

128

37

Bn

C-4

32

32

64

16

128

128

128

38

Cy

C-5

16

32

16

8

64

64

64

39

CH2Cy

C-5

128

128

>128

128

>128

128

>128

40

Bn

C-5

32

64

32

16

128

64

32

-

1

1

4

1

>16

0.5

0.5

Vancomycin -

_________________________________________________________________________
Table 3.5 – Primary screening data for compounds 35 – 40 in μg/mL (MIC values). RT 700057 tested at
UWA and RT027 tested at Monash (The data for compounds 14 – 16 from reference 89).
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The dicationic compounds 47 – 49 were designed from compounds 38 – 40 by
switching the position of the phenyl and triazole rings. These modifications did not
increase the antibacterial activity against the two Gram-positive C. difficile strains (Table
3.6). The testing of compounds 47 – 49 is in progress.

_______________________________________________________________
E.
S.
E.
S. aureus faecalis pneumoniae coli
C. difficile
Compound
R position ATCC NCTC ATCC
ATCC ATCC ATCC
132
29213 10442 29212
49619 25922 700057 (RT027)
__________________________________________________________________________
ipentyl

1

-

-

2

2

2

2

16

8

16

38

Cy

C-5

16

32

16

8

64

64

64

39

CH2Cy

C-5

128

128

>128

128

>128

128

>128

40

Bn

C-5

32

64

32

16

128

64

32

47

Cy

C-5

-

-

-

-

-

-

>40

48

CH2Cy

C-5

-

-

-

-

-

-

>40

49

Bn

C-5

-

-

-

-

-

-

>40

-

1

1

4

1

>16

0.5

0.5

Vancomycin -

__________________________________________________________________________
Table 3.6 – Primary screening data for compounds 47 – 49 in μg/mL (MIC values). RT 700057 tested at
UWA and RT027 tested at Monash.
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Overall SAR trend:
The dicationic binaphthyl derivatives 18 – 20 showed MIC values in the range 2
– 8 μg/mL against all Gram-positive and Gram-negative bacteria tested, except for C.
difficile (MIC = 16 – 32 μg/mL), while the modified derivatives 41 – 46 displayed MIC
values in the range of 4 – 16 μg/mL against all Gram-positive bacteria, including C.
difficile (Table 3.2). Similarly, the monocationic binaphthyl derivatives 10 – 12 exhibited
MIC values in the range of 2 – 8 μg/mL against all Gram-positive bacteria (except C.
difficile), whereas the modified derivatives 29 – 34 exhibited MIC values in the range of
4 – 8 μg/mL (Table 3.3). The dicationic derivatives 41 and 43 both exhibited MIC values
of 8 μg/mL against the C. difficile but none of the monocationic derivatives were as active.
The above results suggest that most of the modified naphthyl dicationic derivatives
41 – 46 (Table 3.2) were less active (MIC = 8 – 64 μg/mL) against Gram positive bacteria
(except C. difficile), whereas modified naphthyl monocationic derivatives 29 – 34 (Table
3.3) were more active (MIC = 4 – 8 μg/mL) against Gram positive bacteria (except C.
difficile). Furthermore, the modified naphthyl dicationic derivatives 41 and 43 (Table 3.2)
were more active (MIC = 8 μg/mL) against Gram positive C. difficile strains, whereas the
modified naphthyl monocationic derivatives 29 – 34 (Table 3.3) were not active (MIC =
32 – >128 μg/mL) against these C. difficile strains. These results promoted compound 41
to be chosen for in vivo studies in a murine model against CDI.
Furthermore, the dicationic biphenyl derivatives 14 – 16 had MIC values in the
range of 2 – 8 μg/mL against all Gram-positive bacteria, whereas the modified derivatives
35 – 40 and 47 – 49 exhibited MIC values in the range of 8 – 32 μg/mL (Tables 3.5 and
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3.6). Similarly, the monocationic biphenyl derivatives 6 – 8 exhibited antibacterial
activity (MIC) in the range of 4 – 8 μg/mL against all Gram-positive bacteria but the
modified derivatives 21 – 28 exhibited MIC values in the range of 32 – 64 μg/mL (Table
3.4). These results suggested that changing a phenyl ring of the biphenyl moiety with a
triazole ring often led to a decrease in the antibacterial activity.
The potency of naphthalene dicationic derivative 41 against the C. difficile (MIC
= 8 μg/mL; Table 3.2) was particularly better than the potency of the related naphthalene
monocationic derivative 29 (MIC = 32 μg/mL; Table 3.3).
The compounds 41 – 43 displayed antimicrobial activity against the Gram-positive
bacteria in the range of 8 – 16 μg/mL but were not active against E. coli (Table – 3.2).
Additionally, two compounds (41 and 43) were recognized as potential CDI inhibitors
due to their in vitro activities against the C. difficile strains (MIC = 8 μg/mL) and their
good water solubility profiles (see section 3.2.6 and Table – 3.9).
Out of the 29 compounds tested, only 12 derivatives from the mono- and dicationic derivatives of 1,4-disubstituted-naphthyl-1,2,3-triazoles 29 – 31 and 41 – 43 and
1,5-disubstituted-naphthyl-1,2,3-triazoles 32 – 34 and 44 – 46 exhibited MIC values in
range of 4 – 16 μg/mL against S. aureus in secondary screening. None of the compounds
exhibited antibacterial activity against Gram-negative bacteria but surprisingly a few
compounds, 29 – 30, 33 and 43 – 45, exhibited weak antifungal activity (MIC = 8 – 32
μg/mL) against C. albicans and C. neoformans (Tables 3.7). The compounds 41 and 42
showing MIC values of 4 μg/mL against C. neoformans (Tables 3.7).
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Secondary Screening Data
________________________________________________________
Compound

S.
aur.

P.
aer.

K.
pneu.

A.
bau.

E.
coli

C.
alb.

C.
neo.

CC50

________________________________________________________
21

16

>32

>32

>32

>32

>32

32

>32

22

32

>32

>32

>32

>32

>32

>32

>32

23

32

>32

>32

>32

>32

>32

>32

>32

24

32

>32

>32

>32

>32

>32

>32

>32

25

32

>32

>32

>32

>32

>32

>32

>32

26

32

>32

>32

>32

>32

>32

>32

>32

27

16

>32

>32

>32

>32

>32

>32

>32

28

32

>32

>32

>32

>32

>32

>32

>32

29

8

>32

>32

>32

32

32

16

32

30

4

>32

>32

>32

32

16

8

32

31

8

>32

>32

>32

32

32

16

32

32

8

32

>32

32

32

32

>32

21.9

33

4

>32

>32

32

32

16

8

>32

34

16

>32

>32

>32

>32

32

>32

23.5

35

16

>32

>32

>32

>32

32

>32

>32

36

32

>32

>32

>32

>32

32

>32

>32

37

16

>32

>32

>32

32

16

32

>32

38

16

>32

>32

>32

>32

16

16

>32

39

32

>32

>32

>32

>32

>32

16

32

40

32

>32

>32

>32

>32

16

16

>32

41

8

32

>32

32

32

>32

4

32

42

4

16

32

32

32

32

4

16

43

8

32

>32

32

32

>32

8

32

__________________________________________________________________
Table 3.7 – Secondary antimicrobial screening data in μg/mL (MIC and CC50 values).
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Secondary Screening Data
________________________________________________________
Compound

S.
aur.

P.
aer.

K.
pneu.

A.
bau.

E.
C.
C.
coli__ alb.__ neo.

CC50

________________________________________________________
44

8

32

>32

32

32

>32

8

>32

45

8

32

>32

32

32

32

8

>32

46

16

32

>32

>32

32

>32

>32

>32

_________________________________________________________________
Table 3.7 (Continued) – Secondary antimicrobial screening data in μg/mL (MIC and CC50 values).

Most of the compounds were tested for partial cytotoxicity by using the same
concentration (32 μg/mL) that was utilized for the initial MIC testing at CO-ADD.
Compounds are usually analyzed for cytotoxicity at significantly higher concentrations.
This low-concentration analysis allows the calculation of CC50 data (i.e. the concentration
of drug which is cytotoxic to 50% of cells) via curve-fitting and extrapolation of the lowconcentration cytotoxicity data. Some of the potent derivatives were unable to display
significant cytotoxicity at low concentrations and hence curve fitting was impossible; a
CC50 value could not be inferred from the data. These compounds have recorded a CC50
value > 32 μg/mL as they are unable to display significant cytotoxicity at the verified
concentrations. Cytotoxicity tests were achieved in replicate and the lower CC 50 data is
reported in Table 3.7.
Most of the compounds showed little cytotoxicity with 32, 34 and 42 exhibiting
cytotoxicity (CC50) at 21.9 μg/mL, 23.5 μg/mL and 16 μg/mL, respectively (Table 3.7).
The di-cationic compounds 35 – 41 and 43 – 46 displayed little cytotoxicity (CC50 >32
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μg/mL); but compound 42 showed significant cytotoxicity (CC50 – 16 μg/mL). Notably,
the lead compound 41 (MIC – 8 μg/mL against C. difficile) displayed moderate
cytotoxicity (CC50 = 32 μg/mL).
(CO-ADD) Secondary Screening - Control Data:
In the CO-ADD screening, vancomycin and colistin were used as positive controls
for the Gram-positive and Gram-negative bacteria, respectively (Table 3.8). Fluconazole
was used as a positive control for C. albicans and C. neoformans (Table 3.8). Tamoxifen
was used as a positive control for cytotoxicity assay (Table 3.8). The antibiotics were
provided in 4 concentrations, with 2 above and 2 below its MIC value, and plated into the
first 8 wells of column 23 of the 384 – well NBS plates.
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Secondary Screening - Control Data
_________________________________________________________________________________________________________________________________

Compound

S.
aureus
ATCC
43000
(MRSA)

P.
aeruginosa
ATCC
27853

K.
pneumoniae
ATCC
700603

A.
baumannii
ATCC
19606

E.
coli
ATCC
25922

C.
albicans
ATCC
90028

C.
Cytotoxicity
neoformans (CC50)
ATCC
(HEK-293)
208821
ATCC
CRL-1573

_________________________________________________________________________________________________________________________________

Vancomycin

1

>32

>32

>32

>32

-

-

-

Colistin

>32

0.25

0.25

0.25

0.125

-

-

-

Fluconazole

-

-

-

-

-

0.125

0.25

-

Tamoxifen

-

-

-

-

-

-

-

13.06

_________________________________________________________________________________________________________________________________
Table 3.8 – MIC or CC50 values for the various control inhibitors utilized in the secondary antimicrobial screening – reported in μg/mL.
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3.2.3 –Overview of MIC assay results and lead compound identification
The newly synthesized compounds displayed antimicrobial activities in a range from
active (MIC = 4 μg/mL) to inactive (MIC = >128 μg/mL) (Table 3.2 – 3.6 and 3.8). Many of
the compounds showed an antibacterial activity against the Gram-positive bacteria rather
than the Gram-negative bacteria; compounds generally being 2 – 4 times more potent against
the Gram-positive strains. For example, compound 30 displayed an MIC value of 4 μg/mL
against S. aureus but against E. coli the MIC value was 32 μg/mL (Table 3.3). Additionally,
all the Gram-positive strains, including C. difficile, was less susceptible to the assessed
compounds especially the hypervirulent C. difficile strain (RT027) (Tables 3.2 – 3.6). The
additional membrane of Gram-negative bacteria is identified as an interruption for drug
absorption.13 MIC values in the range of 4 – 32 μg/mL were observed against the Grampositive bacteria (Tables 3.2 – 3.6), whereas against the Gram-negative bacteria the MIC
values are in the range of 32 – >128 μg/mL (Tables 3.2 – 3.6).

Lead compounds:
Compounds 41 – 43 exhibited the best antibacterial activities against both strains of
C. difficile from the 29 derivatives tested in the primary and secondary screening.
Compounds 41 – 43 also exhibited antimicrobial activity (MIC = 4 – 32 μg/mL) against
Gram-positive bacteria. Compound 42 exhibited some activity (MIC = 16 μg/mL) against
Gram-negative P. aeruginosa. Compounds 41 – 43 (Figure 3.2) exhibited antibacterial
activities of 8 – 16 μg/mL against C. difficile in the primary screening. Compounds 41 and
43 showed low cytotoxicity (CC50 = 32 μg/mL and 32 μg/mL), however compound 42
exhibited some cytotoxicity (CC50 = 16 μg/mL) (Figure – 3.2). These studies concluded that
either compounds 41 or 43 should be further tested in an in vivo murine model of CDI.
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Figure 3.2 – MIC and CC50 values (μg/mL) for lead compounds 41 – 43.
(See Table 3.1 for the specific bacterial strains that were tested)

Compound 41 was chosen for an in vivo CDI mouse model study as it exhibited an
MIC value of 8 μg/mL against the C. difficile in preliminary screening at University of
Western Australia and follow-up screening against the hypervirulent C. difficile strain
(M7404 – RT027) at Monash University disclosed the same MIC value of 8 μg/mL.
Additionally, compound 41 exhibited only mild cytotoxicity (CC50 = 32 μg/mL; Table 3.8)
and good water solubility (Table 3.9).
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3.2.4 – Mechanism of action
MBC (minimum bactericidal concentration) screening of all synthesized compounds
were performed at UWA. Several reports have earlier disclosed that ‘membrane
depolarization’ was a possible mechanism of action for the antimicrobial potency of
numerous cationic peptide compounds.73-76 Other reports have specified that ‘lysis of the
cellular membrane’ was another mechanism of action that causes the death of bacteria
through enzyme mediated lysis which occurs after the drug causes the bacteria to form a
defective cell wall.73, 76 The MBC data was not included in the analysis as most of the
compounds displayed MBC data that were almost equally related with their measured MIC
data.

3.2.5 – HPLC purity assay
To confirm sample purity for the in vivo CDI murine model, compound 41 was
subjected to reverse-phase HPLC analysis by using acetonitrile (non-polar) and H2O (polar)
(both with 0.1% v/v TFA) as solvents. A gradient elution from 0:100 → 100:0
(acetonitrile:H2O) over 40 min was applied and the compound was eluted between 30 – 40
min. At 215 nm, HPLC analysis was confirmed the purity of the compound 41 was > 98%.

3.2.6 – Comparative solubility assay
The previously prepared binaphthyl compounds were generally insoluble in the 10%
DMSO/H2O solution which was used in the mouse model study of CDI. Hence, a
comparative solubility assay was established to examine the solubility profile of the prepared
compounds. This was useful to identify compounds that are expected to perform well in the
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mouse model of CDI. Lead compound 1 (AVX-13616) was employed as a model compound
for this assay and all other final derivatives were compared with this lead.
Five milligrams of lead compound 1 was dissolved in 50 μL of DMSO and then 5 μL
H2O aliquots were added with sufficient manual agitation in between H 2O additions.
Addition of H2O was continued until a precipitation or turbidity and cloudiness was apparent
(which was did not disappear upon agitation). Compound 1 precipitated after the addition of
15 μL H2O.
For example, if a test compound required 30 μL of water to produce precipitation or
turbidity and cloudiness from its DMSO solution, then that test compound solubility was
calculated as two times more soluble than compound 1 (i.e. solubility ratio – 2). This
solubility ratio was used to calculate the relative solubility of the test compound allowing
comparison between several similar compounds. The solubility assay was performed on eight
compounds to determine their solubility ratio against the lead compound 1 (Table 3.9).
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Solubility Assay Data
______________________________________________________________________
Compound

H2O ppt. vol
(µL)

Solubility Ratio
ClogP
(Compound :
Compound-1)
______________________________________________________________________
1

15

1

7.47

37

110

7.33

2.73

40

105

7

3.98

29

90

6

4.01

41

75

5

4.46

42

70

4.66

4.99

43

60

4

3.91

44

70

4.66

4.39

46

60

4

3.93

_____________________________________________________________________
Table 3.9 – Comparative solubility assay data and CLogP calculated using (Chemdraw 16.0) of compounds.

The CLogP data (calculated using Chemdraw 16.0) for the tested compounds are also
added to the solubility table (Table – 3.9). The ClogP data confirmed that the tested
compounds showed ClogP values in the range of 2.73 – 4.99 due to the replacement of the
hydrophobic binaphthyl ring in compound 1 (ClogP 7.47) with the more polar phenyl-1,2,3trizole or naphthyl-1,2,3-triazole group. The phenyltriazole compound 37 showed a ClogP
value of 2.73, lower than that of the naphthyltriazole compound 42 (Table – 3.9) which
showed a ClogP value of 4.99 due to the more hydrophobic naphthyl ring system. This result
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was as expected with the larger hydrophobic groups decreasing the solubility of the
compound in water.
As expected, the dicationic phenyltriazole compound 37 was more soluble than its
related naphthyl analogue 43 (Table 3.9). This impact is further illustrated by the dicationic
naphthalenetriazole derivative 46 and the subsequent phenyltriazole analogue 40 which is
almost two times more soluble (Table 3.9). Moreover, altering the position of the isopentyl
group from the C – 4 position to the C – 5 position does not have an impact on solubility; for
example, compound 37 (isopentyl group at the C – 4 position on the triazole) has the same
solubility as the corresponding isomer 40 (isopentyl group at C – 5 position on the triazole).
This effect is further illustrated by the compounds 43 and 46 which both have the same
solubilities (Table 3.9). Furthermore, a flexible hydrocarbon termini (i.e. Cy) was usually
more soluble than an aromatic termini i.e. Bn.

3.3 – In vivo assay: murine model of CDI
3.3.1 – General methodology
The murine model of CDI was conducted with project collaborators at Monash
University. The murine model of CDI was performed by pretreating cohorts of five mice that
had been earlier infected via oral gavage with hypervirulent M7404 C. difficile spores. The
infection was allowed to develop for 12 h before the trial drug was administered every 12 h
for five days. The mice received a single dosage of 2.5 mg of compound 41 (i.e. 100 mg/kg
for an average 25 g mouse) administered in a solvent mixture of 10% DMSO and H 2O at
each 12 h dosing period. The mice body weight was checked every day. If a mouse lost 10%
of its body weight in the first 24 h, then the infection was developing, and the mouse was
separated from the trial and culled for ethical reasons. The whole survival rate for every drug
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cohort was utilized to measure effectiveness of that drug. Other physiological parameters
such as cage appearance scores and faecal consistency scores were additional measures for
the efficacy of the drug in this murine trial. The experimental data of the in vivo CDI model
can be found in Section 3.3.3 and the experimental procedures can be found in Section 6.4.3.

3.3.2 – Preliminary trials
Compound 41 was selected for a murine model of CDI study because of its better
antimicrobial potency against C. difficile and its better water solubility profile (Section 3.2.7).
Compound 41 was prepared on a larger scale i.e. nearly 300 mg for the purpose of in vivo
mouse model of CDI at Monash University. In the first trial, attempts were made to
administer compound 41 through drinking water, but the mice refused to drink the adulterated
water. As a result, the mice were dehydrated and lost weight due the effects of the infection.

3.3.3 – Secondary trial
In the secondary CDI mouse model trial, the solution (10% v/v DMSO/H2O) of the
compound 41 was administered to mice by oral gavage.
The mice that were treated with compound 41 (orange line in Figure 3.3) showed
80% survival rate until 24 h, then continued at the same survival rate for another 6 h. After
42 h, the survival rate dropped to 60 – 65% (compared with a 40% survival rate in the DMSO
control cage group).
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Kaplan-Meier survival curve:

Figure 3.3 – Kaplan-Meier survival curve for the in vivo CDI mouse trial of compound – 41 (Orange).
XX refer to other compounds, not described in this thesis, that were tested concurrently with 41.

The mice that were treated with compound 41 lost the least amount of weight at 24 h
(Figure 3.4) and after 42 h, the mice lost 18% weight.

Weight loss percentage:

Figure 3.4 – Percentage weight loss for the compound – 41 (Orange) cohort in the in vivo CDI mouse model.
XX refer to other compounds, not described in this thesis, that were tested concurrently with 41.

The mice that were treated with compound 41 had moderately soft stools, that appeared
very moist and sign of soiling around the anus based on the score from faecal consistency
(Figures 3.5).
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Faecal consistency:

Figure 3.5 – Faecal consistency scores for the compound – 41 (Orange) cohort in the in vivo CDI mouse
model. XX refer to other compounds, not described in this thesis, that were tested concurrently with 41.

Stool scoring system:
(0)

Normal stool: Solid stool that is firm when subjected to pressure with forceps. Mouse
has no sign of soiling around the anus and passes the stool quickly and easily.

(1)

Mildly soft stool: Formed stools that appear moist on the outside and have a slightly
sticky consistency. Stools will easily submit to pressure applied with forceps. Mouse
has no sign of soiling around the anus but passes faeces quickly and easily.

(2)

Moderately soft stool: Irregularly formed stools that do not hold a normal shape. Stool
appears very moist and is difficult to pick up with forceps. Mouse has some signs of
soiling around anus and takes a longer than normal time to pass the stool.

(3)

Diarrhoea: Stool has no form and/or has a mucous-like liquid appearance with
minimal solid present. Considerable soiling around the anus and the fur around tail.
Mouse takes a long time to pass stool if at all.

The mice given compound 41 had a lower cage appearance score when compared to
the DMSO controls which suggested that this compound was delaying diarrhoea (Figures
3.6).
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Cage condition:

Figure 3.6 – Cage condition score for the compound – 41 cohort in the in vivo CDI mouse model.
XX refer to other compounds, not described in this thesis, that were tested concurrently with 41.

Cage appearance scoring system:

0 – Normal cage.
1 – Faeces stuck to the side of cage, but clean nest and saw dust.
2 – Mildly soiled nest.
3 – Moderately soiled nest.
4 – Severely soiled nest.
The mice appeared to be physically changed based on the score of physiological
appearance as they showed signs of reduced grooming with their coats starting to appear
rough/scruffy with slight piloerection (Figures 3.7).
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Physiological appearance:

Figure 3.7 – Physiological appearance score for the compound – 41 cohort in the in vivo CDI mouse model.
XX refer to other compounds, not described in this thesis, that were tested concurrently with 41.

Physiological appearance scoring system:

0 – Normal activity, alertness, breathing and movement/gait.
1 – Mouse shows signs of reduced grooming with coat starting to appear rough/scruffy with
slight piloerection.
2 – Mouse appears slightly hunched with mildly scruffy coat but moves when the cage is
disturbed. Possible diminished alertness, squinted eyes or lethargy.
3 – Mouse has isolated itself from cage mates, displays hunched posture and unkempt coat.
Mouse does not move when cage is disrupted and has little response to external
environment or handling. Possible laboured breathing or eye discharge.

3.3.4 – Conclusions from murine model of CDI study
In the initial murine model of CDI study, attempts were made to administer
compound 41 through the drinking water, but the mice refused to drink the adulterated water.
Therefore, the mice were dehydrated, followed by lost weight because of the infection.
In the secondary trial of this study, compound 41 was administered via oral gavage.
At 24 hours post-infection, compound 41 appeared to be protecting the mice from disease.
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The mice given compound 41 lost the least amount of weight at 24 hours and had the mild
diarrhoea (as shown by the faecal consistency score and cage appearance score).
Furthermore, the mice had a lower cage appearance score when compared to the DMSO
controls, (suggesting that this compound was also delaying diarrhoea) and also mice had
survived until 42 hours. Compound 41 displayed some promising activity, despite not
completely protecting the mice in the murine model of CDI study and the mice had to be
culled after 42 h due to weight loss from the disease (Figure 3.4).
Compound 43 also displayed similar in vitro antimicrobial potency as compound 41
(MIC = 8.0 µg/mL) against hypervirulent C. difficile with better water solubility, indicating
that this compound should be prepared on a larger scale for future in vivo mouse model
studies. Further drug developments will likely focus on structural modifications of the Nnaphthyltriazole series. These modifications could include switching the positions of
naphthalene group and triazole ring. These modifications might produce novel
peptidomimetics with increasing antibacterial activity and good water solubility; which is an
essential requirement for the future development of this project.
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4.0 – Click methodology: results and discussion
In Chapter 2, it was noted that the attempted synthesis of 5-isopentyl-1-(2methoxynaphthalen-1-yl)-1H-1,2,3-triazole 83 from 1-azido-2-methoxynaphthalene 82
using Cp*RuCl(PPh3)2 in 1,4-dioxane at 70 °C for 12 h (Chapter 2; Section – 2.1.1.4; Scheme
2.7), resulted in the formation of 1-amino-2-methoxynaphthalene 81 in 16% yield. None of
the desired 1,5-triazole product 83 was formed. It was suspected that the 0.2 equivalents of
PPh3 from the ruthenium catalyst resulted in the formation of the amine 81 via a Staudinger
reaction of the azide group of 82. To confirm the involvement of PPh3, when the azide 82
was treated with Cp*RuCl(PPh3)2 in the absence of 5-methyl-1-hexyne at 70 °C in 1,4dioxane the amine 81 was also produced in 16% yield (Scheme 4.1). The steric bulk of the
arylazide and the Cp*RuCl(PPh3)2 catalyst were most likely the reason for the lack of
formation of the 1,5-triazole 83.

Scheme 4.1 – Attempted synthesis of the click products 83, 111 and 114 from azides 82, 97 and 99

Consistent with this premise was the fact that the reaction of azide 97 (R = Me) with
5-methyl-1-hexyne in the presence of Cp*RuCl(PPh3)2 at 70 °C for 12 h resulted in formation
of the amine 96 in 14% yield and none of the desired triazole 111 was formed (Scheme 4.1).
In contrast, the less hindered azide 99 produced the desired cycloaddition product 114 in 63%
yield and amine 98 in 12% yield, when treated with 5-methyl-1-hexyne in the presence of
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Cp*RuCl(PPh3)2 at 70 °C for 12 h (Scheme 4.1). These results suggest that the more hindered
azides 82 and 97 are undergoing a Staudinger reaction with the PPh3 derived from the Rucatalyst rather than undergoing the desired cycloaddition reaction. These results initiated our
study using as an alternative method, the Mg-promoted click reaction conditions developed
by Sharpless et al.92 We assumed that this would result in a less sterically demanding reactive
intermediate and would be more fruitful. This chapter reports the outcomes of a study of the
cycloaddition reactions of hindered naphthyl azides and alkynes.
4.1 – Synthesis of 1,5-triazoles via magnesium-promoted cycloaddition reactions
The results of the study of the magnesium-promoted cycloaddition reactions of the
azides 82, 97 and 99 with a variety of relatively hindered, electron rich and electron deficient
alkynes are shown in Schemes 4.2 – 4.4. The results of the reactions with azide 82 are shown
in Scheme 4.2. The alkynes were first treated with EtMgCl (1.2 equivalents) in dry THF at
50 °C for 30 min to generate the corresponding chloromagnesium acetylide. A solution of
the azide in dry THF was then added slowly dropwise to the acetylide at rt and the mixture
was then heated at 50 °C for 3 – 12 h.

Scheme 4.2 – Synthesis of the cycloaddition products 83 and 100 – 110 from azide 82
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The reaction between azide 82 and chloromagnesium-5-methyl-1-hexylide gave the
1,5-triazole 83 (Scheme 4.2) in 81% yield. The 1H NMR spectrum of 83 displayed the
characteristic resonances of the naphthalene group as a doublet resonance at δH 8.03 (J = 9.1
Hz, 1H), a doublet of doublet resonance at δH 7.85 (J = 7.4, 2.0 Hz, 1H) and as multiplet
resonances at δH 7.45 – 7.37 (3H) and δH 6.99 – 6.96 (1H) (Figure 4.1). The characteristic
singlet resonance at δH 3.87 was assigned for the OMe group (Figure 4.1). The characteristic
resonances (11H) that were assigned to the isopentyl group appeared as multiplet resonances
at δH 2.45 – 2.34 (2H), δH 1.47 – 1.35 (3H) and the two doublet resonances at δH 0.74 (J =
7.8 Hz, 3H) and δH 0.71 (J = 7.8 Hz, 3H) (Figure 4.1). The characteristic singlet resonance
at δH 7.71 was assigned to the triazole ring proton H-4 (Figure 4.1).

Figure 4.1: 1H NMR spectrum of compound 83 (400 MHz, CDCl3)

The C-4 carbon of the triazole ring resonated at δC 131.6 and was assigned from the
gHSQC spectrum (Figure 4.2).
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Figure 4.2: gHSQC spectrum of compound 83 (500 MHz, CDCl3). The one bond correlation
between the triazole proton and C-4 is highlighted

The gHMBC spectrum of 83 allowed the assignment of the resonance at δC 140.7 to
the quaternary C-5 carbon of the triazole ring (Figure 4.3).

Figure 4.3: gHMBC spectrum of compound 83 (500 MHz, CDCl3). The two-bond correlation
between the triazole proton and C-5 is highlighted
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Furthermore, the triazole proton did not show a correlation with the naphthalene C –
N carbon (C1'') in the gHMBC spectrum. This was consistent with 83 having the expected
1,5-disubstituted triazole structure (Scheme 4.2), whereas its regioisomers 123 (Figure 4.13)
showed a correlation between the naphthalene C1'' and the C5 triazole proton, indicating the
presence of the triazole-1,4-regioisomer.. The molecular structure of compound 83 was
further established by the presence of the ion peak at m/z 296.1750 in the HRMS (ESI) that
was assigned to the protonated molecular ion ([M + H] +) (calculated for C18H22N3O
296.1763).
The 1,5-triazoles 100 – 105 were also successfully prepared from azide 82 in yields
ranging from 52 – 89% (Scheme 4.2). The reactions involving 3-fluorophenylacetylene and
2,4,6-trimethylphenylacetylene required extended reaction times (5 h and 6 h, respectively)
presumably due to electronic effects (strongly electron withdrawing) and steric effects (2
ortho Me groups), respectively. The reaction of azide 82 and 3-fluorophenylacetylene gave
the desired 1,5-triazole 104 (Scheme 4.2) in 86% yield, but the synthesis of 107 from the
reaction of azide 82 with 4-fluorophenylacetylene was unsuccessful possibly due to the more
electron-withdrawing effect from fluorine substitution at the para position of the arylalkyne.
The synthesis of the 1,5-triazoles 106 – 110 (Scheme 4.2) from azide 82 was unsuccessful
due to the steric hinderance (106 and 110) and electron-withdrawing properties (107 – 109)
of the corresponding alkynes. The reason for the unsuccessful synthesis of 106 is not clear
since sterically this product should be more favored than that of 105. In the case of 3- and 4nitrophenylacetylenes, the addition of EtMgCl resulted in a black solution indicating an
undesired reaction between EtMgCl and the alkyne, possible due to an electron transfer
reaction to the NO2 group.
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Under similar reaction conditions to those used for 82, the reactions of the azide 97
(Scheme 4.3) with alkynes (R = isopentyl, 2-MeO-Ph and 1-naphthyl) were not successful
due to the more sterically hindered nature of the azide 97 (2-Me substituent is more sterically
demanding than the 2-OMe group of azide 82).

Scheme 4.3 – Attempted synthesis of the cycloaddition products 111 – 113 from azide 97

The less sterically demanding naphthyl azide 99 gave the 1,5-triazoles 114 – 116 in
yields of 10 – 88%. The reaction of the azide 99 with more hindered 2-MeO-phenylacetylene
giving a low yield of 10%, after heating at 50 °C for 12 h (Scheme 4.4). The synthesis of the
1,5-triazole 117 was unsuccessful due to the more sterically hindered nature of the alkyne
(i.e. 1-ethynylnaphthalene).

Scheme 4.4 – Synthesis of the cycloaddition products 114 – 117 from azide 99

The reaction between azide 99 and chloromagnesium-5-methyl-1-hexylide gave the
1,5-triazole 114 (Scheme 4.4) in 88% yield. The 1H NMR spectrum of the 1,5-triazole 114
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displayed characteristic resonances for the naphthalene group i.e. δH 8.04 (d, J = 8.3 Hz, 1H),
δH 7.95 (d, J = 8.2 Hz, 1H), δH 7.61 – 7.54 (m, 2H), δH 7.50 – 7.47 (m, 2H) and δH 7.16 (dd,
J = 8.5, 0.8 Hz, 1H) (Figure 4.4). The isopentyl group showed resonances at δH 2.45 – 2.42
(m, 2H), δH 1.46 – 1.36 (m, 3H) and δH 0.71 (d, J = 6.2 Hz, 6H) (Figure 4.4). The singlet
resonance at δH 7.70 was assigned for the triazole ring proton H-4 (Figure 4.4).

Figure 4.4: 1H NMR spectrum of compound 114 (500 MHz, CDCl3)

The gHSQC spectrum allowed the resonance at δC 131.8 to be assigned to C-4 (Figure 4.5).
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Figure 4.5: gHSQC spectrum of compound 114 (500 MHz, CDCl3). The one bond correlation
between the triazole proton and C-4 is highlighted

The gHMBC spectrum allowed the resonance at δC 140.3 to be assigned to quaternary
C-5 of the triazole (Figure 4.6).
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Figure 4.6: gHMBC spectrum of compound 114 (500 MHz, CDCl3). The two-bond correlation
between the triazole proton and C-5 is highlighted

The triazole proton did not show a correlation with the naphthalene C – N carbon
(C1''), which was consistent with the 1,5-disubstituted triazole structure of 114 (Scheme –
4.4). The molecular structure of compound 114 was further confirmed by the presence of the
ion peak at m/z 266.1668 in the HRMS (ESI) that was assigned to the protonated molecular
ion ([M + H]+) (calculated for C17H20N3 266.1657).
The synthesis of the 1,5-triazole 117 (Scheme – 4.4) from the azide 99 was
unsuccessful due to the highly sterically hindered nature of the alkyne (i.e., 1ethynylnaphthalene). The mechanism of Mg-promoted cycloaddition reaction was discussed
in section – 2.1.1.4; Scheme – 2.9 of Chapter-2.
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4.2 – Synthesis of 1,5-disubstituted-1,2,3-triazoles using pentamethylcyclopentadienyl
bis(triphenylphosphine)ruthenium(II) chloride
A study of the synthesis of phenyl 1,5-triazoles 119 – 122 was also undertaken. The
azide 118 was treated with four different alkynes using Cp*RuCl(PPh3)2 (10 mol%) as the
catalyst in 1,4-dioxane at 70 °C for 12 – 48 h. The results are shown in Scheme - 4.5.

Scheme 4.5 – Synthesis of the cycloaddition products 119 – 122 from azide 118

The reaction of azide 118 with 5-methyl-1-hexyne gave the 1,5-triazole 119 in 87%
yield. The 1H NMR spectrum of the 1,5-triazole 119 displayed the characteristic resonances
of the phenyl group as a multiplet resonance at δH 7.50 – 7.47 (1H), a doublet of doublet
resonance at δH 7.32 (J = 7.9, 1.7 Hz, 1H) and as multiplet resonance at δH 7.11 – 7.06 (2H)
(Figure 4.7). The characteristic singlet resonance at δH 3.78 was assigned to the OMe group.
The characteristic resonances of the isopentyl group were observed at δH 2.47 (t, J = 7.9 Hz,
2H), δH 1.56 – 1.41 (m, 3H) and δH 0.82 (d, J = 8.0 Hz, 6H) (Figure 4.7). The characteristic
singlet resonance at δH 7.55 was assigned to the triazole ring proton H-4 (Figure 4.7).
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Figure 4.7: 1H NMR spectrum of compound 119 (500 MHz, CDCl3)

The C-4 carbon of the triazole ring assigned at δC 131.3 was assigned from the gHSQC
spectrum (Figure 4.8).

Figure 4.8: gHSQC spectrum of compound 119 (500 MHz, CDCl3). The one bond correlation
between the triazole proton and C-4 is highlighted
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The gHMBC spectrum of 119 allowed the assignment of the resonance at δC 140.0 to
the quaternary C-5 carbon of the triazole ring (Figure 4.9).

Figure 4.9: gHMBC spectrum of compound 119 (500 MHz, CDCl3). The two-bond correlation
between the triazole proton and C-5 is highlighted

The triazole proton did not show a correlation with the phenyl C – N carbon (C1'');
which was consistent with the 1,5-disubstituted triazole structures of 120 – 122 (Scheme –
4.5). The molecular structure of compound 119 was further verified by the presence of the ion
peak at m/z 246.1618 in the HRMS (ESI) that was assigned to the protonated molecular ion
([M + H]+) (calculated for C14H20N3O 246.1606).
The longer reaction time and the lower yield of 121 (58%) was attributed due to the
more sterically hindered nature of the alkyne. The low yield of 122 (7%) was attributed to
the highly sterically hindered nature of the alkyne (Scheme – 4.5). The mechanism of the Rucatalyzed cycloaddition reaction was discussed in section – 2.1.1.3; Scheme – 2.5 of
Chapter-2.
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4.3 – Synthesis of 1,4-disubstituted-1,2, 3-triazoles from CuAAC reaction
In this study, the CuAAC reactions of the azides 82 and 118 with a variety of relatively
sterically hindered alkynes were also examined (Scheme – 4.6). In the case of azide 82, the
reaction yields were high (79 – 92%) including those for hindered alkynes (R = 2-MeO-Ph,
1-naphthyl and CMe2OH) and relatively electron deficient alkynes (4-F-Ph and 4-NO2-Ph).

Scheme 4.6 – Synthesis of the cycloaddition products 123 – 132 from azides 82 and 118

The reaction of azide 82 with 5-methyl-1-hexyne gave the 1,4-triazole 123 in 85%
yield. The 1H NMR spectrum of the triazole product 123 displayed characteristic resonances
for the naphthalene group i.e., δH 7.98 (d, J = 11.4 Hz, 1H), δH 7.83 (d, J = 9.5 Hz, 1H), δH
7.46 – 7.35 (m, 3H) and δH 7.16 (dd, J = 10.5, 0.9 Hz, 1H) (Figure 4.10). The characteristic
singlet resonance at δH 3.87 was assigned to the OMe group. The isopentyl group showed
resonances at δH 2.91 – 2.87 (m, 2H), δH 1.73 – 1.69 (m, 3H) and δH 0.99 (d, J = 7.9, 6H)
(Figure 4.10). The characteristic singlet resonance at δH 7.52 was assigned to the triazole ring
proton (Figure 4.10).
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Figure 4.10: 1H NMR spectrum of compound 123 (500 MHz, CDCl3)

The gHSQC spectrum allowed the resonance at δC 124.3 to be assigned to C-5 (Figure 4.11).

Figure 4.11 gHSQC spectrum of compound 123 (500 MHz, CDCl3). The one bond correlation
between the triazole proton and C-5 is highlighted
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The gHMBC spectrum allowed the resonance at δC 148.1 to be assigned to quaternary
C-4 of the triazole (Figure 4.12).

Figure 4.12: gHMBC spectrum of compound 123 (500 MHz, CDCl3). The two-bond correlation
between the triazole proton and C-4 is highlighted

Unlike its 1,5-triazole regioisomer 83, the triazole proton of 1,4-triazole 123 showed
a correlation with the naphthalene C – N carbon at δC 113.1 (C1") (Figure 4.13); which was
consistent with the 1,4-disubstituted triazole structure of 123 (Scheme – 4.6).
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Figure 4.13: gHMBC spectrum of compound 123 (500 MHz, CDCl3). The two-bond correlation
between the triazole proton and C-1'' is highlighted

The molecular structure of compound 123 was further confirmed by the presence of
the ion peak at m/z 296.1771 in the HRMS (ESI) that was assigned to the protonated
molecular ion ([M + H]+) (calculated for C18H22N3O 296.1763). The CuAAC reactions of
phenylazide 118 were also efficient giving the 1,4-triazoles 130 – 132 in yields of 60 – 96%.
The results are shown in Scheme – 4.6. The mechanism of CuAAC reaction was discussed
in section – 2.1.1.1; Scheme – 2.2 of Chapter-2.
The 1H NMR spectrum of the 1,5-triazole 83 (Scheme – 4.2) showed the characteristic
singlet resonance at δH 7.71 for the triazole ring proton, whereas the triazole proton in its
regioisomer 1,4-triazole 123 (Scheme – 4.6) resonated at δH 7.52. The 13C NMR spectrum of
the 1,5-triazole 83 (Scheme – 4.2) showed the C-4 resonances at δC 131.6 and the quaternary
C-5 at δC 140.7, whereas its regioisomeric 1,4-triazole 123 (Scheme – 4.6) showed
resonances for the quaternary C-4 at δC 148.1 and C-5 at δC 124.3.
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Similarly, the 1H NMR spectrum of the 1,5-triazole 119 (Scheme – 4.5) revealed a
characteristic singlet resonance at δH 7.55 for the triazole ring proton, whereas its regioisomer
1,4-triazole 130 (Scheme – 4.6) showed the corresponding resonance at δH 7.81. For the 1,5triazole 119 (Scheme – 4.5), the resonance for the C-4 was at δC 131.3 and for the quaternary
C-5 at δC 140.0, whereas for its regioisomer 1,4-triazole 130 (Scheme – 4.6) the C-5 and
quaternary C-4 resonances were at δC 122.7 and δC 147.9, respectively.
As a general trend, the C-5 carbon resonances of the 1,4-disubstituted 1,2,3-triazoles
resonated around δc 124 ± 3 ppm, whereas the corresponding C-4 carbon resonances of the
1,5-disubstituted 1,2,3-triazoles appeared around 132 ± 2 ppm (Figure 4.14).

Figure 4.14: 13C NMR as a tool for distinguishing between 1,4- and 1,5- disubstituted 1,2,3-triazoles

In conclusion, the Mg-promoted cycloaddition reactions produced the 1,5-triazoles
83, 100 – 105 (Scheme 4.2) in yields ranging from 52 – 89% for the azide 82 and the
corresponding alkynes

(i.e. 5-methyl-1-hexyne, cyclohexylacetylene,

2-

and

4-

methoxyphenylacetylene, 2-methylphenylacetylene, 3-fluorophenylacetylene and 2,4,6trimethylphenylacetylene). The synthesis of the 1,5-triazoles 106 – 110 (Scheme 4.2) from
azide 82 were unsuccessful due to the steric hindrance of the corresponding alkynes (2,6dimethoxyphenylacetylene and 1-naphthylacetylene) and the electron-withdrawing effects of
the corresponding alkynes (4-fluorophenylacetylene, 3- and 4-nitrophenylacetylene).
Under similar reaction conditions to those used for 82, the reactions of the azide 97
(Scheme 4.3) with the corresponding alkynes (5-methyl-1-hexyne, 2-methoxyphenyl
acetylene and 1-naphthylacetylene) were unsuccessful due to the more sterically hindered
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nature of the azide 97 (2-Me substituent is more sterically demanding than the 2-OMe group
of azide 82).
Under similar reaction conditions to that for 82, the less hindered naphthyl azide 99
gave the 1,5-triazoles 114 – 116 in yields ranging from 10 – 88% using the alkynes 5-methyl1-hexyne, cyclohexylacetylene and 2-methoxyphenylacetylene. The reaction of the azide 99
with the more hindered 2-methoxyphenylacetylene produced the desired 1,5-triazole 116 in
a low yield of 10% after heating for an extended time (12 h) (Scheme 4.4). The synthesis of
the triazole 117 was unsuccessful due to the more sterically hindered nature of the alkyne (1naphthylacetylene).
The Ru-catalysed cycloaddition reaction produced 1,5-phenyl triazoles 119 – 122 in
yields ranging 7 – 87% from the reaction of the azide 118 with four different alkynes (5methyl-1-hexyne,

cyclohexylacetylene,

2-methoxyphenylacetylene

and

1-naphthyl

acetylene) at 70 °C for 12 – 48 h (Scheme 4.5). 1-Naphthylacetylene produced a low yield
of 7% of the corresponding 1,5-triazole 122 after heating for 48 h due to its sterically hindered
nature.
The Cu-catalysed cycloaddition reaction produced 1,4-triazoles 123 – 132 in yields
ranging 60 – 96% from azides 82 and 118 with a variety of sterically hindered alkynes
(Scheme 4.6). All of the reactions were successful and the effect of steric hindrance was
observed in the case of three alkynes (5-methyl-1-hexyne, cyclohexylacetylene and 2methoxyphenyl acetylene) as they required longer reaction times of 36 h – 48 h.
The advantages of the Grignard method over the Ru-catalyzed method is the low-cost
of the reagent and its small in size allowing reactions of more hindered substrates to proceed
in shorter periods of time.
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The disadvantages of Ru-method – Cp*RuCl(PPh3)2 catalyst is highly expensive,
larger in size and failed to produce sterically hindered 1,5-triazoles from sterically hindered
aryl azide even in a longer period of reaction time.
The magnesium-promoted ‘click’ reaction may have further applications to sterically
hindered situations including, drug discovery allowing the attachment of sterically hindered
chromophores for drug monitoring in biological systems, the synthesis of sterically
demanding and novel chiral ligands and organocatalysts for asymmetric chemical synthesis
and asymmetric chemical methodologies.
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5.0 – Conclusions and future directions
A diverse set of twenty-nine novel antibacterial phenyltriazole and naphthyltriazole
peptidomimetic derivatives were designed and synthesized as part of an ongoing project into
the development of new antibacterial agents against C. difficile. This range of compounds
were realized through derivatization of eleven key intermediates 58 – 68 via the incorporation
of benzyl and alkyl substituents on the 1,2,3-triazole ring at the hydrophobic region. The
eleven key intermediates 58 – 68 were achieved through implementation of a modular multistep synthesis that utilized eight key building block precursors 50 – 57. This modular
approach should allow for easy diversification and manipulation of future synthesized
derivatives based upon the resultant SAR data.
The targeted compounds were designed to incorporate an alkyl substituted naphthyl1,2,3-triazole or a phenyl-1,2,3-triazole moiety into the hydrophobic backbone to replace the
binaphthyl and biphenyl core of the lead compounds 2 and 3 (Figure 5.1); this was to improve
the solubility of the peptoids, so they could be used as an oral CDI chemotherapeutic and still
retain antibacterial activity. Following synthesis and spectroscopic characterization, the
compounds were subjected to antimicrobial and toxicity assays to screen for improved
activity. The results of these assays were used to explore the SAR trends of the compounds
and thus, to identify a lead compound or other vital structural components necessary for both
C. difficile antibacterial activity as well as general antibacterial activity.
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Figure 5.1 – The replacement of the biphenyl and binaphthyl core of the lead compounds 2 and 3 with
alkyl substituted phenyl and naphthyl-1,2,3-triazole moieties at the hydrophobic backbone.
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All synthesized compounds exhibited some level of antibacterial activity; the least
potent MIC value observed against Gram-positive bacteria was 128 μg/mL, with most of the
compounds having MIC values ranging from 4 – 16 μg/mL against Gram-positive bacteria.
All of the monocationic derivatives failed to exhibit antibacterial activity against C.
difficile. The dicationic derivatives (41 and 43) exhibited less Gram-positive antibacterial
efficacy but exhibited antibacterial activity against the C. difficile strains with MIC values of
8 μg/mL (Figure 5.2).

Figure 5.2 – Development of the potential CDI hit compounds 41 and 43 from lead compound 2.
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These dicationic derivatives 41 and 42 exhibited fungal activity against C.
neoformans. Compound 2 exhibited the strongest broad-spectrum antibacterial efficacy, but
it had poor water solubility. Compounds 41 and 43 exhibit less broad-spectrum antibacterial
efficacy than compound 2 but they had five times better water solubility. The replacement of
the binaphthyl group with a phenyl-1,2,3-triazole or naphthyl-1,2,3-triazole moiety led to
increased compound solubility which often translated to a decrease in Gram-positive
antibacterial activity.
As seen in Figure 5.2, the novel antibacterial molecules 41 and 43, designed from
compound 2 led to the development of distinct structural derivatives that exhibited an
increase in desirable properties for an antibacterial chemotherapeutic. Furthermore,
compound 41 exhibited antibacterial activity against C. difficile.
Compound 41 was selected as a potential hit compound based upon its in vitro activity
against C. difficile and good water solubility. It was synthesized on larger scale and used in
an in vivo CDI mouse model at Monash University. The data of the CDI mouse model trial
revealed that mice fed compound 41 showed 80% survival rate after 24 h; both mouse weight
loss and disease progression were significantly slowed by compound 41 during the
administration of the trial. Compound 41 exhibited selectivity for Gram-positive bacteria –
it was much less active against all the Gram-negative bacteria that were tested. This
selectivity could be the reason for the drugs positive performance in the CDI mouse model
study; by not eliminating the commensal, Gram-negative Bacteroides spp. and E. coli,
compound 41 was likely quite effective at selectively killing C. difficile without destroying
the entire enteric microflora. If successful in further antibacterial trials, the compound 41 will
be studied and possibly developed as a potential CDI chemotherapeutic.
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A solubility assay was also developed and performed on selected compounds to
ascertain the role of solubility in the efficacy and administration of the phenyl and naphthyl
peptide derivatives.
In summary, a total of 29 novel antibacterial compounds were synthesized and fully
characterized. The synthesis of these derivatives involved the synthesis of 96 intermediate
compounds in total, i.e., 87 novel intermediate compounds and nine known compounds. A
modular synthetic route to various novel phenyltriazole and naphthyltriazole peptide
scaffolds was realized and the resultant synthetic derivatives represent a potential new
direction for developing novel antibiotics for the treatment of CDI and other bacterial
infections. The compounds synthesized and identified in this project are the subject of
ongoing studies into the development of a novel CDI treatment. Therefore, the current and
future chemical and biological research focused on these phenyl and naphthyl peptide
derivatives will aim towards the advancement of an effective and potent CDI
chemotherapeutic.
Future drug discovery research will likely involve two target areas. One area will
focus on scale-up of compound 43 for further in vivo mouse model study and the second
target area will likely focus on modifications of compounds 44 – 46. These modifications
might produce novel peptidomimetics with good water solubility and increasing antibacterial
efficacy – this is an important biological study requirement needed for novel medications
that work against drug-resistant C. difficile and other Gram-positive bacteria.
During the synthetic part of this project, it was revealed that the synthesis of sterically
hindered 1,5-disubstituted-1,2,3-triazoles from hindered aryl azides and alkynes was not
successful using Cp*RuCl(PPh3)2 as a catalyst due to the sterically hindered nature of the
catalyst and the azide substrate. Also, PPh 3 derived from the Cp*RuCl(PPh3)2 catalyst
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converted some of the azide to an amine in an undesired reaction. This led to a study of the
magnesium-promoted click reaction which was initially developed by Sharpless. et al.92 The
study involved the regioselective synthesis of 1,5-disubstituted-1,2,3-triazole via the addition
of chloromagnesium acetylides to azides. By applying this methodology, sterically hindered
1,5-disubstituted-1,2,3-triazoles were prepared by treating chloromagnesium acetylides with
less and more hindered azides in yields ranging from 52-89%.
In

summary,

the

lead

compound 1 (AVX-13616;

Figure

1.11)

and

its

derivatives 2 and 3 displayed exceptional in vitro antimicrobial potency (MIC) of 8.0 µg/mL
against hypervirulent C. difficile (Figure 1.12 and 1.13)54. These compounds had poor water
solubility making mouse models studies difficult and the results unreliable. In this study
we have designed and synthesized new compounds having related cationic peptidomimetic
features to compounds 2 and 3 with modifications of the hydrophobic 1,1'-binaphthyl
moiety to N-phenyltriazole and N-naphthyltriazole moieties. These modifications produced
better water-soluble compounds and for compound 41 and 43 retained antimicrobial potency
(MIC) of 8.0 µg/mL against C. difficile. The data of the CDI mouse model trial revealed that
mice fed compound 41 showed 80% survival rate after 24 h; both mouse weight loss and
disease progression were significantly slowed by compound 41 during the administration of
the trial. Based on analysis of these results, future research will be focused on the scale up of
compound 43 for in vivo mouse model studies.
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6.0 – Experimental
6.1 – General information
Synthesis
Unless otherwise stated, all solvents and chemicals were laboratory or reagent grade
and were purchased from commercial sources and used as received. Water was purified via
Millipore filtration prior to use. HOBt was purchased with added stabilizers (10% w/w H 2O);
therefore, the quantities required for reactions were adjusted accordingly and are reflected in
the reagent masses reported in the experimental (whereas the reported mmol quantities reflect
the true quantity of a chemical). All reactions were conducted under normal atmosphere and
cold reaction temperatures were obtained by an ice bath (0 ºC) or ice/salt bath (–10 ºC).
Heating of reactions was performed with a paraffin oil bath. Small quantities of liquid
reagents were measured and added to reactions via syringe or autopipette. Unless otherwise
noted, all filtrations were conducted as vacuum filtration through a sintered glass funnel
(medium porosity). Vacuum filtration was achieved with the aid of a water aspirator. Solvent
removal via concentration was performed on a rotary evaporator under reduced pressure. All
solvent mixtures are expressed in terms of volume ratio (i.e. v/v). Thin layer chromatography
(TLC) was performed on aluminium-backed SiO2 gel plates (F254 grade - 0.20 mm
thickness). Visualization was achieved with UV light, ninhydrin stain or cerium ammonium
molybdate stain. Flash chromatography was performed on SiO 2 gel 60 with a positive air
pressure. All synthesized compounds were dried under high vacuum (< 1 mbar) before
determination of chemical yields and spectroscopic characterization. Optical rotations of
only the final deprotected compounds were recorded rather than non-final compounds.
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Characterization and analysis
1

H NMR spectra were recorded on a Bruker Avance 400 (400 MHz), Avance 500

(500 MHz), a Varian VNMRS PS54 500 (500 MHz), a Varian Inova 500 (500 MHz) or a
Varian Mercury 400 (400 MHz) NMR spectrometer. Chemical shifts are reported in ppm and
were measured relative to the internal standard. Samples were dissolved in CDCl 3 (with TMS
as the internal standard – 0.00 ppm), CD3OD (solvent resonance as internal standard – 3.31
ppm) or DMSO-d6 (solvent resonance as internal standard – 2.50 ppm). The 1H NMR data
is reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q =
quartet, dd = doublet of doublet, dt = doublet of triplets, m = multiplet, br = broad), coupling
constants (Hz), integration and assignment 13C NMR spectra were recorded on a Bruker
Avance 400 (101 MHz), Avance 500 (126 MHz), a Varian VNMRS PS54 500 (126 MHz), a
Varian Inova 500 (126 MHz) or a Varian Mercury 400 (101 MHz) NMR spectrometer with
complete 1H decoupling. Chemical shifts are reported in ppm and were measured relative to
the internal standard. Samples were dissolved in CDCl3 (solvent resonance as the internal
standard – 77.16 ppm), CD3OD (solvent resonance as the internal standard – 49.20 ppm) or
DMSO-d6 (solvent resonance as internal standard – 39.50 ppm). Variable temperature NMR
experiments were performed at 90 °C on the Bruker Avance 400 NMR spectrometer. 1H and
13

C NMR resonances assignments were confirmed by analysis of NMR experiments: APT,

gCOSY, gHSQC, gHMBC, zTOCSY and NOESY. Carbon resonances that required 2-D
NMR analysis for assignment (i.e. not observed via 1-D 13C NMR analysis) are marked with
the label “observed by gHMBC” or “observed by gHSQC”. Compounds that exhibited nonobservable carbon resonances in both 1-D and 2-D NMR analysis are denoted and explained
with footnotes. Unassigned aromatic hydrogens are labelled as “Ar”, whereas
specific/assigned aromatic hydrogens are labelled with the normal nomenclature (i.e. Ar3 =
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hydrogen atom attached to aromatic carbon #3). NMR spectra were processed and prepared
with MestReNova (version 6.0) NMR software. Low resolution mass spectra (LRMS) were
obtained via electrospray ionization (ESI) on a Shimadzu LC-2010 mass spectrometer.
LRMS data was recorded as the ion mass/charge ratio (m/z). High resolution mass
spectrometry (HRMS) was performed on a Waters Quadrupole-Time of Flight (QTOF) Xevo
spectrometer via ESI and with Leucine-Enkephalin as an internal standard. All mass
spectrometry samples were dissolved in high performance liquid chromatography (HPLC)
grade MeOH (containing <1% formic acid for ionization). Optical rotations were measured
on a Jasco P-2000 polarimeter with a 10 cm path length; rotation values (α) are expressed in
units of “deg cm3 g-1 dm-1” with concentration (c) expressed in units of “g/100 mL”. Solidstate infrared spectroscopy was performed on a Shimadzu IRAffinity-1 FTIR spectrometer
in combination with a MIRacle 10 Single Reflection Attenuated Total Reflectance accessory
outfitted with a 1.5 mm round diamond crystal. IR peaks are reported as the wavenumber
(𝜈̅ max in cm-1) of the maximum absorption.

6.2 – General synthetic procedures
General Procedure I: Alkylation of phenols (with ethyl bromoacetate)
To a stirred solution of the phenol (1 eq) in dry DMF (5 mL/mmol substrate) was
added K2CO3 (3 eq), followed by ethyl bromoacetate (1.3 eq) at room temperature and the
reaction was allowed to stir at rt for 12 h. The reaction mixture was diluted with EtOAc (2 x
50 mL), washed with water (2 x 50 mL), brine (2 x 50 mL) and dried (MgSO4). The solution
was filtered, concentrated under vacuum and the residue was subjected to silica gel flash
column chromatography over SiO2 gel to afford the desired ester product.
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General Procedure II: Ester hydrolysis (with KOH)
To a stirred solution of the ester (1 eq) in ethanol (10 mL/mmol substrate) was added
7% KOH solution (5 mL/mmol) at rt and the reaction was allowed to stir at rt for 2 h. The
reaction mixture was acidified with 1 M HCl (25 mL) and extracted with EtOAc (2 x 25 mL).
The combined organic extracts were washed with brine (50 mL) and dried (MgSO4). The
solution was filtered, concentrated under vacuum to afford the acid product.

General Procedure III: Amide coupling
The amine (1.0 eq), carboxylic acid (1.0 eq), EDC.HCl (1.2 eq), HOBt (1.1 eq) and
TEA (1 eq) were combined in a dichloromethane/acetonitrile solution (10 mL/mmol amine)
and stirred at rt for the specified time. The solvent was removed (not required for ≤ 5.0 mL
dichloromethane/acetonitrile) and the residue was dissolved in EtOAc (25 mL for reactions
that contained ≤ 1.0 mmol amine or 25 mL/mmol amine for larger scale reactions). The
organic solution was washed successively with aqueous HCl (1.0 M – 2 x 25 mL), saturated
aqueous NaHCO3 (3 x 25 mL) and brine (1 x 25 mL). The EtOAc solution was dried
(MgSO4), filtered and concentrated. If necessary, the residue was subjected to further
purification via flash chromatography over SiO2 gel to furnish the targeted amide product.

General Procedure IV: Copper-catalyzed azide-alkyne cycloaddition
To a stirred solution of the azide (1.0 eq) and alkyne (2.0 – 3.0 eq) in tertbutanol/water (4:1) at rt was added CuSO4∙5H2O (0.2 eq), followed by sodium ascorbate (0.4
eq). Stirring was continued at rt (unless noted otherwise) for the specified time. Aqueous
saturated NH4Cl solution (1 mL), then water (20 mL) was added, and the mixture was
extracted with EtOAc (20 mL for reactions that contained ≤ 1.0 mmol azide or 20 mL/mmol
azide for larger scale reactions). The combined extracts were washed with water (2 x 25 mL),
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brine (2 x 25 mL) and dried (MgSO4). The solution was filtered, concentrated under vacuum
and the residue was subjected to flash chromatography over SiO2 gel to afford the desired
1,4-disubstituted 1,2,3-triazole product.

General Procedure V: Ruthenium-catalyzed azide-alkyne cycloaddition
To a stirred solution of the azide (1 eq) in dry 1,4-dioxane (2 mL/mmol substrate), in
a dried flask equipped with a condenser and under an atmosphere of nitrogen at room
temperature, was added the alkyne (1.1 eq), followed by pentamethylcyclopentadienylbis
(triphenylphosphine)ruthenium(II) chloride (0.1 eq). The mixture was stirred and heated at
70 °C for 12 h. The reaction mixture was cooled to room temperature and saturated aqueous
NH4Cl solution (1 mL), then water (25 mL) was added, and the mixture was extracted with
EtOAc (2 x 25 mL). The combined extracts were washed with water (2 x 25 mL), brine (2 x
25 mL) and dried (MgSO4). The solution was filtered, concentrated under vacuum and the
residue was subjected to flash chromatography over SiO2 gel to afford the desired 1,5disubstituted 1,2,3-triazole product.

General Procedure VI: Magnesium-promoted azide-alkyne cycloaddition
To a dried flask equipped with a condenser and containing a solution of EtMgCl (2
M in diethyl ether, 1.2 eq) in dry THF (10 mL/mmol) under a nitrogen atmosphere at room
temperature, was added dropwise, via a syringe, the alkyne (1.1 eq). The mixture was stirred
and heated at 50 °C for 30 min. The solution was cooled to rt and a solution of the azide (1
eq) in dry THF (10 mL/mmol) was added dropwise over a period of 5 min at rt. After a further
10 min, the reaction mixture was stirred and heated at 50 °C for 3-5 h. Aqueous saturated
NH4Cl solution (1 mL), then water (25 mL) was added, and the mixture was extracted with
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EtOAc (2 x 25 mL). The combined extracts were washed with water (2 x 25 mL), brine (2 x
25 mL) and dried (MgSO4). The solution was filtered, concentrated under vacuum and the
residue was subjected to silica gel flash column chromatography over SiO2 gel to afford the
desired 1,5-disubstituted 1,2,3-triazole product.

General Procedure VII: Amine deprotection (N-Boc and/or N-Pbf removal)
The N-protected amine (1.0 eq) was dissolved in a CH2Cl2 (30 mL/mmol substrate)
with magnetic stirring. If the substrate molecule contained an N-Pbf moiety then H2O (20.0
eq) was also added to the solution. TFA (30.0 mL/mmol substrate) was then added and the
reaction mixture was stirred at rt overnight (> 16 h) followed by removal of the solvent. The
residue was dissolved in CH2Cl2 (30 mL/mmol substrate), an excess amount of anhydrous
HCl (2.0 M in Et2O, 15 mL/mmol substrate, 30.0 eq) was added and the solvent was then
removed. The resulting residue was dissolved in a minimal volume of CH 2Cl2 (or MeOH)
and excess Et2O (25 mL for ≤ 0.1 mmol substrate) was added to precipitate the hydrochloride
salt of the amine. The reaction mixture was filtered, resulting filtrate was collected and
concentrated, then triturated with Et2O (3 x 20 mL). The product was collected by dissolution
in MeOH; concentration followed by drying in vacuo gave the final mono or di-hydrochloride
salt as a thin, translucent film that was routinely scratched with a spatula into a fine
hygroscopic powder or amorphous gum.

6.3 – Synthesis
6.3.1 – Precursor Building Blocks (Aromatic Cores)
6.3.1.1 – Triazole linked phenolic acids
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2-(1-Benzyl-1H-1,2,3-triazol-4-yl)phenol (70)
Following General Procedure IV, benzyl azide (1.00 g, 7.51 mmol, 0.5
M in CH2Cl2), 2-ethynylphenol 69 (0.89 g, 7.51 mmol), CuSO4∙5H2O
(0.37 g, 1.50 mmol) and sodium ascorbate (0.59 g, 3.01 mmol) were
stirred in t-BuOH (10 mL) and H2O (2.5 mL) at rt for 12 h to give the
triazole 70 (1.51 g, 80%) as a translucent tan gum after flash chromatography over SiO 2 gel
(EtOAc/n-hexane - 20:80). TLC (EtOAc/n-hexane - 40:60): Rf = 0.6; 1H NMR (500 MHz,
CDCl3) δ 10.82 (brs, 1H, -OH), 7.72 (s, 1H, H5), 7.41-7.39 (m, 3H, H6', H3''/H5''), 7.34-7.30
(m, 3H, H2''/H4''/H6''), 7.23 (apparent t, J = 8.0 Hz, 1H, H4'), 7.04 (d, J = 8.0 Hz, 1H, H3'),
6.85 (apparent t, J = 8.0 Hz, 1H, H5'), 5.59 (s, 2H, CH2Ph); 13C NMR (126 MHz, CDCl3) δ
156.0 (C2'), 148.3 (C4), 134.2 (C1''), 129.9 (C4'), 129.4 (C3''/C5''), 129.2 (C2''/C6''), 128.3
(C6'), 125.9 (C5), 119.5 (C4''), 118.8 (C5'), 117.8 (C1'), 114.0 (C3'), 54.7 (CH2Bn); IR (neat)
𝜈̅ max 3021, 3138, 3033, 1617, 1580, 1478, 1449, 1356, 1277, 1247, 1235, 1213, 1157, 1071,
1056, 1033, 728, 692, 653 cm-1; MS (ESI +ve) m/z 252 ([M + H]+, 100%) ; HRMS (ESI +ve
TOF) calcd for C15H14N3O 252.1137, found 252.1136 ([M+H]+).

2-(2-(1-Benzyl-1H-1,2,3-triazol-4-yl)phenoxy)acetic acid (50)
To a stirred solution of 2-(1-benzyl-1H-1,2,3-triazol-4-yl)phenol 70
(1.50 g, 5.97 mmol) in dry THF (10 mL) was added K2CO3 (2.47 g,
17.92 mmol), followed by bromoacetic acid (1.24 g, 8.95 mmol) at rt
and the reaction was stirred and heated at 80 °C for 12 h. The reaction
mixture was cooled to rt, diluted with water (50 mL) and extracted with Et2O (50 mL). The
aqueous layer was cooled to 0 °C, acidified with 1 M HCl solution (25 mL) and the resultant
white color precipitate was filtered and dried under vacuum to afford the acid 50 (1.56 g,
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80%) as a white solid. M.P: 138 - 140 °C. TLC (MeOH/CH2Cl2 - 10:90): Rf = 0.5; 1H NMR
(500 MHz, CDCl3) δ 8.64 (s, 1H, H5), 8.23 (d, J = 8.0 Hz, 1H, H6'), 7.40-7.33 (m, 5H,
H2'''/H3'''/H4'''/H5'''/H6'''), 7.30 (apparent t, J = 8.3 Hz, 1H, H4'), 7.11 (apparent t, J = 8.0
Hz, 1H, H5'), 6.88 (d, J = 8.3 Hz, 1H, H3'), 5.60 (s, 2H, CH2Ph), 4.68 (s, 2H, H1''), COOH
resonance was not observed; 13C NMR (126 MHz, CDCl3) δ 170.6 (C=O), 153.7 (C2'), 143.3
(C4), 134.9 (C1'''), 129.0 (C3'''/C5'''), 128.9 (C4'), 128.5 (C2'''/C6'''), 127.9 (C6'), 127.4 (C5),
124.3 (C4'''), 121.9 (C5'), 119.5 (C1'), 111.8 (C3'), 65.3 (C1''), 54.1 (CH2Ph); IR (neat) 𝜈̅ max
2950, 1735, 1608, 1586, 1550, 1490, 1438, 1351, 1290, 1224, 1126, 1078, 1047, 835, 756,
725, 696, 648 cm-1; MS (ESI +ve) m/z 348 ([M + K]+, 100%), 310 ([M + H]+, 25%); HRMS
(ESI +ve TOF) calcd for C17H15N3O3Na 332.1011, found 332.1003 ([M + Na]+).

Ethyl 2-(2-iodophenoxy)acetate (72)78
Following General Procedure I, 1-iodophenol 71 (5.00 g, 22.72
mmol), K2CO3 (9.42 g, 68.18 mmol) and ethyl bromoacetate (4.93 g,
29.54 mmol) were stirred in dry DMF (40 mL) at rt for 16 h to give
the ester 72 (6.52 g, 93%) as a pale brown oil after flash chromatography over SiO 2 gel
(EtOAc/n-hexane - 10:90). The spectroscopic data was found to be in agreement with those
previously reported.78 TLC (EtOAc/n-hexane - 20:80): Rf = 0.6; 1H NMR (500 MHz, CDCl3)
δ 7.78 (d, J = 8.0 Hz, 1H, H6), 7.28-7.25 (m, 1H, H4), 6.78-6.71 (m, 2H, H3/H5), 4.67 (s,
2H, H1'), 4.25 (q, J = 7.0 Hz, 2H, OCH2CH3), 1.28 (t, J = 7.0 Hz, 3H, OCH2CH3); 13C NMR
(126 MHz, CDCl3) δ 168.3 (C=O), 156.8 (C2), 139.7 (C6), 129.6 (C4), 123.6 (C5), 112.6
(C3), 86.5 (C1), 66.5 (C1') , 61.6 (OCH2CH3), 14.1 (OCH2CH3); IR (neat) 𝜈̅ max 3480, 2984,
2940, 1743, 1621, 1501, 1461, 1448, 1379, 1350, 1293, 1209, 1152, 1104, 802, 763 cm-1;
MS (ESI +ve) m/z 329 ([M + Na]+, 100%).
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Ethyl 2-(2-(4-isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetate (73)
To a stirred solution of ethyl 2-(2-iodophenoxy)acetate 72 (1.00 g,
3.26 mmol), 5-methyl-1-hexyne (0.94 g, 9.80 mmol), CuI (0.12 g,
0.65 mmol), NaN3 (0.23 g, 3.59 mmol) and sodium ascorbate (0.26
g, 1.30 mmol) in DMSO (10 mL)/H2O (2 mL) was added racemic
trans-N,N'-dimethylcyclohexane-1,2-diamine (0.09 g, 0.65 mmol) at
rt under nitrogen atmosphere. The reaction mixture was stirred and heated at 75 °C for 16 h.
The reaction was cooled to rt and aqueous saturated NH4Cl solution (10 mL) was added and
the mixture was extracted with EtOAc (2 x 50 mL). The combined extracts were washed with
water (50 mL), brine (50 mL) and dried (MgSO4). The solution was filtered, concentrated
under vacuum and the residue was subjected to silica gel flash column chromatography over
SiO2 gel (EtOAc/n-hexane - 10:90 → 100:0) to afford 73 (0.91 g, 87%) as a yellow waxy
solid. TLC (EtOAc/n-hexane - 20:80); Rf = 0.5; 1H NMR (500 MHz, CDCl3) δ 8.16 (s, 1H,
H5), 7.87 (d, J = 7.5 Hz, 1H, H6'), 7.35 (apparent t, J = 7.5 Hz, 1H, H4'), 7.13 (apparent t, J
= 7.5 Hz, 1H, H5'), 6.96 (d, J = 7.5 Hz, 1H, H3'), 4.68 (s, 2H, H1'''), 4.25 (q, J = 7.0 Hz, 2H,
OCH2CH3), 2.81 (t, J = 7.5 Hz, 2H, H1''), 1.70-1.61 (m, 3H, H2''/H3''), 1.29 (t, J = 7.5 Hz,
3H, OCH2CH3), 0.96 (d, J = 6.0 Hz, 6H, H4''/H5'');

C NMR (126 MHz, CDCl3) δ 168.0

13

(C=O), 149.0 (C2'), 148.1 (C4), 129.4 (C4'), 127.2 (C6'), 125.4 (C5'), 123.1 (C5), 122.4 (C3'),
113.3 (C1'), 65.9 (C1'''), 61.6 (OCH2CH3), 38.5 (C2''), 27.7 (C1''), 23.7 (C3''), 22.4 (C4''/C5'';
Observed by gHMBC), 14.1 (OCH2CH3); IR (neat) 𝜈̅ max 2957, 2870, 1755, 1601, 1548, 1509,
1466, 1379, 1296, 1230, 1203, 1167, 1129, 1073, 977, 758 cm-1; MS (ESI +ve) m/z 318 ([M
+ H]+, 100%); HRMS (ESI +ve TOF) calcd for C17H24N3O3 318.1818, found 318.1831 ([M
+ H]+).
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2-(2-(4-Isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetic acid (51)
Following General Procedure II, ethyl 2-(2-(4-isopentyl-1H-1,2,3triazol-1-yl)phenoxy) acetate 73 (0.90 g, 2.84 mmol) and 7% KOH
solution (3 mL) were stirred in ethanol (10 mL) at rt for 2 h to give the
product acid 51 (0.71 g, 85%) as a white solid. M.P: 118 - 120 °C. TLC
(EtOAc/n-hexane - 100:0): Rf = 0.2; 1H NMR (500 MHz, CDCl3) δ
9.36 (brs, 1H, COOH), 8.19 (s, 1H, H5), 7.77 (d, J = 7.5 Hz, 1H, H6'), 7.39 (apparent t, J =
7.5 Hz, 1H, H4'), 7.13 (apparent t, J = 7.5 Hz, 1H, H5'), 7.04 (d, J = 7.5 Hz, 1H, H3'), 4.76
(s, 2H, H1'''), 2.80 (t, J = 7.5 Hz, 2H, H1''), 1.64-1.59 (m, 3H, H2''/H3''), 0.92 (d, J = 5.5 Hz,
6H, H4''/H5'');

C NMR (126 MHz, CDCl3) δ 170.8 (C=O), 149.4 (C2'), 147.9 (C4), 130.2
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(C4'), 126.7 (C6'), 125.4 (C5'), 123.7 (C5), 122.5 (C3'), 113.6 (C1'), 65.9 (C1'''), 38.3 (C2''),
27.7 (C1''), 23.2 (C3''), 22.4 (C4''/5''; Observed by gHMBC); IR (neat) 𝜈̅ max 3160, 2955, 2930,
1737, 1602, 1505 1471, 1439, 1294, 1219, 1181, 1129, 1065, 835, 753 cm-1; MS (ESI +ve)
m/z 290 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C15H20N3O3 290.1505, found
290.1513 ([M + H]+).

Ethyl 2-(2-azidophenoxy)acetate (77)
To a stirred solution of ethyl 2-(2-iodophenoxy)acetate 72 (1.00 g,
3.26 mmol), CuI (0.06 g, 0.32 mmol), NaN3 (0.24 g, 3.59 mmol) and
sodium ascorbate (0.06 g, 0.32 mmol) in DMSO (10 mL)/H2O (2 mL)
was added racemic trans-N,N'-dimethylcyclohexane-1,2-diamine (0.07 g, 0.49 mmol) at rt
under nitrogen atmosphere. The reaction mixture was stirred and heated at 80 °C for 5 h. The
reaction was diluted with water (100 mL) and extracted with EtOAc (2 x 100 mL). The
combined extracts were washed with water (100 mL), brine (50 mL) and dried (MgSO4). The
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solution was filtered, concentrated under vacuum and the residue was subjected to silica gel
flash column chromatography over SiO2 gel (EtOAc/n-hexane - 10:90 → 100:0) to afford 77
(0.51 g, 70%) as a yellow waxy solid. TLC (EtOAc/CH2Cl2/n-hexane – 10:10:80); Rf = 0.5;
H NMR (400 MHz, CDCl3) δ 7.08-6.95 (m, 3H, H4/H5/H6), 6.81 (dd, J = 8.1, 1.3 Hz, 1H,

1

H3), 4.67 (s, 2H, H1'), 4.26 (q, J = 7.1 Hz, 2H, OCH2CH3), 1.28 (t, J = 7.1 Hz, 3H,
OCH2CH3); 13C NMR (101 MHz, CDCl3) δ 168.3 (C=O), 150.2 (C2), 129.1 (C1), 125.4 (C6),
122.6 (C4), 120.7 (C5), 113.8 (C3), 66.2 (C1'), 61.4 (OCH2CH3), 14.12 (OCH2CH3); IR
(neat) 𝜈̅ max 2984, 2116, 1756, 1738, 1592, 1495, 1473, 1454, 1379, 1297, 1199, 1106, 1072,
1020, 749 cm-1; MS (ESI +ve) m/z 194 ([M + H – N2]+, 100%).

Ethyl 2-(2-(5-isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetate (78)
Following General Procedure V, ethyl 2-(2-azidophenoxy)acetate
77 (0.53 g, 2.40 mmol), 5-methyl-1-hexyne (0.46 g, 4.80 mmol) and
pentamethylcyclopentadienylbis(triphenylphosphine) ruthenium(II)
chloride (0.19 g, 0.24 mmol) were stirred and heated in 1,4-dioxane
at 70 °C for 12 h to give the ester 78 (0.28 g, 37%) as a pale-yellow oil after flash
chromatography over SiO2 gel (EtOAc/n-hexane - 20:80). TLC (EtOAc/n-hexane – 50:50):
Rf = 0.3; 1H NMR (400 MHz, CDCl3) δ 7.55 (s, 1H, H4), 7.46 (apparent t, J = 6.8 Hz, 1H,
H4'), 7.37 (d, J = 6.4 Hz, 1H, H6'), 7.14 (apparent t, J = 6.4 Hz, 1H, H5'), 6.92 (d, J = 6.8 Hz,
1H, H3'), 4.55 (s, 2H, H1'''), 4.20 (q, J = 5.6 Hz, 2H, OCH2CH3), 2.64-2.56 (m, 2H, H1''),
1.56-1.42 (m, 3H, H2''/H3''), 1.24 (t, J = 5.6 Hz, 3H, OCH2CH3), 0.81 (d, J = 5.2 Hz, 6H,
H4''/H5''); 13C NMR (101 MHz, CDCl3) δ 168.1 (C=O), 152.6 (C2'), 140.6 (C5), 131.5 (C4),
131.5 (C4'), 129.2 (C6'), 125.8 (C1'), 122.2 (C5'), 113.2 (C3'), 65.7 (C1'''), 61.6 (OCH2CH3),
37.0 (C2''), 27.6 (C1''), 22.3 (C4''/C5''), 21.2 (C3''), 14.2 (OCH2CH3); IR (neat) 𝜈̅ max 2957,
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2935, 2870, 1755, 1602, 1509, 1466, 1445, 1381, 1369, 1295, 1203, 1167, 1129, 1073, 1025,
977, 757 cm-1; MS (ESI +ve) m/z 340 ([M + Na]+, 100%); HRMS (ESI +ve TOF) calcd for
C17H23N3O3Na 340.1637, found 340.1638 ([M + Na]+).

2-(2-(5-Isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetic acid (52)
Following General Procedure II, ethyl 2-(2-(5-isopentyl-1H-1,2,3triazol-1-yl)phenoxy)acetate 78 (0.28 g, 0.88 mmol) and 7% KOH
solution (4 mL) were stirred in ethanol (4 mL) at rt for 2 h to give the
product acid 52 (0.21 g, 78%) as a pale brown solid. M.P: 128-130 °C.
TLC (EtOAc/n-hexane - 100:0): Rf = 0.2; 1H NMR (500 MHz, CDCl3) δ 8.10 (brs, 1H,
COOH), 7.62 (s, 1H, H4), 7.49 (apparent t, J = 8.0 Hz, 1H, H4'), 7.35 (d, J = 7.5 Hz, 1H,
H6'), 7.15 (apparent t, J = 7.5 Hz, 1H, H5'), 7.03 (d, J = 8.0 Hz, 1H, H3'), 4.64 (s, 2H, H1'''),
2.61 (t, J = 7.5 Hz, 2H, H1''), 1.56-1.42 (m, 3H, H2''/H3''), 0.81 (d, J = 6.5 Hz, 6H, H4''/H5'');
13

C NMR (126 MHz, CDCl3) δ 170.6 (C=O), 152.4 (C2'), 140.6 (C5), 131.9 (C4), 131.6

(C4'), 128.5 (C6'), 125.6 (C1'), 122.6 (C5'), 114.1 (C3'), 66.0 (C1'''), 37.1 (C2''), 27.6 (C1''),
22.3 (C4''/C5''; Observed by gHMBC), 21.3 (C3''); IR (neat) 𝜈̅ max 2960, 2929, 2871, 1722,
1602, 1509, 1465, 1371, 1296, 1231, 1164, 1110, 1072, 995, 840, 760 cm-1; MS (ESI +ve)
m/z 328 ([M + K]+, 100%), 290 ([M + H]+, 60%); HRMS (ESI +ve TOF) calcd for
C15H19N3O3Na 312.1324, found 312.1329 ([M + Na]+).

6.3.1.2 – Triazole linked naphthalic acids
Ethyl 2-((1-iodonaphthalen-2-yl)oxy)acetate (75)
Following General Procedure I, 1-iodonaphthol 74 (1.00 g,
3.70 mmol), K2CO3 (1.53 g, 11.11 mmol) and ethyl
156

bromoacetate (0.80 g, 4.81 mmol) were stirred in DMF (8 mL) at rt for 16 h to give the ester
75 (0.68 g, 52%) as a pale yellow waxy solid after flash chromatography over SiO2 gel
(EtOAc/n-hexane - 10:90). TLC (EtOAc/n-hexane - 20:80): Rf = 0.6; 1H NMR (400 MHz,
CDCl3) δ 8.16 (d, J = 7.2 Hz, 1H, H8), 7.78 (d, J = 7.2 Hz, 1H, H5), 7.72 (d, J = 8.0 Hz, 1H,
H4), 7.54 (t, J = 7.2 Hz, 1H, H7), 7.39 (t, J = 7.2 Hz, 1H, H6), 7.08 (d, J = 8.0 Hz, 1H, H3),
4.80 (s, 2H, H1'), 4.27 (q, J = 5.6 Hz, 2H, OCH2CH3), 1.29 (t, J = 5.6 Hz, 3H, OCH2CH3);
13

C NMR (101 MHz, CDCl3) δ 168.7 (C=O), 155.6 (C2), 135.8 (C8a), 131.7 (C4a), 130.6

(C4), 130.5 (C8), 128.4 (C7), 128.3 (C5), 121.1 (C6), 114.4 (C3), 89.47 (C1), 67.6 (C1'),
61.7 (OCH2CH3) 14.3 (OCH2CH3); IR (neat) 𝜈̅ max 2981, 1756, 1622, 1593, 1502, 1462, 1349,
1291, 1200, 1151, 1134, 1096, 1028, 801, 764, 747 cm-1; MS (ESI +ve) m/z 379 ([M + Na]+,
100%); HRMS (ESI +ve TOF) calcd for C14H13O3NaI 378.9807, found 378.9801 ([M +
Na]+).

Ethyl 2-((1-(4-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetate (76)
To a stirred solution of ethyl 2-(2-iodophenoxy)acetate 75 (0.20
g, 0.54 mmol), 5-methyl-1-hexyne (0.16 g, 1.64 mmol), CuI
(0.02 g, 0.11 mmol), NaN3 (0.04 g, 0.60 mmol) and sodium
ascorbate (0.04 g, 0.22 mmol) in DMSO (2.5 mL) H2O (0.5
mL) was added racemic trans-N,N'-dimethyl cyclohexane-1,2diamine (0.016 g, 0.11 mmol) at rt under a nitrogen atmosphere. The reaction mixture was
stirred and heated at 75 °C for 16 h. The reaction was cooled to rt and aqueous saturated
NH4Cl solution (3 mL) was added and the mixture was extracted with EtOAc (2 x 25 mL).
The combined extracts were washed with water (25 mL), brine (25 mL) and dried (MgSO4).
The solution was filtered, concentrated under vacuum and the residue was subjected to silica
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gel flash column chromatography over SiO2 gel (EtOAc/n-hexane - 10:90 → 100:0) to afford
76 (0.05 g, 25%) as a yellow waxy solid. TLC (EtOAc/n-hexane - 33:67); Rf = 0.4; 1H NMR
(400 MHz, CDCl3) δ 7.97 (d, J = 7.2 Hz, 1H, H8'), 7.84 (d, J = 6.4 Hz, 1H, H5'), 7.67 (s, 1H,
H5), 7.49-7.41 (m, 2H, H6'/H7'), 7.27-7.25 (m, 2H, H3'/H4'), 4.67 (s, 2H, H1'''), 4.22 (q, J =
5.6 Hz, 2H, OCH2CH3), 2.89 (t, J = 5.6 Hz, 2H, H1''), 1.73-1.67 (m, 3H, H2''/H3''), 1.26 (t, J
= 5.6 Hz, 3H, OCH2OCH3), 0.99 (d, J = 4.0 Hz, 6H, H4''/H5''); 13C NMR (101 MHz, CDCl3)
δ 168.5 (C=O), 150.5 (C2'), 148.1 (C8a'), 131.6 (C4), 131.3 (C4a'), 129.5 (C4'), 128.5 (C5'),
127.9 (C7'), 125.3 (C8'), 124.7 (C6'), 122.1 (C5), 121.3 (C3'), 114.3 (C1'), 66.7 (C1'''), 61.6
(OCH2CH3), 38.6 (C2''), 27.9 (C1''), 23.8 (C3''), 22.5 (C4''/C5''; Observed by gHMBC), 14.2
(OCH2CH3); IR (neat) 𝜈̅ max 2954, 2928, 2868, 1748, 1632, 1600, 1513, 1483, 1454, 1430,
1366, 1288, 1206, 1150, 1117, 1087, 1042, 806, 749 cm-1; MS (ESI +ve) m/z 390 ([M +Na]+,
100%); HRMS (ESI +ve TOF) calcd for C21H26N3O3 368.1974, found 368.1985 ([M + H]+).

2-((1-(4-Isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetic acid (54)
Following General Procedure II, ethyl 2-((1-(4-isopentyl-1H1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetate 76 (0.07 g, 0.19
mmol) and 7% KOH solution (0.5 mL) were stirred in ethanol (2
mL) at rt for 2 h to give after acidification the acid 54 (0.04 g, 62%)
as a white solid. M.P: 152 – 154 °C. TLC (EtOAc/n-hexane 100:0): Rf = 0.2; 1H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 9.0 Hz, 1H, H8'), 7.88 (d, J = 7.5
Hz, 1H, H5'), 7.69 (s, 1H, H5), 7.54-7.46 (m, 2H, H6'/H7'), 7.47-7.29 (m, 2H, H3'/H4'), 4.78
(s, 2H, H1'''), 2.91-2.87 (m, 2H, H1''), 1.71-1.68 (m, 3H, H2''/H3''), 0.98 (d, J = 6.0 Hz, 6H,
H4''/H5''), COOH resonance was not observed; 13C NMR (126 MHz, CDCl3) δ 170.6 (C=O),
150.4 (C2'), 148.4 (C8a'), 132.2 (C4), 130.7 (C4a'), 129.6 (C4'), 128.8 (C5'), 128.2 (C7'),
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125.6 (C8'), 124.9 (C6'), 121.7 (C5), 120.9 (C3'), 114.4 (C1'), 66.8 (C1'''), 38.5 (C2''), 28.0
(C1''), 23.7 (C3''), 22.6 (C4''/C5''; Observed by gHMBC); IR (neat) 𝜈̅ max 3147, 2954, 2929,
2868, 1731, 1631, 1600, 1514, 1483, 1429, 1366, 1284, 1213, 1151, 1118, 1087, 1062, 923,
806, 748 cm-1; MS (ESI +ve) m/z 362 ([M + Na]+, 40%), 340 ([M + H]+, 100%); HRMS (ESI
+ve TOF) calcd for C19H22N3O3 340.1661, found 340.1667 ([M + H]+).

2-Methoxy-1-nitronaphthalene (80)80
To an ice-cold solution of 2-methoxynaphthalene 79 (3.00 g, 18.96 mmol)
in acetic anhydride (35 mL) was added fuming HNO3 (1.32 g, 20.85
mmol) dropwise at 0 °C. The mixture was stirred at rt for 1 h and placed
in a freezer for 16 h. The deposited crystals were filtered, washed with acetic anhydride,
water and dried under vacuum for 3 h to afford nitro compound 80 (0.86 g, 22%) as a yellow
solid. TLC (EtOAc/n-hexane - 20:80): Rf = 0.5; The spectroscopic data were found to be in
agreement with that previously reported.80 1H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 8.2 Hz,
1H, H8), 7.84 (d, J = 9.1 Hz, 1H, H4), 7.68 (dd, J = 8.5, 0.8 Hz, 1H, H5), 7.61-7.57 (m, 1H,
H7), 7.47-7.43 (m, 1H, H6), 7.34 (d, J = 9.1 Hz, 1H, H3), 4.03 (s, 3H, OMe); 13C NMR (101
MHz, CDCl3) δ 148.6 (C2), 132.1 (C8a), 129.1 (C4), 128.2 (C4a), 128.1 (C7), 128.0 (8),
125.6 (C6), 125.1 (C1), 120.4 (C5), 113.0 (C3), 57.0 (OMe); IR (neat) 𝜈̅ max 3030, 2944, 2846,
1636, 1602, 1515, 1459, 1436, 1357, 1280, 1259, 1220, 1155, 1079, 809, 795 cm-1; MS (ESI
+ve) m/z 204 ([M + H]+, 100%).

2-Methoxynaphthalen-1-amine (81)81
Iron powder (0.14 g, 0.49 mmol) was added to a stirred solution of 2methoxy-1-nitronaphthalene 80 (0.10 g, 0.49 mmol) in EtOH:H2O:AcOH
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(2 mL : 1 mL : 2 mL) at rt and the mixture was sonicated for 2 h. The reaction was basified
with aqueous KOH solution (3 mL) and extracted with EtOAc (2 x 25 mL). The combined
extracts were washed with water (25 mL), brine (25 mL) and dried (MgSO4). The solution
was filtered, concentrated under vacuum and the residue was subjected to silica gel flash
column chromatography over SiO2 gel (EtOAc/n-hexane - 10:90 → 100:0) to afford 81 (0.07
g, 82%) as a brown oil. TLC (EtOAc/n-hexane - 20:80); Rf = 0.5; The spectroscopic data
were found to be in agreement with those previously reported.81 1H NMR (400 MHz, CDCl3)
δ 7.76-7.73 (m, 2H, H8/H5), 7.43-7.39 (m, 1H, H7), 7.33-7.29 (m, 2H, H4/H6), 7.22 (d, J =
8.8 Hz, 1H, H3), 4.22 (brs, 2H, NH2), 3.95 (s, 3H, OMe); 13C NMR (101 MHz, CDCl3) δ
142.5 (C2), 129.5 (C4), 129.4 (C4a), 128.3 (C8a), 125.0 (C5), 123.9 (C7), 123.5 (C8), 120.2
(C1), 118.4 (C6), 113.5 (C3), 56.7 (OMe); IR (neat) 𝜈̅ max 3452, 3366, 2936, 2837, 1683,
1609, 1513, 1475, 1407, 1268, 1242, 1097, 1047, 794, 744 cm-1; MS (ESI +ve) m/z 174 ([M
+ H]+, 60%), 142 (60%), 91 (100%).

1-Azido-2-methoxynaphthalene (82)
A solution of NaNO2 (0.04 g, 0.60 mmol) in H2O (0.5 mL) was added
dropwise to a stirred suspension of 2-methoxynaphthalen-1-amine 81
(0.07 g, 0.40 mmol) in 3 N HCl solution (2 mL) at 0 °C and stirring at
0 °C was continued for 15 min. Then NaN3 (0.05 g, 0.80 mmol) in H2O (0.5 mL) was
added at 0 °C and after 10 min the mixture was continued stirring at rt for 3 h. The reaction
was diluted with water (10 mL) and extracted with EtOAc (2 x 20 mL). The combined
extracts were washed with water (20 mL), brine (20 mL) and dried (MgSO4). The solution
was filtered, concentrated under vacuum and the residue was subjected to silica gel flash
column chromatography over SiO2 gel (EtOAc/n-hexane - 5:95 → 100:0) to afford 82 (0.025
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g, 31%) as a brown waxy solid. TLC (EtOAc/n-hexane – 20:80); Rf = 0.7; 1H NMR (400
MHz, CDCl3) δ 8.07 (dd, J = 8.5, 1.0 Hz, 1H, H8), 7.72 (d, J = 8.2 Hz, 1H, H5), 7.62 (d, J =
9.0 Hz, 1H, H4), 7.47-7.43 (m, 1H, H7), 7.37-7.33 (m, 1H, H6), 7.23 (d, J = 9.0 Hz, 1H, H3),
4.01 (s, 3H, OMe);

13

C NMR (101 MHz, CDCl3) δ 150.3 (C2), 129.3 (C8a), 127.7 (C4),

127.5 (C4a), 126.5 (C5), 125.6 (C8), 124.4 (C7), 122.4 (C1), 121.4 (C6), 114.0 (C3), 57.1
(OMe); IR (neat) 𝜈̅ max 3058, 3005, 2938, 2841, 2103, 2045, 1591, 1507, 1441, 1375, 1290,
1146, 1084, 1017, 912, 806, 747 cm-1; MS (ESI +ve) m/z 172 ([M + H – N2]+, 100%).

5-Isopentyl-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole (83)
Following General Procedure VI, 1-azido-2-methoxynaphthalene 82
(0.05 g, 0.25 mmol) was treated with 5-methyl-1-hexyne (0.03 g, 0.27
mmol) and EtMgCl (0.03 g, 0.3 mmol; 2 M in Et 2O) in dry THF (2
mL) at 50 °C for 3 h to give the triazole 83 (0.06 g, 81%) as a pale
brown waxy solid after flash chromatography over SiO2 gel (EtOAc/n-hexane - 20:80). TLC
(EtOAc/n-hexane - 20:80): Rf = 0.3; 1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 9.1 Hz, 1H,
H8'), 7.85 (dd, J = 7.4, 2.0 Hz, 1H, H5'), 7.71 (s, 1H, H4), 7.45-7.37 (m, 3H, H6', H7' and
H4'), 6.97 (d, J = 9.0 Hz, 1H, H3'), 3.87 (s, 3H, OMe), 2.45-2.34 (m, 2H, H1''), 1.47-1.35 (m,
3H, H2'' and H3''), 0.73 (d, J = 7.9 Hz, 3H, H5''), 0.72 (d, J = 7.9 Hz, 3H, H4''); 13C NMR
(101 MHz, CDCl3) δ 152.7 (C2'), 140.7 (C5), 132.0 (C8a'), 131.6 (C4), 131.4 (C4a'), 128.7
(C4'), 128.3 (C5'), 127.9 (C7'), 124.6 (C8'), 121.2 (C6'), 117.9 (C3'), 113.1 (C1'), 56.5 (OMe),
36.7 (C2''), 27.2 (C1''), 22.08 (C5''), 22.07 (C4''), 20.8 (C3''); IR (neat) 𝜈̅ max 2954, 2868, 1630,
1599, 1507, 1457, 1275, 1255, 1064, 1040, 809, 748 cm-1; MS (ESI +ve) m/z 318 ([M + Na]+,
50%), 296 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C18H22N3O 296.1763, found
296.1750 ([M + H]+).
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1-(5-Isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-ol (84)
BBr3 (0.13 g, 0.51 mmol) was added dropwise to a stirred solution of
5-isopentyl-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole 83 (0.05
g, 0.17 mmol) in CH2Cl2 (1 mL) at -78 °C and after 30 min the mixture
was allowed to stir at rt for 36 h. The reaction was quenched with
MeOH (0.5 mL), diluted with EtOAc (25 mL), washed with water (25 mL), brine (25 mL)
and dried (MgSO4). The solution was filtered, concentrated under vacuum and the residue
was subjected to silica gel flash column chromatography over SiO2 gel (EtOAc/n-hexane 20:80 → 100:0) to afford alcohol 84 (0.04 g, 82%) as a pale brown solid. M.P: 164 - 166 °C.
TLC (EtOAc/n-hexane – 40:60); Rf = 0.5; 1H NMR (400 MHz, CDCl3) δ 10.31 (brs, 1H,
OH), 7.78-7.74 (m, 2H, H8'/H5'), 7.62 (s, 1H, H4), 7.44 (d, J = 8.5 Hz, 1H, H4'), 7.38-7.29
(m, 2H, H7'/H6'), 6.84 (d, J = 8.5 Hz, 1H, H3'), 2.52-2.32 (m, 2H, H1''), 1.42-1.24 (m, 3H,
H2''/H3''), 0.69 (d, J = 6.2 Hz, 3H, H5''), 0.65 (d, J = 6.2 Hz, 3H, H4''); 13C NMR (101 MHz,
CDCl3) δ 151.6 (C2'), 141.5 (C5), 131.9 (C8a'), 131.4 (C4), 131.2 (C4a'), 128.3 (C4'), 128.0
(C5'), 127.9 (C7'), 123.8 (C8'), 120.4 (C6'), 119.1 (3'), 115.0 (C1'), 36.5 (C2''), 27.2 (C1''),
22.0 (C4''/C5''), 20.8 (C3''); IR (neat) 𝜈̅ max 3061, 2957, 2869, 1638, 1583, 1512, 1440, 1360,
1287, 1245, 1149, 997, 951, 818, 749 cm-1; MS (ESI +ve) m/z 304 ([M + Na]+, 100%); HRMS
(ESI +ve TOF) calcd for C17H20N3O 282.1606, found 282.1602 ([M + H]+).

Ethyl 2-((1-(5-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetate (85)
Following General Procedure I, 1-(5-isopentyl-1H-1,2,3triazol-1-yl)naphthalen-2-ol 84 (0.04 g, 0.14 mmol), K2CO3
(0.06 g, 0.42 mmol) and ethyl bromoacetate (0.03 g, 0.18
mmol) were stirred in DMF (1 mL) at rt for 16 h to give the
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ester 85 (0.03 g, 58%) as a pale brown oil after flash chromatography over SiO 2 gel
(EtOAc/n-hexane - 20:80). TLC (EtOAc/n-hexane - 40:60): Rf = 0.6; 1H NMR (400 MHz,
CDCl3) δ 8.00 (d, J = 7.2 Hz, 1H, H8'), 7.86 (dd, J = 7.3, 2.0 Hz, 1H, H5'), 7.71 (s, 1H, H4),
7.46-7.40 (m, 2H, H6'/H7'), 7.24 (d, J = 8.5 Hz, 1H, H4'), 7.02 (d, J = 8.5 Hz, H3'), 4.66
(ABq, J = 19.0 Hz, 2H, H1'''), 4.22 (q, J = 5.6 Hz, 2H, OCH2CH3), 2.63-2.55 (m, 1H, H1''),
2.44-2.38 (m, 1H, H1''), 1.48-1.41 (m, 3H, H2''/H3''), 1.24 (t, J = 5.6 Hz, 3H, OCH2CH3),
0.75 (d, J = 5.1 Hz, 3H, H5''), 0.72 (d, J = 5.0 Hz, 3H, H4''); 3C NMR (101 MHz, CDCl3) δ
168.2 (C=O), 151.0 (C2'), 141.2 (C5), 131.9 (C8a'), 131.6 (C4), 131.4 (C4'), 129.3 (C4a'),
128.4 (C5'), 127.9 (C7'), 125.1 (C8'), 121.5 (C6'), 118.9 (C3'), 113.8 (C1'), 66.2 (C1'''), 61.5
(OCH2CH3), 36.6 (C2''), 27.3 (C1''), 22.1 (C5''), 22.0 (C4''), 20.8 (C3''), 14.1 (OCH2CH3); IR
(neat) 𝜈̅ max 2956, 2930, 2869, 1752, 1631, 1600, 1512, 1483, 1292, 1202, 1152, 1095, 1025,
808, 749 cm-1; MS (ESI +ve) m/z 390 ([M + Na]+, 100%); HRMS (ESI +ve TOF) calcd for
C21H26N3O3 368.2356, found 368.2363 ([M + H]+).

2-((1-(5-Isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetic acid (54)
Following General Procedure II, ethyl 2-((1-(5-isopentyl-1H1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetate 85 (0.28 g, 0.76
mmol) and 7% KOH solution (3 mL) were stirred in ethanol (3
mL) at rt for 2 h to give the acid 54 (0.22 g, 85%) as a white solid.
M.P: 148 - 150 °C. TLC (EtOAc/n-hexane - 100:0): Rf = 0.2; 1H NMR (400 MHz, CDCl3) δ
8.01 (d, J = 9.0 Hz, 1H, H8'), 7.88-7.86 (m, 1H, H5'), 7.75 (s, 1H, H4), 7.49-7.42 (m,
H6'/H7'), 7.30 (d, J = 8.5 Hz, 1H, H4'), 7.01 (d, J = 8.5 Hz, 1H, H3'), 4.72 (s, 2H, H1'''), 4.59
(brs, 1H, COOH), 2.57-2.49 (m, 1H, H1''), 2.44-2.37 (m, 1H, H1''), 1.46-1.33 (m, 3H,
H2''/H3''), 0.72 (d, J = 6.2 Hz, 3H, H5''), 0.70 (d, J = 6.1 Hz, 3H, H4''); 13C NMR (101 MHz,
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CDCl3) δ 170.4 (C=O), 151.1 (C2'), 141.6 (C5), 132.3 (C8a'), 131.2 (C4), 131.2 (4'), 129.3
(C4a'), 128.6 (C5'), 128.1 (C7'), 125.2 (C8'), 121.3 (C6'), 118.6 (3'), 113.9 (C1'), 66.2 (C1'''),
36.5 (C2''), 27.2 (C1''), 22.0 (C4''/C5''), 20.9 (C3''); IR (neat) 𝜈̅ max 2956, 2935, 2869, 1738,
1631, 1601, 1513, 1484, 1428, 1277, 1218, 1152, 1093, 811, 751 cm-1; MS (ESI +ve) m/z
362 ([M + Na]+, 30%), 340 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C19H22N3O3
340.1661, found 340.1666 ([M + H]+).

6.3.1.3 – Alternate phenyl triazole acids
2-Azidophenol (87)79
A solution of NaNO2 (5.06 g, 73.39 mmol) in H2O (5 mL) was added dropwise
to a stirred suspension of 2-aminophenol 86 (4.00 g, 36.69 mmol) in 3 N HCl
solution (50 mL) at 0 °C and stirring was continued at 0 °C for 15 min. A
solution of NaN3 (4.77 g, 73.39 mmol) in H2O (5 mL) was added at 0 °C and after 10 min
the mixture was stirred at rt for 3 h. The reaction was diluted with water (50 mL) and
extracted with EtOAc (2 x 100 mL). The combined extracts were washed with water (100
mL), brine (100 mL) and dried (MgSO4). The solution was filtered, concentrated under
vacuum and the residue was subjected to silica gel flash column chromatography over SiO2
gel (EtOAc/n-hexane - 10:90 → 100:0) to afford 87 (3.10 g, 60%) as a brown waxy solid.
TLC (EtOAc/n-hexane – 20:80); Rf = 0.5; The spectroscopic data were found to be in
agreement with those previously reported.79 1H NMR (500 MHz, CDCl3) δ 7.07-7.02 (m, 2H,
H4/H6), 6.94-6.90 (m, 2H, H3/H5), 5.39 (brs, 1H, OH); 13C NMR (126 MHz, CDCl3) δ 147.1
(C2), 125.8 (C1), 125.8 (C4), 121.1 (C6), 118.2 (C5), 115.9 (C3); IR (neat) 𝜈̅ max 3341, 2121,
1586, 1576, 1496, 1297, 1206, 852, 747 cm-1.
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1-Azido-2-(isopentyloxy)benzene (88)
Following General Procedure I, 2-azidophenol 87 (2.00 g, 14.80
mmol), K2CO3 (6.13 g, 44.40 mmol) and 1-bromo-3-methylbutane
(2.46 g, 16.28 mmol) were stirred in dry DMF (16 mL) at rt for 48 h
to give compound 88 (2.56 g, 84%) as a brown oil after flash chromatography over SiO2 gel
(EtOAc/n-hexane-10:90). TLC (EtOAc/n-hexane-20:80): Rf = 0.6; 1H NMR (400 MHz,
CDCl3) δ 7.05-7.02 (m, 1H, H4), 6.92 (dd, J = 8.2, 1.8 Hz, 1H, H6), 6.87-6.84 (m, 2H,
H3/H5), 4.01 (t, J = 6.7 Hz, 2H, H1'), 1.88-1.82 (m, 1H, H3'), 1.71 (q, J = 6.7 Hz, 2H, H2'),
0.96 (d, J = 6.6 Hz, 6H, H4'/H5'); 13C NMR (126 MHz, CDCl3) δ 152.0 (C2), 128.3 (C1),
125.7 (C6), 121.4 (C4), 120.8 (C5), 112.9 (C3), 67.4 (C1'), 37.8 (C2'), 25.1 (C3'), 22.6
(C4'/C5'); IR (neat) 𝜈̅ max 2956, 2871, 2107, 1592, 1495, 1451, 1386, 1304, 1239, 1149, 1042,
980, 741 cm-1; MS (ESI +ve) m/z 178 ([M – N2 + H]+, 100%).

1-(2-(Isopentyloxy)phenyl)-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-1,2,3triazole (89)
Following General Procedure VI, 1-azido-2-(isopentyloxy)benzene
88 (1.30 g, 6.34 mmol) was treated with tetrahydro-2-(2propynyloxy)-2H-pyran (0.98 g, 6.97 mmol) and EtMgCl (0.67 g,
7.61 mmol; 2 M in Et2O) in dry THF (13 mL) at 50 °C for 48 h to give triazole 89 (1.20 g,
55%) as a pale brown oil after flash chromatography over SiO2 gel (EtOAc/n-hexane - 10:90).
TLC (EtOAc/n-hexane - 20:80): Rf = 0.4; 1H NMR (500 MHz, CDCl3) δ 7.76 (s, 1H, H4),
7.48-7.44 (m, 1H, H4'), 7.39 (dd, J = 7.9, 1.7 Hz, 1H, H6'), 7.08-7.05 (m, 2H, H3'/H5'), 4.69
(d, J = 13.1 Hz, 1H, CHAHBOTHP), 4.52 (t, J = 3.2 Hz, 1H, H2'''), 4.46 (d, J = 13.1 Hz, 1H,
CHAHBOTHP), 3.98 (t, J = 6.5 Hz, H1''), 3.56-3.52 (m, 1H, H6'''), 3.40-3.37 (m, 1H, H6'''),
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1.69-1.64 (m, 1H, H3''), 1.61-1.37 (m, 8H, H2''/H3'''/H4'''/H5'''), 0.83 (d, J = 6.4 Hz, 6H,
H4''/H5''); 13C NMR (126 MHz, CDCl3) δ 153.5 (C2'), 136.5 (C5), 132.8 (C4), 131.5 (C4'),
128.6 (C6'), 125.4 (C1'), 120.7 (C5'), 113.1 (C3'), 97.8 (C2'''), 67.5 (C1''), 61.6 (C6'''), 57.9
(CHAHBOTHP), 37.6 (C2''), 30.1 (C3'''), 25.3 (C5'''), 25.0 (C3''), 22.5 (C4''), 22.4 (C5''), 18.7
(C4'''); IR (neat) 𝜈̅ max 2952, 2871, 1602, 1509, 1465, 1387, 1350, 1287, 1261, 1247, 1123,
1056, 1033, 975, 871, 816, 755 cm-1; MS (ESI +ve) m/z 346 ([M + H]+, 100%); HRMS (ESI
+ve TOF) calcd for C19H27N3O3Na 368.1950, found 368.1964 ([M + Na]+).

(1-(2-(Isopentyloxy)phenyl)-1H-1,2,3-triazol-5-yl)methanol (90)
To a stirred solution of 1-(2-(isopentyloxy)phenyl)-5-(((tetrahydro2H-pyran-2-yl)oxy)methyl)-1H-1,2,3-triazole 89 (1.17 g, 3.39
mmol) in MeOH (15 mL) was added p-toluene sulfonic acid
monohydrate (0.71 g, 3.73 mmol) at rt and the mixture was allowed to stir at rt for 16 h. The
reaction mixture was concentrated under vacuum and the residue was subjected to silica gel
flash column chromatography over SiO2 gel (MeOH/CH2Cl2 - 5:95 → 100:0) to afford 90
(0.71 g, 80%) as a light brown oil. TLC (MeOH/CH2Cl2 – 10:90); Rf = 0.4; 1H NMR (500
MHz, CDCl3) δ 7.71 (s, 1H, H4), 7.50-7.46 (m, 1H, H4'), 7.37-7.35 (m, 1H, H6'), 7.09-7.06
(m, 2H, H3'/H5'), 4.58 (s, 2H, CH2OH), 3.99 (t, J = 6.6 Hz, 2H, H1''), 3.95 (brs, 1H, OH),
1.55-1.47 (m, 3H, H2''/H3''), 0.81 (d, J = 6.4 Hz, 6H, H4''/H5''); 13C NMR (126 MHz, CDCl3)
δ 153.2 (C2'), 139.4 (C5), 132.3 (C4), 131.8 (C4'), 128.7 (C6'), 125.0 (C1'), 121.2 (C5'),
113.5 (C3'), 67.9 (C1''), 53.9 (CH2OH), 37.5 (C2''), 25.0 (C3''), 22.5 (C4''/C5''); IR (neat) 𝜈̅ max
2955, 2871, 1602, 1508, 1464, 1387, 1368, 1287, 1244, 1164, 1127, 1099, 1048, 1019, 978,
831, 756, 660 cm-1; MS (ESI +ve) m/z 262 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd
for C14H20N3O2 262.1569, found 262.1556 ([M + H]+).
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Ethyl 2-((1-(2-(isopentyloxy)phenyl)-1H-1,2,3-triazol-5-yl)methoxy)acetate (91)
To a stirred solution of (1-(2-(isopentyloxy)phenyl)-1H-1,2,3triazol-5-yl)methanol 90 (0.25 g, 0.96 mmol) in dry THF (2 mL)
at 0 °C under a nitrogen atmosphere was added NaH (0.06 g, 1.43
mmol; 60 %), followed by ethyl bromoacetate (0.21 g, 1.24 mmol).
After 10 min the mixture was allowed to stir at rt for 16 h. The reaction was diluted with
water (10 mL) and extracted with EtOAc (2 x 25 mL). The combined extracts were washed
with water (2 x 25 mL), brine (2 x 25 mL) and dried (MgSO4). The solution was filtered,
concentrated under vacuum and the residue was subjected to silica gel flash column
chromatography over SiO2 gel (EtOAc/n-hexane - 20:80 → 100:0) to afford 91 (0.23 g, 69%)
as a brown gummy solid. TLC (EtOAc/n-hexane – 40:60); Rf = 0.6; 1H NMR (400 MHz,
CDCl3) δ 7.82 (s, 1H, H4), 7.50-7.47 (m, 1H, H6'), 7.41 (ddd, J = 7.7, 7.7, 1.6 Hz, 1H, H4'),
7.11-7.06 (m, 2H, H3'/H5'), 4.62 (s, 2H, CH2OCOOEt), 4.16 (q, J = 7.1 Hz, 2H, OCH2CH3),
3.98 (t, J = 6.6 Hz, 2H, H1''), 3.95 (s, 2H, H1'''), 1.56-1.48 (m, 3H, H2''/H3''), 1.24 (t, J = 7.1
Hz, 3H, OCH2CH3), 0.83 (d, J = 6.4 Hz, 6H, H4''/H5''); 13C NMR (101 MHz, CDCl3) δ 170.0
(C=O), 153.6 (C2'), 135.7 (C5), 133.6 (C4), 132.0 (C4'), 128.8 (C6'), 125.2 (C1'), 121.2 (C5'),
113.4 (C3'), 67.8 (C1'''), 67.5 (C1''), 62.3 (CH2O), 61.4 (OCH2CH3), 37.8 (C2''), 25.2 (C3''),
22.8 (C4''/C5''), 14.5 (OCH2CH3); IR (neat) 𝜈̅ max 2957, 2872, 1750, 1602, 1509, 1465, 1386,
1369, 1287, 1265, 1247, 1207, 1135, 1048, 1025, 977, 756 cm-1; MS (ESI +ve) m/z 370 ([M
+ Na]+, 70%), 348 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C18H26N3O4 348.1923,
found 348.1922 ([M + H]+).
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2-((1-(2-(Isopentyloxy)phenyl)-1H-1,2,3-triazol-5-yl)methoxy)acetic acid (55)
To a stirred solution of ethyl 2-((1-(2-(isopentyloxy)phenyl)-1H1,2,3-triazol-5-yl)methoxy)acetate 91 (0.23 g, 0.66 mmol) in
THF:H2O (3 mL:1mL) was added LiOH.H2O (0.14 g, 3.31 mmol) at
rt and the reaction was allowed to stir at rt for 16 h. The reaction
mixture was diluted with water (5 mL), acidified with 1 M HCl (5 mL) and extracted
with EtOAc (2 x 25 mL). The combined organic extracts were washed with brine (50 mL)
and dried (MgSO4). The solution was filtered, concentrated under vacuum to afford the acid
55 (0.17 g, 81%) as a pale brown waxy solid. TLC (EtOAc/n-hexane – 100:0); Rf = 0.2;
H NMR (400 MHz, CDCl3) δ 8.76 (brs, 1H, COOH), 7.88 (s, 1H, H4), 7.50-7.46 (m, 1H,

1

H4'), 7.40 (d, J = 7.6 Hz, 1H, H6'), 7.10-7.05 (m, 2H, H3'/H5'), 4.63 (s, 2H, H1'''), 4.00 (s,
2H, CH2O), 3.98-3.97 (m, 2H, H1''), 1.57-1.47 (m, 3H, H2''/H3''), 0.82 (d, J = 6.2 Hz, 6H,
H4''/H5''); 13C NMR (101 MHz, CDCl3) δ 173.0 (C=O), 153.3 (C2'), 135.7 (C5), 132.7 (C4),
131.9 (C4'), 128.4 (C6'), 124.6 (C1'), 120.9 (C5'), 113.2 (C3'), 67.6 (C1'''), 67.0 (C1''), 61.9
(C-C5), 37.5 (C2''), 24.9 (C3''), 22.4 (C4''/C5''); IR (neat) 𝜈̅ max 2955, 2931, 2871, 2533, 1733,
1602, 1508, 1464, 1429, 1368, 1287, 1246, 1163, 1116, 1049, 994, 846, 755, 662 cm -1; MS
(ESI +ve) m/z 342 ([M + Na]+, 100%), 320 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd
for C16H22N3O4 320.1610, found 320.1603 ([M + H]+).
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6.3.2 – Synthesis of N-protected β-azido-amines
(9H-Fluoren-9-yl)methyl (R)-(1-hydroxy-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydro
benzofuran-5-yl)sulfonyl)guanidino)pentan-2-yl)carbamate (93)77
Commercial Fmoc-(D)-Arg(Pbf)-OH 92 (10.00 g, 15.41
mmol) was dissolved in THF (80 mL) with magnetic
stirring. The solution was cooled to −10 °C (ice/salt
bath) followed by sequential dropwise addition of
isobutyl chloroformate (2.31 g, 16.95 mmol) and Nmethylmorpholine (1.70 g, 16.95 mmol). The mixture
was stirred at −10 °C for 30 min and filtered through a small pad of Celite, which was rinsed
with fresh, cold THF (5 x 20 mL) and the combined filtrates were kept cold (ice bath). The
cold filtrate was added dropwise to a cold aqueous solution of NaBH4 (0.90 g, 23.68 mmol
in 10 mL H2O) with vigorous magnetic stirring. After the addition was complete, the mixture
was stirred for 5 min and added to H2O (50 mL) with vigorous stirring. The reaction was
stirred for 10 min and then the aqueous mixture was extracted with EtOAc (2 x 200 mL). The
combined organic extracts were washed with H2O (2 x 200 mL), brine (200 mL), dried
(MgSO4), filtered and concentrated. The residue was subjected to flash chromatography over
SiO2 gel to afford the alcohol 93 (8.10 g, 82%) as a translucent gum. The spectroscopic data
were found to be in agreement with those previously reported. 77 TLC (MeOH/CH2Cl2 –
10:90): Rf = 0.7; 1H NMR (500 MHz, CDCl3) δ 7.71 (d, J = 7.7 Hz, 2H, H4''/H5''), 7.54 (d, J
= 7.5 Hz, 2H, H1''/H8''), 7.34 (t, J = 7.4 Hz, 2H, H3''/H6''), 7.25-7.20 (m, 2H, H2''/H7''), 6.326.05 (m, 3H, N5-H/NH2 (guanidine)), 5.67-5.51 (brs, 1H, N2-H), 4.34 (d, J = 7.0 Hz, 2H,
H10''), 4.13 (t, J = 7.0 Hz, 1H, H9''), 3.71-3.47 (m, 3H, H1/H2), 3.25-3.14 (m, 2H, H5), 2.89
(s, 2H, H3'), 2.56 (s, 3H, C6'-CH3), 2.49 (s, 3H, C4'-CH3), 2.06 (s, 3H, C7'-CH3), 1.65-1.45
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(m, 4H, H3/H4), 1.41 (s, 6H, C2'-(CH3)2); 13C NMR (126 MHz, CDCl3) δ 158.9 (C7a'), 157.0
(C=O), 156.3 (C=N), 143.9 (C1a''/C8a''), 143.8 (C4a''), 141.3 (C5a''), 138.4 (C3a'), 132.6
(C6'), 132.3 (C4'), 127.7 (C5'), 127.1 (C3''/C6''), 125.1 (C2''/C7''), 124.7 (C4''/C5''), 119.9
(C1''/ C8''), 117.6 (C7'), 86.5 (C2'), 66.7 (C10''), 64.7 (C1), 52.5 (C2), 47.2 (C9''), 43.2 (C3'),
40.0 (C5), 28.6 (C3, C2'-(CH3)2), 25.6 (C4), 19.3 (C4'-CH3), 18.0 (C6'-CH3), 12.5 (C7'-CH3);
MS (ESI +ve) m/z 657 ([M + Na]+, 100%).

(R)-N-(Amino((4-amino-5-azidopentyl)amino)methylene)-2,2,4,6,7-pentamethyl-2,3dihydrobenzofuran-5-sulfonamide (56)47
A solution of triphenylphosphine (1.82 g, 6.94 mmol), iodine (1.76
g, 6.94 mmol), imidazole (0.52 g, 7.57 mmol) in CH2Cl2 (15 mL)
was stirred at rt for 10 min followed by the addition of a solution of
the alcohol 93 (4.00 g, 6.31 mmol) in CH2Cl2 (5 mL). The reaction
was stirred at rt for 25 h, diluted with CH2Cl2 (50 mL) and filtered
to remove the white precipitate. The filtrate was concentrated, and the residue was subjected
to flash chromatography over SiO2 gel (EtOAc/Et2O – 50:50) to give a mixture of the
intermediate iodide and triphenylphosphine oxide. The mixture was dissolved in DMF (25
mL) and NaN3 (2.05 g, 31.51 mmol) was added to the solution followed by vigorous stirring
at rt for 4 h. After the azidation reaction was shown to be complete by TLC analysis
(EtOAc/n-hexane. – 80:20), the reaction was heated at 50 °C (oil bath) overnight (12 h) to
remove the N-Fmoc protecting group. The reaction mixture was cooled to rt and then
partitioned between EtOAc (200 mL) and aqueous HCl (0.5 M – 200 mL) with magnetic
stirring for 5 min. The acidic aqueous phase was separated and washed with EtOAc (3 x 100
mL). The aqueous phase was made alkaline (pH > 10) with aqueous NaOH solution (10%
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w/w) and was extracted with EtOAc (3 x 100 mL). The organic extracts were combined and
washed with H2O (100 mL), brine (100 mL), dried (MgSO4), filtered and concentrated to
afford the amine 56 (2.00 g, 73% over two steps) as an off-white foam that collapsed into a
translucent, pale yellow gum. The spectroscopic data were found to be in agreement with
those previously reported.47 TLC (MeOH/CH2Cl2 – 10:90): Rf = 0.21; 1H NMR (500 MHz,
CDCl3) δ 6.38-6.08 (m, 3H, N1-H/NH2 (guanidine)), 3.37 (m, 1H, H1A or H1B), 3.27-3.09
(m, 3H, H5, H1A or H1B), 2.95 (s, 2H, H3'), 2.93-2.87 (m, 1H, H2), 2.58 (s, 3H, C4'-CH3),
2.51 (s, 3H, C6'-CH3), 2.10 (s, 3H, C7'-CH3), 1.73 (s, 2H, -NH2), 1.71-1.58 (m, 2H, H4),
1.58-1.48 (m, 1H, H3A or H3B), 1.46 (s, 6H, C2'-(CH3)2), 1.42-1.29 (m, 1H, H3A or H3B);
13

C NMR (126 MHz, CDCl3) δ 158.8 (C7a'); 156.2 (C=N), 138.3 (C3a'), 132.9 (C6'), 132.3

(C4'), 124.7 (C5'), 117.5 (C7'), 86.4 (C2'), 58.3 (C1), 50.8 (C2), 43.3 (C3'), 41.0 (C5), 31.0
(C3), 28.6 (C2'-(CH3)2), 25.8 (C4), 19.3 (C4'-CH3), 17.9 (C6'-CH3), 12.5 (C7'-CH3); MS (ESI

+ve) m/z 460 ([M + Na]+, 20%), 438 ([M + H]+, 100%).

(9H-Fluoren-9-yl)methyl tert-butyl ((R)-6-(((R)-1-azido-5-(2-((2,2-dimethyl-2,3-dihydro
benzofuran-5-yl)sulfonyl)guanidino)pentan-2-yl)amino)-6-oxohexane-1,5-diyl)
dicarbamate (95).
To a reaction vessel charged with azide 56 (1.38
g, 3.16 mmol), Fmoc-L-Lys(Boc)-OH 94 (1.62
g, 3.50 mmol), EDCI (0.67 g, 3.50 mmol) and
HOBt (0.53 g, 3.50 mmol) was added CH2Cl2
(10 mL) and the mixture was stirred at rt for 12
h. The reaction mixture was concentrated and
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diluted with water (100 mL) and extracted with EtOAc (3 x 100 mL). The organic extracts
were combined and washed with HCl (1 M – 100 mL), aqueous NaHCO3 (100 mL), brine
(25 mL), dried (MgSO4) and concentrated to give a pale-yellow residue. This residue was
purified via flash chromatography over SiO2 (MeOH/ CH2Cl2 = 4:96) to afford 95 as an offwhite foam (1.50 g, 54%). TLC (MeOH/CH2Cl2 – 10:90) Rf = 0.52; 1H-NMR (400 MHz,
CDCl3) δ 7.77-7.70 (m, 2H, H4''/H5''), 7.55 (d, J = 7.5 Hz, 2H, H1''/H8''), 7.55 (brs, 1H,
βCONH), 7.41-7.32 (m, 2H, H2''/H7''), 7.29-7.21 (m, 2H, H3''/H6''), 7.17 (brs, 1H, αCONH),
6.31-6.24 (m, 2H, NH2 (guanidine)), 6.19-6.09 (brs, 1H, N5-H), 4.82-4.72 (brs, 1H, LysN1H), 4.33 (d, J = 7.4 Hz, 2H, H10''), 4.25-4.07 (m, 2H, Lys5/H9''), 4.07-3.97 (m, 1H, H2),
3.41-3.23 (m, 2H, H1), 3.23-2.98 (m, 4H, H5/Lys1), 2.89 (s, 2H, H3'), 2.55 (s, 3H, C6'-CH3),
2.48 (s, 3H, C4'-CH3), 2.06 (s, 3H, C7'-CH3), 1.67 (s, 6H, C2'-CH3), 1.55-1.35 (m, 19H,
H3/H4/Lys2/ Lys3/Lys4/C(CH3)3); 13C NMR (101 MHz, CDCl3) δ 172.7 (Cβ), 158.8 (C7a'),
156.7 (Cα), 156.4 (C=N), 156.2 (COOC(CH3)3), 143.85 (C1a''or C8a''), 143.83 (C8a'' or
C1a''), 143.82 (C4a'' or C5a''), 143.6 (C5a'' or C4a''), 138.3 (C3a'), 132.8 (C6'), 132.2 (C4'),
127.8 (C3''/C6''), 127.1 (C4''/C5''), 125.0 (C2''/C7''), 124.7 (C5'), 120.0 (C1''/C8''), 117.6
(C7'), 86.4 (C2'), 79.3 (C(CH3)3), 67.3 (C10''), 55.1 (Lys5), 54.8 (C1), 48.8 (C2), 47.0 (C9''),
43.2 (C3'), 40.9 (C5), 39.9 (Lys1), 31.9 (Lys2), 29.5 (Lys4), 29.3 (C3), 28.6 (C2'-(CH3)2),
28.4 (C(CH3)3), 25.5 (C4), 22.5 (Lys3), 19.3 (C6'-CH3), 17.9 (C4'-CH3), 12.5 C7'-CH3); IR
(neat) 𝜈̅ max 3322, 2101, 1634, 1548, 1450, 1248, 1165, 1092, 739, 567 cm-1; MS (ESI +ve)
m/z 910 ([M + Na]+, 80%), 888 ([M + H]+, 100%),; HRMS (ESI +ve TOF) calcd for
C45H61N9O8SNa 910.4262, found 910.4218 ([M + Na]+).
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Tert-butyl ((R)-5-amino-6-(((R)-1-azido-5-(2-((2,2-dimethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)amino)-6-oxohexyl)carbamate (57).
To a solution of Fmoc-protected amine 95 (1.50 g, 1.69 mmol) in
acetonitrile (15 mL) was added piperidine (0.25 mL, 1.5 eq.) and
the reaction was stirred vigorously at rt for 12 h. The reaction
mixture was diluted with MeOH (50 mL) and extracted with
hexane (50 mL) multiple times until TLC analysis showed no
byproduct (dibenzofulvene piperidine adduct) present in the
MeOH layer. Then MeOH extract was concentrated under
reduced pressure to give 57 as an off-white foam (0.80 g, 71%).
TLC (MeOH/CH2Cl2 – 10:90) Rf =0.2; 1H-NMR (500 MHz, CDCl3) δ 7.61 (brs, 1H, N2-H),
6.42-6.20 (m, 3H, N5-H/ NH2 (guanidine)), 4.82-4.72 (m, 1H, LysN1-H), 4.12-3.99 (m, 1H,
Lys5), 3.46-3.29 (m, 3H, H1/H2), 3.29-3.14 (m, 2H, H5), 3.14-3.04 (m, 2H, Lys1), 2.96 (s,
2H, C3'), 2.58 (s, 3H, C6'-CH3), 2.52 (s, 3H, C4'-CH3), 2.10 (s, 3H, C7'-CH3), 1.62-1.31 (m,
25H, H3/H4/Lys2/Lys3/Lys4/C(CH3)3/C2'-(CH3)2), N5H2 resonance was not observed; 13CNMR (126 MHz, CDCl3) δ 158.8 (C7a'), 156.6 (C=O), 156.4 (C=N), 138.5 (C3a'), 133.2
(C4'), 132.4 (C6'), 124.7 (C5'), 117.6 (C7'), 86.5 (C2'), 79.4 ((C(CH3)3), 55.1 (Lys5), 55.0
(C1), 46.9 (C2), 43.4 (C3'), 40.9 (C5), 40.4 (Lys1), 34.7 (Lys4), 30.1 (Lys2), 29.8 (C3), 28.8
(C2'-(CH3)2), 28.6 (C(CH3)3), 25.8 (C4), 22.7 (Lys3), 19.4 (C6'-CH3), 18.1 (C4'-CH3), 12.6
(C7'-CH3), COO(C(CH3)3) resonance was not observed; IR (neat) 𝜈̅ max 3327, 2101, 1685,
1620, 1551, 1454, 1366, 1278, 1250, 1168, 1094, 665, 569 cm-1; MS (ESI +ve) m/z 688 ([M
+ Na]+, 20%), 666 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C30H52N9O6S
666.3761, found 666.3741 ([M + H]+).
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6.3.3 – Synthesis of the N-protected β-azides
(R)-N-(1-Azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)
guanidino)pentan-2-yl)-2-(2-(1-benzyl-1H-1,2,3-triazol-4-yl)phenoxy)acetamide (58)
Following General Procedure III, 2-(2-(1benzyl-1H-1,2,3-triazol-4-yl)phenoxy)acetic
acid 50 (0.05 g, 0.16 mmol), (R)-N-(amino ((4amino-5-azidopentyl)amino)methylene)-2,2,4,
6,7-pentamethyl-2,3-dihydrobenzofuran-5sulfonamide 56 (0.07 g, 0.16 mmol), EDCI.HCl
(0.03 g, 0.17 mmol), HOBt (0.03 g, 0.17 mmol)
and TEA (0.01 g, 0.16 mmol) were stirred in CH2Cl2 (2 mL) at rt for 16 h to give the
acetamide 58 (0.08 g, 69%) as a yellow waxy solid. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.5;
H NMR (400 MHz, CDCl3) δ 7.81 (s, 1H, H5), 7.51 (brs, 1H, CONH), 7.35-7.25 (m, 7H,

1

Ar6/Ar4/Ar2'/Ar3'/Ar4'/Ar5'/Ar6'), 7.00 (t, J = 7.5 Hz, 1H, Ar5), 6.88 (d, J = 8.5 Hz, 1H,
Ar3), 6.28-6.20 (m, 3H, N5'-H/ NH2 (guanidine)), 5.55 (ABq, J = 15.0 Hz, 2H, OCHAHB),
4.61 (s, 2H, CH2Ph), 4.12-4.08 (m, 1H, H2'), 3.48-3.32 (m, 2H, H1'), 3.24-3.10 (m, 2H, H5'),
2.88 (s, 2H, H3''), 2.52 (s, 3H, C4''-CH3), 2.45 (s, 3H, C6''-CH3), 2.70 (s, 3H, C7''-CH3), 1.801.66 (m, 1H, H3'), 1.64-1.40 (m, 3H, H3'/H4'), 1.42 (s, 6H, C2''-(CH3)2);
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C NMR (101

MHz, CDCl3) δ 169.6 (C=O), 158.7 (C7a''), 156.4 (C=N), 154.3 (Ar2), 145.6 (C4), 138.45
(Ar1'), 138.44 (C4''/C6''), 134.6 (C7''), 133.1 (C3a''), 132.3 (C5''), 130.0 (C5), 129.2 (Ar4),
128.9 (Ar3'/Ar5'), 128.2 (Ar2'/Ar6'), 124.7 (Ar6), 122.1 (Ar4'), 119.3 (Ar1), 117.5 (Ar5),
113.3 (Ar3), 86.5 (C2''), 67.9 (OCHAHB), 60.5 (CH2Ph), 54.5 (C1'), 54.3 (C2'), 49.1 (C5'),
43.3 (C3''), 41.0 (C3'), 29.7 (C2''-(CH3)2), 25.5 (C4'), 19.4 (C4''-CH3), 18.0 (C6''-CH3), 12.6
(C7''-CH3); IR (neat) 𝜈̅ max 3438, 3332, 3227, 3139, 2970, 2867, 2101, 1666, 1619, 1551,
174

1487, 1454, 1407, 1384, 1370, 1354, 1291, 1262, 1152, 1106, 1093, 1060, 1040, 994, 976,
852, 784, 757, 664, 642 cm-1; MS (ESI +ve) m/z 767 ([M + K]+, 25%), 751 ([M + Na]+,
100%); HRMS (ESI +ve TOF) calcd for C36H44N10O5SNa 751.3109, found 751.3108 ([M +
Na]+).

Tert-butyl ((R)-6-(((R)-1-azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)amino)-5-(2-(2-(1-benzyl-1H-1,2,3-triazol-4yl)phenoxy)acetamido)-6-oxohexyl)carbamate (59)
Following General Procedure III,
2-(2-(1-benzyl-1H-1,2,3-triazol-4yl)phenoxy)acetic acid 50 (0.09 g,
0.30

mmol),

tert-butyl

((R)-5-

amino-6-(((R)-1-azido-5-(2-((2,2dimethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)

guanidino)pentan-2-

yl)amino)-6-oxohexyl)carbamate
57 (0.20 g, 0.30 mmol), EDCI.HCl (0.06 g, 0.33 mmol), HOBt (0.05 g, 0.33 mmol) and TEA
(0.03 g, 0.30 mmol) were stirred in CH2Cl2 (3 mL) at rt for 16 h to give the acetamide 59
(0.14 g, 49%) as a white solid. M.P: 244 - 246 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.5;
H NMR (400 MHz, CDCl3) δ 8.98 (brs, 1H, βCONH), 7.93 (s, 1H, H5), 7.69-7.67 (m, 1H,

1

αCONH), 7.36-7.26 (m, 7H, Ar6/Ar4/Ar2'/Ar3'/Ar4'/Ar5'/Ar6'), 7.11-7.10 (m, 1H, LysN1H), 7.04 (t, J = 7.5 Hz, 1H, Ar5), 6.92 (d, J = 8.5 Hz, 1H, Ar3), 6.28-6.20 (m, 2H, NH2
(guanidine)), 6.18-6.10 (m, 1H, N5'-H (guanidine)), 5.61 (ABq, J = 15.0 Hz, 2H, OCHAHB),
4.80-4.72 (m, 1H, Lys5), 4.64-4.60 (m, 1H, H1'), 4.64 (s, 2H, CH2Ph), 4.56-4.46 (m, 1H,
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H1'), 4.08-3.98 (m, 1H, H2'), 3.32-3.20 (m, 2H, H5'), 3.20-3.06 (m, 2H, Lys1), 2.92 (s, 2H,
H3''), 2.56 (s, 3H, C4''-CH3), 2.49 (s, 3H, C6''-CH3), 2.07 (s. 3H, C7''-CH3), 2.02-1.80 (m,
6H, Lys4/H3'/H4'), 1.48-1.42 (m, 4H, Lys2/Lys3), 1.44 (s, 9H, C(CH3)3), 1.40 (s, 6H, C2''(CH3)2); 13C NMR (101 MHz, CDCl3) δ 172.6 (βC=O), 169.5 (αC=O), 158.8 (C7a''), 156.4
(C=N), 156.3 (Ar2), 154.1 (COOC(CH3)3), 145.0 (C4), 138.4 (Ar1' ), 135.0 (C4''), 133.2
(C6''), 132.4 (C3a''), 129.9 (Ar4), 129.3 (C5''), 129.2 (C5), 129.1 (C7''), 129.0 (Ar3'), 128.8
(Ar5'), 128.2 (Ar2'), 124.7 (Ar6'), 122.5 (Ar4'), 122.4 (Ar6), 119.6 (Ar5), 117.6 (Ar3), 113.3
(Ar1), 86.5 (C2''), 79.2 (C(CH3)3), 67.8 (OCHAHB), 60.6 (Lys5), 55.0 (CH2Ph), 54.3 (C1'),
53.9 (C2'), 53.6 (C5'), 43.4 (C3''), 40.9 (Lys1), 40.2 (Lys4), 31.6 (C3'), 29.5 (Lys2), 28.7
(C(CH3)3), 28.6 (C2''-(CH3)2), 25.6 (C4'), 23.1 (Lys3), 19.4 (C4''-CH3), 18.1 (C6''-CH3), 12.6
(C7''-CH3); IR (neat) 𝜈̅ max 3426, 3322, 3156, 3065, 2973, 2932, 2865, 2100, 1660, 1619,
1547, 1489, 1454, 1406, 1392, 1366, 1247, 1165, 1105, 1092, 1042, 994, 976, 941, 904, 852,
783, 756, 698, 642 cm-1; MS (ESI +ve) m/z 979 ([M + Na]+, 100%); HRMS (ESI +ve TOF)
calcd for C47H64N12O8SNa 979.4583, found 979.4587 ([M + Na]+).

(R)-N-(1-Azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)
guanidino)pentan-2-yl)-2-(2-(4-isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamide (60)
Following General Procedure III, 2-(2-(4isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetic
acid 51 (0.13 g, 0.46 mmol), (R)-N-(amino ((4amino-5-azidopentyl)amino)methylene)2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran5-sulfonamide 56 (0.20 g, 0.46 mmol),
EDCI.HCl (0.10 g, 0.50 mmol), HOBt (0.08 g,
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0.50 mmol) and TEA (0.05 g, 0.46 mmol) were stirred in CH2Cl2 (3 mL) at rt for 14 h to give
the acetamide 60 (0.19 g, 58%) as a pale-yellow solid. M.P: 234 - 236 °C. TLC (MeOH/
CH2Cl2 - 10:90): Rf = 0.5; 1H NMR (500 MHz, CDCl3) δ 7.64 (s, 1H, H5), 7.42 (t, J = 7.5
Hz, 1H, Ar4), 7.39 (d, J = 8.0 MHz, 1H, Ar6), 7.22 (brs, 1H, CONH), 7.16 (t, J = 7.5 Hz,
1H, Ar5), 7.09 (d, J = 8.0 Hz, 1H, Ar3), 6.36 (brs, 1H, N5'-H (guanidine)), 6.29 (brs, 2H,
NH2, (guanidine)), 4.61 (ABq, J = 9.5 Hz, 2H, OCHAHB), 4.08-3.94 (m, 1H, H2'), 3.40-3.30
(m, 2H, H1'), 3.30-3.20 (m, 2H, H5'), 2.94 (s, 2H, H3''), 2.80 (t, J = 8.0 Hz, 2H, H1'''), 2.57
(s, 3H, C4''-CH3), 2.51 (s, 3H, C6''-CH3), 2.07 (s, 3H, C7''-CH3), 1.70-1.44 (m, 7H,
H2'''/H3'''/H3'/H4'), 1.44 (s, 6H, C2''-(CH3)2), 0.95 (d, J = 6.0 Hz, 6H, H5'''/H4'''); 13C NMR
(126 MHz, CDCl3) δ 168.1 (C=O), 158.3 (C7a''), 156.3 (C=N), 151.8 (Ar2), 140.5 (C4''),
138.0 (C6''), 133.1 (C4), 133.0 (C3a''), 132.6 (C5''), 131.4 (Ar4), 127.8 (Ar6), 125.2 (C7''),
124.4 (Ar5), 122.2 (C5), 117.5 (Ar3), 113.3 (Ar1), 86.4 (C2''), 67.8 (OCHAHB), 55.2 (C1'),
47.6 (C2'), 43.8 (C2'''), 40.1 (C5'), 36.1 (C3''), 29.9 (C1'''), 29.6 (C3'), 26.1 (C2''-(CH3)2), 24.5
(C3'''), 22.5 (C4'), 22.4 (C4'''/C5'''), 20.9 (C4''-CH3), 18.6 (C6''-CH3), 12.8 (C7''-CH3); IR
(neat) 𝜈̅ max 3430, 3419, 3338, 3332, 3152, 3076, 2956, 2869, 2101, 1680, 1618, 1550, 1508,
1457, 1407, 1385, 1369, 1288, 1252, 1162, 1153, 1106, 1093, 1056, 1038, 994, 978, 852,
815, 784, 760, 667, 642 cm-1; MS (ESI +ve) m/z 731 ([M + Na]+, 100%), 709 ([M + H]+,
20%); HRMS (ESI +ve TOF) calcd for C34H48O5N10SNa 731.3422, found 731.3430 ([M +
Na]+).
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Tert-butyl ((R)-6-(((R)-1-azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)amino)-5-(2-(2-(4-isopentyl-1H-1,2,3-triazol-1yl)phenoxy)acetamido)-6-oxohexyl)carbamate (61)
Following General Procedure III,
2-(2-(4-isopentyl-1H-1,2,3-triazol1-yl)phenoxy)acetic acid 51 (0.10 g,
0.34

mmol),

tert-butyl

((R)-5-

amino-6-(((R)-1-azido-5-(2-((2,2dimethyl-2,3-dihydrobenzofuran-5yl) sulfonyl)guanidino)pentan-2-yl)
amino)-6-oxohexyl)carbamate

57

(0.23 g, 0.34 mmol), EDCI.HCl
(0.07 g, 0.38 mmol), HOBt (0.06 g, 0.38 mmol) and TEA (0.03 g, 0.34 mmol) were stirred
in CH2Cl2 (5 mL) at rt for 16 h to give the acetamide 61 (0.25 g, 78%) as an off-white solid.
M.P: 256 - 258 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.5; 1H NMR (400 MHz, CDCl3) δ
7.78-7.74 (m, 1H, Ar6), 7.70 (s, 1H, H5), 7.54-7.36 (m, 3H, Ar4/Ar5/βCONH), 7.20-7.04
(m, 2H, αCONH/Ar3), 6.40-6.10 (m, 3H, N5'-H/NH2 (guanidine)), 5.04-4.96 (m, 1H, LysN1H), 4.65-4.56 (m, 2H, OCHAHB), 4.44-4.38 (m, 1H, Lys5), 4.04-3.96 (m, 1H, H2'), 3.32-3.24
(m, 2H, H1'), 3.22-2.98 (m, 4H, H5'/Lys1), 2.92 (s, 2H, H3''), 2.84-2.74 (m, 2H, H1'''), 2.54
(s, 3H, C4''-CH3), 2.48 (s, 3H, C6''-CH3), 2.06 (s, 3H, C7''-CH3), 1.90-1.70 (m, 2H, Lys4),
1.64-1.58 (m, 4H, H4'/Lys2), 1.56-1.26 (m, 7H, H3'/ Lys3/H2'''/ H3'''), 1.46 (s, 9H, C(CH3)3),
1.44 (s, 6H, C2''-(CH3)2), 0.33 (d, J = 5.5 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CDCl3)
δ 168.5 (βC=O), 168.1 (αC=O), 158.1 (C7a''), 156.4 (C=N), 150.4 (COO(CH3)3), 145.9
(Ar2), 138.4 (C4), 132.4 (C4''), 131.1 (C6''), 130.8 (C3a''), 129.6 (C5''), 126.6 (Ar4), 126.4
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(C7''), 124.7 (Ar6), 122.6 (Ar5), 117.5 (C5), 117.3 (Ar3), 111.3 (Ar1), 86.4 (C2''), 79.1
(C(CH3)3), 67.4 (OCHAHB), 54.9 (Lys5), 53.7 (C1'), 43.4 (C2'), 40.9 (C2'''), 38.5 (C5'), 31.5
(C3''), 31.3 (Lys1), 29.8 (Lys4), 29.4 (C3'), 28.7 (Lys2), 28.5 (C1'''), 27.85 (C(CH3)3), 27.83
(C2''-(CH3)2), 25.5 (C4'), 23.5 (C3'''), 22.9 (Lys3), 22.5 (C4'''/C5'''), 19.3 (C4''-CH3), 18.0
(C6''-CH3), 12.5 (C7''-CH3); IR (neat) 𝜈̅ max 3316, 3071, 2953, 2932, 2868, 2100, 1662, 1619,
1602, 1546, 1508, 1459, 1420, 1389, 1365, 1250, 1195, 1165, 1109, 1056, 1026, 982, 913,
834, 816, 755, 665, 644, 622 cm-1; MS (ESI +ve) m/z 959 ([M + Na]+, 100%); HRMS (ESI
+ve TOF) calcd for C45H69N12O8S 937.5082, found 937.5098 ([M+H]+).

(R)-N-(1-Azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)
guanidino)pentan-2-yl)-2-(2-(5-isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamide (62)
Following General Procedure III, 2-(2-(5isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetic
acid 52 (0.14 g, 0.48 mmol), (R)-N-(amino((4amino-5-azidopentyl)amino)methylene)2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran5-sulfonamide 56 (0.21 g, 0.48 mmol),
EDCI.HCl (0.10 g, 0.53 mmol), HOBt (0.08 g,
0.53 mmol) and TEA (0.05 g, 0.48 mmol) were stirred in CH2Cl2 (3 mL) at rt for 16 h to give
the acetamide 62 (0.22 g, 65%) as an off-white solid. M.P: 228 - 230 °C. TLC (MeOH/
CH2Cl2 - 10:90): Rf = 0.5; 1H NMR (400 MHz, CDCl3) δ 7.67 (s, 1H, H4), 7.60-7.55 (m, 1H,
Ar4), 7.33 (dd, J = 7.7, 1.5 Hz, 1H, Ar6), 7.24-7.20 (m, 1H, Ar5), 7.13 (d, J = 8.2 Hz, 1H,
Ar3), 6.60 (brs, 1H, CONH), 6.36 (brs, 1H, N5'-H (guanidine)), 6.28 (brs, 2H, NH2
(guanidine)), 4.57 (ABq, J = 14.8 Hz, 2H, OCHAHB), 4.00-3.92 (m, 1H, H2'), 3.60-3.23 (m,
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4H, H1'/H5'), 2.95 (s, 2H, H3''), 2.60 (s, 3H, C4''-CH3), 2.58-2.54 (m, 2H, H1'''), 2.53 (s, 3H,
C6''-CH3), 2.08 (s, 3H, C7''-CH3), 1.92-1.82 (m, 2H, H3'), 1.56-1.52 (m, 1H, H3'''), 1.52-1.42
(m, 4H, H2'''/H4'), 1.45 (s, 6H, C2''-(CH3)2), 0.83 (d, J = 6.3 Hz, 6H, H5'''/H4'''); 13C NMR
(101 MHz, CDCl3) δ 167.4 (C=O), 158.5 (C7a''), 156.3 (C=N), 152.1 (Ar2), 140.7 (C5),
138.3 (C3a''), 133.3 (C4), 132.35 (C4''), 132.30 (C6''), 131.7 (C5''), 128.0 (Ar4), 124.8 (Ar6),
124.4 (C7''), 122.4 (Ar1), 117.3 (Ar5), 113.6 (Ar3), 86.2 (C2''), 67.1 (OCHAHB), 54.6 (C1'),
48.9 (C2'), 43.2 (C2'''), 40.7 (C5'), 37.0 (C3''), 29.1 (C3'), 28.6 (C2''-(CH3)2), 27.4 (C1'''), 25.3
(C4'), 22.1 (C4'''/C5'''), 22.0 (C3'''), 21.1 (C4''-CH3), 19.2 (C6''-CH3), 12.4 (C7''-CH3); IR
(neat) 𝜈̅ max 3448, 3419, 3153, 3076, 2957, 2869, 2101, 1680, 1619, 1550, 1508, 1456, 1407,
1385, 1369, 1288, 1256, 1163, 1153, 1107, 1092, 1056, 1037, 994, 978, 852, 783, 734, 669,
642 cm-1; MS (ESI +ve) m/z 731 ([M + Na]+, 100%); HRMS (ESI +ve TOF) calcd for
C34H48N10O5SNa 731.3422, found 731.3423 ([M + Na]+).

Tert-butyl ((R)-6-(((R)-1-azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)amino)-5-(2-(2-(5-isopentyl-1H-1,2,3-triazol-1yl)phenoxy)acetamido)-6-oxohexyl)carbamate (63)
Following General Procedure III,
2-(2-(5-isopentyl-1H-1,2,3-triazol1-yl)phenoxy)acetic acid 52 (0.03 g,
0.10

mmol),

tert-butyl

((R)-5-

amino-6-(((R)-1-azido-5-(2-((2,2dimethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)
amino)-6-oxohexyl)carbamate

57
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(0.07 g, 0.10 mmol), EDCI.HCl (0.02 g, 0.11 mmol), HOBt (0.02 g, 0.11 mmol) and TEA
(0.01 g, 0.10 mmol) were stirred in CH2Cl2 (2 mL) at rt for 12 h to give the acetamide 63
(0.07 g, 74%) as an off-white solid. M.P: 242 - 244 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf =
0.5; 1H NMR (400 MHz, CDCl3) δ 7.60 (s, 1H, H4), 7.54 (t, J = 8.1 Hz, 1H, Ar4), 7.52 (brs,
1H, βCONH), 7.34-7.14 (m, 3H, Ar6/Ar5/Ar3), 7.04-6.98 (brs, 1H, αCONH), 6.12-6.08 (m,
3H, N5'-H/NH2 (guanidine)), 5.20-5.14 (m, 1H, LysN1-H), 4.65-4.53 (m, 2H, OCHAHB),
4.38-4.31 (m, 1H, Lys5), 3.99-3.96 (m, 1H, H2'), 3.30-3.24 (m, 2H, H1'), 3.10-3.01 (m, 4H,
H5'/Lys1), 2.94 (s, 2H, H3''), 2.56 (s, 3H, C4''-CH3), 2.49 (s, 3H, C6''-CH3), 2.49-2.45 (m,
2H, H1'''), 2.07 (s, 3H, C7''-CH3), 1.80-1.70 (m, 2H, Lys4), 1.54-1.40 (m, 9H,
H3'/H4'/Lys2/H2'''/H3'''), 1.45 (s, 9H, C(CH3)3), 1.42 (s, 6H, C2''-(CH3)2), 1.30-1.26 (m, 2H,
Lys3), 0.83 (d, J = 6.4 Hz, 3H, H4'''), 0.81 (d, J = 6.4 Hz, 3H, H5'''); 13C NMR (101 MHz,
CDCl3) δ 171.8 (βC=O), 168.4 (αC=O), 158.6 (C7a''), 156.2 (C=N), 152.1 (COOC(CH3)3),
140.2 (Ar2), 138.2 (C5), 133.1 (C4''), 132.1 (C6''), 132.0 (C3a''), 131.9 (C5''), 128.1 (C4),
128.0 (Ar4), 124.9 (C7''), 124.5 (Ar6), 122.4 (Ar1), 117.3 (Ar5), 113.8 (Ar3), 86.3 (C2''),
78.9 (C(CH3)3), 67.3 (OCHAHB), 54.6 (Lys5), 53.4 (C1'), 53.4 (C2'), 48.7 (C2'''), 43.2 (C5'),
40.6 (C3''), 40.1 (Lys1), 37.0 (Lys4), 31.5 (C3'), 29.2 (Lys2), 28.5 (C(CH3)3), 28.4 (C2''(CH3)2), 28.2 (C1'''), 27.4 (C4'), 25.4 (C3'''), 22.8 (C4'''), 22.7 (C5'''), 22.1 (Lys3), 19.2 (C4''CH3), 17.9 (C6''-CH3), 12.4 (C7''-CH3); IR (neat) 𝜈̅ max 3319, 3073, 2953, 2933, 2869, 2101,
1662, 1602, 1546, 1508, 1459, 1420, 1390, 1366, 1251, 1195, 1165, 1109, 1057, 1024, 984,
913, 882, 833, 755, 665, 622, 580 cm-1; MS (ESI +ve) m/z 959 ([M + Na]+, 100%), 937 ([M
+ H]+, 60%); HRMS (ESI +ve TOF) calcd for C45H69N12O8S 937.5076, found 937.5077 ([M
+ H]+).
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(R)-N-(1-Azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)
guanidino)pentan-2-yl)-2-((1-(4-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2yl)oxy)acetamide (64)
Following General Procedure III, 2-((1(4-isopentyl-1H-1,2,3-triazol-1-yl)
naphthalen-2-yl)oxy)acetic acid 53 (0.14
g, 0.41 mmol), (R)-N-(amino((4-amino-5azidopentyl)amino)methylene)-2,2,4,6,7pentamethyl-2,3-dihydrobenzofuran-5sulfonamide 56 (0.18 g, 0.41 mmol),
EDCI.HCl (0.09 g, 0.45 mmol), HOBt (0.07 g, 0.45 mmol) and TEA (0.04 g, 0.41 mmol)
were stirred in CH2Cl2 (5 mL) at rt for 12 h to give the acetamide 64 (0.21 g, 67%) as an offwhite solid. M.P: 238 - 240 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.5; 1H NMR (400 MHz,
CDCl3) δ 8.08 (d, J = 9.2 Hz, 1H, Ar8), 7.92 (d, J = 8.2 Hz, 1H, Ar5), 7.66 (s, 1H, H5), 7.567.47 (m, 2H, Ar6/Ar7), 7.35 (d, J = 8.2 Hz, 1H, Ar4), 7.19 (d, J = 8.2 Hz, 1H, Ar3), 6.66
(brs, 1H, CONH), 6.54-6.58 (m, 3H, N5'-H/ NH2 (guanidine)), 4.69 (ABq, 14.8 Hz, 2H,
OCHAHB), 3.99-3.94 (m, 1H, H2'), 3.55-3.20 (m, 4H, H1'/H5'), 2.93 (s, 2H, H3''), 2.91-2.88
(m, 2H, H1'''), 2.58 (s, 3H, C4''-CH3), 2.52 (s, 3H, C6''-CH3), 2.07 (s, 3H, C7''-CH3), 1.781.76 (m, 2H, H3'), 1.74-1.58 (m, 3H, H2'''/H3'''), 1.52-1.46 (m, 2H, H4'), 1.44 (s, 6H, C2''(CH3)2), 1.00 (d, J = 6.2 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CDCl3) δ 167.5 (C=O),
158.5 (C7a''), 156.3 (Ar2), 149.9 (C=N), 149.1 (Ar8a), 138.3 (C3a''), 133.4 (C4''), 132.7
(C6''), 132.3 (C4), 130.3 (C5''), 129.2 (Ar4), 129.1 (Ar4a), 128.4 (C7''), 125.6 (Ar5), 124.9
(Ar7), 124.4 (Ar8), 120.6 (C5), 119.7 (Ar6), 117.3 (Ar3), 113.0 (Ar1), 86.2 (C2''), 67.6
(OCHAHB), 54.6 (C1'), 48.9 (C2'), 43.2 (C2'''), 40.7 (C5'), 38.4 (C3''), 29.1 (C3'), 28.5 (C2''182

(CH3)2), 27.8 (C1'''), 25.3 (C4'), 23.5 (C3'''), 22.4 (C4'''/C5'''), 19.2 (C4''-CH3), 17.9 (C6''CH3), 12.4 (C7''-CH3); IR (neat) 𝜈̅ max 3435, 3418, 3332, 3141, 2954, 2869, 2100, 1677, 1627,
1600, 1548, 1483, 1452, 1407, 1383, 1369, 1278, 1254, 1150, 1107, 1091, 1044, 809, 782,
734, 664, 642, 619, cm-1; MS (ESI +ve) m/z 781 ([M + Na]+, 60%), 759 ([M + H]+, 100%);
HRMS (ESI +ve TOF) calcd for C38H50N10O5SNa 781.3584, found 781.3620 ([M + Na]+).

Tert-butyl ((R)-6-(((R)-1-azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)amino)-5-(2-((1-(4-isopentyl-1H-1,2,3-triazol-1yl)naphthalen-2-yl)oxy)acetamido)-6-oxohexyl)carbamate (65)
Following

General

Procedure

III,

2-((1-(4-

isopentyl-1H-1,2,3-triazol-1yl)naphthalen-2-yl)oxy)acetic
acid 53 (0.12 g, 0.35 mmol),
tert-butyl

((R)-5-amino-6-

(((R)-1-azido-5-(2-((2,2-di
methyl-2,3-dihydrobenzo
furan-5-yl)sulfonyl)
guanidino)pentan-2-yl)amino)-6-oxohexyl) carbamate 57 (0.24 g, 0.35 mmol), EDCI.HCl
(0.08 g, 0.39 mmol), HOBt (0.06 g, 0.39 mmol) and TEA (0.03 g, 0.35 mmol) were stirred in
CH2Cl2 (5 mL) at rt for 12 h to give the acetamide 65 (0.22 g, 64%) as an off-white solid. M.P:
236 – 238 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.5; 1H NMR (400 MHz, CDCl3) δ 8.05
(d, J = 8.5 Hz, 1H, Ar8), 7.89 (d, J = 8.5 Hz, 1H, Ar5), 7.65 (s, 1H, H5), 7.54-7.47 (m, 2H,
Ar4/βCONH ), 7.37 (d, J = 8.5 Hz, 1H, Ar7), 7.26-7.19 (m, 2H, Ar6/Ar3), 6.85 (brs, 1H,
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αCONH), 6.36-6.08 (m, 3H, N5'-H/NH2 (guanidine)), 5.00 (brs, 1H, LysN1-H), 4.69 (ABq, J
= 16.5 Hz, 2H, OCHAHB), 4.42-4.36 (m, 1H, Lys5), 4.02-3.96 (m, 1H, H2'), 3.44-2.94 (m,
6H, H1'/H5'/Lys1), 2.88 (s, 2H, H3''), 2.88-2.84 (m, 2H, H1'''), 2.55 (s, 3H, C4''-CH3), 2.48 (s,
3H, C6''-CH3), 2.06 (s, 3H, C7''-CH3), 2.00-1.86 (m, 4H, H4'/Lys4), 1.84-1.60 (m, 7H,
H3'/Lys3/H2'''/H3'''), 1.44 (s, 6H, C2''(CH3)2), 1.39 (s, 9H, C(CH3)3), 1.32-1.22 (m, 2H, Lys2),
0.9 (d, J = 5.0 Hz, 6H, H4'''/H5''');

C NMR (101 MHz, CDCl3) δ 171.9 (βC=O), 168.1
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(αC=O), 158.7 (C7a''), 156.4 (C=N), 150.1 (Ar2), 149.1 (COOC(CH3)3), 138.4 (Ar8a), 133.4
(C4), 132.6 (C4''), 132.46 (C6''), 132.44 (C3a''), 130.6 (C5''), 129.4 (Ar4), 129.1 (Ar4a),
128.48 (C7''), 128.47 (Ar5), 125.7 (Ar7), 124.7 (Ar8), 121.1 (C5), 120.3 (Ar6), 117.5 (Ar3),
113.8 (Ar1), 86.5 (C2''), 79.2 (C(CH3)3), 68.0 (OCHAHB), 54.8 (Lys5), 53.6 (C1'), 43.4 (C2'),
40.8 (C2'''), 40.2 (C5'), 38.6 (C3''), 38.5 (Lys1), 31.79 (Lys4), 31.74 (C3'), 29.4 (Lys2), 28.7
(C2''-(CH3)2), 28.6 ((CH3)3), 28.0 (C1'''), 25.5 (C4'), 23.8 (C3'''), 22.8 (C4'''/C5'''), 22.6 (Lys3),
19.4 (C4''-CH3), 18.1 (C6''-CH3), 12.6 (C7''-CH3); IR (neat) 𝜈̅ max 3405, 3317, 3415, 3057,
2953, 2868, 2100, 1664, 1631, 1600, 1546, 1514, 1484, 1452, 1406, 1390, 1366, 1265, 1247,
1165, 1106, 1090, 1044, 994, 970, 852, 781, 733, 661, 641 cm-1; MS (ESI +ve) m/z 987 ([M
+ H]+, 100%); HRMS (ESI +ve TOF) calcd for C49H71N12O8S 987.5239, found 987.5272 ([M
+ H]+).
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N-((R)-1-Azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)
guanidino)pentan-2-yl)-2-((1-(5-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2yl)oxy)acetamide (66)
Following General Procedure III, 2-((1(5-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetic acid 54 (0.15 g,
0.44 mmol), (R)-N-(amino((4-amino-5azido pentyl)amino)methylene)-2,2,4,6,7pentamethyl-2,3-dihydrobenzofuran-5sulfonamide 56 (0.19 g, 0.44 mmol),
EDCI.HCl (0.09 g, 0.48 mmol), HOBt (0.07 g, 0.48 mmol) and TEA (0.04 g, 0.44 mmol)
were stirred in CH2Cl2 (5 mL) at rt for 16 h to give the acetamide 66 (0.22 g, 66%) as an offwhite solid. M.P: 248 - 250 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.6; 1H NMR (400 MHz,
CDCl3) δ 8.11 (d, J = 7.3 Hz, 1H, Ar8), 7.94-7.92 (m, 1H, Ar5), 7.78 (s, 1H, H4), 7.55-7.49
(m, 2H, Ar6/Ar7), 7.41 (d, J = 7.4 Hz, 1H, Ar4), 7.04-7.02 (m, 1H, Ar3), 6.48 (brs, 1H,
CONH), 6.35 (brs, 2H, NH2 (guanidine)), 6.29 (brs, 1H, N5'-H (guanidine)), 4.65 (ABq, J =
11.8 Hz, 2H, OCHAHB), 3.96-3.93 (m, 1H, H2'), 3.44-3.21 (m, 2H, H1'), 3.20-3.10 (m, 2H,
H5'), 2.94 (s, 2H, H3''), 2.61 (s, 3H, C4''-CH3), 2.54 (s, 3H, C6''-CH3), 2.50-2.37 (m, 2H,
H1'''), 2.08 (s, 3H, C7''-CH3), 1.58-1.34 (m, 7H, H3'/H4'/H2'''/H3'''), 1.46 (s, 6H, C2''-(CH3)2),
0.73 (d, J = 5.0 Hz, 6H, H4'''/H5''');

C NMR (101 MHz, CDCl3, major rotamer) δ 167.9
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(C=O), 158.5 (C7a''), 156.4 (Ar2), 150.5 (C=N), 150.4 (C5), 141.8 (Ar8a), 138.3 (C4''), 133.3
(C6''), 133.1 (C4), 132.3 (C3a''), 131.9 (C5''), 130.5 (Ar4), 129.3 (Ar4a), 129.1 (C7''), 128.5
(Ar5), 125.6 (Ar7), 124.4 (Ar8), 120.7 (Ar6), 118.3 (Ar3), 113.2 (Ar1), 86.2 (C2''), 67.3
(CHAHB), 54.4 (C1'), 48.7 (C2'), 43.2 (C2'''), 40.7 (C5'), 36.6 (C3''), 29.2 (C3'), 28.8 (C2''185

(CH3)2), 28.6 (C1'''), 27.2 (C4'), 25.4 (C3'''), 22.0 (C4'''/C5'''), 19.2 (C4''-CH3), 17.9 (C6''CH3), 12.4 (C7''-CH3); IR (neat) 𝜈̅ max 3435, 3332, 3141, 3076, 2954, 2868, 2100, 1677, 1627,
1600, 1548, 1483, 1452, 1407, 1369, 1278, 1254, 1150, 1107, 1091, 1044, 994, 852, 809,
782, 749, 734, 664, 619 cm-1; MS (ESI +ve) m/z 803 ([M + HCOO-], 100%), 757 ([M - H],
90%); HRMS (ESI +ve TOF) calcd for C38H49N10O5S 757.3608, found 757.3604 ([M - H]).

Tert-Butyl ((5R)-6-(((R)-1-azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran5-yl)sulfonyl)guanidino)pentan-2-yl)amino)-5-(2-((1-(5-isopentyl-1H-1,2,3-triazol-1yl)naphthalen-2-yl)oxy)acetamido)-6-oxohexyl)carbamate (67)
Following
Procedure

General
III,

2-((1-(5-

isopentyl-1H-1,2,3-triazol-1yl)naphthalen-2-yl)oxy)acetic
acid 54 (0.13 g, 0.38 mmol),
tert-butyl

((R)-5-amino-6-

(((R)-1-azido-5-(2-((2,2-di
methyl-2,3-dihydrobenzo
furan-5-yl)sulfonyl)guanidino)pentan-2-yl)amino)-6-oxohexyl)carbamate 57 (0.26 g, 0.38
mmol), EDCI.HCl (0.08 g, 0.42 mmol), HOBt (0.06 g, 0.42 mmol) and TEA (0.04 g, 0.38
mmol) were stirred in CH2Cl2 (5 mL) at rt for 16 h to give the acetamide 67 (0.25 g, 67%) as
a pale brown solid. M.P: 242 - 244 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.5; 1H NMR
(400 MHz, CDCl3) δ 8.14-8.09 (m, 1H, Ar8), 7.93 (d, J = 7.3 Hz, 1H, Ar5), 7.83 (s, 1H, H4),
7.66-7.36 (m, 3H, Ar4/βCONH/Ar7), 7.08-6.95 (m, 2H, Ar6/Ar3), 6.54-6.52 (m, 1H,
αCONH), 6.34-6.24 (m, 3H, N5'-H/NH2 (guanidine)), 5.13 (brs, 1H, LysN1-H), 4.64 (ABq, J
186

= 16.5 Hz, 2H, OCHAHB), 4.42-4.36 (m, 1H, Lys5), 4.02-3.96 (m, 1H, H2'), 3.30-2.94 (m,
6H, H1'/H5'/Lys1), 2.94 (s, 2H, H3''), 2.57 (s, 3H, C4''-CH3), 2.51 (s, 3H, C6''-CH3), 2.482.32 (m, 2H, H1'''), 2.08 (s, 3H, C7''-CH3), 1.82-1.76 (m, 2H, H4'), 1.58-1.16 (m, 11H,
H3'/Lys2/Lys3/Lys4/H2'''/H3'''), 1.44 (s, 6H, C2''-(CH3)2), 1.40 (s, 9H, C(CH3)3), 0.74 (d, J
= 5.5 Hz, 3H, H4'''), 0.71 (d, J = 6.0 Hz, 3H, H5''');
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C NMR (101 MHz, CDCl3, major

rotamer) δ 171.4 (βC=O), 167.6 (αC=O), 158.5 (C7a''), 156.2 (C=N), 150.6 (Ar2), 150.5
(COOC(CH3)3), 141.4 (C5), 138.2 (Ar8a), 133.2 (C4), 133.0 (C4''), 132.2 (C6''), 130.6
(C3a''), 129.3 (C5''), 129.0 (Ar4), 128.8 (Ar4a), 128.4 (C7''), 125.6 (Ar5), 124.5 (Ar7), 120.8
(Ar8), 118.2 (Ar6), 117.3 (Ar3), 113.5 (Ar1), 86.3 (C2''), 78.9 (C(CH3)3), 67.7 (OCHAHB),
54.5 (Lys5), 53.4 (C1'), 43.2 (C2'), 40.7 (C2'''), 40.2 (C5'), 36.7 (C3''), 31.8 (Lys1), 29.3
(Lys4), 29.1 (C3'), 28.5 (Lys2), 28.4 (C2''-(CH3)2), 28.4 ((CH3)3), 27.2 (C1'''), 25.4 (C4'),
22.9 (C3'''), 22.0 (C4'''/C5'''), 20.9 (Lys3), 19.2 (C4''-CH3), 17.9 (C6''-CH3), 12.4 (C7''-CH3);
IR (neat) 𝜈̅ max 3406, 3317, 3144, 3057, 2953, 2868, 2100, 1664, 1631, 1600, 1545, 1514,
1484, 1452, 1406, 1390, 1366, 1265, 1165, 1151, 1090, 1044, 1024, 994, 913, 852, 807, 781,
733, 660, 641, 566 cm-1; MS (ESI +ve) m/z 988 ([M + H]+, 100%); HRMS (ESI +ve TOF)
calcd for C49H72N12O8S 988.5317, found 988.5337 ([M+H]+).
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Tert-Butyl ((R)-6-(((R)-1-azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)amino)-5-(2-((1-(2-(isopentyloxy)phenyl)-1H-1,2,3triazol-5-yl)methoxy)acetamido)-6-oxohexyl)carbamate (68)
Following General Procedure
III,

2-((1-(2-(isopentyloxy)

phenyl)-1H-1,2,3-triazol-5-yl)
methoxy)acetic acid 55
(0.12 g, 0.37 mmol), tert-butyl
((R)-5-amino-6-(((R)-1-azido-5(2-((2,2-dimethyl-2,3dihydrobenzofuran-5-yl)
sulfonyl)guanidino)pentan-2-yl)amino)-6-oxohexyl) carbamate 57 (0.25 g, 0.37 mmol),
EDCI.HCl (0.08 g, 0.41 mmol), HOBt (0.06 g, 0.41 mmol) and TEA (0.04 g, 0.37 mmol)
were stirred in CH2Cl2 (3 mL) at rt for 16 h to give the acetamide 68 (0.25 g, 70%) as a pale
brown solid. M.P: 220 - 222 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.6; 1H NMR (400
MHz, CDCl3) δ 7.82 (s, 1H, H4), 7.49 (ddd, J = 8.2, 1.6 Hz, 1H, Ar4), 7.40 (dd, J = 8.0, 1.6
Hz, 1H, Ar6), 7.11-7.0 (m, 3H, Ar5/Ar3/βCONH), 6.97 (brs, 1H, αCONH), 6.34-6.24 (m,
3H, N5'-H/NH2 (guanidine)), 4.75 (t, J = 5.8 Hz, 1H, LysN1-H), 4.63-4.55 (m, 2H, C5-CH2),
4.35 (t, J = 6.5 Hz, 1H, Lys5), 4.01-3.74 (m, 3H, H2'/H1'''), 3.89-3.74 (m, 2H, OCHAHB),
3.38-3.28 (m, 2H, H1'), 3.44-3.40 (m, 2H, H5'), 3.07-3.00 (m, 2H, Lys1), 2.94 (s, 2H, H3''),
2.56 (s, 3H, C4''-CH3), 2.50 (s, 3H, C6''-CH3), 2.08 (s. 3H, C7''-CH3), 1.85-1.80 (m, 2H,
Lys4), 1.64-1.45 (m, 9H, H2'''/H3'''/Lys2/H3'/H4'), 1.45 (s, 6H, C2''(CH3)2), 1.41 (s, 9H,
C(CH3)3), 1.36-1.20 (m, 2H, Lys3), 0.82 (d, J = 6.3 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz,
CDCl3) δ 171.7 (βC=O), 169.1 (αC=O), 158.7 (C7a''), 156.2 (C=N), 153.1 (COO(CH3)3),
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138.3 (Ar2), 135.0 (C5), 133.1 (C4''), 132.9 (C6''), 132.2 (C3a''), 131.8 (C4), 128.3 (C5''),
124.9 (C7''), 124.8 (Ar4), 124.6 (Ar6), 121.1 (Ar1), 117.4 (Ar5), 113.3 (Ar3), 86.4 (C2''),
79.2 (C(CH3)3), 69.1 (OCHAHB), 67.7 (C1'''), 62.1 (C5-CH2), 54.6 (Lys5), 52.7 (C1'), 43.2
(C2'), 40.7 (C5'), 39.9 (C3''), 37.5 (Lys1), 32.0 (C2'''), 29.7 (Lys4), 29.3 (Lys2), 29.2 (C3'),
28.6 (C2''-(CH3)2), 28.4 ((CH3)3), 25.5 (C4'), 24.9 (C3'''), 22.5 (C4'''/C5'''), 22.4 (Lys3), 19.2
(C4''-CH3), 17.9 (C6''-CH3), 12.4 (C7''-CH3); IR (neat) 𝜈̅ max 3325, 3147, 3076, 2963, 2930,
2869, 2100, 1661, 1620, 1549, 1510, 1459, 1404, 1390, 1367, 1286, 1250, 1166, 1107, 1050,
1036, 996, 978, 852, 808, 783, 757, 734, 663, 642, 569 cm-1; MS (ESI +ve) m/z 989 ([M +
Na]+, 100%); HRMS (ESI +ve TOF) calcd for C46H70N12O9SNa 989.5007, found 989.5029
([M + Na]+).

6.3.4 – Synthesis of the derivatives 21 – 49
(R)-2-(2-(1-Benzyl-1H-1,2,3-triazol-4-yl)phenoxy)-N-(1-(4-(cyclohexylmethyl)-1H1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)acetamide hydrochloride (21)
Following General Procedure IV, azide 58 (0.08 g,
0.11 mmol), 3-cyclohexyl-1-propyne (0.04 g, 0.33
mmol), CuSO4∙5H2O (0.005 g, 0.02 mmol) and
sodium ascorbate (0.009 g, 0.04 mmol) were stirred
in t-BuOH (2 mL) and H2O (0.5 mL) for 16 h to give
the intermediate 133 as an off-white gum after flash chromatography over SiO2 gel
(MeOH/CH2Cl2 – 0:100 → 4:96). Following General Procedure VII, the intermediate 133
(0.07 g, 0.08 mmol) was dissolved in CH 2Cl2 (2 mL), treated with H2O (0.03 g, 1.6 mmol)
and CF3COOH (1 mL) followed by work-up with ethereal HCl (2 mL) to give the amine salt
21 (0.03 g, 43% over two steps) as a pale brown solid that rapidly transitioned to a sticky
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1
gum. [𝛼]23
𝐷 +63.1 (c 0.0053, MeOH). H NMR (400 MHz, CD3OD) δ 8.59 (s, 1H, H5), 7.98

(s, 1H, Hα), 7.80 (apparent t, J = 7.5 Hz, 1H, Ar4), 7.44-7.30 (m, 6H, Ar6/Ar2'/Ar3'/Ar4'/Ar5'
/Ar6'), 7.09 (apparent t, J = 7.5 Hz, 1H, Ar5), 6.99 (d, J = 7.5 Hz, 1H, Ar3), 4.88-4.72 (m,
3H, OCHAHB/H1'), 4.66-4.52 (m, 3H, H1'/CH2Ph), 4.48-4.42 (m, 1H, H2'), 3.22-3.12 (m,
2H, H5'), 2.36-2.24 (m, 3H, βC-CH2/H1''), 1.84-1.40 (m, 9H, H3'/H4'/H2''/H3''/H4''/
H5''/H6''), 1.16-1.02 (m, 3H, H2''/H4''/H6''), 0.88-0.78 (m, 2H, H3''/H5'');
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C NMR (101

MHz, CD3OD) δ 171.7 (C=O), 158.7 (C=N), 155.9 (Ar2), 145.8 (C4), 145.6 (Ar1'), 136.8
(Ar6), 131.3 (Cβ), 131.2 (C5), 130.2 (Ar4), 129.7 (Ar3'), 129.6 (Ar5'), 129.5 (Ar2'), 129.3
(Ar6'), 127.4 (Ar4'), 125.4 (Cα), 123.4 (Ar5), 120.2 (Ar1), 114.4 (Ar3), 68.8 (OCHAHB), 56.2
(C1'), 55.4 (CH2Ph), 50.7 (C2'), 42.0 (C5'), 39.0 (C1''), 33.8 (βC-CH2), 32.7 (C2''/C6''), 29.9
(C3'), 27.3 (C4''), 27.1 (C3''/C5''), 26.4 (C4'); IR (neat) 𝜈̅ max 3343, 3272, 3184, 3072, 2926,
2853, 2475, 1900, 1667, 1585, 1549, 1489, 1449, 1351, 1289, 1224, 1179, 1167, 1127, 1079,
1049, 978, 936, 858, 759, 723, 696, 672, 648, 584 cm-1; MS (ESI +ve) m/z 599 ([M – HCl +
H]+, 100%), 300 ([M – HCl + H]2+, 70%); HRMS (ESI +ve TOF) calcd for C32H43N10O2
599.3565, found 599.3562 ([M – HCl + H]+).

(R)-N-(1-(4-Cyclohexyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2-(4isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamide hydrochloride (22)
Following General Procedure IV, azide 60
(0.07 g, 0.09 mmol), cyclohexylacetylene (0.03
g, 0.27 mmol), CuSO4∙5H2O (0.005 g, 0.02
mmol) and sodium ascorbate (0.008 g, 0.04
mmol) were stirred in t-BuOH (2 mL) and H2O
(0.5 mL) for 16 h to give the intermediate 134 as an off-white solid after flash
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chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 3:97). Following General
Procedure VII, the intermediate 134 (0.06 g, 0.07 mmol) was dissolved in CH2Cl2 (2 mL),
treated with H2O (0.03 g, 1.46 mmol) and CF3COOH (1 mL) followed by work-up with
ethereal HCl (2 mL) to give the amine salt 22 (0.03 g, 55% over two steps) as a pale brown
1
solid that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +68.1 (c 0.0047, MeOH). H NMR (400

MHz, CD3OD) δ 8.46 (s, 1H, H5), 8.36 (s, 1H, Hα), 7.65 (apparent t, J = 7.5 Hz, 1H, Ar4),
7.55 (d, J = 7.3 Hz, 1H, Ar6), 7.28-7.18 (m, 2H, Ar5/Ar3), 4.84-4.78 (m, 1H, H1'), 4.72-4.58
(m, 3H, OCHAHB/H1'), 4.50-4.40 (m, 1H, H2'), 3.30-3.20 (m, 2H, H5'), 2.90-2.80 (m, 2H,
H1'''), 2.04-1.94 (m, 2H, H3'), 1.86-1.50 (m, 11H, H4'/H2'''/H3'''/H1''/H2''/H3''/H4''/H5''/
H6''), 1.48-1.20 (m, 5H, H2''/H3''/H4''/H5''/H6''), 0.99 (d, J = 5.0 Hz, 6H, H4'''/H5''');
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C

NMR (101 MHz, CD3OD) δ 170.9 (C=O), 158.7 (C=N), 152.1 (Ar2), 147.9 (Cβ), 132.8 (C4),
127.7 (Ar4), 127.3 (Ar6), 125.9 (C5), 125.3 (Cα), 123.8 (Ar5), 122.3 (Ar3), 115.7 (Ar1),
69.1 (C1'), 67.0 (OCHAHB), 57.2 (C2'), 50.7 (C2'''), 42.1 (C5'), 39.6 (C1''), 33.3 (C2''), 33.2
(C6''), 29.8 (C3'), 29.0 (C1'''), 26.8 (C4''), 26.7 (C3''), 26.5 (C5''), 24.1 (C3'''), 23.6 (C4'), 22.9
(C4'''/C5'''); IR (neat) 𝜈̅ max 3339, 3276, 3180, 2931, 2857, 2481, 1906, 1670, 1603, 1549,
1507, 1465, 1451, 1386, 1368, 1289, 1230, 1168, 1130, 1048, 981, 937, 855, 821, 800, 761,
701, 669 cm-1; MS (ESI +ve) m/z 565 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd
for C29H45N10O2 565.3727, found 565.3731 ([M – HCl + H]+).
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(R)-N-(1-(4-Cyclopentyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2-(4isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamide hydrochloride (23)
Following General Procedure IV, azide 60 (0.07
g, 0.09 mmol), cyclopentylacetylene (0.03 g, 0.29
mmol), CuSO4∙5H2O (0.005 g, 0.02 mmol) and
sodium ascorbate (0.008 g, 0.04 mmol) were
stirred in t-BuOH (2 mL) and H2O (0.5 mL) for
16 h to give the intermediate 135 as an off-white solid after flash chromatography over SiO2
gel (MeOH/CH2Cl2 – 0:100 → 3:97). Following General Procedure VII, the intermediate
135 (0.06 g, 0.07 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.03 g, 1.4
mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (2 mL) to give the
amine salt 23 (0.025 g, 57% over two steps) as a brown solid that rapidly transitioned to a
1
sticky gum. [𝛼]23
𝐷 +58.0 (c 0.0052, MeOH). H NMR (400 MHz, CD3OD) δ 8.58 (s, 1H, H5),

8.45 (brs, 1H, Hα), 7.68-7.58 (m, 1H, Ar6), 7.56-7.46 (m, 1H, Ar4), 7.22-7.06 (m, 2H,
Ar5/Ar3), 4.70-4.56 (m, 2H, OCHAHB), 4.50-4.40 (m, 1H, H1'), 4.38-4.30 (m, 1H, H1'), 4.204.12 (m, 1H, H2'), 3.14-3.02 (m, 3H, H5'/H1''), 2.76-2.62 (m, 2H, H1'''), 1.96-1.84 (m, 2H,
H3'), 1.68-1.38 (m, 13H, H4'/H2'''/H3'''/H2''/H3''/H4''/H5''), 0.90 (d, J = 5.6 Hz, 6H, H4'''/
H5'''); 13C NMR (101 MHz, CD3OD) δ 167.2 (C=O), 156.7 (C=N), 150.6 (Ar2), 149.6 (Cβ),
146.7 (C4), 129.9 (Ar4), 125.9 (Ar6), 125.1 (Cα), 123.5 (C5), 121.6 (Ar5), 121.5 (Ar3), 113.9
(Ar1), 69.7 (C1'), 58.4 (OCHAHB), 50.7 (C2'), 42.3 (C2'''), 39.2 (C5'), 36.1 (C1''), 33.9 (C3'),
29.8 (C1'''), 28.9 (C2''/C5''), 26.7 (C3''/C4''), 26.2 (C3'''), 24.0 (C4'), 22.9 (C4'''/C5'''); IR
(neat) 𝜈̅ max 3344, 3276, 3184, 2957, 2871, 2478, 2110, 1895, 1722, 1668, 1603, 1551, 1505,
1469, 1453, 1385, 1368, 1288, 1229, 1168, 1131, 1080, 1050, 993, 939, 854, 801, 760, 653,
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586 cm-1; MS (ESI +ve) m/z 551 ([M – HCl + H]+, 100%), 276 ([M – HCl + H]2+, 80%);
HRMS (ESI +ve TOF) calcd for C28H43N10O2 551.3565, found 551.3572 ([M – HCl + H]+).

(R)-N-(1-(4-(4-Fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2-(4isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamide hydrochloride (24)
Following General Procedure IV, azide 60
(0.06 g, 0.09 mmol), 1-ethynyl-4-fluoro
benzene (0.03 g, 0.27 mmol), CuSO4∙5H2O
(0.005 g, 0.02 mmol) and sodium ascorbate
(0.008 g, 0.04 mmol) were stirred in t-BuOH (2
mL) and H2O (0.5 mL) for 16 h to give the intermediate 136 as an off-white solid after flash
chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 3:97). Following General
Procedure VII, the intermediate 136 (0.06 g, 0.07 mmol) was dissolved in CH2Cl2 (2 mL),
treated with H2O (0.03 g, 1.4 mmol) and CF3COOH (1 mL) followed by work-up with
ethereal HCl (2 mL) to give the amine salt 24 (0.03 g, 54% over two steps) as an off-white
1
solid that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +74.2 (c 0.0051, MeOH). H NMR (400

MHz, DMSO-d6) δ 8.51 (s, 1H, H5), 8.39 (brs, 2H, N5-H/C=NH), 7.86-7.78 (m, 3H,
NH2.HCl), 7.59 (d, J = 7.5 Hz, 1H, Ar6), 7.50-7.38 (m, 1H, CONH), 7.32-7.22 (m, 4H,
Hα/Ar4/H2''/H6''), 7.08 (t, J = 7.5 Hz, 1H, Ar3), 7.02 (d, JH-F = 8.5 Hz, 2H, H3''/H5''), 7.026.90 (m, 1H, Ar5), 4.65 (ABq, J = 15.8 Hz, 2H, OCHAHB), 4.54-4.40 (m, 2H, H1'), 4.284.18 (m, 1H, H2'), 3.12-3.02 (m, 2H, H5'), 2.64 (t, J = 7.5 Hz, 2H, H1'''), 1.62-1.40 (m, 7H,
H3'/H4'/H2'''/H3'''), 0.88 (d, J = 6.5 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, DMSO-d6) δ
167.5 (C=O), 161.7 (d, JC-F = 196.4 Hz, C4''), 156.9 (C=N), 149.7 (Ar2), 146.9 (Cβ), 145.3
(C4), 130.0 (Ar4), 127.3 (d, JC-F = 3.0 Hz, C1''), 127.2 (Ar6), 127.1 (Cα), 126.1 (C5), 125.3
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(Ar5), 123.7 (Ar3), 121.8 (d, JC-F = 22.3 Hz, C2''/C6''), 115.8 (d, JC-F = 16.9 Hz, C3''/C5''),
114.0 (Ar1), 67.3 (C1'), 64.9 (OCHAHB), 52.7 (C2'), 48.7 (C2'''), 40.3 (C5'), 28.3 (C3'), 27.1
(C1'''), 25.0 (C3'''), 22.9 (C4'), 22.3 (C4'''/C5'''); IR (neat) 𝜈̅ max 3342, 3273, 3182, 2957, 2871,
2489, 1895, 1667, 1559, 1501, 1469, 1414, 1387, 1367, 1286, 1230, 1191, 1166, 1132, 1081,
1049, 993, 975, 941, 843, 816, 759, 666, 654, 600, 585 cm-1; MS (ESI +ve) m/z 577 ([M –
HCl + H]+, 100%), 289 ([M – HCl + H]2+, 20%); HRMS (ESI +ve TOF) calcd for
C29H37N10O2ClF 611.2768, found 611.2771 ([M + H]+).

(R)-N-(1-(4-Benzyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2-(4-isopentyl1H-1,2,3-triazol-1-yl)phenoxy)acetamide hydrochloride (25)
Following General Procedure IV, azide 60 (0.07
g, 0.09 mmol), 3-phenyl-1-propyne (0.03 g, 0.27
mmol), CuSO4∙5H2O (0.005 g, 0.02 mmol) and
sodium ascorbate (0.008 g, 0.04 mmol) were
stirred in t-BuOH (2 mL) and H2O (0.5 mL) for
16 h to give the intermediate 137 as an off-white gum after flash chromatography over SiO2
gel (MeOH/CH2Cl2 – 0:100 → 3:97). Following General Procedure VII, the intermediate
137 (0.06 g, 0.07 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.03 g, 1.4
mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (2 mL) to give the
amine salt 25 (0.029 g, 53% over two steps) as a brown solid that rapidly transitioned to a
1
sticky gum. [𝛼]23
𝐷 +68.1 (c 0.0042, MeOH). H NMR (400 MHz, CD3OD) δ 8.76 (brs, 1H,

H5), 8.38 (brs, 1H, Hα), 7.68 (d, J = 7.5 Hz, 1H, Ar6), 7.55 (t, J = 8.0 Hz, 1H, Ar4), 7.327.20 (m, 6H, Ar5/H2''/H3''/H4''/H5''/H6''), 7.15 (d, J = 8.0 Hz, 1H, Ar3), 4.82-4.76 (m, 1H,
OCHAHB), 4.68-4.56 (m, 3H, OCHAHB/H1'), 4.48-4.40 (m, 1H, H2'), 4.15 (s, 2H, CH2Ph),
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3.28-3.16 (m, 2H, H5'), 2.92-2.84 (m, 2H, H1'''), 1.84-1.50 (m, 7H, H3'/H4'/H2'''/H3'''), 0.99
(d, J = 4.0 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 170.4 (C=O), 158.6 (C=N),
151.8 (Ar2), 137.6 (Cβ), 133.1 (C4), 131.1 (C1''), 130.8 (Ar4), 130.0 (C2''/C6''), 129.8 (Ar6),
129.7 (C3''/C5''), 128.34 (C5), 128.33 (C4''), 127.2 (Cα), 123.64 (Ar5), 123.63 (Ar3), 115.4
(Ar1), 68.7 (C1'), 66.8 (OCHAHB), 56.8 (C2'), 50.5 (C2'''), 41.9 (C5'), 38.8 (C3'), 29.5
(CH2Ph), 28.8 (C1'''), 26.2 (C3'''), 23.4 (C4'), 22.6 (C4'''/C5'''); IR (neat) 𝜈̅ max 3338, 3274,
3182, 3073, 2957, 2934, 2870, 2470, 1902, 1669, 1603, 1549, 1507, 1465, 1386, 1368, 1288,
1230, 1167, 1132, 1049, 983, 936, 855, 799, 760, 721, 697, 669, 644 cm-1; MS (ESI +ve) m/z
573 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd for C30H41N10O2 573.3414, found
573.3434 ([M – HCl + H]+).

(R)-N-(1-(4-Cyclohexyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2-(5isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamide hydrochloride (26)
Following General Procedure IV, azide 62
(0.07 g, 0.09 mmol), cyclohexylacetylene (0.03
g, 0.27 mmol), CuSO4∙5H2O (0.005 g, 0.02
mmol) and sodium ascorbate (0.008 g, 0.04
mmol) were stirred in t-BuOH (2 mL) and H2O
(0.5 mL) for 16 h to give the intermediate 138 as a pale brown solid after flash
chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 5:95). Following General
Procedure VII, the intermediate 138 (0.06 g, 0.07 mmol) was dissolved in CH2Cl2 (2 mL),
treated with H2O (0.03 g, 1.46 mmol) and CF3COOH (1 mL) followed by work-up with
ethereal HCl (3 mL) to give the amine salt 26 (0.03 g, 56% over two steps) as a pale brown
1
solid that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +59.7 (c 0.0058, MeOH). H NMR (400
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MHz, CD3OD) δ 7.98 (d, J = 8.4 Hz, 1H, Ar4), 7.75 (s, 1H, H4), 7.74 (s, 1H, Hα), 7.63-7.57
(m, 1H, Ar6), 7.48 (dd, J = 7.7, 1.6 Hz, 1H, Ar5), 7.09 (d, J = 8.4 Hz, 1H, Ar3), 4.59 (ABq,
J = 15.1 Hz, 2H, OCHAHB), 4.51-4.46 (m, 1H, H1'), 4.40-4.33 (m, 1H, H1'), 4.26-4.16 (m,
1H, H2'), 3.18-3.08 (m, 2H, H1'''), 2.72-2.62 (m, 2H, H5'), 2.00-1.88 (m, 2H, H3'), 1.84-1.68
(m, 3H, H1''/H2'''), 1.62-1.18 (m, 13H, H3'''/H2''/H3''/ H4''/H5''/H6''/H4'), 0.82 (d, J = 6.4 Hz,
6H, H4'''/H5''');

C NMR (101 MHz, CD3OD) δ 167.4 (C=O), 157.3 (C=N), 152.8 (Ar2),
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152.0 (Cβ), 140.4 (C5), 133.4 (C4), 132.0 (Ar4), 131.6 (Ar6), 128.9 (Ar1), 125.0 (Cα), 121.8
(Ar5), 114.0 (Ar3), 67.1 (OCHAHB), 53.0 (C1'), 49.0 (C2'), 36.8 (C5'), 34.8 (C2'''), 32.89
(C1''), 32.85 (C2''/C6''), 28.9 (C3'), 27.3 (C3'''), 26.0 (C1'''), 25.9 (C4''), 25.3 (C3''/C5''), 22.4
(C4'), 20.7 (C4'''/C5'''); IR (neat) 𝜈̅ max 3339, 3276, 3185, 2932, 2858, 2476, 1907, 1670, 1603,
1549, 1507, 1465, 1451, 1386, 1368, 1289, 1230, 1169, 1131, 1048, 983, 954, 938, 855, 822,
800, 762, 700, 669, 643 cm-1; MS (ESI +ve) m/z 565 ([M – HCl + H]+, 100%); HRMS (ESI
+ve TOF) calcd for C29H45N10O2 565.3727, found 565.3734 ([M + H]+).

(R)-N-(1-(4-(Cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2(5-isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamide hydrochloride (27)
Following General Procedure IV, azide 62 (0.07
g, 0.09 mmol), 3-cyclohexyl-1-propyne (0.03 g,
0.27 mmol), CuSO4∙5H2O (0.005 g, 0.02 mmol)
and sodium ascorbate (0.008 g, 0.04 mmol) were
stirred in t-BuOH (2 mL) and H2O (0.5 mL) for 16
h to give the intermediate 139 as a white solid after flash chromatography over SiO2 gel
(MeOH/CH2Cl2 – 0:100 → 5:95). Following General Procedure VII, the intermediate 139
(0.07 g, 0.08 mmol) was dissolved in CH 2Cl2 (2 mL), treated with H2O (0.03 g, 1.6 mmol)
196

and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL) to give the amine salt
27 (0.03 g, 54% over two steps) as a pale-yellow solid that rapidly transitioned to a sticky
1
gum. [𝛼]23
𝐷 +62.1 (c 0.0051, MeOH). H NMR (400 MHz, CD3OD) δ 8.27 (brs, 1H, H4),

7.95 (brs, 1H, Hα), 7.63 (t, J = 7.4 Hz, 1H, Ar4), 7.47 (d, J = 7.4 Hz, 1H, Ar6), 7.30-7.22 (m,
2H, Ar5/Ar3), 4.79-4.69 (m, 1H, H1'), 4.63-4.49 (m, 3H, OCHAHB/H1'), 4.47-4.39 (m, 1H,
H2'), 3.22-3.10 (m, 2H, H1'''), 2.77-2.61 (m, 4H, βC-CH2/H5'), 1.84-1.36 (m, 13H,
H3'/H4'/H2'''/H3'''/H1''/H2''/H3''/H4''/H5''/H6''), 1.34-1.09 (m, 3H, H2''/H4''/H6''), 1.04-0.90
(m, 2H, H3''/H5''), 0.81 (d, J = 6.1 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 168.7
(C=O), 157.2 (C=N), 152.5 (Ar2), 145.6 (Cβ), 140.8 (C5), 140.1 (Ar4), 132.6 (C4), 131.7
(Ar6), 128.5 (Ar1), 123.8 (Cα), 122.2 (Ar5), 113.9 (Ar3), 67.1 (OCHAHB), 56.1 (C1'), 49.1
(C2'), 40.5 (C5'), 37.3 (C2'''), 36.6 (C1''), 32.2 (βC-CH2), 30.6 (C2''/C6''), 28.2 (C3'), 27.2
(C3'''), 25.7 (C1'''), 25.6 (C4''), 24.9 (C3''/C5''), 21.1 (C4'), 20.9 (C4'''/C5'''); IR (neat) 𝜈̅ max
3345, 3275, 3186, 2953, 2927, 2854, 2482, 1909, 1670, 1603, 1550, 1507, 1465, 1450, 1386,
1368, 1288, 1229, 1168, 1130, 1084, 1049, 983, 958, 935, 854, 761, 669, 648, 585 cm-1; MS
(ESI +ve) m/z 579 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd for C30H47N10O2
579.3877, found 579.3876 ([M – HCl + H]+).

(R)-N-(1-(4-Benzyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2-(5-isopentyl1H-1,2,3-triazol-1-yl)phenoxy)acetamide hydrochloride (28)
Following General Procedure IV, azide 62
(0.07 g, 0.09 mmol), 3-phenyl-1-propyne (0.03
g, 0.27 mmol), CuSO4∙5H2O (0.005 g, 0.02
mmol) and sodium ascorbate (0.008 g, 0.04
mmol) were stirred in t-BuOH (2 mL) and H2O
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(0.5 mL) for 16 h to give the intermediate 140 as an off-white gum after flash chromatography
over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 5:95). Following General Procedure VII, the
intermediate 140 (0.07 g, 0.08 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O
(0.03 g, 1.6 mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL) to
give the amine salt 28 (0.03 g, 55% over two steps) as a pale brown solid that rapidly
1
transitioned to a sticky gum. [𝛼]23
𝐷 +73.6 (c 0.0046, MeOH). H NMR (400 MHz, CD3OD)

δ 8.22 (brs, 1H, H4), 8.11 (brs, 1H, Hα), 7.62 (t, J = 7.7 Hz, 1H, Ar4), 7.48 (d, J = 7.3 Hz,
1H, Ar6), 7.31-7.22 (m, 6H, Ar5/H2''/H3''/H4''/H5''/H6''), 7.17 (d, J = 7.7 Hz, 1H, Ar3), 4.804.70 (m, 1H, H1'), 4.52-4.44 (m, 3H, OCHAHB/H1'), 4.42-4.32 (m, 1H, H2'), 4.16 (s, 2H,
CH2Ph), 3.24-3.12 (m, 2H, H1'''), 2.72-2.62 (m, 2H, H5'), 1.83-1.42 (m, 7H, H3'/H4'/
H2'''/H3'''), 0.81 (d, J = 5.6 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 167.4 (C=O),
157.3 (C=N), 152.8 (Ar2), 146.1 (Cβ), 140.4 (C5), 139.9 (C1''), 132.0 (C4), 131.6 (Ar4),
128.9 (C2''/C6''), 128.8 (C3''/C5''), 128.7 (Ar6), 126.5 (C4''), 125.0 (Ar1), 123.6 (Cα), 121.9
(Ar5), 114.0 (Ar3), 67.0 (OCHAHB), 55.3 (C1'), 52.9 (C2'), 40.5 (C5'), 36.7 (C2'''), 31.6
(CH2Ph), 28.9 (C3'), 27.3 (C3'''), 25.3 (C1'''), 22.4 (C4'), 20.7 (C4'''/C5'''); IR (neat) 𝜈̅ max 3341,
3276, 3181, 3088, 3075, 2956, 2934, 2870, 2470, 1914, 1669, 1603, 1549, 1507, 1465, 1385,
1368, 1288, 1229, 1168, 1131, 1049, 982, 936, 855, 799, 759, 721, 698, 669, 645 cm-1; MS
(ESI +ve) m/z 573 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd for C30H41N10O2
573.3414, found 573.3420 ([M – HCl + H]+).
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(R)-N-(1-(4-Cyclohexyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-((1-(4isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamide hydrochloride (29)
Following General Procedure IV, azide
64 (0.07 g, 0.09 mmol), cyclohexyl
acetylene

(0.03

g,

0.27

mmol),

CuSO4∙5H2O (0.005 g, 0.01 mmol) and
sodium ascorbate (0.008 g, 0.03 mmol)
were stirred in t-BuOH (2.0 mL) and H2O
(0.5 mL) for 16 h to give the intermediate 141 as an off-white gum after flash chromatography
over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 6:94). Following General Procedure VII, the
intermediate 141 (0.06 g, 0.06 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O
(0.03 g, 1.26 mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL)
to give the amine salt 29 (0.03 g, 72% over two steps) as a pale brown solid that rapidly
1
transitioned to a sticky gum. [𝛼]23
𝐷 +58.1 (c 0.0061, MeOH); H NMR (400 MHz, CD3OD)

δ 8.36 (brs, 1H, H5), 8.18 (s, 1H, Hα), 8.19 (d, J = 8.9 Hz, 1H, Ar8), 8.00 (d, J = 7.9 Hz, 1H,
Ar5), 7.59-7.46 (m, 3H, Ar4/Ar6/Ar7), 7.16 (d, J = 8.1 Hz, 1H, Ar3), 4.80-4.68 (m, 3H,
OCHAHB/H1'), 4.62-4.60 (m, 1H, H1'), 4.58-4.42 (m, 1H, H2'), 3.15-3.14 (m, 2H, H5'), 2.942.91 (m, 2H, H1'''), 2.72 (brs, 1H, H1''), 1.91-1.88 (m, 2H, H3'), 1.79-1.57 (m, 10H,
H4'/H2'''/H3'''/H2''/H3''/H4''/H5''/H6''), 1.20-1.16 (m, 5H, H2''/H3''/H4''/H5''/H6''), 1.01 (d, J
= 5.8 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 169.2 (C=O), 157.1 (C=N), 150.6
(Ar2), 149.3 (C4), 147.6 (Cβ), 132.7 (Ar8a), 130.2 (Ar4), 129.3 (Ar4a), 128.2 (Ar5), 128.1
(Ar7), 127.0 (Ar8), 125.7 (C5), 125.2 (Cα), 120.2 (Ar6), 119.3 (Ar3), 113.8 (Ar1), 67.7
(OCHAHB), 55.7 (C1'), 49.1 (C2'), 40.4 (C5'), 37.9 (C2'''), 33.3 (C1''), 31.5 (C2''), 31.4 (C6''),
28.1 (C1'''), 27.5 (C3'), 25.16 (C3'''), 25.13 (C4''), 25.0 (C3''), 24.8 (C5''), 22.6 (C4'), 21.3
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(C4'''/C5'''); IR (neat) 𝜈̅ max 3342, 3275, 3181, 2931, 2856, 1669, 1633, 1601, 1550, 1513,
1483, 1451, 1384, 1367, 1280, 1231, 1172, 1152, 1118, 1081, 1049, 860, 812, 778, 749, 668,
648, 588 cm-1; MS (ESI +ve) m/z 615 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd
for C33H47N10O2 615.5300, found 615.3877 ([M – HCl + H]+).

(R)-N-(1-(4-(Cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-((1(4-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamide hydrochloride (30)
Following General Procedure IV, azide 64
(0.07 g, 0.09 mmol), 3-cyclohexyl-1-propyne
(0.03 g, 0.27 mmol), CuSO4∙5H2O (0.005 g,
0.02 mmol) and sodium ascorbate (0.008 g,
0.04 mmol) were stirred in t-BuOH (2 mL)
and H2O (0.5 mL) for 16 h to give the
intermediate 142 as an off-white gum after flash chromatography over SiO2 gel
(MeOH/CH2Cl2 – 0:100 → 5:95). Following General Procedure VII, the intermediate 142
(0.06 g, 0.06 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.03 g, 1.36 mmol)
and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL) to give the amine salt
30 (0.03 g, 66% over two steps) as a pale-yellow solid that rapidly transitioned to a sticky
1
gum. [𝛼]23
𝐷 +74.1 (c 0.0056, MeOH). H NMR (400 MHz, CD3OD) δ 8.19 (s, 1H, H5), 8.14

(d, J = 8.0 Hz, 1H, Ar8), 8.00 (t, J = 8.9 Hz, 1H, Ar5), 7.70-7.62 (m, 1H, Ar6), 7.61 (s, 1H,
Hα), 7.58-7.45 (m, 1H, Ar7), 7.39 (d, J = 8.1 Hz, 1H, Ar4), 6.99 (d, J = 8.1 Hz, 1H, Ar3),
4.62 (s, 2H, OCHAHB), 4.48-4.36 (m, 1H, H1'), 4.36-4.24 (m, 1H, H1'), 4.22-4.08 (m, 1H,
H2'), 3.08-2.96 (m, 2H, H5'), 2.80-2.70 (m, 2H, H1'''), 2.37 (d, J = 6.2 Hz, 2H, βC-CH2),
1.70-1.32 (m, 13H, H3'/H4'/H2'''/H3'''/H1''/H2''/H3''/H4''/H5''/H6''), 1.16-0.99 (m, 3H, H2''/
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H4''/H6''), 0.92 (d, J = 2.4 Hz, 6H, H4'''/H5'''), 0.81-0.78 (m, 2H, H3''/H5''); 13C NMR (101
MHz, CD3OD) δ 167.8 (C=O), 157.4 (C=N), 150.9 (Ar2), 147.4 (C4), 145.2 (Cβ), 132.1
(Ar8a), 130.7 (Ar4), 128.96 (Ar4a), 128.93 (Ar5), 128.5 (Ar7), 125.9 (Ar8), 125.3 (C5),
123.7 (Cα), 121.3 (Ar6), 119.9 (Ar3), 115.2 (Ar1), 68.1 (OCHAHB), 53.1 (C1'), 49.1 (C2'),
40.7 (C5', Observed by gHMBC), 38.5 (C2'''), 37.8 (βC-CH2), 33.0 (C1'', Observed by
gHMBC), 32.9 (C2''), 32.7 (C6''), 28.9 (C1'''), 27.6 (C3'), 26.4 (C3'''), 26.4 (C4'', Observed
by gHMBC), 26.0 (C3''), 25.4 (C5''), 23.5 (C4'), 22.8 (C4'''/C5'''); IR (neat) 𝜈̅ max 3339, 3273,
3177, 2953, 2927, 2854, 1907, 1668, 1634, 1601, 1549, 1514, 1483, 1450, 1383, 1367, 1350,
1281, 1231, 1221, 1153, 1117, 1083, 1052, 1025, 964, 919, 862, 811, 778, 750, 647, 608 cm; MS (ESI +ve) m/z 629 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd for

1

C34H49N10O2 629.4034, found 629.4032 ([M – HCl + H]+).

(R)-N-(1-(4-Benzyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-((1-(4-isopentyl1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamide hydrochloride (31)
Following General Procedure IV, azide
64 (0.07 g, 0.09 mmol), 3-phenyl-1propyne (0.03 g, 0.27 mmol), CuSO4∙5H2O
(0.005 g, 0.02 mmol) and sodium ascorbate
(0.008 g, 0.04 mmol) were stirred in tBuOH (2 mL) and H2O (0.5 mL) for 16 h
to give the intermediate 143 as a pale-yellow solid gum after flash chromatography over SiO2
gel (MeOH/CH2Cl2 – 0:100 → 4:96). Following General Procedure VII, the intermediate
143 (0.06 g, 0.06 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.03 g, 1.2
mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL) to give the
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amine salt 31 (0.028 g, 68% over two step) as a pale brown solid that rapidly transitioned to
1
a sticky gum. [𝛼]23
𝐷 +66.1 (c 0.0048, MeOH). H NMR (400 MHz, CD3OD) δ 8.42 (s, 1H,

H5), 8.21 (s, 1H, Hα), 8.16 (d, J = 8.9 Hz, 1H, Ar8), 7.99 (d, J = 7.9 Hz, 1H, Ar5), 7.60-7.48
(m, 2H, Ar6/Ar7), 7.41 (d, J = 9.0 Hz, 1H, Ar4), 7.27-7.15 (m, 6H, Ar3/H2''/H3''/H4''/H5''/
H6''), 4.78-4.72 (m, 1H, H1'), 4.67 (ABq, J = 17.6 Hz, 2H, OCHAHB), 4.60-4.52 (m, 1H,
H1'), 4.42-4.34 (m, 1H, H2'), 4.08 (s, 2H, CH2Ph), 3.22-3.08 (m, 2H, H5'), 3.00-2.88 (m, 2H,
H1'''), 1.84-1.46 (m, 7H, H3'/H4'/H2'''/H3'''), 0.99 (d, J = 5.7 Hz, 6H, H4'''/H5'''); 13C NMR
(101 MHz, CD3OD) δ 169.1 (C=O), 157.1 (C=N), 150.6 (Ar2), 147.0 (C4), 144.4 (Cβ), 136.0
(C1''), 132.9 (Ar8a), 130.0 (Ar4), 129.2 (Ar4a), 128.9 (Ar5), 128.68 (C2''), 128.65 (C6''),
128.3 (C3''/C5''), 128.1 (Ar7), 127.8 (C4''), 127.0 (Ar8), 126.8 (C5), 125.3 (Cα), 120.1 (Ar6),
118.8 (Ar3), 113.7 (Ar1), 67.7 (OCHAHB), 55.4 (C1'), 49.2 (C2'), 40.5 (C5'), 37.6 (C2'''),
34.9 (CH2Ph, Observed by gHMBC), 29.3 (C1'''), 28.1 (C3'), 27.5 (C3'''), 24.8 (C4'), 22.3
(C4'''/C5'''); IR (neat) 𝜈̅ max 3339, 3272, 3182, 3067, 2956, 2869, 1901, 1669, 1634, 1601,
1550, 1513, 1496, 1482, 1454, 1433, 1382, 1367, 1281, 1232, 1221, 1153, 1120, 1080, 1049,
967, 931, 863, 811, 778, 750, 721, 698, 674, 648 cm-1; MS (ESI +ve) m/z 623 ([M – HCl +
H]+, 100%); HRMS (ESI +ve TOF) calcd for C34H43N10O2 623.3564, found 623.3561 ([M –
HCl + H]+).
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N-((R)-1-(4-Cyclohexyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-((1-(5isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamide hydrochloride (32)
Following General Procedure IV, azide
66 (0.07 g, 0.09 mmol), cyclohexyl
acetylene

(0.03

g,

0.27

mmol),

CuSO4∙5H2O (0.005 g, 0.02 mmol) and
sodium ascorbate (0.008 g, 0.04 mmol)
were stirred in t-BuOH (2 mL) and H2O (0.5 mL) for 16 h to give the intermediate 144 as a
brown gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 4:96).
Following General Procedure VII, the intermediate 144 (0.07 g, 0.08 mmol) was dissolved
in CH2Cl2 (2 mL), treated with H2O (0.03 g, 1.6 mmol) and CF3COOH (1 mL) followed by
work-up with ethereal HCl (3 mL) to give the amine salt 32 (0.036 g, 52% over two steps)
as a pale brown solid that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +65.6 (c 0.0062,
MeOH). 1H NMR (400 MHz, CD3OD) δ 8.41 (brs, 1H, H4), 8.34-8.16 (m, 2H, Hα/HAr8),
8.08-8.00 (m, 2H, Ar5/Ar4), 7.60-7.50 (m, 2H, Ar6/Ar7), 6.99 (d, J = 9.6 Hz, 1H, Ar3), 4.864.78 (m, 2H, OCHAHB), 4.70-4.56 (m, 2H, H1'), 4.44-4.32 (m, 1H, H2'), 3.05 (t, J = 7.0 Hz,
2H, H5'), 2.66-2.58 (m, 1H, H1''), 2.56-2.44 (m, 2H, H1'''), 2.04-1.50 (m, 10H,
H4'/H2'''/H3'''/H2''/H3''/H4''/H5''/H6''), 1.48-1.06 (m, 7H, H3'/H2''/H3''/H4''/H5''/H6''), 0.69
(d, J = 7.0 Hz, 3H, H4'''), 0.67 (d, J = 7.1 Hz, 3H, H5'''); 13C NMR (101 MHz, CD3OD) δ
169.1 (C=O), 157.2 (C=N), 151.3 (Ar2), 142.9 (Cβ), 133.1 (C5), 131.7 (Ar8a), 130.5 (C4),
129.3 (Ar4), 128.9 (Ar4a), 128.3 (Ar5), 126.2 (Ar7), 125.3 (Ar8), 120.26 (Ar6), 120.23 (Cα),
117.7 (Ar3), 113.8 (Ar1), 67.6 (OCHAHB), 55.9 (C1'), 49.3 (C2'), 40.6 (C5'), 36.5 (C2'''),
33.3 (C1''), 31.5 (C2''), 31.4 (C6''), 28.3 (C1'''), 27.0 (C3'), 25.2 (C3'''), 25.1 (C4''), 25.0 (C3''),
24.8 (C5''), 20.9 (C4'), 20.6 (C4'''/C5'''); IR (neat) 𝜈̅ max 3338, 3268, 3179, 3073, 2932, 2857,
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2481, 1903, 1669, 1632, 1601, 1549, 1512, 1482, 1451, 1385, 1367, 1351, 1272, 1234, 1224,
1170, 1154, 1132, 1090, 1048, 990, 972, 941, 920, 858, 816, 750, 652 cm-1; MS (ESI +ve)
m/z 616 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd for C33H47N10O2 615.3883,
found 615.3873 ([M – HCl + H]+).

N-((R)-1-(4-(Cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-((1(5-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamide hydrochloride (33)
Following General Procedure IV, azide 66
(0.07 g, 0.09 mmol), 3-cyclohexyl-1-propyne
(0.03 g, 0.27 mmol), CuSO4∙5H2O (0.005 g,
0.02 mmol) and sodium ascorbate (0.008 g,
0.04 mmol) were stirred in t-BuOH (2 mL) and
H2O (0.5 mL) for 16 h to give the intermediate 145 as an off-white gum after flash
chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 4:96). Following General
Procedure VII, the intermediate 145 (0.07 g, 0.08 mmol) was dissolved in CH2Cl2 (2 mL),
treated with H2O (0.03 g, 1.6 mmol) and CF3COOH (1 mL) followed by work-up with
ethereal HCl (3 mL) to give the amine salt 33 (0.03 g, 51% over two steps) as a pale brown
1
solid that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +58.1 (c 0.0044, MeOH). H NMR (400

MHz, CD3OD) δ 8.35 (s, 1H, H4), 8.19 (s, 1H, Hα), 8.08-8.00 (m, 2H, Ar8/Ar5), 7.58-7.50
(m, 3H, Ar4/Ar6/Ar7), 6.99 (d, J = 9.6 Hz, 1H, Ar3), 4.78 (ABq, J = 19.0 Hz, 2H, OCHAHB),
4.67-4.54 (m, 2H, H1'/H2'), 4.44-4.30 (m, 1H, H1'), 3.26-3.20 (m, 1H, H1'''), 3.11-2.93 (m,
1H, H1'''), 2.67 (d, J = 12.8 Hz, 1H, βC-CH2), 2.54-2.44 (m, 3H, H5'/βC-CH2), 1.85-1.30 (m,
13H, H3'/H4'/H2'''/H3'''/H1''/H2''/H3''/H4''/H5''/H6''), 1.29-1.04 (m, 3H, H2''/H4''/H6''), 1.020.78 (m, 2H, H3''/H5''), 0.72-0.62 (m, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 168.8
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(C=O), 157.0 (C=N), 151.0 (Ar2), 142.9 (C5), 132.9 (Ar8a), 131.6 (C4), 130.6 (Cβ), 129.4
(Ar4), 128.9 (Ar4a), 128.3 (Ar5), 126.8 (Ar7), 125.3 (Ar8), 120.3 (Ar6), 120.2 (Cα), 117.7
(Ar3), 113.8 (Ar1), 67.6 (OCHAHB), 55.5 (C1'), 49.3 (C2'), 37.5 (C2'''), 36.5 (C5'), 33.9
(C1''), 33.0 (Cβ-CH2), 32.3 (C2''), 32.2 (C6''), 30.9 (C3'), 30.7 (3'''), 28.3 (C1'''), 28.1 (C4''),
27.0 (C3''), 25.7 (C5''), 25.7 (C4'), 25.6 (C4'''/5'''); IR (neat) 𝜈̅ max 3341, 3271, 3180, 3082,
2953, 2927, 2854, 2468, 1916, 1670, 1632, 1601, 1549, 1512, 1483, 1450, 1384, 1368, 1349,
1223, 1169, 1154, 1132, 1091, 1049, 1025, 991, 973, 935, 918, 863, 814, 780, 750, 678, 651
cm-1; MS (ESI +ve) m/z 630 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd for
C34H49N10O2 629.4040, found 629.4059 ([M – HCl + H]+).

N-((R)-1-(4-Benzyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-((1-(5-isopentyl1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamide hydrochloride (34)
Following General Procedure IV, azide
66 (0.07 g, 0.09 mmol), 3-phenyl-1propyne (0.03 g, 0.27 mmol), CuSO4∙5H2O
(0.005 g, 0.02 mmol) and sodium ascorbate
(0.008 g, 0.04 mmol) were stirred in tBuOH (2 mL) and H2O (0.5 mL) for 16 h to give the intermediate 146 as an off-white gum
after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 6:94). Following
General Procedure VII, the intermediate 146 (0.07 g, 0.08 mmol) was dissolved in CH2Cl2
(2 mL), treated with H2O (0.03 g, 1.6 mmol) and CF3COOH (1 mL) followed by work-up
with ethereal HCl (3 mL) to give the amine salt 34 (0.034 g, 57% over two steps) as a brown
1
solid that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +73.7 (c 0.0051, MeOH). H NMR (400

MHz, CD3OD) δ 8.23-8.08 (m, 3H, H4/Hα/Ar8), 8.02 (d, J = 8.2 Hz, 1H, Ar5), 7.60-7.38
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(m, 3H, Ar4/Ar6/Ar7), 7.31-7.13 (m, 5H, H2''/H3''/H4''/H5''/H6''), 7.00 (d, J = 8.5 Hz, 1H,
Ar3), 4.71 (ABq, J = 18.2 Hz, 2H, OCHAHB), 4.64-4.56 (m, 1H, H1'), 4.56-4.46 (m, 1H,
H2'), 4.42-4.28 (m, 1H, H1'), 4.15 (s, 1H, CH2Ph), 4.01 (s, 1H, CH2Ph), 3.21-3.15 (m, 1H,
H1'''), 3.10-2.99 (m, 1H, H1'''), 2.51 (m, 2H, H5'), 1.82-1.52 (m, 3H, H2'''/H3'''), 1.50-1.29
(m, 4H, H3'/H4'), 0.69 (d, J = 5.7 Hz, 3H, H4'''), 0.66 (d, J = 7.2 Hz, 3H, H5'''); 13C NMR
(101 MHz, CD3OD) δ 167.5 (C=O), 157.8 (C=N), 151.8 (Ar2), 149.6 (C5), 140.4 (Ar8a),
138.5 (C1''), 133.3 (C4), 132.5 (Cβ), 130.3 (Ar4), 129.2 (Ar4a), 128.86 (C2''/C6''), 128.82
(Ar5), 128.74 (C3''/C5''), 128.71 (C4''), 128.6 (Ar7), 126.5 (Ar8), 125.3 (Ar6), 121.1 (Cα),
115.5 (Ar3), 115.4 (Ar1), 68.3 (OCHAHB), 62.7 (C1'), 53.0 (C2'), 41.1 (C2'''), 40.8 (C5'),
36.8 (CH2Ph), 31.8 (C3'), 31.7 (3'''), 29.1 (C1'''), 25.3 (C4'), 22.1 (C4'''/5'''); IR (neat) 𝜈̅ max
3343, 3273, 3181, 3065, 2956, 2934, 2869, 2469, 1906, 1669, 1633, 1601, 1549, 1512, 1497,
1482, 1454, 1384, 1367, 1351, 1277, 1234, 1223, 1169, 1153, 1132, 1086, 1049, 992, 972,
934, 919, 863, 813, 780, 751, 722, 698, 652 cm-1; MS (ESI +ve) m/z 624 ([M – HCl + H]+,
100%); HRMS (ESI +ve TOF) calcd for C34H43N10O2 623.3570, found 623.3581 ([M – HCl
+ H]+).
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(R)-6-Amino-N-((R)-1-(4-benzyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2(2-(1-benzyl-1H-1,2,3-triazol-4-yl)phenoxy)acetamido)hexanamide

dihydrochloride

(35)
Following General Procedure IV,
azide 59 (0.07 g, 0.07 mmol), 3-phenyl1-propyne

(0.03

g,

0.22

mmol),

CuSO4∙5H2O (0.004 g, 0.01 mmol) and
sodium ascorbate (0.006 g, 0.03 mmol)
were stirred in t-BuOH (2 mL) and H2O
(0.5 mL) for 16 h to give the intermediate 147 as an off-white solid after flash
chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 6:94). Following General
Procedure VII, the intermediate 147 (0.06 g, 0.056 mmol) was dissolved in CH2Cl2 (2 mL),
treated with H2O (0.02 g, 1.11 mmol) and CF3COOH (1 mL) followed by work-up with
ethereal HCl (2 mL) to give the amine salt 35 (0.03 g, 55% over two steps) as a pale brown
1
solid that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +65.3 (c 0.0052, MeOH). H NMR (400

MHz, CD3OD) δ 8.74 (s, 1H, H5), 8.23-7.83 (m, 2H, Hγ/Ar4), 7.50-7.14 (m, 13H,
Ar6/Ar5/Ar3/Ar2'/Ar3'/Ar4'/Ar5'/Ar6'/H2''/H3''/H4''/H5''/H6''), 5.69 (s, 2H, CH2Ph), 4.924.76 (m, 2H, OCHAHB), 4.84-4.70 (m, 2H, H1'), 4.40-4.32 (m, 1H, Lys5), 4.30-4.22 ((m, 1H,
H2'), 4.03 (s, 2H, δC-CH2), 3.23-3.07 (m, 2H, H5'), 2.95-2.78 (m, 2H, Lys1), 1.80-1.50 (m,
8H, Lys4/H3'/Lys2 /H4'), 1.36-1.20 (m, 2H, Lys3); 13C NMR (101 MHz, CD3OD) δ 174.5
(βC=O), 169.7 (αC=O), 158.7 (C=N), 156.0 (Ar2), 143.1 (C4), 139.0 (Ar1'), 136.5 (C1''),
131.7 (Ar6), 130.3 (Cδ), 130.0 (C5), 129.9 (Ar4), 129.8 (C2''/C6''), 129.5 (Ar3'/Ar5'/C3''/
C5''), 129.4 (Ar2'/Ar6'), 128.9 (Ar4'/C4''), 128.1 (Cγ), 123.4 (Ar5), 119.3 (Ar1), 114.4 (Ar3),
69.0 (OCHAHB), 56.1 (C1'), 55.9 (Lys5), 55.0 (CH2Ph), 50.9 (C2'), 42.1 (C5'), 40.7 (Lys1),
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32.5 (δC-CH2), 31.8 (Lys4), 30.0 (C3'), 28.1 (Lys2), 26.4 (C4'), 24.0 (Lys3); IR (neat) 𝜈̅ max
3351, 3265, 3203, 3065, 2950, 2870, 1658, 1585, 1546, 1490, 1455, 1441, 1360, 1290, 1229,
1181, 1165, 1125, 1075, 1053, 978, 907, 840, 804, 758, 725, 698, 670, 644, 586 cm-1; MS
(ESI +ve) m/z 721 ([M – 2HCl + H]+, 10%), 361 ([M – 2HCl + H]2+, 100%); HRMS (ESI
+ve TOF) calcd for C38H49N12O3 721.4045, found 721.4046 ([M – 2HCl + H]+).

(R)-6-Amino-2-(2-(2-(1-benzyl-1H-1,2,3-triazol-4-yl)phenoxy)acetamido)-N-((R)-1-(4(cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)hexanamide
dihydrochloride (36)
Following General Procedure IV, azide 59
(0.09 g, 0.09 mmol), 3-cyclohexyl-1propyne (0.03 g, 0.28 mmol), CuSO4∙5H2O
(0.005 g, 0.02 mmol) and sodium ascorbate
(0.007 g, 0.04 mmol) were stirred in t-BuOH
(2 mL) and H2O (0.5 mL) for 16 h to give the
intermediate 148 as an off-white gum after flash chromatography over SiO2 gel
(MeOH/CH2Cl2 – 0:100 → 6:94). Following General Procedure VII, the intermediate 148
(0.06 g, 0.055 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.02 g, 1.10 mmol)
and CF3COOH (1 mL) followed by work-up with ethereal HCl (2 mL) to give the amine salt
36 (0.025 g, 35% over two steps) as a pale-yellow solid that rapidly transitioned to a sticky
1
gum. [𝛼]23
𝐷 +57.6 (c 0.0054, MeOH). H NMR (400 MHz, CD3OD) δ 8.82 (s, 1H, H5), 8.25

(s, 1H, Hγ), 7.91 (apparent t, J = 7.0 Hz, 1H, Ar4), 7.44-7.36 (m, 6H, Ar6/Ar5/Ar2'/Ar3'/Ar5'/
Ar6'), 7.16-7.10 (m, 2H, Ar4'/Ar3), 5.75 (s, 2H, CH2Ph), 4.88-4.70 (m, 3H, OCHAHB/H1'),
4.66-4.50 (m, 1H, H1'), 4.46-4.32 (m, 1H, Lys5), 4.28-4.19 (m, 1H, H2'), 3.24-3.10 (m, 2H,
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δC-CH2), 2.92-2.84 (m, 2H, H5'), 2.66-2.60 (m, 2H, Lys1), 1.82-1.58 (m, 14H, Lys4/H3'/
Lys2/H4'/H1''/H2''/H3''/H4''/H5''/H6''), 1.44-1.28 (m, 2H, H2''/H6''), 1.26-1.12 (m, 3H,
H3''/H4''/ H5''), 0.94-0.86 (m, 2H, Lys3);

C NMR (101 MHz, CD3OD) δ 174.5 (βC=O),
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171.6 (αC=O), 158.7 (C=N), 156.1 (Ar2), 145.1 (C4), 144.3 (Ar1'), 136.5 (Cδ), 131.8 (Ar6),
130.3 (C5/Ar4), 130.0 (Ar3'/Ar5'), 129.5 (Ar4'), 128.5 (Ar2'/Ar6'), 126.4 (Cγ), 123.3 (Ar5),
119.1 (Ar1), 114.4 (Ar3), 68.8 (OCHAHB), 57.2 (C1'), 55.9 (Lys5), 55.3 (CH2Ph), 50.9 (C2'),
42.1 (C5'), 40.7 (Lys1), 38.9 (C1''), 33.9 (C2''/C6''), 33.8 (δC-CH2), 32.4 (Lys4), 32.3 (C4''),
29.7 (C3'), 28.1 (Lys2), 27.3 (C3''), 27.1 (C5''), 26.4 (C4'), 24.3 (Lys3); IR (neat) 𝜈̅ max 3348,
3266, 3192, 3066, 2927, 2854, 2667, 1659, 1586, 1545, 1490, 1450, 1382, 1351, 1227, 1167,
1126, 1076, 1050, 977, 937, 911, 846, 805, 760, 725, 696, 675, 647, 585 cm-1; MS (ESI +ve)
m/z 727 ([M – 2HCl + H]+, 20%), 364 ([M – 2HCl + H]2+, 100%); HRMS (ESI +ve TOF)
calcd for C38H55N12O3 727.4514, found 727.4513 ([M – 2HCl + H ]+).

(R)-6-Amino-N-((R)-1-(4-benzyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2(2-(4-isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamido)hexanamide dihydro
chloride (37)
Following General Procedure IV, azide
61 (0.07 g, 0.07 mmol), 3-phenyl-1propyne

(0.03

g,

0.21

mmol),

CuSO4∙5H2O (0.004 g, 0.01 mmol) and
sodium ascorbate (0.006 g, 0.02 mmol)
were stirred in t-BuOH (2 mL) and H2O
(0.5 mL) for 16 h to give the intermediate
149 as an off-white solid after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100
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→ 5:95). Following General Procedure VII, the intermediate 149 (0.06 g, 0.06 mmol) was
dissolved in CH2Cl2 (2 mL), treated with H2O (0.02 g, 1.10 mmol) and CF3COOH (1 mL)
followed by work-up with ethereal HCl (3 mL) to give the amine salt 37 (0.030 g, 56% over
two steps) as a pale-yellow solid that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +68.1 (c
0.0052, MeOH). 1H NMR (400 MHz, CD3OD) δ 8.54 (s, 1H, H5), 8.12 (s, 1H, Hγ), 7.65 (t,
J = 7.5 Hz, 1H, Ar4), 7.54 (d, J = 8.0 Hz, 1H, Ar6), 7.32-7.20 (m, 7H, Ar5/Ar3/H2''/H3''/
H4''/H5''/H6''), 4.84-4.74 (m, 2H, OCHAHB), 4.68-4.62 (m, 1H, H1'), 4.58-4.48 (m, 1H, H1'),
4.36-4.28 (m, 1H, Lys5), 4.20-4.12 (m, 1H, H2'), 4.12 (s, 2H, δC-CH2), 3.24-3.10 (m, 2H,
H5'), 2.94-2.80 (m, 4H, Lys1/H1'''), 1.82-1.50 (m, 11H, H2'''/H3'''/H3'/Lys4/H4'/Lys2), 1.361.24 (m, 2H, Lys3), 0.96 (d, J = 5.0 Hz, 6H, H4'''/H5''');

C NMR (101 MHz, CD3OD) δ
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173.9 (βC=O), 170.4 (αC=O), 158.4 (C=N), 152.0 (Ar2), 137.5 (Cδ), 133.5 (C4), 131.1
(C1''), 130.2 (C2''/C6''), 129.9 (C3''/C5''), 127.6 (C4''/Ar4), 127.4 (Ar6), 126.2 (C5), 125.9
(Cγ), 123.9 (Ar5), 123.3 (Ar1), 115.7 (Ar3), 69.7 (OCHAHB), 57.6 (C1'), 54.9 (Lys5), 49.6
(C2'), 42.6 (C2'''), 40.7 (C5'), 38.5 (Lys1), 32.8 (δC-CH2), 31.6 (C3'), 29.8 (Lys4), 29.6
(C1'''), 28.6 (Lys2), 28.2 (C3'''), 25.8 (C4'), 23.2 (C4'''/C5'''), 22.8 (Lys3); IR (neat) 𝜈̅ max 3375,
2956, 2932, 2870, 1653, 1572, 1548, 1508, 1462, 1381, 1367, 1288, 1254, 1228, 1150, 1113,
1058, 1005, 914, 883, 837, 793, 759, 721, 697, 670, 657 cm-1; MS (ESI +ve) m/z 701 ([M –
2HCl + H]+, 100%), 351 ([M – 2HCl + H]2+, 40%); HRMS (ESI +ve TOF) calcd for
C36H55N12O3Cl2 773.1236, found 773.1240 ([M + H]+).
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(R)-6-Amino-N-((R)-1-(4-cyclohexyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2(2-(2-(5-isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamido)hexanamide
dihydrochloride (38)
Following General Procedure IV,
azide

63

(0.02

g,

0.02

mmol),

cyclohexylacetylene (0.007 g, 0.06
mmol), CuSO4∙5H2O (0.001 g, 0.004
mmol) and sodium ascorbate (0.002 g,
0.008 mmol) were stirred in t-BuOH
(1.2 mL) and H2O (0.3 mL) for 16 h to give the intermediate 150 as an off-white gum after
flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 4:96). Following General
Procedure VII, the intermediate 150 (0.02 g, 0.02 mmol) was dissolved in CH2Cl2 (2 mL),
treated with H2O (0.01 g, 0.40 mmol) and CF3COOH (1 mL) followed by work-up with
ethereal HCl (2 mL) to give the amine salt 38 (0.015 g, 98% over two steps) as an off-white
1
solid that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +65.8 (c 0.0026, MeOH). H NMR (400

MHz, CD3OD) δ 8.35 (s, 1H, H4), 7.93 (s, 1H, Hγ), 7.68-7.60 (m, 1H, Ar4), 7.47 (d, J = 7.0
Hz, 1H, Ar6), 7.33 (t, J = 7.0 Hz, 1H, Ar5), 7.28-7.20 (m, 1H, Ar3), 4.80-4.68 (m, 3H,
OCHAHB/H1'), 4.60-4.50 (m, 1H, H1'), 4.42-4.32 (m, 1H, Lys5), 4.16-4.08 (m, 1H, H2'),
3.28-3.14 (m, 2H, H1'''), 3.00-2.84 (m, 3H, H5'/H1''), 2.70-2.62 (m, 2H, Lys1), 1.88-1.56 (m,
13H, H2'''/H3'''/H3'/Lys4/H4'/Lys2/Lys3), 1.54-1.38 (m, 8H, H2''/H3''/H4''/H5''/H6''), 1.381.24 (m, 2H, H3''/H5''), 0.81 (d, J = 6.0 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ
174.4 (βC=O), 170.2 (αC=O), 158.8 (C=N), 154.2 (Ar2), 143.4 (Cδ), 139.4 (C5), 134.0 (C4),
129.8 (Ar4), 127.1 (Ar6), 125.8 (Ar1), 123.56 (Cγ), 123.52 (Ar5), 115.5 (Ar3), 68.6
(OCHAHB), 57.3 (C1'), 54.9 (Lys5), 50.9 (C2'), 42.1 (C2'''), 40.7 (C5'), 38.2 (Lys1), 35.1
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(C1''), 33.3 (C3'), 32.6 (C2''/C6''), 29.7 (Lys4), 29.6 (Lys2), 28.8 (C3'''), 28.1 (C1'''), 26.9
(C4''), 26.7 (C3''/C5''), 24.2 (C4'), 23.6 (C4'''/C5'''), 22.7 (Lys3); IR (neat) 𝜈̅ max 3378, 3350,
3265, 3066, 2932, 2864, 1915, 1664, 1603, 1548, 1508, 1464, 1452, 1384, 1367, 1286, 1272,
1250, 1230, 1167, 1114, 1090, 1057, 983, 956, 915, 892, 882, 837, 819, 802, 794, 761, 720,
667, 645, 628, 581 cm-1; MS (ESI +ve) m/z 693 ([M – 2HCl + H]+, 10%), 347 ([M – 2HCl +
H]2+, 100%); HRMS (ESI +ve TOF) calcd for C35H59N12O3Cl2 765.4210, found 765.4248
([M + H]+).

(R)-6-Amino-N-((R)-1-(4-(cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2-(2-(5-isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamido)hexanamide
dihydrochloride (39)
Following General Procedure IV, azide 63
(0.10 g, 0.10 mmol), 3-cyclohexyl-1propyne (0.04 g, 0.32 mmol), CuSO4∙5H2O
(0.005 g, 0.02 mmol) and sodium ascorbate
(0.008 g, 0.04 mmol) were stirred in tBuOH (2 mL) and H2O (0.5 mL) for 16 h to
give the intermediate 151 as an off-white solid after flash chromatography over SiO2 gel
(MeOH/CH2Cl2 – 0:100 → 4:96). Following General Procedure VII, the intermediate 151
(0.07 g, 0.06 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.02 g, 1.32 mmol)
and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL) to give the amine salt
39 (0.050 g, 64% over two steps) as an off-white solid that rapidly transitioned to a sticky
1
gum. [𝛼]23
𝐷 +61.4 (c 0.0048, MeOH). H NMR (400 MHz, CD3OD) δ 8.43 (s, 1H, H4), 8.18

(s, 1H, Hγ), 7.67 (apparent t, J = 8.9 Hz, 1H, Ar4), 7.51 (d, J = 9.1 Hz, 1H, Ar6), 7.35 (d, J
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= 9.1 Hz, 1H, Ar5), 7.26 (t, J = 8.9 Hz, 1H, Ar3), 4.74-4.60 (m, 3H, OCHAHB/H1'), 4.514.43 (m, 1H, H1'), 4.38-4.30 (m, 1H, Lys5), 4.14-4.08 (m, 1H, H2'), 3.22-3.13 (m, 2H, H1'''),
2.96-2.87 (m, 2H, H5'), 2.66-2.60 (m, 4H, δC-CH2/Lys1), 1.78-1.54 (m, 14H, H1''/Lys4/Lys2
/Lys3/H3'/H4'/H2'''/H3'''), 1.50-1.36 (m, 5H, H2''/H3''/H4''/H5''/H6''), 1.33-1.12 (m, 3H,
H2''/H4''/ H6''), 1.05-0.91 (m, 2H, H3''/H5''), 0.80 (d, J = 6.4 Hz, 6H, H4'''/H5'''); 13C NMR
(101 MHz, CD3OD) δ 172.9 (βC=O), 168.5 (αC=O), 157.2 (C=N), 152.5 (Ar2), 152.4 (Cδ),
142.9 (C5), 132.9 (C4), 129.3 (Ar4), 128.3 (Ar6), 127.8 (Ar1), 123.7 (Cγ), 121.9 (Ar5), 114.0
(Ar3), 67.1 (OCHAHB), 56.3 (C1'), 53.4 (Lys5), 49.4 (C2'), 40.5 (C2'''), 39.2 (C5'), 37.3
(Lys1), 36.4 (C1''), 32.3 (δC-CH2), 32.2 (C2''), 31.0 (C6''), 30.4 (C3'), 28.1 (Lys4), 27.2
(Lys2), 26.5 (C3'''), 25.7 (C1'''), 25.6 (C4''), 24.8 (C3''/C5''), 22.6 (C4'), 21.1 (C4'''/C5'''), 20.9
(Lys3); IR (neat) 𝜈̅ max 3351, 3268, 3195, 3066, 2927, 2856, 2667, 2067, 1916, 1662, 1543,
1508, 1465, 1451, 1386, 1368, 1290, 1229, 1168, 1129, 1051, 985, 958, 936, 916, 846, 762,
668, 646, 585 cm-1; MS (ESI +ve) m/z 707 ([M – 2HCl + H]+, 100%); HRMS (ESI +ve TOF)
calcd for C36H59N12O3 707.4827, found 707.4824 ([M – 2HCl + H]+).

(R)-6-Amino-N-((R)-1-(4-benzyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2(2-(5-isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamido)hexanamide dihydrochloride
(40)
Following General Procedure IV,
azide 63 (0.03 g, 0.03 mmol), 3-phenyl1-propyne

(0.01

g,

0.09

mmol),

CuSO4∙5H2O (0.002 g, 0.006 mmol) and
sodium ascorbate (0.003 g, 0.012 mmol)
were stirred in t-BuOH (1.5 mL) and
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H2O (0.3 mL) for 16 h to give the intermediate 152 as an off-white gum after flash
chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 4:96). Following General
Procedure VII, the intermediate 152 (0.03 g, 0.03 mmol) was dissolved in CH2Cl2 (2 mL),
treated with H2O (0.01 g, 0.56 mmol) and CF3COOH (1 mL) followed by work-up with
ethereal HCl (2 mL) to give the amine salt 40 (0.012 g, 52% over two steps) as an off-white
1
solid that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +66.5 (c 0.0028, MeOH). H NMR (400

MHz, CD3OD) δ 8.16 (s, 1H, H4), 7.64 (s, 1H, Hγ), 7.63 (apparent t, J = 7.0 Hz, 1H, Ar4),
7.48-7.41 (m, 1H, Ar6), 7.36-7.20 (m, 7H, Ar5/Ar3/H2''/H3''/H4''/H5''/H6''), 4.80-4.58 (m,
3H, OCHAHB/H1'), 4.57-4.44 (m, 1H, H1'), 4.36-4.28 (m, 1H, Lys5), 4.20-4.08 (m, 3H,
H2'/H1'''), 3.26-3.14 (m, 2H, H5'), 2.92-2.82 (m, 2H, CH2Ph), 2.68-2.60 (m, 2H, Lys1), 1.801.36 (m, 11H, Lys4/Lys2/H3'/H4'/H2'''/H3'''), 1.30-1.20 (m, 2H, Lys3), 0.79 (d, J = 5.5 Hz,
3H, H4'''), 0.76 (d, J = 6.0 Hz, 3H, H5''');

C NMR (101 MHz, CD3OD) δ 174.2 (βC=O),
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170.0 (αC=O), 158.7 (C=N), 154.1 (Ar2), 154.0 (Cδ), 138.4 (C5), 134.1 (C1''), 130.1 (C4),
130.0 (Ar4), 129.9 (C2''/C6''), 129.89 (Ar6), 129.86 (C3''/C5''), 128.3 (C4''), 125.7 (Ar1),
123.5 (Cγ), 115.4 (Ar5), 111.5 (Ar3), 68.6 (OCHAHB), 56.4 (C1'), 54.8 (Lys5), 50.8 (C2'),
42.1 (C2'''), 40.6 (C5'), 38.1 (Lys1), 32.5 (CH2Ph), 31.4 (C3'), 29.9 (Lys4), 29.8 (Lys2), 28.7
(C3'''), 28.1 (C1'''), 26.4 (C4'), 23.9 (Lys3), 22.7 (C4'''/C5'''); IR (neat) 𝜈̅ max 3374, 3075, 2956,
2932, 2870, 1654, 1572, 1548, 1508, 1462, 1381, 1367, 1288, 1253, 1229, 1150, 1113, 1058,
1005, 914, 883, 838, 793, 759, 720, 697, 670, 657 cm-1; MS (ESI +ve) m/z 701 ([M – 2HCl
+ H]+, 70%), 351 ([M – 2HCl + H]2+, 100%); HRMS (ESI +ve TOF) calcd for
C36H55N12O3Cl2 773.3897, found 773.3914 ([M + H]+).
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(R)-6-Amino-N-((R)-1-(4-cyclohexyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2(2-((1-(4-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamido)hexanamide
dihydrochloride (41)
Following General Procedure
IV, azide 65 (0.08 g, 0.08mmol),
cyclohexylacetylene (0.03 g, 0.24
mmol), CuSO4∙5H2O (0.004 g,
0.01 mmol) and sodium ascorbate
(0.006 g, 0.03 mmol) were stirred
in t-BuOH (2.0 mL) and H2O (0.5
mL) for 16 h to give the intermediate 153 as an off-white gum after flash chromatography
over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 8:92). Following General Procedure VII, the
intermediate 153 (0.06 g, 0.05 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O
(0.02 g, 1.00 mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL)
to give the amine salt 41 (0.03 g, 46% over two steps) as an off-white solid that rapidly
1
transitioned to a sticky gum. [𝛼]23
𝐷 +59.1 (c 0.0052, MeOH); H NMR (400 MHz, CD3OD)

δ 8.30 (s, 1H, H5), 8.29 (s, 1H, Hγ), 8.18 (d, J = 9.2 Hz, 1H, Ar8), 7.98 (d, J = 7.5 Hz, 1H,
Ar5), 7.61 (ddd, J = 9.2, 9.2, 1.7 Hz, 1H, Ar7), 7.57-7.49 (m, 2H, Ar6/Ar4), 7.14 (d, J = 8.3
Hz, 1H, Ar3), 4.93-4.89 (m, 2H, OCHAHB), 4.77-4.72 (m, 1H, H1'), 4.59-4.53 (m, 1H, H1'),
4.37-4.32 (m, 1H, Lys5), 4.12-4.09 (m, 1H, H2'), 3.18-3.14 (m, 2H, H5'), 2.95-2.91 (m, 2H,
Lys1), 2.84-2.78 (m, 3H, H1'''/H1''), 2.00-1.96 (m, 2H, Lys4), 1.74-1.60 (m, 14H,
H2'''/H3'''/Lys2/H3'/H4'/H2''/H3''/H4''/H5''/H6''), 1.48-1.21 (m, 7H, Lys3/H2''/H3''/H4''/H5''/
H6''), 1.01 (d, J = 6.2 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 173.0 (βC=O),
169.1 (αC=O), 157.1 (C=N), 150.8 (Ar2), 148.7 (C4), 147.6 (Cδ), 132.5 (Ar8a), 130.3 (Ar4),
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129.1 (Ar4a), 128.6 (Ar5), 128.0 (Ar7), 126.9 (Ar8), 125.5 (C5), 125.1 (Cγ), 120.2 (Ar6),
119.1 (Ar3), 113.9 (Ar1), 67.4 (OCHAHB), 55.7 (C1'), 53.5 (Lys5), 49.3 (C2'), 40.4 (C5'),
39.0 (Lys1), 37.9 (C2'''), 33.4 (C1''), 31.6 (C2''), 31.5 (C6''), 30.9 (Lys4), 28.1 (Lys2), 27.5
(C1'''), 26.5 (C3'), 25.2 (C4''), 25.0 (C3''/C5''), 24.8 (C3'''), 22.6 (C4'), 22.5 (C4'''/C5'''), 21.3
(Lys3); IR (neat) 𝜈̅ max 3348, 3265, 3202, 3066, 2932, 2860, 1662, 1544, 1514, 1483, 1451,
1384, 1366, 1349, 1279, 1220, 1168, 1117, 1081, 1049, 816, 749, 668, 585 cm -1; MS (ESI
+ve) m/z 743 ([M – 2HCl + H]+, 60%), 372 ([M – 2HCl + H]2+, 100%); HRMS (ESI +ve
TOF) calcd for C39H59N12O3 743.4833, found 743.4866 ([M – 2HCl + H]+).

(R)-6-Amino-N-((R)-1-(4-(cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2-((1-(4-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamido)
hexanamide dihydrochloride (42)
Following General Procedure IV,
azide 65 (0.07 g, 0.07 mmol), 3cyclohexyl-1-propyne (0.03 g, 0.21
mmol), CuSO4∙5H2O (0.004 g, 0.01
mmol) and sodium ascorbate (0.006 g,
0.02 mmol) were stirred in t-BuOH (2
mL) and H2O (0.5 mL) for 16 h to give
the intermediate 154 as a light brown waxy solid after flash chromatography over SiO 2 gel
(MeOH/CH2Cl2 – 0:100 → 5:95). Following General Procedure VII, the intermediate 154
(0.05 g, 0.05 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.02 g, 0.10 mmol)
and CF3COOH (1 mL) followed by work-up with ethereal HCl (2 mL) to give the amine salt
42 (0.03 g, 52% over two steps) as a pale brown solid that rapidly transitioned to a sticky
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1
gum. [𝛼]23
𝐷 +65.3 (c 0.0052, MeOH). H NMR (400 MHz, CD3OD) δ 8.23 (s, 2H, H5/Hγ),

8.13 (d, J = 8.2 Hz, 1H, Ar8), 7.90 (d, J = 7.5 Hz, 1H, Ar5), 7.55 (ddd, J = 8.2, 8.2, 1.6 Hz,
1H, Ar7), 7.52-7.40 (m, 2H, Ar6/Ar4), 7.08 (d, J = 7.5 Hz, 1H, Ar3), 4.88-4.80 (m, 2H,
OCHAHB), 4.76-4.66 (m, 1H, H1'), 4.56-4.46 (m, 1H, H1'), 4.34-4.26 (m, 1H, Lys5), 4.104.02 (m, 1H, H2'), 3.16-3.06 (m, 2H, H5'), 2.90-2.82 (m, 2H, Lys1), 2.78-2.74 (m, 2H, H1'''),
2.62-2.56 (m, 3H, H1''/δC-CH2), 1.80-1.50 (m, 18H, Lys4/Lys2/Lys3/H2'''/H3'''/H3'/H4'/
H2''/H3''/H4''/ H5''/H6''), 1.26-1.08 (m, 5H, H2''/H3''/H4''/H5''/H6''), 0.95 (d, J = 4.0 Hz, 6H,
H4'''/H5''');

C NMR (101 MHz, CD3OD) δ 172.9 (βC=O), 169.1 (αC=O), 157.1 (C=N),
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150.8 (Ar2), 147.6 (C4), 143.4 (Cδ), 132.5 (Ar8a), 130.4 (Ar4), 129.1 (Ar4a), 128.6 (Ar5),
128.0 (Ar7), 127.0 (Ar8), 126.8 (C5), 125.1 (Cγ), 120.3 (Ar6), 119.1 (Ar3), 113.9 (Ar1), 67.5
(OCHAHB), 65.5 (C1'), 55.7 (Lys5), 53.5 (C2'), 49.3 (C5'), 40.5 (Lys1), 39.0 (C2'''), 38.0
(C1''), 37.3 (δC-CH2), 32.3 (C2''), 32.2 (C6''), 30.8 (Lys4), 30.7 (Lys2), 28.1 (C4''), 27.5
(C1'''), 26.5 (C3'), 25.7 (C3''), 25.6 (C5''), 24.8 (C3'''), 22.7 (C4'), 22.6 (C4'''/C5'''), 21.4
(Lys3); IR (neat) 𝜈̅ max 3346, 3266, 3193, 3063, 2950, 2927, 2855, 1664, 1602, 1543, 1514,
1483, 1451, 1383, 1367, 1349, 1280, 1219, 1168, 1154, 1117, 1080, 1050, 963, 933, 916,
863, 815, 779, 749, 673, 648, 586 cm-1; MS (ESI +ve) m/z 757 ([M – 2HCl + H]+, 50%), 379
([M – 2HCl + H]2+, 100%); HRMS (ESI +ve TOF) calcd for C40H61N12O3 757.4990, found
757.4969 ([M – 2HCl + H]+).
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(R)-6-Amino-N-((R)-1-(4-benzyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2((1-(4-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamido)hexanamide
dihydrochloride (43)
Following General Procedure IV,
azide 65 (0.07 g, 0.07 mmol), 3phenyl-1-propyne (0.02 g, 0.21
mmol), CuSO4∙5H2O (0.004 g,
0.01 mmol) and sodium ascorbate
(0.006 g, 0.02 mmol) were stirred
in t-BuOH (2 mL) and H2O (0.5
mL) for 16 h to give the intermediate 155 as a pale brown solid after flash chromatography
over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 6:94). Following General Procedure VII, the
intermediate 155 (0.060 g, 0.05 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O
(0.02 g, 1.08 mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL)
to give the amine salt 43 (0.03 g, 52% over two steps) as a brown solid that rapidly
1
transitioned to a sticky gum. [𝛼]23
𝐷 +57.3 (c 0.0042, MeOH). H NMR (400 MHz, CD3OD)

δ 8.41 (brs, 1H, H5), 8.28-8.16 (m, 2H, H2''/H6''), 7.99 (brs, 1H, Hγ), 7.66-7.48 (m, 4H, Ar8/
Ar5/Ar7/Ar6), 7.34-7.22 (m, 4H, H3''/H5''/Ar4/Ar3), 7.20-7.14 (m, 1H, H4''), 4.92-4.80 (m,
2H, OCHAHB), 4.74-4.66 (m, 1H, H1'), 4.60-4.52 (m, 1H, H1'), 4.42-4.32 (m, 1H, Lys5),
4.28-4.14 (m, 3H, CH2Ph/H2'), 3.22-3.12 (m, 2H, H5'), 3.02-2.84 (m, 2H, Lys1), 2.84-2.76
(m, 2H, H1'''), 1.82-1.52 (m, 10H, Lys4/Lys2/H3'/H4'/H2'''), 1.50-1.42 (m, 1H, H3'''), 1.341.20 (m, 2H, Lys3), 1.01 (d, J = 4.8 Hz, 6H, H4'''/H5''');

C NMR (101 MHz, CD3OD) δ
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172.0 (βC=O), 168.1 (αC=O), 156.3 (C=N), 150.0 (Ar2), 149.9 (C4), 143.7 (Cδ), 135.5
(C1''), 132.0 (Ar8a), 129.4 (Ar4), 128.9 (Ar4a), 128.3 (Ar5), 128.0 (Ar7), 127.8 (C2''/C6''),
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127.6 (C3''/C5''), 127.2 (Ar8), 126.1 (C5), 125.8 (C4''), 124.3 (Cγ), 119.3 (Ar6), 118.0 (Ar3),
113.1 (Ar1), 66.8 (OCHAHB), 64.7 (C1'), 54.5 (Lys5), 52.6 (C2'), 48.5 (C5'), 39.7 (Lys1),
38.2 (C2'''), 36.9 (CH2Ph), 30.1 (Lys4), 28.7 (Lys2), 27.4 (C1'''), 26.7 (C3'), 25.7 (C3'''), 24.0
(C4'), 21.6 (C4'''/C5'''), 20.6 (Lys3); IR (neat) 𝜈̅ max 3349, 3266, 3195, 3063, 2954, 2869, 1662,
1602, 1545, 1515, 1497, 1484, 1454, 1382, 1367, 1347, 1279, 1232, 1221, 1166, 1153, 1116,
1079, 1050, 969, 926, 909, 865, 812, 779, 750, 722, 699, 675, 667, 647 cm-1; MS (ESI +ve)
m/z 751 ([M – 2HCl + H]+, 20%), 376 ([M – 2HCl + H]2+, 100%); HRMS (ESI +ve TOF)
calcd for C40H56N12O3Cl 787.4287, found 787.4312 ([M – HCl + H]+).

(2R)-6-Amino-N-((R)-1-(4-cyclohexyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)2-(2-((1-(5-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamido)hexanamide
dihydrochloride (44)
Following General Procedure
IV, azide 67 (0.08 g, 0.08 mmol),
cyclohexylacetylene (0.03 g, 0.24
mmol), CuSO4∙5H2O (0.004 g,
0.02 mmol) and sodium ascorbate
(0.006 g, 0.04 mmol) were stirred
in t-BuOH (2 mL) and H2O (0.5 mL) for 16 h to give the intermediate 156 as an off-white
gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 5:95). Following
General Procedure VII, the intermediate 156 (0.07 g, 0.06 mmol) was dissolved in CH2Cl2
(2 mL), treated with H2O (0.02 g, 1.27 mmol) and CF3COOH (1 mL) followed by work-up
with ethereal HCl (3 mL) to give the amine salt 44 (0.036 g, 55% over two steps) as a pale
1
brown solid that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +71.9 (c 0.0052, MeOH). H

219

NMR (400 MHz, CD3OD) δ 8.25 (s, 1H, H4), 8.25-8.21 (m, 1H, Ar8), 7.99 (s, 1H, Hγ), 8.037.97 (m, 1H, Ar5), 7.64 (ddd, J = 9.2, 2.3 Hz, 1H, Ar7), 7.56-7.50 (m, 2H, Ar6/Ar4), 6.996.95 (m, 1H, Ar3), 5.01-4.65 (m, 3H, OCHAHB/H1'), 4.58-4.48 (m, 1H, H1'), 4.40-4.28 (m,
1H, Lys5), 4.12-4.04 (m, 1H, H2'), 3.23-3.12 (m, 2H, H5'), 3.00-2.76 (m, 2H, H1'''), 2.722.63 (m, 1H, H1''), 2.54-2.44 (m, 2H, Lys1), 2.08-1.91 (m, 2H, Lys4), 1.90-1.08 (m, 21H,
H2'''/H3'''/H3'/H4'/Lys2/Lys3/H2''/H3''/H4''/H5''/H6''), 0.71-0.66 (m, 6H, H4'''/H5''');
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C

NMR (101 MHz, CD3OD) δ 176.7 (βC=O), 172.6 (αC=O), 161.0 (C=N), 155.3 (Ar2), 146.0
(Cδ), 136.7 (C5), 136.6 (Ar8a), 135.3 (C4), 134.7 (Ar4), 133.3 (Ar4a), 132.5 (Ar5), 132.1
(Ar7), 129.0 (Ar8), 128.1 (Ar6), 124.2 (Cγ), 121.2 (Ar3), 118.0 (Ar1), 71.3 (OCHAHB), 58.8
(C1'), 57.4 (Lys5), 53.2 (C2'), 44.4 (C2'''), 43.0 (C5'), 40.5 (Lys1), 37.9 (C1''), 36.0 (Lys4),
35.9 (C3'), 34.9 (Lys2), 30.9 (C2''), 30.5 (C6''), 29.4 (C4''), 29.3 (C3''), 29.2 (C5''), 28.7
(C3'''), 26.4 (1'''), 26.3 (C4'), 24.9 (C4'''/C5'''), 24.4 (Lys3); IR (neat) 𝜈̅ max 3343, 3264, 3185,
3063, 2931, 2860, 1663, 1601, 1541, 1513, 1483, 1451, 1385, 1367, 1347, 1278, 1220, 1170,
1154, 1131, 1082, 1049, 990, 973, 931, 919, 859, 818, 779, 750, 678, 652 cm-1; MS (ESI
+ve) m/z 744 ([M – 2HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd for C39H59N12O3
743.4833, found 743.4839 ([M – 2HCl + H]+).
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(2R)-6-Amino-N-((R)-1-(4-(cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2-((1-(5-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamido)
hexanamide dihydrochloride (45)
Following General Procedure IV,
azide 67 (0.08 g, 0.08 mmol), 3cyclohexyl-1-propyne (0.03 g, 0.24
mmol), CuSO4∙5H2O (0.004 g, 0.02
mmol) and sodium ascorbate (0.006 g,
0.04 mmol) were stirred in t-BuOH (2
mL) and H2O (0.5 mL) for 16 h to give the intermediate 157 as an off-white gum after flash
chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 5:95). Following General
Procedure VII, the intermediate 157 (0.06 g, 0.05 mmol) was dissolved in CH2Cl2 (2 mL),
treated with H2O (0.02 g, 1.05 mmol) and CF3COOH (1 mL) followed by work-up with
ethereal HCl (3 mL) to give the amine salt 45 (0.036 g, 54% over two steps) as a brown solid
1
that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +66.1 (c 0.0050, MeOH). H NMR (400 MHz,

CD3OD) δ 8.33 (s, 1H, H4), 8.29 (s, 1H, Hγ), 8.25-8.21 (m, 1H, Ar8), 8.06-8.00 (m, 1H,
Ar5), 7.64 (ddd, J = 9.2, 9.2, 2.3 Hz, 1H, Ar7), 7.58-7.49 (m, 2H, Ar6/Ar4), 7.00-6.94 (m,
1H, Ar3), 5.04-4.68 (m, 3H, OCHAHB/H1'), 4.62-4.48 (m, 1H, H1'), 4.40-4.28 (m, 1H, Lys5),
4.12-4.04 (m, 1H, H2'), 3.23-3.10 (m, 2H, H5'), 3.01-2.85 (m, 1H, H1'''), 2.77-2.58 (m, 3H,
H1'''/Lys1), 2.54-2.44 (m, 2H, δC-CH2), 1.85-1.49 (m, 14H, H2'''/H3'''/H3'/H4'/Lys2/Lys3/
Lys4/H1''), 1.46-1.08 (m, 8H, H2''/H3''/H4''/H5''/H6''), 1.03-0.80 (m, 2H, H3''/H5''), 0.740.64 (m, 6H, H4'''/H5''');

C NMR (101 MHz, CD3OD) δ 171.5 (βC=O), 167.3 (αC=O),

13

157.9 (C=N), 151.9 (Ar2), 145.5 (Cδ), 141.1 (C5), 132.4 (Ar8a), 131.7 (C4), 131.4 (Ar4),
129.2 (Ar4a), 128.7 (Ar5), 128.5 (Ar7), 125.3 (Ar8), 123.4 (Ar6), 121.1 (Cγ), 118.4 (Ar3),
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115.5 (Ar1), 68.4 (OCHAHB), 53.1 (C1'), 49.5 (Lys5), 39.1 (C2'), 37.86 (C2'''), 37.83 (C5'),
36.9 (Lys1), 32.99 (δC-CH2), 32.92 (C1''), 31.8 (Lys4), 29.1 (C3'), 27.1 (Lys2), 26.98 (C2''),
26.95 (C6''), 26.4 (C4''), 26.03 (C3''), 26.01 (C5''), 25.3 (C3'''), 22.5 (C1'''), 22.4 (C4'), 22.2
(C4'''/C5'''), 20.7 (Lys3); IR (neat) 𝜈̅ max 3345, 3264, 3187, 3061, 2952, 2927, 2855, 2666,
1663, 1634, 1602, 1542, 1513, 1483, 1450, 1385, 1368, 1347, 1279, 1220, 1168, 1154, 1131,
1082, 1050, 1025, 992, 972, 932, 863, 818, 780, 749, 680, 651 cm-1; MS (ESI +ve) m/z 758
([M – 2HCl + H]+, 70%), 380 ([M – 2HCl + H]2+, 100%); HRMS (ESI +ve TOF) calcd for
C40H61N12O3 757.4990, found 757.5007 ([M – 2HCl + H]+).

(2R)-6-Amino-N-((R)-1-(4-benzyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2((1-(5-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamido)hexanamide
dihydrochloride (46)
Following General Procedure IV,
azide 67 (0.08 g, 0.08 mmol), 3phenyl-1-propyne (0.03 g, 0.24
mmol), CuSO4∙5H2O (0.004 g,
0.02 mmol) and sodium ascorbate
(0.006 g, 0.04 mmol) were stirred
in t-BuOH (2 mL) and H2O (0.5 mL) for 16 h to give the intermediate 158 as an off-white
gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 6:94). Following
General Procedure VII, the intermediate 158 (0.07 g, 0.06 mmol) was dissolved in CH2Cl2
(2 mL), treated with H2O (0.02 g, 1.27 mmol) and CF3COOH (1 mL) followed by work-up
with ethereal HCl (3 mL) to give the amine salt 46 (0.035 g, 53% over two steps) as a white
1
solid that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +58.9 (c 0.0052, MeOH). H NMR (400
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MHz, CD3OD) δ 8.25-8.18 (m, 1H, Ar8), 8.03-7.93 (m, 2H, Ar5/Ar7), 7.95 (s, 1H, H4), 7.637.50 (m, 3H, Ar6/Ar4/Hγ), 7.33-7.17 (m, 5H, H2''/H3''/H4''/H5''/H6''), 6.99-6.95 (m, 1H, Ar3),
4.99-4.68 (m, 2H, OCHAHB), 4.62-4.55 (m, 1H, H1'), 4.49-4.39 (m, 1H, H1'), 4.36-4.27 (m,
1H, Lys5), 4.17-4.02 (m, 3H, H2'/δC-CH2), 3.18-3.12 (m, 2H, H5'), 2.92-2.84 (m, 1H, H1'''),
2.77-2.67 (m, 1H, H1'''), 2.58-2.42 (m, 2H, Lys1), 1.77-1.44 (m, 8H, H3'/H4'/Lys2/Lys4),
1.43-1.30 (m, 3H, H2'''/H3'''), 1.28-1.00 (m, 2H, Lys3), 0.71-0.66 (m, 6H, H4'''/H5''');

13

C

NMR (101 MHz, CD3OD) δ 171.5 (βC=O), 167.2 (αC=O), 157.9 (C=N), 151.8 (Ar2), 146.0
(Cδ), 141.2 (C5), 141.1 (Ar8a), 140.0 (C4), 132.0 (C1''), 131.7 (Ar4), 131.4 (Ar4a), 129.2
(C2''), 128.9 (C6''), 128.79 (C3''), 128.74 (C5''), 128.5 (Ar5), 126.48 (Ar7), 126.46 (Ar8),
125.3 (Ar6), 125.2 (C4''), 123.4 (Cγ), 121.1 (Ar3), 115.5 (Ar1), 68.4 (OCHAHB), 53.0 (C1'),
49.5 (Lys5), 39.1 (C2'), 36.9 (C2'''), 31.8 (δC-CH2), 29.1 (C5'), 27.1 (Lys1), 26.99 (Lys4),
26.96 (C3'), 25.3 (Lys2), 22.5 (C3'''), 22.4 (1'''), 22.23 (C4'), 22.20 (C4'''/C5'''), 20.7 (Lys3);
IR (neat) 𝜈̅ max 3342, 3264, 3190, 3064, 2955, 2935, 2869, 1662, 1601, 1543, 1513, 1483, 1455,
1384, 1367, 1346, 1279, 1221, 1170, 1154, 1131, 1080, 1049, 991, 972, 930, 864, 815, 780,
750, 723, 698, 678, 652 cm-1; MS (ESI +ve) m/z 752 ([M – 2HCl + H]+, 100%); HRMS (ESI
+ve TOF) calcd for C40H55N12O3 751.4520, found 751.4544 ([M – 2HCl + H]+).
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(R)-6-Amino-N-((R)-1-(4-cyclohexyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2(2-((1-(2-(isopentyloxy)phenyl)-1H-1,2,3-triazol-5-yl)methoxy)acetamido)hexanamide
dihydrochloride (47)
Following General Procedure IV,
azide 68 (0.07 g, 0.07 mmol),
cyclohexylacetylene (0.02 g, 0.21
mmol), CuSO4∙5H2O (0.003 g, 0.01
mmol) and sodium ascorbate (0.006
g, 0.02 mmol) were stirred in tBuOH (2 mL) and H2O (0.5 mL) for 16 h to give the intermediate 159 as an off-white gum
after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 6:94). Following
General Procedure VII, the intermediate 159 (0.06 g, 0.05 mmol) was dissolved in CH2Cl2
(2 mL), treated with H2O (0.02 g, 1.11 mmol) and CF3COOH (1 mL) followed by work-up
with ethereal HCl (3 mL) to give the amine salt 47 (0.034 g, 61% over two steps) as a light
1
brown solid that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +57.1 (c 0.0052, MeOH). H

NMR (400 MHz, CD3OD) δ 8.05 (s, 2H, H4/Hγ), 7.57 (ddd, J = 8.0, 8.0, 3.0 Hz, 1H, Ar4),
7.45-7.42 (m, 1H, Ar6), 7.27-7.25 (m, 1H, Ar5), 7.16-7.11 (m, 1H, Ar3), 4.66 (m, 3H, C5CH2/H1'), 4.46 (apparent t, J = 10.5 Hz, 1H, H1'), 4.40-4.31 (m, 1H, Lys5), 4.19-4.15 (m,
1H, H2'), 4.06 (t, J = 6.0 Hz, 2H, H1'''), 3.88 (s, 2H, OCHAHB), 3.20-3.17 (m, 2H, H5'), 2.932.90 (m, 2H, Lys1), 2.84-2.74 (m, 1H, H1''), 2.08-1.96 (m, 2H, H3'), 1.86-1.79 (m, 2H, Lys4),
1.78-1.55 (m, 9H, Lys2/H4'/H2''/H3''/H4''/H5''/H6''), 1.54-1.37 (m, 8H, H2'''/H3'''/H2''/H3''/
H4''/H5''/H6''), 1.35-1.18 (m, 2H, Lys3), 0.82 (d, J = 6.2 Hz, 6H, H4'''/H5'''); 13C NMR (101
MHz, CD3OD) δ 172.6 (βC=O), 170.2 (αC=O), 157.2 (C=N), 153.5 (Ar2), 132.06 (C5),
132.02 (Cδ), 128.4 (C4), 124.8 (Ar4), 120.66 (Ar6), 120.61 (Cγ), 115.7 (Ar1), 113.3 (Ar5),
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111.8 (Ar3), 68.8 (OCHAHB), 67.2 (C1'''), 61.5 (C5-CH2), 54.2 (C1'), 52.8 (Lys5), 49.1 (C2'),
40.5 (C5'), 39.1 (Lys1), 37.3 (C2'''), 34.5 (C1''), 32.3 (C2''/C6''), 31.3 (Lys4), 28.5 (C3'), 26.6
(Lys2), 25.6 (C4''), 25.4 (C3''/C5''), 24.8 (C3'''), 24.7 (C4'), 22.3 (C4'''/C5'''), 21.3 (Lys3); IR
(neat) 𝜈̅ max 3396, 3372, 3358, 3285, 3274, 3263, 3212, 3198, 3067, 2931, 2865, 2162, 2126,
1978, 1965, 1659, 1533, 1509, 1464, 1386, 1368, 1345, 1288, 1247, 1229, 1161, 1129, 1052,
979, 759, 672, 618, 572 cm-1; MS (ESI +ve) m/z 723 ([M – 2HCl + H]+, 100%); HRMS (ESI
+ve TOF) calcd for C36H59N12O4 723.4782, found 723.4810 ([M – 2HCl + H]+).

(R)-6-Amino-N-((R)-1-(4-(cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2-((1-(2-(isopentyloxy)phenyl)-1H-1,2,3-triazol-5-yl)methoxy)acetamido)
hexanamide dihydrochloride (48)
Following General Procedure IV, azide
68 (0.07 g, 0.07 mmol), 3-cyclohexyl-1propyne

(0.03

g,

0.21

mmol),

CuSO4∙5H2O (0.003 g, 0.01 mmol) and
sodium ascorbate (0.006 g, 0.02 mmol)
were stirred in t-BuOH (2 mL) and H2O
(0.5 mL) for 16 h to give the intermediate 160 as an off-white gum after flash chromatography
over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 5:95). Following General Procedure VII, the
intermediate 160 (0.06 g, 0.05 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O
(0.02 g, 1.10 mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL)
to give the amine salt 48 (0.037 g, 83% over two steps) as a pale brown solid that rapidly
1
transitioned to a sticky gum. [𝛼]23
𝐷 +62.3 (c 0.0052, MeOH). H NMR (400 MHz, CD3OD)

δ 8.19 (s, 1H, H4), 7.97 (s, 1H, Hγ), 7.61-7.56 (m, 1H, Ar4), 7.46-7.44 (m, 1H, Ar6), 7.27225

7.25 (m, 1H, Ar5), 7.15-7.11 (m, 1H, Ar3), 4.72-4.44 (m, 4H, C5-CH2/H1'), 4.42-4.26 (m,
1H, Lys5), 4.22-4.12 (m, 1H, H2'), 4.06 (t, J = 7.6 Hz, 2H, H1'''), 3.91 (s, 2H, OCHAHB),
3.24-3.16 (m, 2H, H5'), 2.97-2.87 (m, 2H, Lys1), 2.70-2.62 (m, 2H, δC-CH2), 1.78-1.54 (m,
14H, H3'/Lys2/Lys4/H4'/H1''/H2''/H3''/H4''/H5''/H6''), 1.58-1.44 (m, 3H, H2''/H4''/H6''),
1.38-1.10 (m, 5H, H2'''/H3'''/Lys3), 1.06-0.91 (m, 2H, H3''/H5''), 0.82 (d, J = 7.7 Hz, 6H,
H4'''/H5''');

C NMR (101 MHz, CD3OD) δ 172.7 (βC=O), 170.2 (αC=O), 157.2 (C=N),
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153.6 (Ar2), 132.0 (C5), 128.1 (Cδ), 125.9 (C4), 124.5 (Ar4), 120.67 (Ar6), 120.64 (Cγ),
115.5 (Ar1, Observed by gHMBC), 113.39 (Ar5), 113.36 (Ar3), 68.9 (OCHAHB), 67.3 (C1'''),
61.4 (C5-CH2), 55.0 (C1'), 53.1 (Lys5), 52.9 (C2'), 49.3 (δC-CH2), 40.5 (C5'), 39.1 (Lys1),
37.6 (C2'''), 37.3 (C1''), 32.4 (C2''), 32.3 (C6''), 31.2 (Lys4), 28.3 (C3'), 26.5 (Lys2), 25.8
(C4''), 25.7 (C3''), 25.6 (C5''), 24.8 (C3'''), 24.7 (C4'), 22.4 (C4'''/C5'''), 21.4 (Lys3); IR (neat)
𝜈̅ max 3381, 3359, 3352, 3333, 3284, 3270, 3260, 3250, 3202, 3074, 3063, 2926, 2869, 2176,
2123, 2061, 1999, 1659, 1529, 1509, 1465, 1450, 1386, 1369, 1288, 1246, 1229, 1137, 1056,
998, 981, 849, 756, 667, 638, 619, 588, 572 cm-1; MS (ESI +ve) m/z 737 ([M – 2HCl + H]+,
100%); HRMS (ESI +ve TOF) calcd for C37H61N12O4 737.4939, found 737.4940 ([M – 2HCl
+ H]+).
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(R)-6-Amino-N-((R)-1-(4-benzyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2((1-(2-(isopentyloxy)phenyl)-1H-1,2,3-triazol-5-yl)methoxy)acetamido)hexanamide
dihydrochloride (49)
Following General Procedure IV,
azide 68 (0.08 g, 0.08 mmol), 3phenyl-1-propyne

(0.03

g,

0.24

mmol), CuSO4∙5H2O (0.004 g, 0.01
mmol) and sodium ascorbate (0.006 g,
0.03 mmol) were stirred in t-BuOH (2
mL) and H2O (0.5 mL) for 16 h to give the intermediate 161 as an off-white gum after flash
chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 5:95). Following General
Procedure VII, the intermediate 161 (0.06 g, 0.05 mmol) was dissolved in CH2Cl2 (2 mL),
treated with H2O (0.02 g, 1.10 mmol) and CF3COOH (1 mL) followed by work-up with
ethereal HCl (3 mL) to give the amine salt 49 (0.033 g, 51% over two steps) as a pale brown
1
solid that rapidly transitioned to a sticky gum. [𝛼]23
𝐷 +68.1 (c 0.0048, MeOH). H NMR (400

MHz, CD3OD) δ 8.15 (s, 1H, H4), 8.05 (s, 1H, Hγ), 7.58 (t, J = 7.7 Hz, 1H, Ar4), 7.45 (d, J
= 7.6 Hz, 1H, Ar6), 7.33-7.20 (m, 6H, Ar5/H2''/H3''/H4''/ H5''/H6''), 7.13 (d, J = 7.5 Hz, 1H,
Ar3), 4.73-4.54 (m, 3H, C5-CH2/H1'), 4.56-4.4.45 (m, 1H, H1'), 4.40-4.26 (m, 1H, Lys5),
4.22-4.10 (m, 3H, H2'/OCHAHB), 4.10-4.02 (m, 2H, H5'), 3.91 (t, J = 5.9 Hz, 2H, H1'''), 3.253.11 (m, 2H, Lys1), 2.98-2.81 (m, 2H, δC-CH2), 1.73-1.34 (m, 11H, H3'/Lys2/Lys4/
H4'/H2'''/H3'''), 1.31-1.16 (m, 2H, Lys3), 0.82 (d, J = 6.1 Hz, 6H, H4'''/H5'''); 13C NMR (101
MHz, CD3OD) δ 172.7 (βC=O), 170.1 (αC=O), 157.2 (C=N), 153.5 (Ar2), 137.09 (C5),
137.03 (Cδ), 132.2 (C1''), 128.67 (C2''), 128.65 (C6''), 128.5 (C3''), 128.4 (C5''), 128.1 (C4),
126.9 (Ar4), 126.8 (C4''), 126.7 (Ar6), 125.8 (Cγ), 124.3 (Ar1), 120.6 (Ar5), 113.3 (Ar3),
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68.9 (OCHAHB), 67.3 (C1'''), 61.4 (C5-CH2), 54.9 (C1'), 52.8 (Lys5), 49.2 (C2'), 40.5 (C5'),
39.1 (Lys1), 37.3 (C2'''), 31.2 (δC-CH2), 29.9 (Lys4), 28.3 (C3'), 26.5 (Lys2), 24.8 (C3'''),
24.7 (C4'), 22.5 (C4'''/C5'''), 21.4 (Lys3); IR (neat) 𝜈̅ max 3358, 3273, 3195, 3068, 2955, 2871,
2165, 2101, 2063, 1658, 1533, 1509, 1464, 1386, 1368, 1288, 1245, 1227, 1164, 1137, 1050,
999, 979, 875, 850, 757, 724, 699667, 621, 590 cm-1; MS (ESI +ve) m/z 731 ([M – 2HCl +
H]+, 100%); HRMS (ESI +ve TOF) calcd for C37H55N12O4 731.4469, found 731.4444 ([M –
2HCl + H]+).

6.4 – Experimental-Click chemistry
6.4.1 – Magnesium promoted click reactions
5-Isopentyl-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole (83)
This compound was prepared according to the General procedure
VI, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was
treated with 5-methyl-1-hexyne (0.03 g, 0.27 mmol) and EtMgCl
(0.03 g, 0.3 mmol; 2 M in Et2O) in dry THF (2 mL) at 50 °C for 3 h
to give 83 (0.06 g, 81%) as a pale brown waxy solid after purification by column
chromatography over SiO2 gel (EtOAc/n-hexane - 20:80 → 100:0). TLC (EtOAc/n-hexane
1:4): Rf = 0.2; 1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 9.1 Hz, 1H, H8''), 7.85 (dd, J = 7.4,
2.0 Hz, 1H, H5''), 7.71 (s, 1H, H4), 7.45-7.37 (m, 3H, H6'', H7'' and H4''), 6.99-6.96 (m, 1H,
H3''), 3.87 (s, 3H, OMe), 2.45-2.34 (m, 2H, H1'), 1.47-1.35 (m, 3H, H2' and H3'), 0.73 (d, J
= 7.9 Hz, 3H, H5'), 0.72 (d, J = 7.9 Hz, 3H, H4'); 13C NMR (101 MHz, CDCl3) δ 152.7
(C2''), 140.7 (C5), 132.0 (C8a''), 131.6 (C4), 131.4 (C4a''), 128.7 (C4''), 128.3 (C5''), 127.9
(C7''), 124.6 (C8''), 121.2 (C6''), 117.9 (C3''), 113.1 (C1''), 56.5 (OMe), 36.7 (C2'), 27.2 (C1'),
22.08 (C5'), 22.07 (C4'), 20.8 (C3'); IR (neat) νmax 2954, 2868, 1630, 1599, 1507, 1457, 1275,
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1255, 1064, 1040, 809, 748 cm-1; MS (ESI +ve) m/z 296 ([M + H]+, 100%); HRMS (ESI +ve
TOF) calcd for C18H22N3O 296.1763, found 296.1750 ([M + H]+).

5-Cyclohexyl-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole (100)
This compound was prepared according to the General procedure
VI, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was
treated with ethynylcyclohexane (0.03 g, 0.27 mmol) and EtMgCl
(0.03 g, 0.3 mmol; 2 M in Et2O) in dry THF (2 mL) at 50 °C for 5 h to give 100 (0.06 g, 78%)
as a cream white solid after purification by column chromatography over SiO 2 gel (EtOAc/nhexane - 30:70 → 100:0). M.P: 104-106 °C; TLC (EtOAc/n-hexane 1:4): Rf = 0.1; 1H NMR
(500 MHz, CDCl3) δ 8.03 (d, J = 9.1 Hz, 1H, H8"), 7.87-7.85 (m, 1H, H5"), 7.71 (s, 1H, H4),
7.44-7.38 (m, 3H, H6", H7" and H4"), 6.95 (dd, J = 8.2, 1.2 Hz, 1H, H3"), 3.87 (s, 3H, OMe),
2.31-2.24 (m, 1H, H1'), 1.91-1.88 (m, 1H, H5'), 1.74-1.70 (m, 1H, H4'), 1.60-1.56 (m, 3H,
H6', H2' and H3'), 1.43-1.40 (m, 1H, H5'), 1.32-1.29 (m, 1H, H4'), 1.19-1.10 (m, 2H, H6' and
H3'), 1.01-0.97 (m, 1H, H2'); 13C NMR (126 MHz, CDCl3) δ 152.7 (C2"), 145.7 (C5), 132.0
(C8a"), 131.8 (C4), 130.1 (C4"), 128.7 (C4a"), 128.3 (C5"), 127.9 (C7"), 124.6 (C8"), 121.3
(C6"), 118.1 (C3"), 113.1 (C1"), 56.6 (OMe), 33.3 (C6'), 32.9 (C2'), 32.4 (C1'), 25.9 (C4'),
25.8 (C5'), 25.6 (C3'); IR (neat) νmax 2927, 2852, 1628, 1599, 1510, 1482, 1276, 1245, 1151,
1067, 818, 751 cm-1; MS (ESI +ve) m/z 308 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd
for C19H22N3O 308.1763, found 308.1750 ([M + H]+).
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1-(2-Methoxynaphthalen-1-yl)-5-(4-methoxyphenyl)-1H-1,2,3-triazole (101)
This compound was prepared according to the General
procedure VI, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25
mmol) was treated with 1-ethynyl-4-methoxybenzene (0.04 g,
0.27 mmol) and EtMgCl (0.03 g, 0.3 mmol; 2 M in Et2O) in dry THF (2 mL) at 50 °C for 4
h to give 101 (0.072 g, 86%) as a waxy solid after purification by column chromatography
over SiO2 gel (EtOAc/n-hexane - 40:60 → 100:0). TLC (EtOAc/n-hexane 1:4): Rf = 0.2; 1H
NMR (500 MHz, CDCl3) δ 7.97 (s, 1H, H4), 7.96 (d, J = 9.6 Hz, 1H, H8"), 7.81 (d, J = 8.0
Hz, 1H, H5"), 7.43-7.35 (m, 2H, H6" and H7"), 7.28 (d, J = 9.1 Hz, 1H, H4" ), 7.16 (d, J =
8.3 Hz, 1H, H3"), 7.09-7.06 (m, 2H, H2' and H6'), 6.69-6.66 (m, 2H, H3' and H5'), 3.69 (s,
3H, OMe), 3.66 (s, 3H, H7'); 13C NMR (126 MHz, CDCl3) δ 160.0 (C4'), 152.6 (C2"), 140.2
(C8a"), 132.0 (C4), 131.65 (C4"), 131.63 (C4a"), 128.7 (C2' and C6'), 128.4 (C5"), 127.9
(C7"), 127.8 (C8"), 124.6 (C6"), 121.3 (C3"), 119.2 (C5), 118.6 (C1'), 114.0 (C3' and C5'),
113.2 (C1"), 56.5 (OMe), 55.1 (C7'); IR (neat) νmax 2940, 2839, 1616, 1558, 1507, 1495,
1457, 1276, 1249, 1179, 1067, 1020, 810, 750 cm-1. MS (ESI +ve) m/z 332 ([M + H]+, 100%);
HRMS (ESI +ve TOF) calcd for C20H18N3O2 332.1399, found 332.1386 ([M + H]+).

1-(2-Methoxynaphthalen-1-yl)-5-(2-methoxyphenyl)-1H-1,2,3-triazole (102)
This compound was prepared according to the General procedure
VI, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was
treated with 1-ethynyl-2-methoxybenzene (0.04 g, 0.27 mmol) and
EtMgCl (0.03 g, 0.3 mmol; 2 M in Et2O) in dry THF (2 mL) at 50 °C
for 4 h to give 102 (0.074 g, 89%) as an off-white waxy solid after purification by column
chromatography over SiO2 gel (EtOAc/n-hexane - 40:60 → 100:0). TLC (EtOAc/n-hexane
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2:3): Rf = 0.1; 1H NMR (500 MHz, CDCl3) δ 8.01 (s, 1H, H4), 7.89 (d, J = 9.1 Hz, 1H, H6'),
7.79 (d, J = 8.1 Hz, 1H, H8"), 7.46-7.43 (m, 1H, H5"), 7.39-7.35 (m, 2H, H6" and H7"), 7.217.17 (m, 2H, H4' and H5'), 7.06 (dd, J = 8.0, 1.7 Hz, 1H, H4"), 6.75 (d, J = 7.5 Hz, 1H, H3'),
6.70 (d, J = 8.0 Hz, 1H, H3"), 3.59 (s, 3H, OMe), 3.26 (s, 3H, H7'); 13C NMR (126 MHz,
CDCl3) δ 156.6 (C2'), 151.9 (C2"), 137.2 (C8a"), 133.7 (C4), 131.48 (C6'), 131.46 (C4"),
130.5 (C4'), 130.3 (C4a"), 128.7 (C5"), 127.8 (C7"), 127.6 (C8"), 124.3 (C6"), 122.3 (C5'),
120.1 (C5), 119.3 (C3"), 116.2 (C1'), 113.0 (C1"), 110.7 (C3'), 56.3 (C7'), 54.7 (OMe); IR
(neat) νmax 2938, 2840, 1507, 1486, 1465, 1264, 1150, 1104, 1067, 1020, 806, 749 cm-1. MS
(ESI +ve) m/z 332 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C20H18N3O2 332.1399,
found 332.1388 ([M + H]+).

1-(2-Methoxynaphthalen-1-yl)-5-(o-tolyl)-1H-1,2,3-triazole (103)
This compound was prepared according to the General procedure
VI, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was
treated with 1-ethynyl-2-methylbenzene (0.03 g, 0.27 mmol) and
EtMgCl (0.03 g, 0.3 mmol; 2 M in Et2O) in dry THF (3 mL) at 50 °C
for 3 h to give 103 (0.06 g, 76%) as a cream waxy solid after purification by column
chromatography over SiO2 gel (EtOAc/n-hexane - 30:70 → 100:0). TLC (EtOAc/n-hexane
1:4): Rf = 0.2; 1H NMR (500 MHz, CDCl3) δ 7.92 (s, 1H, H4), 7.90 (d, J = 9.1 Hz, 1H, H8"),
7.80 (d, J = 8.2 Hz, 1H, H5"), 7.50-7.46 (m, 1H, H6"), 7.40-7.37 (m, 1H, H7"), 7.33 (dd, J =
8.8, 0.6 Hz, 1H, H4"), 7.18 (d, J = 8.8 Hz, 1H, H3"), 7.15-7.11 (m, 2H, H3' and H6' ), 6.876.86 (m, 2H, H4' and H5'), 3.67 (s, 3H, OMe), 2.27 (s, 3H, Me); 13C NMR (126 MHz, CDCl3)
δ 152.1 (C2"), 139.5 (C8a"), 137.1 (C2'), 133.5 (C4), 131.8 (C4a"), 131.6 (C4"), 130.1 (C1'),
129.5 (C3'), 129.0 (C8"), 128.6 (C5"), 128.2 (C7"), 127.9 (C4'), 126.5 (C5'), 125.3 (C6"),
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124.5 (C3"), 121.5 (C6'), 118.2 (C5), 112.7 (C1"), 56.1 (OMe), 20.1 (Me); IR (neat) ν max
3140, 2929, 2847, 1599, 1510, 1274, 1109, 1244, 1058, 1021, 815, 760 cm-1. MS (ESI +ve)
m/z 316 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C20H18N3O 316.1450, found
316.1448 ([M + H]+).

5-(3-Fluorophenyl)-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole (104)
This compound was prepared according to the General procedure
VI, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was
treated with 1-ethynyl-3-fluorobenzene (0.03 g, 0.27 mmol) and
EtMgCl (0.03 g, 0.3 mmol; 2 M in Et2O) in dry THF (2 mL) at 50 °C
for 5 h to give 104 (0.069 g, 86%) as a light-yellow solid after purification by column
chromatography over SiO2 gel (EtOAc/n-hexane - 40:60 → 100:0). M.P: 148-150 °C. TLC
(EtOAc/n-hexane 1:4): Rf = 0.3; 1H NMR (500 MHz, CDCl3) δ 8.05 (s, 1H, H4), 8.00 (d, J
= 9.1 Hz, 1H, H8"), 7.84 (d, J = 8.1 Hz, 1H, H5"), 7.46-7.43 (m, 1H, H6"), 7.41-7.37 (m, 1H,
H7"), 7.30 (d, J = 9.1 Hz, 1H, H4"), 7.16-7.11 (m, 2H, H3" and H2'), 6.95-6.86 (m, 3H, H4',
H5' and H6'), 3.72 (s, 3H, OMe); 13C NMR (126 MHz, CDCl3) δ 162.6 (d, 1JC-F = 198.3 Hz,
C3'), 152.7 (C2''), 139.3 (C8a''), 132.56 (C4a''), 132.52 (C4), 131.6 (C8''), 130.4 (d, 2JC-F =
7.0, C1'), 129.1 (d, 3JC-F = 10.1, C5'), 128.79 (C4''), 128.77 (C5''), 128.2 (C3''), 124.8 (C6''),
123.3 (C7''), 121.2 (C6'), 118.3 (C5), 116.1 (d, 4JC-F = 16.9 Hz, C2'), 114.5 (d, 5JC-F = 18.6
Hz, C4'), 113.2 (C1''), 56.6 (OMe); IR (neat) νmax 2937, 2842, 1558, 1507, 1457, 1273, 1149,
1110, 1069, 862, 807, 798, 690 cm-1. MS (ESI +ve) m/z 320 ([M + H]+, 100%); HRMS (ESI
+ve TOF) calcd for C19H15FN3O 320.1199, found 320.1205 ([M + H]+).
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5-Mesityl-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole (105)
This compound was prepared according to the General
procedure VI, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25
mmol) was treated with 2-ethynyl-1,3,5-trimethylbenzene (0.04
g, 0.27 mmol) and EtMgCl (0.03 g, 0.3 mmol; 2 M in Et2O) in
dry THF (2 mL) at 50 °C for 6 h to give 105 (0.045 g, 52%) as a brown waxy solid after
purification by column chromatography over SiO2 gel (EtOAc/n-hexane - 40:60 → 100:0).
TLC (EtOAc/n-hexane 2:3): Rf = 0.1; 1H NMR (500 MHz, CDCl3) δ 7.85 (d, J = 7.3 Hz, 1H,
H8"), 7.83 (s, 1H, H4), 7.77 (d, J = 7.3 Hz, 1H, H5"), 7.50-7.44 (m, 2H, H6" and H4"), 7.387.35 (m, 1H, H7"), 7.12-7.10 (m, 1H, H3"), 6.89 (s, 1H, H5'), 6.57 (s, 1H, H3'), 3.57 (s, 3H,
OMe), 2.25 (s, 3H, H9'), 2.18 (s, 3H, H7'), 1.57 (s, 3H, H8'); 13C NMR (126 MHz, CDCl3) δ
151.6 (C2"), 138.9 (C8a"), 138.8 (C4'), 138.7 (C2'), 137.8 (C6'), 134.4 (C4), 131.8 (C5"),
130.9 (C4a"), 128.9 (C4"), 128.3 (C3'), 128.1 (C5'), 128.0 (C7"), 127.9 (C8"), 124.4 (C6"),
123.3 (C1'), 122.7 (C5), 118.4 (C3"), 112.7 (C1"), 55.6 (OMe), 21.1 (C8'), 20.8 (C9'), 20.7
(C7'); IR (neat) νmax 2924, 2845, 1710, 1630, 1511, 1481, 1357, 1276, 1219, 1066, 1021, 967,
810, 749 cm-1. MS (ESI +ve) m/z 344 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for
C22H22N3O 344.1763, found 344.1758 ([M + H]+).

5-Isopentyl-1-(naphthalen-1-yl)-1H-1,2,3-triazole (114)
This compound was prepared according to the General procedure VI,
1-azidonaphthalene 99 (0.05 g, 0.29 mmol) was treated with 5-methyl1-hexyne (0.03 g, 0.32 mmol) and EtMgCl (0.03 g, 0.3 mmol; 2 M in
Et2O) in dry THF (2 mL) at 50 °C for 4 h to give 114 (0.068 g, 88%)
as a brown waxy solid after purification by column chromatography over SiO2 gel (EtOAc/n233

hexane - 30:70 → 100:0). TLC (EtOAc/n-hexane 1:4): Rf = 0.2; 1H NMR (500 MHz, CDCl3)
δ 8.04 (d, J = 8.3 Hz, 1H, H8"), 7.95 (d, J = 8.2 Hz, 1H, H5"), 7.70 (s, 1H, H4), 7.61-7.54
(m, 2H, H6" and H7"), 7.50-7.47 (m, 2H, H3" and H4"), 7.16 (dd, J = 8.5, 0.8 Hz, 1H, H2"),
2.45-2.42 (m, 2H, H1'), 1.46-1.36 (m, 3H, H2' and H3'), 0.72 (d, J = 6.2 Hz, 6H, H4' and
H5');

C NMR (126 MHz, CDCl3) δ 140.3 (C5), 134.2 (C8a"), 132.7 (C4a"), 131.8 (C4),
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130.7 (C8"), 130.0 (C5"), 128.4 (C4"), 128.0 (C6"), 127.2 (C7"), 125.2 (C3"), 125.1 (C1"),
122.4 (C2"), 37.2 (C2'), 27.4 (C3'), 22.2 (C4' and C5'), 21.3 (C1'); IR (neat) νmax 2955, 2868,
1598, 1468, 1430, 1247, 1077, 960, 802, 773, 661 cm-1. MS (ESI +ve) m/z 266 ([M + H]+,
100%); HRMS (ESI +ve TOF) calcd for C17H20N3 266.1657, found 266.1668 ([M + H]+).

5-Cyclohexyl-1-(naphthalen-1-yl)-1H-1,2,3-triazole (115)
This compound was prepared according to the General procedure
VI, 1-azidonaphthalene 99 (0.05 g, 0.29 mmol) was treated with
ethynylcyclohexane (0.03 g, 0.32 mmol) and EtMgCl (0.03 g, 0.3
mmol; 2 M in Et2O) in dry THF (2 mL) at 50 °C for 4 h to give 115 (0.071 g, 88%) as a
brown gummy solid after purification by column chromatography over SiO 2 gel (EtOAc/nhexane - 40:60 → 100:0). TLC (EtOAc/n-hexane 1:4): Rf = 0.4; 1H NMR (500 MHz, CDCl3)
δ 8.04 (d, J = 8.3 Hz, 1H, H8"), 7.95 (d, J = 8.2 Hz, 1H, H5"), 7.70 (s, 1H, H4), 7.61-7.54
(m, 2H, H6" and H7"), 7.50-7.46 (m, 2H, H3" and H4"), 7.12 (dd, J = 8.5, 0.8 Hz, 1H, H2"),
2.40-2.34 (m, 1H, H1'), 1.77-1.70 (m, 2H, H2' and H6'), 1.66-1.55 (m, 3H, H3', H4' and H5'),
1.41-1.33 (m, 2H, H3' and H5'), 1.20-1.12 (m, 1H, H4'), 1.08-1.00 (m, 2H, H2' and H6'); 13C
NMR (126 MHz, CDCl3) δ 145.3 (C5), 134.2 (C8a"), 132.9 (C4a"), 130.8 (C4), 130.5 (C8"),
130.3 (C5"), 128.3 (C4"), 128.0 (C6"), 127.2 (C7"), 125.2 (C3"), 125.1 (C1"), 122.4 (C2"),
33.4 (C1'), 25.9 (C2', C4', and C6'), 25.6 (C3' and C5'); IR (neat) νmax 2929, 2852, 1710, 1597,
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1448, 1238, 1084, 1005, 960, 802, 772 cm-1. MS (ESI +ve) m/z 278 ([M + H]+, 100%); HRMS
(ESI +ve TOF) calcd for C18H20N3 278.1657, found 278.1659 ([M + H]+).

5-(2-Methoxyphenyl)-1-(naphthalen-1-yl)-1H-1,2,3-triazole (116)
This compound was prepared according to the General procedure
VI, 1-azidonaphthalene 99 (0.05 g, 0.29 mmol) was treated with 1ethynyl-2-methoxybenzene (0.04 g, 0.32 mmol) and EtMgCl (0.03 g,
0.3 mmol; 2 M in Et2O) in dry THF (2 mL) at 50 °C for 12 h to give
116 (0.009 g, 10%) as a brown waxy solid after purification by column chromatography over
SiO2 gel (EtOAc/n-hexane - 30:70 → 100:0). TLC (EtOAc/n-hexane 1:4): Rf = 0.1; 1H NMR
(500 MHz, CDCl3) δ 7.99 (s, 1H, H4), 7.91-7.88 (m, 2H, H8" and H6'), 7.62-7.60 (m, 1H,
H5"), 7.54-7.48 (m, 2H, H6" and H7"), 7.39 (dd, J = 7.4, 1.0 Hz, 1H, H3"), 7.26-7.21 (m,
2H, H4" and H5'), 7.14 (dd, J = 7.4, 1.7 Hz, 1H, H2"), 6.83 (dt, J = 9.4, 1.2 Hz, 1H, H4'),
6.69 (dd, J = 8.4, 1.0 Hz, 1H, H3'), 3.16 (s, 3H, OMe); 13C NMR (126 MHz, CDCl3) δ 156.6
(C2'), 136.8 (C8a"), 134.2 (C4a"), 134.1 (C1'), 133.8 (C4), 131.1 (C5"), 130.9 (C2"), 130.0
(C8"), 129.6 (C4"), 128.0 (C6'), 127.5 (C7"), 126.8 (C6"), 124.8 (C3"), 124.1 (C1"), 123.5
(C5), 120.6 (C4'), 115.8 (C5'), 111.0 (C3'), 54.7 (OMe); IR (neat) νmax 3051, 2928, 1597,
1481, 1464, 1270, 1103, 1050, 1023, 955, 802, 754 cm-1. MS (ESI +ve) m/z 302 ([M + H]+,
100%); HRMS (ESI +ve TOF) calcd for C19H16N3O 302.1293, found 302.1305 ([M + H]+).
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6.4.2 – Ruthenium catalysed click reactions
5-Isopentyl-1-(2-methoxyphenyl)-1H-1,2,3-triazole (119)
This compound was prepared according to the General procedure V,
1-azido-2-methoxybenzene 118 (0.02 g, 0.13 mmol) was treated with 5methyl-1-hexyne (0.014 g, 0.15 mmol) and Cp*RuCl(PPh3)2 (0.01 g,
0.01 mmol) in 1,4-dioxane (2 mL) at 70 °C for 12 h to give 119 (0.028 g, 87%) as a brown
oil after purification by column chromatography over SiO2 gel (EtOAc/n-hexane - 30:70 →
100:0). TLC (EtOAc/n-hexane 2:3): Rf = 0.5; 1H NMR (500 MHz, CDCl3) δ 7.55 (s, 1H,
H4), 7.50-7.47 (m, 1H, H4"), 7.32 (dd, J = 7.9, 1.7 Hz, 1H, H6"), 7.11-7.06 (m, 2H, H3"and
H5"), 3.78 (s, 3H, OMe), 2.47 (t, J = 7.9 Hz, 2H, H1'), 1.56-1.41 (m, 3H, H2' and H3'), 0.82
(d, J = 8.0 Hz, 6H, H4' and H5'); 13C NMR (126 MHz, CDCl3) δ 154.2 (C2"), 140.0 (C5),
131.5 (C4"), 131.3 (C4), 128.7 (C6"), 125.1 (C1"), 120.9 (C5"), 112.1 (C3"), 55.7 (OMe),
36.9 (C2'), 27.4 (C3'), 22.1 (C4' and C5'), 21.0 (C1'); IR (neat) νmax 2954, 2868, 1602, 1506,
1473, 1285, 1251, 1233, 1122, 1043, 1021, 750 cm-1. MS (ESI +ve) m/z 246 ([M + H]+,
100%); HRMS (ESI +ve TOF) calcd for C14H20N3O 246.1606, found 246.1618 ([M + H]+).

5-Cyclohexyl-1-(2-methoxyphenyl)-1H-1,2,3-triazole (120)
This compound was prepared according to the General procedure V,
1-azido-2-methoxybenzene 118 (0.05 g, 0.33 mmol) was treated with
ethynyl cyclohexane (0.04 g, 0.37 mmol) and Cp*RuCl(PPh3)2 (0.03 g,
0.03 mmol) in 1,4-dioxane (2 mL) at 70 °C for 12 h to give 120 (0.066 g, 78%) as a yellow
waxy solid after purification by column chromatography over SiO 2 gel (EtOAc/n-hexane 20:80 → 100:0). TLC (EtOAc/n-hexane 2:3): Rf = 0.5; 1H NMR (500 MHz, CDCl3) δ 7.56
(s, 1H, H4), 7.52-7.48 (m, 1H, H4"), 7.32 (dd, J = 7.6, 1.3 Hz, 1H, H6"), 7.11-7.06 (m, 2H,
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H5" and H3"), 3.77 (s, 3H, OMe), 2.44-2.38 (m, 1H, H1'), 1.89-1.71 (m, 2H, H2' and H6'),
1.67-1.64 (m, 3H, H3', H4' and H5'), 1.38-1.31 (m, 2H, H3' and H5'), 1.27-1.23 (m, 1H, H4'),
1.22-1.16 (m, 2H, H6' and H2');
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C NMR (126 MHz, CDCl3) δ 154.3 (C2"), 144.8 (C5),

131.4 (C4"), 130.0 (C4), 128.8 (C6"), 125.3 (C1"), 120.9 (C5"), 112.2 (C3"), 55.8 (OMe),
33.4 (C1'), 26.0 (C2', C4' and C6'), 25.6 (C3' and C5'); IR (neat) νmax 2928, 2850, 1506, 1457,
1280, 1233, 1046, 1020, 994, 974, 838, 770, 671 cm-1. MS (ESI +ve) m/z 258 ([M + H]+,
100%); HRMS (ESI +ve TOF) calcd for C15H20N3O 258.1606, found 258.1602 ([M + H]+).

1,5-Bis(2-methoxyphenyl)-1H-1,2,3-triazole (121)
This compound was prepared according to the General procedure V, 1azido-2-methoxybenzene 118 (0.05 g, 0.33 mmol) was treated with 1ethynyl-2-methoxybenzene (0.05 g, 0.37 mmol) and Cp*RuCl(PPh3)2
(0.03 g, 0.03 mmol) in 1,4-dioxane (2 mL) at 70 °C for 36 h to give 121
(0.054 g, 58%) as a pale yellow waxy solid after purification by column
chromatography over SiO2 gel (EtOAc/n-hexane - 30:70 → 100:0). TLC (EtOAc/n-hexane
2:3): Rf = 0.3; 1H NMR (500 MHz, CDCl3) δ 7.86 (s, 1H, H4), 7.41 (dd, J = 7.8, 1.7 Hz, 1H,
H3'), 7.38-7.34 (m, 1H, H4"), 7.30-7.26 (m, 1H, H5'), 7.10 (dd, J = 8.0, 1.7 Hz, 1H, H6"),
7.02 (ddd, J = 7.6, 1.2 Hz, 1H, H4'), 6.88-6.85 (m, 2H, H5" and H6'), 6.83 (dd, J = 8.0, 1.0
Hz, 1H, H3"), 3.56 (s, 3H, OMe), 3.46 (s, 3H, H7'); 13C NMR (126 MHz, CDCl3) δ 156.5
(C2'), 153.4 (C2"), 136.1 (C5), 133.6 (C4), 130.7 (C4"), 130.5 (C6'), 130.3 (C4'), 128.0 (C6"),
126.4 (C1"), 120.5 (C5"), 120.3 (C5'), 116.7 (C1'), 112.0 (C3"), 110.9 (C3'), 55.4 (C7'), 55.0
(OMe); IR (neat) νmax 2932, 2838, 1602, 1506, 1471, 1465, 1436, 1283, 1246, 1108, 1022,
989, 753 cm-1. MS (ESI +ve) m/z 282 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for
C16H16N3O2 282.1243, found 282.1244 ([M + H]+).
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1-(2-Methoxyphenyl)-5-(naphthalen-1-yl)-1H-1,2,3-triazole (122)
This compound was prepared according to the General procedure V, 1azido-2-methoxybenzene 118 (0.05 g, 0.33 mmol) was treated with 1ethynylnaphthalene (0.056 g, 0.37 mmol) and Cp*RuCl(PPh3)2 (0.03 g,
0.03 mmol) in 1,4-dioxane (2 mL) at 70 °C for 48 h to give 122 (0.007
g, 7%) as a pale brown waxy solid after purification by column chromatography over SiO 2
gel (EtOAc/n-hexane - 30:70 → 100:0). TLC (EtOAc/n-hexane 1:4): Rf = 0.2; 1H NMR (500
MHz, CDCl3) δ 7.96 (s, 1H, H4), 7.88-7.81 (m, 3H, H4', H7' and H10'), 7.50-7.44 (m, 3H,
H5', H6' and H9'), 7.34-7.28 (m, 2H, H4" and H8'), 7.16 (dd, J = 7.1, 1.1 Hz, 1H, H6"), 6.96
(td, J = 7.7, 1.1 Hz, 1H, H5"), 6.72 (dd, J = 8.3, 0.9 Hz, 1H, H3"), 3.14 (s, 3H, OMe); 13C
NMR (126 MHz, CDCl3) δ 153.2 (C2"), 137.4 (C5), 134.2 (C1'), 133.3 (C4), 131.6 (C3'),
131.0 (C4"), 129.4 (C6"), 128.2 (C2'), 128.1 (C7'), 127.6 (C10'), 126.7 (C8'), 126.2 (C9'),
125.2 (C1"), 125.1 (C4'), 124.9 (C5'), 124.7 (C6'), 120.6 (C5"), 111.8 (C3"), 54.9 (OMe); IR
(neat) νmax 2925, 2849,1602, 1506, 1437, 1275, 1248, 1048, 1021, 977, 803, 778, 755 cm -1.
MS (ESI +ve) m/z 302 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C19H16N3O
302.1293, found 302.1297 ([M + H]+).

6.4.3 – Copper catalysed click reactions
4-Isopentyl-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole (123)

This compound was prepared according to the General procedure IV,
1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was treated with
5-methyl-1-hexyne (0.05 g, 0.5 mmol), CuSO4.5H2O (0.012 g, 0.05
mmol) and Na. ascorbate (0.02 g, 0.1 mmol) in t-BuOH:H2O (1 mL:0.25
mL) at rt for 36 h to give 123 (0.063 g, 85%) as a brown waxy solid after
238

purification by column chromatography over SiO2 gel (EtOAc/n-hexane - 40:60 → 100:0).
TLC (EtOAc/n-hexane 1:4): Rf = 0.4; 1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 11.3 Hz,
1H, H8"), 7.83 (d, J = 9.5 Hz, 1H, H5"), 7.52 (s, 1H, H5), 7.46-7.35 (m, 3H, H6", H7" and
H4"), 7.16 (d, J = 10.5 Hz 1H, H3"), 3.87 (s, 3H, OMe), 2.91-2.87 (m, 2H, H1'), 1.73-1.69
(m, 3H, H2' and H3'), 0.99 (d, J = 7.9, 6H, H4' and H5');

C NMR (126 MHz, CDCl3) δ
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152.1 (C2"), 131.6 (C8a"), 131.2 (C4), 128.6 (C4"), 128.2 (C4a"), 127.8 (C5"), 124.5 (C7"),
124.3 (C8"), 122.1 (C6"), 121.4 (C5), 119.7 (C3"), 113.1 (C1"), 56.7 (OMe), 38.4 (C2'), 27.8
(C1'), 23.7 (C3'), 22.4 (C4' and C5'); IR (neat) νmax 2952, 2869, 2352, 1630, 1600, 1507,
1457, 1365, 1275, 1255, 1149, 1110, 1064, 1041, 905, 809, 747 cm-1. MS (ESI +ve) m/z 296
([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C18H22N3O 296.1763, found 296.1771
([M + H]+).

4-Cyclohexyl-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole (124)
This compound was prepared according to the General procedure IV,
1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was treated
with ethynylcyclohexane (0.054 g, 0.5 mmol), CuSO4.5H2O (0.012 g,
0.05 mmol) and Na. ascorbate (0.02 g, 0.1 mmol) in t-BuOH:H2O (1
mL:0.25 mL) at rt for and 48 h to give 124 (0.062 g, 81%) as a pale yellow waxy solid after
purification by column chromatography over SiO2 gel (EtOAc/n-hexane - 30:70 → 100:0).
TLC (EtOAc/n-hexane 1:4): Rf = 0.4; 1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 9.1 Hz, 1H,
H8"), 7.83-7.81 (m, 1H, H5"), 7.48 (s, 1H, H5), 7.44-7.36 (m, 2H, H6" and H7"), 7.35 (d, J
= 8.8 Hz, 1H, H4"), 7.14 (dd, J = 8.8, 0.7 Hz, 1H, H3"), 3.86 (s, 3H, OMe), 2.93 (tt, J = 11.3,
3.5 Hz, 1H, H1'), 2.24-2.20 (m, 2H, H2' and H6'), 1.86 (m, 2H, H3' and H5'), 1.77-1.74 (m,
1H, H4'), 1.58-1.42 (m, 4H, H2', H3', H5' and H6'), 1.35-1.25 (m, 1H, H4'); 13C NMR (126
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MHz, CDCl3) δ 153.1 (C2"), 152.1 (C4), 131.6 (C8a"), 131.3 (C4"), 128.6 (C4a"), 128.2
(C5"), 127.7 (C7"), 124.5 (C8"), 123.1 (C5), 121.5 (C6"), 119.8 (C3"), 113.1 (C1"), 56.7
(OMe), 35.3 (C1'), 33.0 (C2' and C6'), 26.2 (C4'), 26.1 (C3' and C5'); IR (neat) νmax 2923,
2850, 1739, 1631, 1599, 1487, 1512, 1448, 1364, 1252, 1235, 1069, 1028, 809, 796, 760,
652 cm-1. MS (ESI +ve) m/z 308 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for
C19H22N3O 308.1763, found 308.1775 ([M + H]+).

1-(2-Methoxynaphthalen-1-yl)-4-(2-methoxyphenyl)-1H-1,2,3-triazole (125)
This compound was prepared according to the General procedure
IV, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was
treated with 1-ethynyl-2-methoxybenzene (0.066 g, 0.5 mmol),
CuSO4.5H2O (0.012 g, 0.05 mmol) and Na. ascorbate (0.02 g, 0.1
mmol) in t-BuOH:H2O (1 mL:0.25 mL) at rt for 36 h to give 125
(0.074 g, 89%) as a light brown solid after purification by column chromatography over SiO2
gel (EtOAc/n-hexane - 40:60 → 100:0). M.P: 112-114 °C. TLC (EtOAc/n-hexane 1:4): Rf =
0.4; 1H NMR (500 MHz, CDCl3) δ 8.54 (dd, J = 7.7, 1.7 Hz, 1H, H2'), 8.33 (s, 1H, H5), 8.02
(d, J = 9.1 Hz, 1H, H8"), 7.87-7.85 (m, 1H, H5"), 7.46-7.39 (m, 3H, H6", H7" and H4"),
7.36-7.33 (m, 1H, H4'), 7.25-7.23 (m, 1H, H3'), 7.15 (dd, J = 7.6, 1.0 Hz, 1H, H5'), 7.00 (dd,
J = 8.3 Hz, 1H, H3"), 3.90 (s, 3H, OMe), 3.89 (s, 3H, H7'); 13C NMR (126 MHz, CDCl3) δ
155.6 (C2"), 152.3 (C6'), 142.7 (C4), 131.8 (C8a"), 131.2 (C2'), 128.88 (C4"), 128.84 (C4'),
128.2 (C4a"), 127.8 (C5"), 127.6 (C7"), 126.9 (C5), 124.5 (C8"), 121.4 (C6"), 121.0 (C3'),
119.6 (C1'), 119.3 (C3"), 113.0 (C1"), 110.7 (C5'), 56.7 (C7'), 55.2 (OMe); IR (neat) νmax
2922, 2851, 1601, 1506, 1486, 1465, 1275, 1246, 1076, 1058, 1032, 1020, 795, 751, 742,
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669 cm-1. MS (ESI +ve) m/z 332 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for
C20H18N3O2 332.1399, found 332.1394 ([M + H]+).

4-(4-Fluorophenyl)-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole (126)
This compound was prepared according to the General procedure IV,
1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was treated with
1-ethynyl-4-fluorobenzene (0.06 g, 0.5 mmol), CuSO4.5H2O (0.012 g,
0.05 mmol) and Na. ascorbate (0.02 g, 0.1 mmol) in t-BuOH:H2O (1
mL:0.25 mL) at rt for 12 h to give 126 (0.074 g, 92%) as an off-white
solid after purification by column chromatography over SiO 2 gel (EtOAc/n-hexane - 30:70
→ 100:0). M.P: 109-111 °C. TLC (EtOAc/n-hexane 1:4): Rf = 0.4; 1H NMR (500 MHz,
CDCl3) δ 8.00 (d, J = 9.1 Hz, 1H, H8"), 7.97 (s, 1H, H5), 7.92 (dd, J = 9.1, 2.1 Hz 2H,
H2'/H6'), 7.84 (d, J = 8.0 Hz, 1H, H5"), 7.46-7.37 (m, 3H, H6", H7" and H4"), 7.25 (d, J =
8.3 Hz, 1H, H3"), 7.14 (apparent t, J = 8.6 Hz, 2H, H3'/H5'), 3.88 (s, 3H, OMe); 13C NMR
(126 MHz, CDCl3) δ 162.6 (d, JC-F = 198.7 Hz, C4'), 152.1 (C2"), 146.4 (C4), 132.0 (C8a"),
131.0 (C4a"), 128.5 (d, JC-F = 18.1 Hz, C2'/C6'), 127.9 (C4"), 127.58 (C5"), 127.52 (C5),
126.8 (d, JC-F = 2.0 Hz, C1'), 124.7 (C7"), 123.3 (C8"), 121.3 (C6"), 119.2 (C3"), 115.8 (d,
JC-F = 86.3 Hz C3'/C5'), 113.0 (C1"), 56.7 (OMe); IR (neat) νmax 2919, 2849, 1714, 1598,
1507, 1482, 1457, 1276, 1258, 1223, 1218, 1146, 1079, 1032, 838, 811, 796, 755, 658 cm-1.
MS (ESI +ve) m/z 320 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C19H15FN3O
320.1199, found 320.1213 ([M + H]+).
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1-(2-Methoxynaphthalen-1-yl)-4-(4-nitrophenyl)-1H-1,2,3-triazole (127)
This compound was prepared according to the General procedure
IV, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was
treated with 1-ethynyl-4-nitrobenzene (0.074 g, 0.5 mmol),
CuSO4.5H2O (0.012 g, 0.05 mmol) and Na. ascorbate (0.02 g, 0.1
mmol) in t-BuOH:H2O (1 mL:0.25 mL) at rt for 16 h to give 127 (0.07
g, 79%) as a yellow solid after purification by column chromatography over SiO 2 gel
(EtOAc/n-hexane - 30:70 → 100:0). M.P: 118-120 °C. TLC (EtOAc/n-hexane 1:4): Rf = 0.3;
H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 8.8 Hz, 2H, H3' and H5'), 8.18 (s, 1H, H5), 8.14

1

(d, J = 8.8 Hz, 2H, H2' and H6'), 8.07 (d, J = 9.1 Hz, 1H, H8"), 7.89 (d, J = 8.0 Hz, 1H, H5"),
7.50-7.45 (m, 2H, H6" and H7"), 7.43 (d, J = 9.1 Hz, 1H, H4"), 7.26 (d, J = 9.1 Hz, 1H, H3"),
3.93 (s, 3H, OMe); 13C NMR (126 MHz, CDCl3) δ 152.1 (C2"), 147.3 (C4), 145.1 (C8a"),
136.9 (C1'), 132.3 (C4'), 130.8 (C4"), 128.6 (C4a"), 128.0 (C5"), 126.2 (C2'/C6'), 126.1
(C7"), 125.1 (C5), 124.8 (C8"), 124.3 (C3'/C5'), 121.1 (C6"), 118.9 (C3"), 112.8 (C1"), 56.7
(OMe); IR (neat) νmax 3162, 2943, 2845, 1603, 1510, 1335, 1276, 1257, 1108, 1079, 1059,
1028, 852, 801, 757, 753 cm-1. MS (ESI +ve) m/z 347 ([M + H]+, 100%); HRMS (ESI +ve
TOF) calcd for C19H15N4O3 347.1144, found 347.1152 ([M + H]+).

1-(2-Methoxynaphthalen-1-yl)-4-(naphthalen-1-yl)-1H-1,2,3-triazole (128)
This compound was prepared according to the General procedure
IV, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was
treated

with

1-ethynylnaphthalene

(0.076

g,

0.5

mmol),

CuSO4.5H2O (0.012 g, 0.05 mmol) and Na. ascorbate (0.02 g, 0.1
mmol) in t-BuOH:H2O (1 mL:0.25 mL) at rt for 12 h to give 128
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(0.08 g, 91%) as a pale yellow waxy solid after purification by column chromatography over
SiO2 gel (EtOAc/n-hexane - 40:60 → 100:0). TLC (EtOAc/n-hexane 1:4): Rf = 0.3; 1H NMR
(500 MHz, CDCl3) δ 8.58-8.55 (m, 1H, H10'), 8.09 (s, 1H, H5), 8.02 (d, J = 10.7 Hz, 1H,
H8"), 7.94-7.86 (m, 4H, H5", H2', H4' and H7'), 7.60-7.49 (m, 4H, H6", H7", H9' and H3'),
7.45-7.38 (m, 3H, H4", H3" and H8'), 3.93 (s, 3H, OMe); 13C NMR (126 MHz, CDCl3) δ
152.1 (C2"), 146.2 (C4), 134.0 (C1'), 131.9 (C8a"), 131.2 (C4b'), 131.1 (C8b'), 128.9 (C4a"),
128.7 (C4"), 128.5 (C5'), 128.4 (C8'), 128.0 (C4'), 127.9 (C5"), 127.4 (C7'), 126.6 (C7"),
126.5 (C5), 126.0 (C6'), 125.5 (C8"), 125.4 (C3'), 124.7 (C6"), 121.5 (C2'), 119.4 (C3"),
113.0 (C1"), 56.8 (OMe); IR (neat) νmax 3137, 2936, 2846, 1629, 1506, 1462, 1390, 1278,
1264, 1064, 1044, 1021, 905, 803, 778, 749, 663 cm-1. MS (ESI +ve) m/z 352 ([M + H]+,
100%); HRMS (ESI +ve TOF) calcd for C23H18N3O 352.1450, found 352.1459 ([M + H]+).

2-(1-(2-Methoxynaphthalen-1-yl)-1H-1,2,3-triazol-4-yl) propan-2-ol (129)
This compound was prepared according to the General procedure IV,
1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was treated with
2-methylbut-3-yn-2-ol (0.043 g, 0.5 mmol), CuSO4.5H2O (0.012 g, 0.05
mmol) and Na. ascorbate (0.02 g, 0.1 mmol) in t-BuOH:H2O (1 mL:0.25
mL) at rt for 12 h to give 129 (0.06 g, 86%) as a yellow solid after purification by column
chromatography over SiO2 gel (EtOAc/n-hexane - 40:60 → 100:0). M.P: 122-124 °C; TLC
(EtOAc/n-hexane 1:4): Rf = 0.2; 1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 9.1 Hz, 1H, H8"),
7.84-7.82 (m, 1H, H5"), 7.69 (s, 1H, H5), 7.44-7.38 (m, 2H, H6" and H7"), 7.36 (d, J = 8.7
Hz, 1H, H4"), 7.14 (dd, J = 8.7 Hz, 1H, H3"), 3.87 (s, 3H, OMe), 2.94 (brs, 1H, -OH), 1.77
(s, 6H, H2' and H3'); 13C NMR (126 MHz, CDCl3) δ 155.0 (C2"), 152.1 (C8a"), 131.8 (C4),
131.1 (C4"), 128.5 (C4a"), 128.3 (C5"), 127.8 (C7"), 124.6 (C8"), 123.0 (C5), 121.3 (C6"),
243

119.4 (C3"), 113.0 (C1"), 68.6 (C1'), 56.6 (OMe), 30.5 (C2' and C3'); IR (neat) νmax 3333,
2981, 2919, 2849, 1632, 1511, 1456, 1359, 1275, 1219, 1143, 1067, 1045, 805, 776, 757 cm1

. MS (ESI +ve) m/z 284 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C16H18N3O2

284.1399, found 284.1396 ([M + H]+).

4-Isopentyl-1-(2-methoxyphenyl)-1H-1,2,3-triazole (130)
This compound was prepared according to the General procedure IV, 1azido-2-methoxybenzene 118 (0.05 g, 0.33 mmol) was treated with 5-methyl1-hexyne (0.065 g, 0.66 mmol), CuSO4.5H2O (0.017 g, 0.06 mmol) and Na.
ascorbate (0.026 g, 0.13 mmol) in t-BuOH:H2O (1 mL:0.25 mL) at rt for 12
h to give 130 (0.078 g, 96%) as a pale-yellow oil after purification by column
chromatography over SiO2 gel (EtOAc/n-hexane - 20:80 → 100:0). TLC (EtOAc/n-hexane
1:4): Rf = 0.5; 1H NMR (500 MHz, CDCl 3) δ 7.83 (s, 1H, H5), 7.73 (dd, J = 10.3, 2.2 Hz,
1H, H6"), 7.40-7.35 (m, 1H, H4"), 7.08-7.04 (m, 2H, H5" and H3"), 3.86 (s, 3H, OMe), 2.822.78 (m, 2H, H1'), 1.70-1.60 (m, 3H, H2' and H3'), 0.96 (d, J = 7.8 Hz, 6H, H4' and H5'); 13C
NMR (126 MHz, CDCl3) δ 151.4 (C2"), 147.9 (C4), 129.8 (C4"), 126.5 (C6"), 125.4 (C5"),
122.7 (C5), 121.1 (C3"), 112.2 (C1"), 55.9 (OMe), 38.4 (C2'), 27.7 (C1'), 23.6 (C3'), 22.4
(C4' and C5'); IR (neat) νmax 2953, 2868, 1601, 1506, 1473, 1285, 1251, 1233, 1122, 1043,
1021, 985, 795, 750 cm-1. MS (ESI +ve) m/z 246 ([M + H]+, 100%); HRMS (ESI +ve TOF)
calcd for C14H20N3O 246.1606, found 246.1617 ([M + H]+).
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4-Cyclohexyl-1-(2-methoxyphenyl)-1H-1,2,3-triazole (131)
This compound was prepared according to the General procedure IV, 1azido-2-methoxybenzene 118 (0.05 g, 0.33 mmol) was treated with ethynyl
cyclohexane (0.07 g, 0.66 mmol), CuSO4.5H2O (0.017 g, 0.06 mmol) and
Na. ascorbate (0.026 g, 0.13 mmol) in t-BuOH:H2O (1 mL:0.25 mL) at rt
for 12 h to give 131 (0.077 g, 90%) as a pale-yellow oil after purification by column
chromatography over SiO2 gel (EtOAc/n-hexane - 20:80 → 100:0). TLC (EtOAc/n-hexane
1:4): Rf = 0.5; 1H NMR (500 MHz, CDCl3) δ 7.79 (s, 1H, H5), 7.75-7.73 (m, 1H, H6"), 7.407.35 (m, 1H, H4"), 7.08-7.04 (m, 2H, H5" and H3"), 3.86 (s, 3H, OMe), 2.88-2.80 (m, 1H,
H1'), 2.16-2.11 (m, 2H, H2' and H6'), 1.85-1.71 (m, 3H, H3', H4' and H5'), 1.51-1.40 (m, 4H,
H2', H3', H5' and H6'), 1.34-1.25 (m, 1H, H4'); 13C NMR (126 MHz, CDCl3) δ 153.0 (C2"),
151.1 (C4), 129.7 (C4"), 126.6 (C6"), 125.5 (C5"), 121.5 (C5), 121.1 (C3"), 112.2 (C1"),
55.9 (OMe), 35.3 (C1'), 33.0 (C2' and C6'), 26.2 (C4'), 26.1 (C3' and C5'); IR (neat) νmax
2929, 2849, 1602, 1504, 1473, 1458, 1282, 1248, 1181, 1124, 1049, 1021, 748 cm-1. MS (ESI
+ve) m/z 258 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C15H20N3O 258.1606, found
258.1602 ([M + H]+).

1,4-Bis(2-methoxyphenyl)-1H-1,2,3-triazole (132)
This compound was prepared according to the General procedure IV, 1azido-2-methoxybenzene 118 (0.05 g, 0.33 mmol) was treated with 1ethynyl-2-methoxybenzene (0.09 g, 0.66 mmol), CuSO4.5H2O (0.017 g,
0.06 mmol) and Na. ascorbate (0.026 g, 0.13 mmol) in t-BuOH:H2O (1
mL:0.25 mL) at rt for 12 h to give 132 (0.082 g, 88%) as a pale brown
liquid after purification by column chromatography over SiO2 gel (EtOAc/n-hexane - 20:80
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→ 100:0). TLC (EtOAc/n-hexane 1:4): Rf = 0.2; 1H NMR (500 MHz, CDCl3) δ 8.50 (s, 1H,
H5), 8.40 (dd, J = 9.6, 2.2 Hz, 1H, H2'), 7.74 (dd, J = 9.8, 2.1 Hz, 1H, H6"), 7.41-7.37 (m,
1H, H4"), 7.32-7.28 (m, 1H, H5") , 7.10-7.04 (m, 3H, H3', H4' and H5'), 6.96 (dd, J = 10.4,
1.0 Hz, 1H, H3"), 3.90 (s, 3H, OMe), 3.84 (s, 3H, H7'); 13C NMR (126 MHz, CDCl3) δ 155.7
(C6'), 151.6 (C2"), 142.6 (C4), 130.0 (C2'), 128.8 (C4"), 127.7 (C4'), 126.5 (C6"), 125.7
(C3'), 125.2 (C5), 121.1 (C5"), 121.0 (C1'), 119.5 (C3"), 112.3 (C1"), 110.9 (C5'), 55.9
(OMe), 55.4 (C7'); IR (neat) νmax 2936, 2838, 1601, 1506, 1489, 1465, 1287, 1247, 1161,
1130, 1078, 1022, 748, 689 cm-1. MS (ESI +ve) m/z 282 ([M + H]+, 100%); HRMS (ESI +ve
TOF) calcd for C16H16N3O2 282.1243, found 282.1234 ([M + H]+).

Synthesis of Azides and alkynes:
The known azides 8282, 9783 and 9984 were prepared from their corresponding 1naphthylamines according to the method of Hu et al.85 All alkynes were commercially
sourced expect for 1-ethynylnaphthalene,86 1-ethynyl-4-nitrobenzene,87 and 2-ethynyl-1,3,5trimethylbenzene88 which were prepared by literature methods.

6.5 – Experimental procedures for biological and pharmacological assays
6.5.1 – Minimum inhibitory concentration (MIC)
6.5.1.1 – Primary screening
The primary screening experiments were performed at University of Western
Australia by Dr. Katherine Hammer and Dr. Daniel Knight. MIC analyses were executed on
Staphylococcus aureus (ATCC 29213), methicillin-resistant Staphylococcus aureus (NCTC
10442), Enterococcus faecalis (ATCC 29212) and Escherichia coli (ATCC 25922) in
Mueller Hinton (MH) broth and incubation was completed in ambient air at 35 °C for 24 h.
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Streptococcus pneumoniae (ATCC 49619) was cultivated in MH broth with 2.5% lysed horse
blood and incubated with 5% CO2 at 35 °C for 24 h. MIC tests for Clostridium difficile
(ATCC 700057) and Clostridium difficile (NSW132 – RT027) were performed in Brucella
broth supplemented with haemin and vitamin K and incubation was completed anaerobically
at 35 °C for 48 h. Every compound was dissolved in DMSO at 3 – 5 mg/mL and then diluted
to 512 μg/mL with sterile, distilled water. The compounds were then diluted sequentially in
100 μL volumes of sterile, distilled water in a 96-well microtitre plate. Every testing
bacterium in double strength broth (100 μL) was then added to each well and incubated as
explained above. Testing concentrations of every compound ranged from 0.25 μg/mL to 128
μg/mL. Vancomycin and a control well (i.e. no antibacterial compound present) were
involved in the assays. A DMSO control (5% v/v) was also analyzed to confirm the solvent
did not inhibit bacterial growth. The test was performed in triplicate for each organism and
compound mixture and the average MIC values were verified. The lowest concentration that
inhibits bacterial development completely will be recorded as the compound’s MIC value.
The MBC (minimum bactericidal concentration) was also noted as the lowest concentration
that caused cellular death.

6.5.1.2 – Secondary screening and cytotoxicity assays (CO-ADD)
Antibacterial compounds were screened at CO-ADD for antimicrobial testing by
complete cell development inhibition analyses. The inhibition of development was measured
against five bacterial strains: Escherichia coli (ATCC 25922), Klebsiella pneumoniae
(ATCC 700603), Acinetobacter baumannii (ATCC 19606), Pseudomonas aeruginosa
(ATCC 27853) and Staphylococcus aureus (ATCC 43300), and two fungi: Candida albicans
(ATCC 90028) and Cryptococcus neoformans (ATCC 208821). After MIC screening, the
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compounds were tested for cytotoxicity against a human embryonic kidney cell line
(HEK293) by ascertaining their CC50 value. Antibacterial compound solution was prepared
in DMSO to a final screening concentration of 32 μg/mL and serially diluted 1:2 fold for 8
times. Each compound concentration was prepared in 384 – well plates, non-binding surface
(NBS) plate (Corning 3640) for each bacterial/fungal strain and tissue-culture treated
(Corning 3712/3764) black for mammalian cell types, all in duplicate (n = 2) and keeping the
final DMSO concentration to a maximum of 0.5%. All the compound’s preparation was
accomplished using liquid handling robots.

6.5.1.3 – Bacterial Inhibition
All of the bacterial strains were cultured in cation-adjusted MH broth at 37 °C
overnight. Each compound culture was then diluted 40-fold in fresh broth and incubated at
37 °C for 1 – 3.5 h. The resultant mid-log phase cultures were diluted (CFU/mL measured
by OD600), then added to each well of the compound-containing plates, giving a cell density
of 5 × 105 CFU/mL and a total volume of 50 μL. All plates were protected and incubated at
37 °C for 18 h without shaking. Inhibition of bacterial development was verified by
calculating absorbance at 600 nm (OD600), using a Tecan M1000 Pro monochromator plate
reader. The percentage of growing inhibition was determined for each well, utilizing the
negative control (media only) and positive control (bacteria without inhibitors) on the same
plate as references. The MIC was revealed as the lowest concentration at which bacterial
development was completely inhibited, identified by an inhibition ≥ 80%. Vancomycin was
utilized as a positive control for Gram-positive bacteria and colistin was used as a positive
control for Gram-negative bacteria. Each antibiotic control was given in four concentrations,
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with two above and two below its MIC value, and plated into the first eight wells of column
23 of the 384 – well NBS plates.

6.5.1.4 – Fungal Inhibition
Fungal strains were cultured for three days on Yeast Extract-Peptone Dextrose agar
at 30 °C. A yeast suspension of 1 × 106 to 5 × 106 CFU/mL (as determined by OD530) was
prepared from five colonies. The suspension was diluted and added to each well of the
compound-containing plates giving a final cell density of fungi suspension of 2.5 × 103
CFU/mL and a total volume of 50 μL. All plates were protected and incubated at 35 °C for
36 h without shaking. The inhibition of C. albicans development was decided by evaluating
absorbance at 630 nm (OD630), and the inhibition of C. neoformans development was
decided by assessing the difference in absorbance between 600 and 570 nm (OD600 – 570),
after the addition of resazurin (0.001 % final concentration) and incubation at 35 °C for 2 h.
The absorbance was measured using a Biotek Multiflo Synergy HTX plate reader. The
percentage of growing inhibition for both fungi were calculated for each well, using the
negative control (media only) and positive control (fungi without inhibitors) on the same
plate.
The MIC was decided as the lowest concentration at which the fungal development
was fully inhibited, defined as an inhibition ≥ 80% for C. albicans and an inhibition ≥ 70%
for C. neoformans. Due to the higher difference in growth and inhibition, a lower threshold
was employed to the data for C. neoformans. Fluconazole was used as a positive control for
anti-fungal assay of C. albicans and C. neoformans. The antifungal control was given in four
concentrations, with two above and two below its MIC value, and plated into the first eight
wells of column 23 of the 384 – well NBS plates.
249

6.5.2 – Cytotoxicity Assay
HEK293 cells were counted manually in a Neubauer haemocytometer and then plated
in the 384 – well plates containing the compounds to give a density of 5000 cells/well in a
final volume of 50 μL. Dulbecco’s modified eagle medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) was used as a growth media and the cells were incubated together
with the compounds for 20 h at 37 °C in 5% CO2. Cytotoxicity (cell viability) was evaluated
by fluorescence, ex: 560/10 nm, em: 590/10 nm (F560/590), after addition of 5 μL of 25
μg/mL resazurin (2.3 μg/mL final concentration) and after incubation for further 3 h at 37 °C
in 5% CO2. The intensity of fluorescence was measured using a Tecan M1000 Pro
monochromator plate reader, using automatic gain calculation. CC 50 (concentration at 50%
cytotoxicity) values were calculated by curve-fitting the inhibition values vs.
log(concentration) using a sigmoidal dose-response function, with variable fitting values for
bottom, top and slope. Tamoxifen was used as a positive cytotoxicity control, used in eight
concentrations in two-fold serial dilutions with 50 μg/mL as the highest concentration tested.

6.5.3 – In vivo CDI mouse model (Monash University)
6.5.3.1 – Study design
The in vivo CDI mouse model study was performed by Prof. Dena Lyras, Dr.
Melanie Hutton and Dr. Amy King. Mice were pre-treated with an antibiotic cocktail
containing kanamycin (0.4 mg/mL; Amresco), gentamicin (0.035 mg/mL; Sigma), colistin
(850 mg/mL; Sigma), metronidazole (0.215 mg/mL; Sigma), vancomycin (0.045 mg/mL;
Sigma) and cefaclor (0.3 mg/mL; Sigma) in the drinking water for seven days, followed by
three days of cefaclor alone to obstruct the commensal microbiota to bring infection with C.
difficile. The mice were shifted to clean cages containing plain drinking water on the day of
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infection. Group of infected five mice with 105 C. difficile spores of the RT027 strain M7404.
After six hours post-infection, 2.5 mg of the selected compounds (in 10% aqueous DMSO)
were given to the mice via oral gavage. The mice were then administered fresh compound
every 12 h after the initial dose. The mice were monitored twice in a day for weight loss and
other physiological signs of infection. The blood was collected and left to clot at room
temperature prior to centrifugation. The serum and faeces were collected and frozen at – 80
°C for later pharmacokinetic evaluation. Note that mice were euthanized according to animal
ethics guidelines: i.e. if the mice lose ≥ 10 % of their total body weight in the first 24 h or ≥
15 % at any point after 24 h.

6.5.3.2 – Sample preparation
Each compound was dissolved in 100% DMSO to attain a stock concentration of 250
mg/mL. Twenty minutes before the administration, the compound stock solution was diluted
(1:10) with warm water (37 °C) to accomplish a final concentration of 25 mg/mL. The
compounds were vortexed and carried to the animal house floating in warm water in an
attempt to maintain a homogeneous solution. The compounds were then vortexed again
immediately preceding to gavaging the mice. Each mouse received 100 μL of solution
containing 2.5 mg of compound – this equates to a dose of 100 mg/kg (based on an average
25 g mouse).

6.5.4 – Comparative solubility assay
6.5.4.1 –Procedure
Five milligrams of the target compound was fully dissolved in 50 μL DMSO. Small
aliquots (5 μL) of H2O were added to the DMSO solution with manual agitation after each
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addition; additions were continued until a visible turbidity or cloudiness was apparent that
did not fade after mixing. The quantity of H2O needed for precipitation of the compound was
recorded; this value was then divided by the standard value (i.e. 15 μL = quantity of H 2O
required to precipitate lead compound AVX-13616) to obtain a comparative solubility ratio.
This ratio aided to assess the observed change in solubility that was observed for various
compounds.
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